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Abstract 
This thesis focuses on clinically-relevant questions regarding the care of patients 
with relapsing remitting multiple sclerosis (RRMS), including appraisal of the 
current relevant literature regarding the disease itself and therapeutic 
approaches. An understanding of the nature of MS is detailed in a review of its 
characteristics and natural history in the pre-treatment era, to establish a 
baseline upon which the utility of disease modifying therapies (DMTs) in the 
modern era can be evaluated. A review of the history of therapeutics in MS leads 
into an appraisal of trials in the modern era, including potential and actual 
pitfalls in their design and interpretation. A comprehensive tabulation of the 
pivotal placebo-controlled and head-to-head DMT trials is included and allows an 
appreciation of the complexity in evaluating the evidence-base for the 
therapeutic options currently available. Inter-trial comparisons are often made 
despite differing patient populations, methods and outcome analyses and these 
are discussed. The potential for new therapeutic options is also considered in 
light of emerging evidence for novel treatment approaches. 
The original work in this thesis stems from practical clinical dilemmas in the 
management of patients with RRMS and uses real-world observational data to 
address them. The available evidence-base supports the early initiation of DMTs 
in RRMS on short-term efficacy grounds, but there remains controversy regarding 
the timing and aggressiveness of therapeutic intervention, particularly with 
higher risk treatments, and uncertainty regarding the impact on long-term 
outcomes. We have studied the safety and efficacy of the oral DMTs dimethyl 
fumarate and fingolimod in our own centre, and describe their safety and 
efficacy in real clinical practice. The availability of oral DMTs in MS therapeutics 
was a watershed event and our cohorts exemplify the desire of patients to 
switch from injectable therapies when alternatives became available. Whilst our 
data support the efficacy of these therapies, their side effects remain limiting 
for a proportion of patients, and this was higher than expected from previous 
trials. Additionally, we have been able to describe potential risk factors for 
lymphopaenia with dimethyl fumarate, and identify cases where this can persist 
despite drug discontinuation, which is relevant given its (post-licensing) 
association with progressive multifocal leukoencephalopathy (PML).  
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In identifying RRMS patients with similar disease profiles within two centres in 
Scotland who were often treated differently, we have provided evidence of 
significant variation in practice in a close geographical area. Additionally, whilst 
outcome comparisons were hampered by methodological issues, there were 
significant reductions in some disease measures when DMTs were started sooner 
rather than later in statistically-matched cohorts. These cohorts now provide the 
opportunity for a prospective study to compare more detailed long-term 
outcomes in patients treated or not in the early stages of their disease. Lastly, a 
unique dataset is analysed to evaluate the safety and efficacy of switching from 
one powerful anti-inflammatory immune therapy to another, namely 
natalizumab to alemtuzumab, in highly active RRMS. This is an increasingly used 
strategy since the worldwide licensing of alemtuzumab, despite little evidence 
upon which to base the approach. The use of alemtuzumab in the UK and Ireland 
for many years before this licensing, as a result of its development in 
Cambridge, provided a multicentre cohort of patients with longitudinal follow-up 
unavailable elsewhere, and we have demonstrated that this sequencing appears 
safe and effective. Additionally, the management of the switch between these 
two treatments is a dilemma in itself and we present data to support a direct 
switch and avoiding prolonged delay beyond excluding the possibility of 
(subclinical) infections.  
The studies presented here are therefore of real utility to the practising clinician 
in MS therapeutics. 
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Chapter Summary 
Introduction 
This describes the epidemiology, pathogenesis and clinical features of MS but 
primarily focuses on natural history studies to contextualise the impact of DMTs 
in RRMS, as shown in the pivotal clinical trials which are also described. 
 
Chapter 1: DMT initiation and escalation in RRMS 
This chapter reviews the current literature on DMT initiation and escalation in 
RRMS followed by a summary of real-world studies from our own centre on 
recently-introduced oral DMTs that are used in practice as both initiation and 
escalation agents. 
 
Chapter 2: Multiple sclerosis Outcome Determination Evaluating Real 
Differences After TimE (MODERATE) 
This chapter is a study of DMT initiation in RRMS in Scotland and highlights the 
variability and potential impact on patients of differing approaches.  
 
Chapter 3: Alemtuzumab after Natalizumab Switch in Evolving Rapidly 
Severe Multiple Sclerosis (ANSWERS MS) 
This chapter evaluates the safety and efficacy of sequencing highly-efficacious 
DMTs with profound immunomodulatory effects, based on unique multicentre 
longitudinal data from the UK and Ireland. 
 
Conclusions 
This thesis explores current treatment strategies in RRMS at local, national and 
international levels and their potential impact on patients now and in the 
future. Data presented here are part of the growing body of work recognising 
the necessity and utility of real-world observational studies and includes safety 
and efficacy data on commonly used DMTs in our centre as well as less common 
sequencing strategies with highly efficacious treatments using multicentre data. 
Sequencing highly effective DMTs as a treatment strategy in RRMS has a very 
limited evidence-base but this work provides reassuring data on both safety and 
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efficacy fronts with regards to the use of alemtuzumab after natalizumab, as 
well as favouring a shorter switch period where possible. Additionally, the 
variability of DMT use within Scotland, and the potential impact this can have, is 
demonstrated and provides a basis for further work. The utility of multicentre 
collaboration is inherent in the two main studies, MODERATE and ANSWERS MS, 
and serves a model for future collaborative studies to enhance our 
understanding of the role of current and emerging therapies in improving the 
lives of people with MS.  
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Introduction 
This thesis pertains to the clinical management of Relapsing Remitting Multiple 
Sclerosis (RRMS), specifically the use of available Disease Modifying Treatments 
(DMTs). Multiple Sclerosis (MS) is the most common disease of the central 
nervous system in young adults and affects around 2 million people worldwide1. 
The World Health Organisation (WHO) and the Multiple Sclerosis International 
Federation (MSIF) estimate the global prevalence of MS at 30 per 100 000 
persons2, but this belies wide regional variations. There appear to be significant 
differences between continents in the distribution of MS worldwide3. The highest 
prevalence is found in Western Europe and North America, with lower rates in 
Eastern Europe, the Balkans and Australasia and the lowest rates in Asia, the 
Middle East and Africa. A meta-analysis of available European studies has 
described its epidemiology of MS in detail4. The total estimated prevalence rate 
of MS in Europe for the past 30 years is 83/100000 population, with a 
female:male ratio of around two. Prevalence rates are higher for women in all 
countries studied and the 35-64 years age group had the highest rates overall. 
Prevalence rates varied significantly, with the highest recorded in the north of 
Ireland (Donegal) at 216 cases/100000 (282 in women) and the lowest in Albania, 
11 cases/100000. Similarly, the female:male ratio varied between 1.1 (Albania 
and Cyprus) to 3.4 (Donegal, Ireland). The mean European annual incidence is 
estimated at 4.3 cases/100000, with the highest incidence in Scotland (12 cases 
per 100 00 per year) but with highs of 11.6, 8.7 and 6.8 cases per 100 000 per 
year in Finland, Norway and Sardinia also.  
No single cause of MS has been identified and no pathognomic finding exists in 
vivo. Whilst both genetic and environmental factors have been postulated, it 
seems likely that multiple sclerosis results from interplay between these. The 
relative contribution of genetic and environmental factors on an individual basis 
is likely on a spectrum from predominantly genetic to predominantly 
environmental and, given the lack of homogeneity of the condition, the 
possibility that multiple sclerosis represents the common end-point of a number 
of pathological processes remains. The standard statement that MS is a T-cell-
mediated autoimmune disorder resulting in focal demyelination of CNS white 
matter causing neurological dysfunction has since been challenged by 
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therapeutic responses to targeted B-cell therapies, the presence of diffuse white 
matter inflammation, involvement of grey matter and the meninges, axonal loss 
in the absence of demyelination and early neurodegeneration raising the 
possibility of the inflammatory response being a secondary rather than primary 
insult. The extent to which a failure of normal remyelination, rather than 
demyelination, contributes to the process is also uncertain. 
The most pertinent debate regarding the pathogenesis of MS is that between the 
‘outside-in’ and ‘inside-out’ hypotheses. The ‘outside-in’ hypothesis has most 
widespread historical support and states that MS results from a primary 
dysfunction of the (peripheral) immune system with subsequent autoimmune 
targeting of the CNS causing damage. Indeed, the most widely studied animal 
model from which the majority of immunopathological mechanisms in human MS 
are surmised, Experimental Autoimmune Encephalitis (EAE), is based wholly on 
this hypothesis through inoculating mice with abnormal immune cells. Similarly, 
all current licensed disease-modifying therapies MS target the peripheral 
immune system primarily, albeit some of these drugs may have neuroprotective 
benefits also. The alternative and more recent ‘inside-out’ paradigm 
hypothesises that the primary abnormality is within the CNS and that the 
immune response is a consequence of this, stimulated by antigenic intracellular 
breakdown products liberated by the (degenerative) process. Evidence for both 
hypotheses is available, but the fact that the primary location of MS 
pathogenesis remains obscure provides a sense of the nascent understanding of 
this condition despite extensive research. A major development in the 
understanding of MS pathology was proposed by Luchinetti et al.5, stating that 
four distinct phenotypes of MS can be discerned immunopathologically and, 
further, that this is specific to an individual throughout life6,7. Challenges to 
their findings are made, but along with clinical evidence supporting differing 
therapeutic responses between these phenotypes8, it is tempting to attribute 
both the variable clinical phenotype and treatment response seen in practice to 
such heterogeneous pathology. Notably, these ‘immunopatterns’ do not reliably 
distinguish between the clinical phenotypes of relapsing or progressive MS9.  
Pathological diagnosis is the gold-standard in almost all areas of disease, but the 
inaccessibility of in vivo tissue in MS prevents this and results in a skew towards 
outlier cases that have, by definition, required a brain biopsy or post-mortem. 
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MS pathology includes a mixture of inflammation, demyelination and 
degeneration of variable extent, but which of these occurs first or should be the 
primary therapeutic target remains a matter of debate. In vivo brain biopsy 
samples are exclusively a product of clinical practice, usually to differentiate MS 
from other conditions, as undergoing a brain biopsy for entirely research 
purposes would be unethical given the associated risks. Post-mortem samples 
may be available in younger patients, with shorter disease duration, but more 
often represent an older population with longer disease duration. 
The symptoms and signs of MS are a consequence of the neurological region 
affected by the process such that, essentially, any CNS-dependent function may 
be affected. In practice, however, the lesions of MS have a tendency to occur in 
certain CNS regions with predictable symptoms resulting. Notably, large swathes 
of brain regions can be affected without any symptomatic sequelae and it is well 
recognised that the number of symptomatic lesions usually belies a higher lesion 
load within non-eloquent regions of the CNS. As little as 5-20% of new lesions 
identified on brain MRI are symptomatic, with more recent studies suggesting 
the relationship is at the lower end of this range10. In contrast, lesions within the 
spinal cord are more likely to be symptomatic, given the higher concentration of 
neural pathways in a relatively small area, anatomically, but they too can be 
clinically silent. However, symptoms related to spinal cord lesions are a common 
first presentation of MS (transverse myelitis), as well as a preponderance for the 
optic nerves and brainstem. In fact, some clinicians consider a presentation of 
internuclear ophthalmoplegia (related to a lesion of the medial longitudinal 
fasciculus within the upper brainstem) in a young person as almost pathognomic 
of MS and, whilst other causes are possible of course, there is a rationale to this 
conclusion. Although grey matter involvement is clearly demonstrated as a 
consequence of MS, cortical dysfunction as a first symptom, such as seizure and 
cognitive presentations, are rare. Non-focal symptoms, such as fatigue or 
depression, may well predate focal symptoms but the consensus view remains 
that these are not considered of diagnostic value, albeit they can be more 
debilitating than localisable disability. 
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Understanding the natural history of a condition is crucial in both defining 
prognosis and assessing treatment effects. Studies from the pre-treatment era of 
RRMS are of course most relevant in understanding this. The inclusion of patients 
given treatment (which usually differs from that given today) skews any 
conclusions about its ‘natural’ history, both by the inclusion of patients with 
more severe disease, as well as any treatment effects. The natural history of MS 
is critical to this thesis, given the focus on DMTs, their impact on patients in 
terms of efficacy and safety and prognostic factors. We must be sure that 
treatments truly modify the disease and can only claim this once the natural 
history is understood, therefore this will be discussed first, followed by a 
summary of the pivotal trials for treatments deemed as disease-modifying. 
 
The Natural History of MS 
Longitudinal observational cohort studies of Multiple Sclerosis (MS) have been 
ongoing in a number of developed Western countries since the 1970s. These are 
based largely in Europe and North America and, whilst acknowledging 
methodological weaknesses, provide the most robust evidence available to 
understand the natural history of MS. Indeed, such cohorts are used as 
comparators for contemporary cohorts in order to measure treatment effects of 
subsequently-introduced therapies11 as a pseudo-placebo arm. Of course, there 
are notable drawbacks in this approach, not least the changing definitions of MS 
diagnosis, advances in imaging and unforeseeable ‘unknown unknowns’ which 
may invalidate comparisons between historical and contemporary patients with a 
disease of uncertain aetiology. The purpose of these longitudinal cohort studies, 
however, was to describe the expected course of MS over time on a population-
basis and extrapolate influential (ideally modifiable) factors which may suggest 
treatment targets: this will be the focus of this section. 
The prolonged course of MS necessitates significant longitudinal follow-up to 
describe its natural history accurately. The most prominent and usually 
heralding event in MS is the relapse – an episode of neurological dysfunction 
which generally resolves to some extent. A relapse typically has a clear clinico-
anatomical correlate, with the symptom predictably related to the area of focal 
CNS dysfunction, often reflected by MRI changes in the relevant region of the 
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brain or spinal cord. Yet, as outlined below, the symptoms occurring in a relapse 
are usually transient. Hence, these are not the main cause of disability in the 
longer term (although they may contribute to this). The progressive disability in 
the absence of relapses is the main contributor to loss of function for patients 
and has the greatest societal impact. This is not particularly associated with 
focal CNS dysfunction demonstrable on imaging but, rather, a diffuse, poorly-
understood mechanism causing gradual loss of function over time, appearing 
neurodegenerative rather than the waxing and waning inflammatory nature of 
relapses. It is these two processes which define the course of multiple sclerosis 
in the individual and therefore is the focus of the natural history studies outlined 
here. The relationship between relapses and progressive disability remains 
contentious but is often the overriding clinical basis for DMT use in MS, 
predicated on the assumption that short-term proven reductions in relapse 
frequency and associated imaging correlates will translate into a reduction in 
long-term disability: there is evidence from follow-up studies of DMT-treated 
patients that this assumption holds true, as discussed later. 
There are a number of highly-referenced longitudinal cohort studies from the 
modern era which are taken to describe the natural history of MS12–19. A selection 
of these are outlined for comparison in Table 0-1, adapted from Tremlett et 
al20. The variability of findings from these, particularly with regard to the timing 
of reaching disability milestones, likely reflects differences in methodology and 
diagnostic definitions over time. It may be that the findings represent a true 
divergence of MS natural history within global regions, however. The effect of 
treatments used in each cohort is purported to have no significant impact on the 
results of analyses of each individual cohort, but the apparent increasing 
duration in time to fixed disability (i.e. EDSS 6) in the newer studies (with more 
treated patients) is notable. However, there also appears to be an increasing 
duration of time to reach EDSS 6 in the PPMS cohorts in the newer studies, in the 
absence of any proven DMT benefits, suggesting the disease has become less 
disabling with time or, perhaps, reflecting the milder cases incorporated with 
the use of subsequent diagnostic guidelines. Similarly, there appears an 
increasing predominance of female patients in the more recent studies, which 
may impact upon outcomes, with males generally having a poorer prognosis. 
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The London Ontario cohort could be considered the ‘purest’ natural history study 
given the lack of any DMT use. That said, the broad-spectrum 
immunosuppressant treatments used in the Lyon cohort, for example, are largely 
no longer used because of lack of efficacy in comparison to the MS-specific DMTs 
now widely used. The assumption would therefore be that they do not alter the 
course of the disease in a meaningful way. The findings presented here are 
largely drawn from the London Ontario21, British Columbia15 and Rennes17 
cohorts given the pivotal nature of their reported findings. Across studies, there 
are notable differences in outcomes between patients seen prospectively from 
onset and those whose analyses include retrospective data. In the ‘seen at 
onset’ subgroup of the Ontario cohort, 84.7% were initially diagnosed with 
relapsing-remitting MS in comparison to 65.8% of the total cohort which included 
retrospective data. Similarly, just 28.6% of the prospectively followed subgroup 
had converted to SPMS by years 11-15 from onset in comparison to 57.6% of the 
total cohort. Some of this may reflect the smaller number of patients and 
shorter follow-up times for this sub-group but may also suggest more historical 
accuracy in prospective assessments, expected to be more indicative of the true 
situation.
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Table 0-1: Natural history cohorts summary 
Cohort 
Location 
London, 
Ontario, 
Canada21 
Lyon, France13 Olmstead 
County, 
Minnesota, 
USA14 
British 
Columbia, 
Canada15 
Nova Scotia, 
Canada16 
Rennes, 
France17 
Lorraine, 
France18,19 
Setting Population- 
and Clinic-
based from 
single 
outpatient 
MS specialist 
clinic 
Clinic-based from 
single outpatient 
MS specialist 
clinic (said to be 
‘representative 
of the general 
population’) 
Population-
based from 
patients seen 
at Mayo clinic 
or Olmstead 
Community 
Hospital 
Population-
based from 4 
outpatient MS 
specialist 
clinics serving 
the entire 
province  
Clinic-based 
from Nova 
Scotia’s only 
specialist MS 
centre 
Clinic-based 
from regional 
MS centre in 
West France 
Population-based 
from a single 
region but multiple 
centres 
Years 
included 
1972-1984 1976-1997 1991-2000 1980-2003 1979-2004 1976-2004 1996-2003 
Diagnostic 
criteria 
Probable or 
possible MS, 
Poser 
criteria22 
Definite or 
probable MS, 
Poser criteria22 
Definite MS, Poser criteria22 Definite MS, 
Poser22 or 
McDonald23 
criteria 
Definite MS, 
Poser criteria22 
Definite or 
probable MS, Poser 
criteria22 
Data 
collection 
Retrospective 
and 
prospective 
Retrospective 
from onset to 
first clinic visit, 
prospective 
thereafter 
Retrospective Retrospective from onset to first clinic visit, 
prospective thereafter 
Retrospective and 
prospective 
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Follow-up 
duration 
11.9 yrs from 
onset 
9.8 yrs from 
1st clinic visit 
(PPMS cohort 
only) 
11 yrs from onset 19.3 yrs from 
onset 
20.1 yrs from 
onset 
8 yrs from 
first clinic 
visit 
Not provided 12.8 yrs from 
onset 
13.7 yrs from onset 
N 
% RRMS 
% PPMS 
% Female 
1099 
66 
33* 
66 
1844 
85 
15 
64 
201 
94.5 
5.5 
70 
2837 
88 
12 
70 
1607 
83 
17 
74 
2054 
78 
22 
70 
2871 
87 
13 
72 
Mean age at 
onset (years) 
30.5 31 31.2 30.6 Not provided 31.4 33 
DMT 
treatments**  
 
Nil other 
than steroids 
for relapse 
49% treated 
(AZA>Cyclophos 
>IFN>MTX>Mitox) 
25% treated 
(IFN/GA) 
15.5% treated 
(IFN/GA) 
Not stated  
(By 2014, 
2240 patients 
were included 
with 57% 
treated with 
a DMT at any 
time since 
199816) 
56% treated for 
at least 6 
months (IFN 
>Mitoxantrone> 
AZA>MTX> 
Cyclophos>GA)  
Not stated 
(23% of PPMS 
cohort treated, 
mainly with 
cyclophosphamide8) 
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Disability 
measurement 
DSS 3, 6 and 
8 collected 
retro- and 
prospectively 
EDMUS scale 
collected retro- 
and prospectively 
EDSS via exam 
or phone 
interview 
(E)DSS 
recorded by 
neurologist at 
each clinic 
visit (>95% 
prospective) 
 EDSS recorded by neurologist at each 
clinic visit 
Definition of 
reaching 
EDSS 6 
Not specified All subsequent 
scores ≥6 
Sustained at 6 
months 
Sustained at 6 months and all subsequent EDSS 
≥6.0 
Sustained at 6 
months 
Median time (years) to SPMS from onset of RRMS 
 - 19 - 19 - 16 20 
Median time (years) to EDSS 6 from onset of MS [approx.] 
RRMS 
PPMS 
15 
4.5 
23 
6 
- 
5 
30 
13 
35 
21 
21.7 
10 
24.5 
10 
*Data unavailable for 0.9% of cases 
** Azathioprine (AZA), Cyclophosphamide (Cyclophos), Interferons (IFN), Methotrexate (MTX), Mitoxantrone (Mitox), Glatiramer Acetate 
(GA), Disease Modifying Therapy (DMT)
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Disease characteristics and predictors of outcome 
In the Ontario cohort, detailed analysis of symptomatic onset was undertaken. 
There appeared an over-representation of younger patients (<20yrs) presenting 
with optic neuritis (22.9%) in comparison to older patients (>49yrs), in whom 
only 6.3% presented in this way; conversely, a higher proportion of older 
patients presented with insidious motor weakness (46.8%) in comparison to their 
younger counterparts (3.8%). Sensory symptoms at onset were more common in 
patients with younger onset but the differences were less striking (46.5% vs 
31.9%) and age had even less relevance to ataxic presentations, occurring in 
13.7%of those less than 20yrs old at the time of onset  and 10.6% in those 
presenting beyond 49 years of age21.  
Factors associated with a more severe disease course were investigated in the 
Ontario cohort12,24. With regard to the early disease course, increased frequency 
of relapses within the first 2 years, a reduced interval between the 1st and 2nd 
relapse and a faster rate at which Disability Status Scale (DSS) 3 is reached were 
all found predictive of a more severe disease course over time and associated 
with an earlier need for walking aids (DSS 6). The Disability Status Scale (DSS) is 
a non-linear grading system initially proposed in the 1950s, ranging from 0 (no 
symptoms and normal neurological examination) to 10 (death due to MS); it 
largely relies on motor dysfunction to determine disability and predominantly 
lower limb, with DSS 6 reflecting the need to walk with a stick, for example, and 
was expanded in 1983 to include half-steps in the scale also (EDSS)25,26. In the 
untreated Ontario cohort, 66% had reached DSS 3 at 7 years after onset; in the 
cohort seen from onset, 62% had reached DSS 3 by 2 years. The frequency of 
relapses was higher in the first 2 years after disease onset in those who 
subsequently developed SPMS (within the follow-up period) in comparison to 
those who remained with a relapsing-remitting phenotype (mean 2.08 relapses 
vs. 1.8 in first year after onset in those who developed SPMS and those who did 
not, respectively; the values were 1.08 and 0.55 relapses per year in year 2)12. In 
addition, the following factors were statistically associated with a poorer 
outcome i.e. whether they significantly influenced the time to requiring a 
walking aid by the end of follow-up24: 
• Older age at onset (p<0.001) 
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• Male sex (p=0.004) 
• Ataxia at onset (p<0.001) [controlled for age at onset and gender] 
• Insidious motor involvement at onset (p=0.01) [controlled for age at onset 
and gender] 
• Cerebral, Cerebellar or brainstem involvement at last visit (all p<0.001) 
[controlled for age at onset, ataxia at onset and relapsing-remitting 
course] 
• Higher relapse frequency in first 2 years (p<0.001) [controlled for age at 
onset, relapsing-remitting course, cerebellar and cerebral involvement at 
last visit] 
• Shorter first inter-attack interval (p<0.001) [controlled for age at onset, 
relapsing-remitting course, cerebellar and cerebral involvement at last 
visit] 
• Higher DSS at 2 and/or 5 years (p<0.001) [controlled for age at onset, 
relapsing-remitting course, cerebellar and cerebral involvement at last 
visit] 
Optic neuritis at onset was associated with a better outcome i.e. less likely to 
require a walking aid during the follow-up period (p=0.03) and was controlled for 
age and gender. 
Disease course phenotypes 
A progressive decline in function, largely in the absence of relapses, can occur 
either from onset [Primary Progressive Multiple Sclerosis (PPMS)] or after a 
variable period of relapses and remissions [Secondary Progressive Multiple 
Sclerosis (SPMS)]. The proportion of patients presenting with PPMS appears to 
vary widely amongst cohorts, ranging from 9% in a French cohort in the 1960s27 
up to 37% in a Dutch cohort from the 1980s28. Table 0-1 reflects this variability 
even in modern studies, however. Patients with PPMS tend to present with 
motor, rather than sensory or cerebellar deficits29. Additionally, again from the 
Ontario group, patients with PPMS developed disability quicker and died sooner 
than those who develop SPMS – notably, PPMS tends to present at an older age 
and more commonly in men, however. Axonal reserve is lower with age, 
potentially explaining the more rapid disability and both male sex and increased 
age are associated with increased risk of death in general, hence the 
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contribution of MS to these outcomes is not entirely clear, from this analysis at 
least. Relapses occurred in 27.8% of the Ontario group PPMS cohort: often mild 
and usually remitting, there was no significant difference in disability 
progression between those patients with early relapses and those without, thus 
the terms ‘relapsing-progressive’ and ‘progressive-relapsing’ are equivalent and 
were subsequently both included under the umbrella of PPMS30. Relapses can 
occur at any time in PPMS but tend to be within the first 10 years, as was the 
case for half of the Ontario PPMS cohort. That said, 10% had relapses after 20 
years, up to a maximum of 39 years post-onset. The frequency and distribution 
of relapses was consistent however: most had a single event and were largely 
extra-spinal.  
The conversion from RRMS to SPMS had occurred in approximately 80% of 
patients within 20 years from onset in the Ontario group but there remains 
uncertainty regarding the impact of relapses on the development of progression, 
albeit the progressive phase appears very uniform once it occurs31,32. Among 
patients with PPMS, SPMS and Single-Attack Progressive (SAP) MS [where a 
progressive course develops after a Clinically Isolated Syndrome (CIS)], there 
was no difference in time to disability milestones (DSS 6, 8 and 10). The authors 
conclude that the progressive course is independent of the relapses which occur 
before (or after) the onset of insidious disability progression. Notably, in SAP MS, 
the site of the CIS was not usually where progression began and the degree of 
recovery from the initial event was not related to longer-term outcomes. That 
is, 65% recovered from the initial event with no residual disability while 7% had 
fixed disability as a result, yet the subsequent rate of progression was the same 
for both groups31. Age may be important here, again, in understanding the 
impact on patients. Those with progression from the outset (PPMS) tend to 
become symptomatic at an older age (mean 38.5 years) than either SAP MS 
patients (33.3 years) or those who develop SPMS after a relapsing-remitting 
phase (29.8 years). Those with a single event preceding the progressive phase 
(SAP MS) had a mean latency of 7.6 years following the event before progression 
occurred; in contrast, the relapsing-remitting phase (mean 0.65 relapses/year32) 
took 10.3 years to develop progressive disease (SPMS).  
Once the progressive course begins, the rate of progression appears the same, 
irrespective of the preceding phenotype17,31. This was suggested from the 
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Ontario group and delineated clearly by Leray et al. using the Rennes MS 
databse17. Analyses from this cohort and that from British Columbia are widely 
cited in the understanding of the relationship between relapses and disability. A 
few notable differences exist between the Rennes and British Columbia cohorts, 
although their results appear entirely compatible. Notably, whilst the Rennes 
cohort had an average of 12.8 years follow-up, 35% had reached DSS 6 in 
comparison to 28% of the British Columbia cohort where follow-up was beyond 
20 years. This suggests a more severely affected cohort from Rennes, yet only 
38% developed SPMS after a median of 16 years from onset in comparison to 55% 
in the British Columbia studies33. LeRay et al. found that disability progression 
from DSS3 to DSS6 was independent of the factors from diagnosis to DSS3, 
whether the course was relapsing-remitting or not as shown in Figure 0-1. This 
shows that, once DSS3 was reached, the mean time to DSS6 was 6-9 years 
whether the initial course was progressive or relapsing in 718 patients with MS 
(divided into 5 subgroups based on time to DSS3). Notably, given the higher 
proportion of treated patients in the Rennes cohort, the results were unchanged 
when the untreated cohort was analysed. Similar to the Ontario group, male 
gender, older age at onset, residual deficit after the first relapse and the 
number of relapses in the first 2 years were associated with a shorter time to 
irreversible disability (DSS 3) in the relapsing-remitting cohort.  
Figure 0-1: Two-stage progression in MS (from LeRay et al.17) 
 
 
It is notable that the median age of onset of the progressive phase was similar in 
primary and secondary progressive cases – the authors suggest that MS may 
therefore be a chronic, neurodegenerative, age-related disease, unaffected by 
the initial course17. Whilst patients with PPMS progress at a faster rate, the age 
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at which they reach disability milestones is comparable to those with an initially 
relapsing course. 
 
Relapses and progression 
There remains controversy regarding the relationship between relapses and 
longer-term disability progression. Kremenchutsky et al.31 state that the great 
majority of MS relapses are associated with full or partial recovery in their 
natural history study, whilst Lublin et al.34 cite significant increases in disability 
measures caused by relapses as evidence of a substantial impact. The study by 
Lublin et al. is smaller (n=224) and analyses participants from placebo arms of 
clinical trials in the 1980s-90s. The participants were, on average, older than the 
natural history cohort (mean 35.2 years) and included both relapsing and 
progressive phenotypes but had a longer (retrospective) follow-up (mean disease 
duration <15 years). Assessing EDSS before and after a relapse, Lublin et al. 
found that 42.4% of participants in the placebo arms of clinical trials had an 
increase of ≥0.5 EDSS points, with 28.1% increasing by more than 1 EDSS point. 
Conversely, however, this means that the majority had no change (38.4%) or 
improvement (19%) in EDSS following relapse. In addition, the post-relapse EDSS 
was calculated an average of 2 months, and a maximum of 4 months, following 
the relapse. This is concluded as irreversible disability for those who had an 
increased EDSS score, yet it has since been shown that such short-term 
evaluations are unreliable35. Indeed, even prior to the Lublin study, it had been 
demonstrated that half of those patients who experienced 3- or 6-month 
disability ‘progression’ had reverted to a non-progressed state by the end of a 2-
year clinical trial36. Kalincik et al. take this further by analysing data from 16636 
patients from the global MS Base database who had reliable examination follow-
up over an average of almost 6 years35. ‘Reversal’ of EDSS increases was common 
and dependent on the time to confirmation, with the longest duration being the 
most reliable i.e. likely to persist after 5 years. Almost a third of patients with 
increased EDSS scores, following relapse, ‘confirmed’ at 3 months had reverted 
to their baseline by 5 years; for those confirmed at 2 years, only 11% reverted. 
This, therefore, calls into question the reliability of the Lublin et al. conclusions 
regarding the impact of relapses. Similarly, residual deficits or changes in deficit 
are measured and reported in EDSS units less than 0.5 e.g. 36.5% of patients had 
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a mean residual deficit of 0.24 EDSS points, with an average worsening of 0.24-
0.57 EDSS points per relapse. The EDSS scale is non-linear and categorical, 
resulting in an uncertain interpretation of these values which have no clinical 
correlate. 
As well as the (lack of) effect of relapses on progressive MS disease courses, the 
Ontario group and others have also analysed their relationship with disability in 
patients with a relapsing-remitting course. Certainly, relapse frequency within 
the first 2 years appears to correlate with disability milestones. Those who had 1 
relapse in the first 2 years reached DSS 6, 8 and 10 at 7.6, 12.8 and 20.3 years 
later, respectively, in comparison to those who had more than 3 relapses in the 
first 2 years after onset32. Similarly, relapses within the first 2 years were 
associated with an increased risk of developing SPMS (HR 1.1, p=0.003), with 
relapses in year 2 more predictive than those occurring in the first year following 
disease onset. However, the frequency of relapses after year 2 had no predictive 
value with regard to disability milestones or the time to secondary progression 
(SPMS). Relapse frequency diminishes over time, tending to be highest during 
years 1-2. Perhaps, then, it is the rate of relapses, rather than the total number, 
which is of most relevance. Additionally, the neuroanatomical location of the 
initial relapse is relevant, with brainstem events associated with a shorter time 
to DSS 6 and 8.  
As anticipated, there is a directly proportional relationship between the number 
of relapses in years 1-2 and time to onset of SPMS. Similarly, the longer the 
duration between the first and second relapses, the longer the time until SPMS 
develops. Most interestingly, however, relapses occurring from year 3 until the 
onset of SPMS had an inverse relationship with the time to onset of SPMS. Those 
having no relapses between year 3 and the onset of SPMS developed SPMS at a 
mean of 8.2 years from disease onset whilst this occurred after a mean of 13.6 
years in those have ≥3 relapses after year 3 (p<0.001)32.That is, relapses after 
year 3 appear protective against the onset of SPMS, as shown in Figure 0-2. The 
Hazard Ratio of developing SPMS in those having 5 relapses after year 3 (0.45) 
was nearly half that of those having a single relapse in the same period (0.85). 
Similarly, the risk of reaching DSS 6 reduced with an increased number of 
relapses between year 3 and the onset of SPMS. LeRay et al. found differently, 
however: among patients still relapsing despite reaching DSS 3 (i.e. not 
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developed SPMS), the time from DSS 3 to DSS 6 was longer (12 years) in those 
without relapses after DSS 3 than those who had relapses (9 years) but the 
difference was not statistically significant (p=0.677)17. However, whether 
relapses occurred or not in those with RRMS after reaching DSS 3, the time to 
DSS 6 was significantly longer (9 years) than those with established SPMS who 
had reached DSS 3 (6 years) suggesting that conversion to SPMS was a more 
important influence on disability progression than the occurrence of relapses. 
 
Figure 0-2: Relapses and risk of disability over time (From Scalfari et al.32) 
 
*in comparison to 0 relapses 
 
This apparent dissociation between relapses and disability progression has been 
replicated in other studies, most eloquently in the British Columbia natural 
history cohort33,37. Firstly demonstrating that relapse rates naturally decline with 
time and that older patients have fewer relapses37, Tremlett et al. also 
subsequently showed that relapses in the first 5 years have significantly greater 
impact on the risk of reaching EDSS 6 and the time to SPMS in comparison to 
relapses which occur >10 years after onset33. Both studies included a cohort of 
2477 after exclusions, with between 16.837 – 18%33 having been treated with a 
DMT. Notably, DMTs were initiated a mean of 17.8 years after onset of MS (range 
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2-49 years) and the proportion of time on treatment was small (<3% of follow-up) 
and analyses excluding these patients did not alter the results. Figure 0-3 
demonstrates the effect of time and duration of disease on relapse rates.  
 
Figure 0-3: Relapse rates A) with disease duration B) with age (from Tremlett et 
al.37) 
 
Figure 0-3 demonstrates the decline in relapse frequency both with increasing 
duration from disease onset and the age of the patient at the time. This includes 
20.6 years of follow-up and >11500 relapse events. The mean time from onset to 
first clinic visit was 12.1 years and the concern over retrospective labelling of 
relapses is raised by the authors, meaning potential underestimation of relapse 
frequency.  This bias is, arguably, consistent throughout all epochs studied 
hence should be balanced across the cohort however. Additionally, analysis of 
the subgroup seen within 5 years from onset (n=626, 25%) showed similar results, 
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albeit with increased relapse frequency. Overall, the relapse rate reduced by 
17.5% every 5 years, increasing with increased patent age. Additionally, 77.3% of 
those with more than 5 years follow-up in the relapsing-remitting phase (n=2189) 
experienced a 5-year relapse-free period during the relapsing-remitting phase37. 
This is in the absence of any disease-modifying treatments for the vast majority.  
This natural decline in relapse rate and notable prolonged relapse-free periods 
must be considered when interpreting the impact of DMTs in both research and 
clinical practice, particularly where there is no defined control arm. That said, 
the patients who had prolonged relapse-free periods took more than double the 
time (23 years), on average, to develop SPMS in comparison to those without 
these periods (10.9 years to reach SPMS) [p<0.0005]. This is perhaps evidence 
toward relapses contributing to the progressive phase or simply that disease 
severity is variable within a population and those with fewer relapses have a 
milder form of the disease. Patients under 20 years of age had a small increase 
in relapse frequency over time, peaking between ages 20-30: the decline 
otherwise continued thereafter. The rate of decline in relapses differed 
depending on the age at onset of MS. For every 5-year epoch, relapse rates 
decline by 30.5% for those with onset beyond 40 years of age, 22.9% for those 
aged 30-40, 17% for 20-30 year-olds and 7% for those with onset before age 20.  
Along with the declining frequency of relapses with time, Tremlett et al. also 
found evidence that relapses occurring later in the disease course have a 
gradually diminishing contribution to the risk of disability or entering the 
progressive phase (SPMS). A relapse within 5 years of disease onset was 
associated with an increased hazard in early disease progression, within that 5 
years, of 48% (95% CIs 37-60) for requiring a walking aid (EDSS 6) and 29% (95% 
CIS 20-38) for developing SPMS in comparison to the situation where no relapse 
occurred in this time. In contrast, a relapse occurring after 10 years post-onset 
increased the risk by just 12% (8-17) and 8% (4-11) for these endpoints 
respectively in the long-term if they had not already been reached33 as shown in 
Table 0-2.  Disease onset refers to the first likely symptoms rather than the date 
of diagnosis, notably. 
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Table 0-2: Hazard of reaching endpoints if relapse occurred in time-frame in 
comparison to no relapse occurring  from disease onset (Adapted from Tremlett 
et al.33) 
 
Short-term Hazard 
(0-5yrs) of 
Medium Term 
Hazard 
(5-10yrs) of 
Long-term Hazard 
(>10yrs) of  
EDSS 6 SPMS EDSS 6 SPMS EDSS 6 SPMS 
Relapse at 0-5 
yrs 
1.48 
(1.37-
1.6) 
1.29 
(1.2-
1.38) 
1.25 
(1.17-
1.34) 
1.11 
(1.06-
1.17) 
1.10 
(1.04-
1.16) 
1.02 
(0.98-
1.07) 
Relapse at 5-10 
yrs   
1.31 
(1.22-
1.42) 
1.23 
(1.15-
1.31) 
1.07 
(1.01-
1.13) 
1.06 
(1.02-
1.11) 
Relapse after 
>10yrs     
1.12 
(1.08-
1.17) 
1.08 
(1.04-
1.11) 
 
In this analysis, if EDSS 6 was not reached within 5 years after onset, every 
relapse within the first 5 years was associated with a 25% (95% CIs 17-34) 
increased hazard of this occurring in the next 5 years. Similarly, the risk of 
developing SPMS was increased by 23% for every relapse during this time in 
comparison to the scenario where no relapse occurred in the first 5 years 
(p=0.05). The risks dropped to a 12% increase (95% CIs  8-17) for EDSS 6 and 8% 
(95% CIs 4-11) for SPMS if the relapse occurred after 10 years. There was no 
significant difference in the hazard of reaching EDSS 6 or SPMS in the long-term 
(>10 years post-onset) whether a relapse occurred earlier or later in the disease 
course. Increased frequency of relapses within the first 5 years was highly 
associated with an increased risk of reaching EDSS 6 and SPMS 10 and even 30 
years later, however, including after adjustment for gender, age at onset and 
symptoms (p<0.0005 for both EDSS 6 and SPMS using the log-rank test).  
The association of relapses with disability and SPMS development was age-
dependent, being greatest (i.e. higher association with disability endpoints) in 
patients aged less than 25 at disease onset and least in those older than 35. In 
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those over 35 years of age, there was no statistically significant increased risk of 
reaching EDSS 6 if a relapse occurred more than 5 years after disease onset or 
developing SPMS if it occurred 10 years after disease onset. Relapses occurring 
within the first 10 years of disease of those with onset at less than 25 years of 
age have a significantly greater impact on their risk of disability than in a 
patient whose disease started after 35 years of age. Relapses occurring during 
the secondary progressive phase had little or no impact on the future risk of 
reaching EDSS 6 if this had not already occurred by the time of SPMS onset. 
Overall, using a multivariate model, women were at a 30% (95%CIs 16-42) and 
31% (23-39) lower hazard of reaching EDSS 6 and SPMS respectively in comparison 
to men. There was a 17% (12-23) increased risk of reaching EDSS 6 and 25% (21-
28) for SPMS for every 5-year increase in age at disease onset.  
 
For all of these results, it is notable that a substantial proportion of the cohort 
had not reached the defined endpoint by study end, meaning they were 
censored from the analyses: over 70% had not reached EDSS 6 and almost 50% 
had not developed SPMS. Much of the findings are therefore based on a minority 
of patients who reached the proposed endpoints and therefore had a relatively 
severe disease course. The analyses also suffer from attrition of the at-risk 
cohort with time, such that, for some analyses e.g. endpoints beyond 20 years, 
the results are based on a cohort size of double figures only. Of course, the true 
impact of relapses on the life of a patient could only be assessed if the entire 
cohort were followed until all reached the pre-defined endpoints, but this is an 
impractical goal and these data provide the best longitudinal analyses available.  
 
In summary, these findings suggest that a relapse within the first 5 years from 
disease onset confers an increased risk of developing irreversible disability or 
SPMS in the short-term, but the risk of an early relapse has much less impact on 
long-term future risk. A higher frequency of relapses within the first 5 years is 
associated with a higher risk of disability in the long-term, however. For those 
with disease onset before age 25, the risk of irreversible disability and SPMS 
remains increased even from a relapse occurring 10 years after diagnosis but the 
magnitude of this risk declines with time. In contrast, those with disease onset 
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after 35 years of age have less increased risk of irreversible disability or SPMS 
from a relapse occurring after 5 years from disease onset and no statistically 
significantly increased risk for a relapse occurring after 10 years from onset. 
Relapses during the secondary progressive phase do not appear to have a 
discernible impact on disability in general, as measured by EDSS at least. These 
data would suggest that targeting relapse-reducing therapies at younger patients 
in the earliest stages of their disease is likely to have most impact, in the short-
term at least, whilst the benefits of aggressive treatment in older patients with 
long disease duration are much less certain and relapse-reduction in SPMS is 
unlikely to outweigh any risk of treatment, if maintenance of mobility or 
preventing increased EDSS are the goals. The impact of relapses, in terms of 
disability or risk of SPMS, being highest in the immediate aftermath of a relapse 
(within 5 years of the event) suggests that the British Columbia studies may be 
capturing relapse-related disability (albeit irreversible) rather than 
neurodegenerative progression where, as above, a causative relationship with 
relapse remains unproven. 
 
MS treatment and trial considerations 
In the early 19th century, multiple sclerosis was recognised as one of the 
‘paraplegias’, a sub-class of the known ‘nervous disorders’ at the time. 
Apoplexy, epilepsy, neurosyphilis, congenital idiocy and brain fever were the 
other classifications from which the paraplegias were differentiated by the 
occurrence of progressive weakness. Whilst Charcot is credited with the first 
recognition of MS, his attempts at treatment were unsuccessful38.  Meat diets, 
bleeding, cooling, strychnine, quinine, belladonna, arsenic, atropine, ergot and 
alkaloids were all cited as ineffective by William Moxom in 1875, who had first 
described MS in the UK. The evidence on which this conclusion was based, 
however, is unclear. In Germany, electrical and magnetic stimulation were used 
with, presumably, equally unsatisfying results given the subsequent departure 
from this. The first critical review of MS treatments was undertaken by Russell 
Brain in 1930, where he describes the understanding of the condition at the time 
and the past experience of treatments used39. As well as some of the treatments 
considered by Moxom previously, vaccines and other pyrogenic agents are 
included but similarly considered ineffective. An interesting conclusion of 
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Brain’s, which still has some relevance today perhaps, is that ‘the multiplication 
of remedies is eloquent of the inefficacy’. It is certainly the case that 
treatments today are more effective but there remains no panacea.  
Whilst antibiotics and antifungals were also trialled, ineffectively, after their 
widespread introduction in the 1940s, no major advances were made until the 
introduction of randomised control trials in the 1960s. The first RCT in MS 
assessed the utility of aspirin and steroids in a 3-armed placebo-controlled 
study40. In fact, this found no difference in outcomes between the three arms, 
but was primarily testing the hypothesis that MS was an allergic, inflammatory 
condition. Brown et al. published detailed and thoughtful guidelines on the 
design and conduct of clinical trials in MS in response to the perceived 
inadequacy of previous research41. This international panel recognised the 
difficulties in MS clinical research highlighted previously by Schumacher42 and, 
indeed, some of these remain today. The lack of diagnostic precision, 
unpredictable course and difficulties in quantifying disease severity and 
maintaining large groups of patients on standard treatments for extended 
periods were relevant both then and now. Specifically, the inability to prove the 
diagnosis in life was raised by Brown et al., who were concerned that poorly 
designed studies were wasteful and lead to false hopes for patients and 
clinicians. Importantly, they considered the ultimate goal of MS treatment to be 
the prevention of its first clinical manifestation or the complete prevention of 
even the subclinical form. With a pragmatic approach, however, they recognised 
the lack of understanding of the aetiology of MS and hence considered treatment 
and prevention of relapses and progression as more achievable goals. This has 
really set the tone for future research, particularly the pivotal DMT trials. 
Randomisation, blinding, sample size, inclusion and exclusion criteria, follow-up 
of dropouts, statistical analyses, funding and collaboration are all discussed as 
issues to be considered in the planning of MS trials in this detailed appraisal. 
Interestingly, the paper also suggests the need for publication of all data related 
to a trial (as a supplement); this anticipates the very recent advocates of full 
disclosure but, as yet, is not widespread.  
Despite the detailed guidance from Brown et al in the 1970s, modern clinical 
trials of MS treatments have been criticised on a number of fronts, both in their 
design and analyses43,44. The natural inter- and intra-patient variability in the 
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course of MS results in a higher risk of analysis errors. The falling rates of 
relapses in modern cohorts in both treatment and placebo arms, for a variety of 
reasons as described below, necessitates larger cohort sizes to demonstrate 
statistically and clinically significant differences. This requires recruitment from 
multiple specialist centres, often internationally, and hence added complexity in 
the design and conduct of the trial as well as increased heterogeneity in both 
the study participants and healthcare teams. The sample size must be even 
larger when the comparator is a known effective treatment, rather than 
placebo, in order to demonstrate differences against a new treatment under 
study. Whether the trial is placebo-controlled or against an active comparator 
will also affect the population included: those with milder disease are more 
likely to consider a placebo-controlled trial whereas those with active disease, 
and their physicians, will be keen to ensure they are definitely receiving a 
treatment. Similarly, in modern trials, the availability of effective treatments 
results in a larger proportion of non-responders recruited to trials with active 
comparators only when they have already failed on a licensed therapy. This may 
bias the cohort towards poorer outcomes. Additionally, the cost of such huge 
studies cannot be borne by governments or academic institutions, resulting in a 
frontline role for the pharmaceutical industry. The commercial trial industry is 
now the main vehicle for large-scale international research trials but leaves any 
analyses and conclusions open to criticism given the inherent bias when industry 
has any role other than purely funding.  
A number of potential errors in the design and analysis of clinical trials in MS 
have been highlighted and these must be borne in mind when appraising the 
evidence of DMTs currently in use or purported for future use. Strictly speaking, 
trials provide no evidence for the effectiveness of treatments in individuals who 
have characteristics other than those included in the study45 but, in practice, 
the results are generally extrapolated to the general MS population. This is, 
arguably, invalid but even the purported effect sizes in the target population 
will not necessarily be reflected in a real-world population: Montalban 
differentiates this as the difference between efficacy and effectiveness44. 
Efficacy is the effect demonstrated in a clinical trial, whilst effectiveness 
corresponds to the treatment effect in everyday practice. Of course, in everyday 
practice, the population, intervention, monitoring and quality of care are not 
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standardised in the same way as a research study. Misdiagnosis, prescription 
errors, concordance and failure of follow-up are just some of the issues which 
can arise to jeopardise the replication of trial results in the real world. To some 
extent, this is addressed by intention to treat analyses, rather than per protocol, 
but even this does not account for the daily shortcomings of clinical practice and 
less motivated patients in real life. Whilst a (theoretical) treatment may be 
efficacious in the vast majority of the trial population who adhere to the 
regime, even small increases in the proportion with misdiagnosis, prescription 
errors, concordance issues and inadequate follow-up will have an additive effect 
that soon reduces the effectiveness of the treatment to well below that found in 
the trial. In addition, the patient populations may differ in international trials, 
particularly where treatment is only available to those who participate in the 
trial or have to pay for it otherwise. 
The statistical analyses and interpretation of results from clinical trials has 
become increasingly complex and more challenging for the non-statistician 
clinician to translate into meaningful conclusions for both themselves and their 
patients. The p-value is a case in point. The statistical significance of a result 
relates to its believability – it is the effect size which relates to its clinical 
importance. Trials with large effects of marginal significance or significant 
effects of marginal importance should both be judged as providing equivocal 
evidence43. The utility of the p-value is in setting a pre-experiment significance 
value rather than the significance of a result once the data has been collected. 
The p-value has gained increasing importance in published results but its origins 
were not clearly intent on this use. A p-value <0.05 has been widely agreed as an 
acceptable level of certainty of excluding chance findings in medical research 
and can be interpreted as meaning there is a less than 0.05 probability (5% or 1 
in 20) that the value found (or a value more extreme) occurred by chance. 
Crucially, a p value of 0.05 does not, however, imply that there is a 95% chance 
that the effect is real.  
Over time, it seems the p-value and the alpha error rate (Type 1 error) have 
become considered interchangeable but they have different origins and are 
conceptually different. The alpha (Type 1) error rate is the probability of 
incorrectly rejecting the null hypothesis i.e. concluding there is a difference 
between two groups when, in fact, there is not. An observation with a p-value 
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equal to 0.05 actually has an alpha error of 13% in a one-sided hypothesis test 
and 21% in a two-sided test. The p-value represents an area under a curve whilst 
an observed value occurs at a single point and, hence, Goodin advises that a p-
value of <0.01 for an observed value is actually required to ensure the alpha 
error rate is less than the conventional 5% and p-values between 0.01 and 0.05 
should be considered marginally significant45. The alpha error rate and its beta 
counterpart (the probability of incorrectly accepting the null hypothesis i.e. 
concluding there is no difference when there actually is) were devised as part of 
the Neyman-Pearson hypothesis test in 192846. The alpha and beta rates were 
created to define ‘critical regions’ in the distribution of any summary statistic 
(e.g. mean value), within which any value was prone to either of these errors. 
Indeed, if a value fell into these critical regions then the null hypothesis was to 
be rejected and the alternative hypothesis accepted; equally, values outwith the 
critical regions suggested the null hypothesis was correct and that the 
alternative hypothesis should be rejected. On completion of the experiment, 
(Fisher’s) p-value was used to report whether the result fell within the critical 
region or not; it was not intended to show where in the critical region it fell, 
however. Neyman stated that there is no objective difference in a p-value of 
0.04 in comparison to a p-value of 0.00001 as both are significant at alpha equal 
to 0.05. Indeed, the ‘equal to’ is contentious also. A p-value can be reported 
precisely (p=x) or imprecisely (p<x). The imprecise value conveys meaning to the 
value and anything more extreme, whilst the precise value only represents the 
border of the tail on a distribution curve – it does not imply anything about more 
extreme values. Using the precise value overestimates the case against the null 
hypothesis (i.e. suggests there is a difference between the groups). Goodman 
exemplifies this with clinical results where p is given as < 0.05 having a less than 
3% chance of the null hypothesis being true, as opposed to 25% where a p value 
is given as equal to 0.05. Again, this difference diminishes when p values ≤0.001 
are used but values between 0.001 and 0.05 may lead to overestimation of the 
plausibility of results46. The beta error rate relates to sample size and power and 
can be considered in trial design, with planned recruitment and stated effect 
sizes considered relevant, but cannot be adjusted for after the collection of data 
other than stating the study may have been underpowered. 
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There are other statistical pitfalls to be wary of which are relevant to all 
medical research but particularly so to MS studies and have occurred in 
published literature. Post-hoc analysis is fraught with statistical pitfalls and, in 
general, should be interpreted with extreme caution. This is where analyses are 
considered only after the data has been collected and is prone to ‘fishing’ for 
positive results or correlations, particularly if the primary endpoint was not met. 
If an analysis has not been planned a priori then the cohort and data are unlikely 
to have been collected in a valid way to answer the question which arises later. 
Subgroup post-hoc analysis can detect statistically significant differences in 
groups separated on entirely arbitrary grounds43. Additionally, when more than 
one hypothesis test is undertaken on the same dataset e.g. multiple comparisons 
to evaluate for significant differences, this must be considered in the resultant 
p-value. If multiple comparisons are made, the chance of rare events occurring 
increases and hence so does the risk of making a Type 1 error i.e. incorrectly 
rejecting the null hypothesis. The Bonferroni adjustment can account for this to 
some extent and requires that the desired alpha rate is divided by the number of 
tests conducted. Thus, if 0.05 is taken as the acceptable significance level (for a 
single result being tested for significance), this must be reduced if more than 
one hypothesis is being tested in the same data. If five hypotheses are being 
tested, for example, only an alpha rate of (0.05/5) 0.01 should be considered 
statistically significant.  
Regression to the mean is another statistical pitfall to which MS studies are 
potentially prone. Particularly in earlier studies, cohorts were specifically 
selected for their high disease activity relative to the general MS population. 
This aimed to ensure adequate disease activity would occur over the trial period 
in order to attain pre-set endpoints: an active group will have more activity and 
hence require shorter follow-up to demonstrate differences between groups. 
Indeed, this holds true for placebo-controlled trials but is invalid in any study 
without a control group. By definition, the individuals selected for these studies 
are unusual in their phenotype but, as a universal truth, they will tend to 
become more ‘usual’ over time i.e. ’regress to the mean’. This must be 
considered in any single-arm or crossover study as, without any intervention, 
those with initially high disease activity will tend to have less over time. 
Similarly, this means one cannot compare intra-group changes between two 
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groups. It is not valid to compare the change within a group with that of another 
group undergoing a different intervention – only the difference between the 
groups can be considered relevant. Goodin cites the European North American 
Comparative Efficacy (EVIDENCE) trial to demonstrate this error43,47. Participants 
in this study, comparing Avonex® with Rebif®, were offered open-label Rebif® 
at the end of the trial after it was demonstrated this was the more effective of 
the two. Relapse rates in the last 6 months of the trial were compared with 
those in the open-label phase and demonstrated a significant (p<0.001) 
reduction in relapses in those who switched from Avonex® to Rebif® but a 
smaller reduction in those remaining on Rebif® continuously (p=0.03). However,  
the comparison was between the reduction in relapse rate in each group, rather 
than comparing the reduction between groups and, in fact, there was only a 
minimal difference between the groups when analysed in this way (p=0.05). Only 
this difference is a valid comparison and the previously stated p-values are 
irrelevant and misleading. 
Studies where inclusion is dependent on the occurrence of an intervention at a 
time after recruitment, in comparison to no intervention, are at risk of immortal 
time bias (also known as survivor treatment selection bias). In this error, the 
participants in the intervention arm will, by definition, have the intervention 
whilst participants in the non-intervention arm have no requirement for this. 
Therefore, any event occurring between recruitment and the intervention which 
prevents those in the intervention arm from having it (e.g. death) will bias the 
study toward a milder intervention group - death would not exclude those in the 
non-intervention group from the analysis. Participants in the intervention group 
who die between recruitment and the intervention will not be included in the 
analysis if the occurrence of the intervention is necessary for inclusion. The 
intervention group, when considered in this way, are therefore ‘immortal’ for 
the period between recruitment and the intervention, whilst those dying in the 
non-intervention group will be included in the analysis and hence provide the 
appearance of a more severely affected cohort. This holds true for any event of 
interest being recorded between recruitment and the intervention, if the event 
may influence the likelihood of a participant receiving the intervention. This 
error can be eliminated by setting the time of intervention as the beginning of 
the study or by using time-dependent covariates in any survival analysis48. 
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The lack of multi-arm comparator studies of DMTs in MS necessitates 
extrapolation of the comparative efficacy of each treatment, but this is fraught 
with potential problems. Ideally, all available DMTs (or a group of them) would 
be subject to a multi-arm randomised trial in order to demonstrate their 
comparative safety and efficacy. The different methods of administration would 
make blinding almost impossible, however, as exemplified by the CARE-MS trials 
comparing Alemtuzumab, an annual intravenous infusion, with Rebif, a thrice-
weekly subcutaneous injection49. Similarly, the differing risk profiles would make 
recruitment challenging given the potential of randomisation to treatments with 
significantly more safety issues or perceived reduced efficacy. Sample sizes 
would have to be well in excess of the usual two-arm trials, which are already 
necessarily large and complex, particularly with the falling levels of disease 
activity seen in recent trials44. In addition, this would require significant 
financial backing and the agreement of all manufacturers of the drugs included, 
in the knowledge that their product is at risk of obsolescence if definitively 
proven less safe and/or effective relative to the other options included. It seems 
unlikely that such a study will be undertaken given these design and practical 
barriers. Much debate is undertaken, therefore, on how best to decide which is 
the safest and most effective treatment for the patient in clinic. Of course, even 
such a multi-arm theoretical trial would not answer this for an individual patient 
given the reliance on group effects to demonstrate safety and efficacy and the 
lack of individualisation of responses. The role of individualisation of prognosis 
and treatment is a new frontier in medicine and studies in MS are already trying 
to address this. 
 Whether inter-study comparisons of DMT trials in MS are valid, or at least 
reasonable, remains a matter of debate50,51. Some suggest that the relatively 
standardised inclusion criteria and measures of disability and disease means 
patients included in many modern MS treatment trials can be compared50. 
Similarly, a fairly narrow range of outcome measures have been used in the 
pivotal DMT trials (e.g. EDSS, ARR, MRI) and, hence could be considered 
comparable also. Post-hoc approaches to allow comparative analysis of 
independent DMT trials i.e. network meta-analysis have also been used and are 
considered a valid tool for this purpose50,52,53. From a practical point of view, the 
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costs of the studies and development of new therapeutics is unlikely to be borne 
by anyone other than multinational pharmaceutical industries and the risk of 
their disengagement from this, in the event of a move toward multi-arm head-
to-head trials, could jeopardise future research endeavours. Finally, it is 
recognised that trial populations do not represent fully the target treatment 
population in the ‘real world’ and, hence, large post-licensing registries with 
appropriate follow-up data and pharmacovigilance would provide much of the 
evidence required to compare DMTs in terms of efficacy and safety. Indeed, if 
these data were included as part of a multi-centre (or multi-national) 
prospective observational study the results would be potentially comparable to 
that of a randomised trial54.  
Others believe efficacy comparisons using independent DMT trials are not valid51. 
Arguably, the change in the natural history of the condition, with the broadening 
inclusion of milder phenotypes, precludes rational comparisons between trial 
cohorts in the early 1990s with those today for example. Similarly, as well as the 
definition of the disease changing, the definition of disease activity is variable 
between independent trials. Newer trials have more emphasis on imaging (and 
with more powerful scanners with more available sequences) than in the past; 
relapses are defined differently in each trial, with the most recent being more 
stringently-defined in general. Stricter definitions of what constitutes a relapse 
e.g. whether an examination or EDSS change is required, will lead to fewer 
recorded relapses than in studies without this. Additionally, the frequency of 
study visits is proportional to the number of relapses documented, given the 
closer monitoring and questioning of participants. Measurements of disease 
progression are inadequate and can be misleading over short periods, yet 3- or 6-
month disability (EDSS) worsening is the mainstay to define this in large DMT 
trials, despite there being a known reversibility of ‘progression’ when defined in 
this way35. When MRI outcomes are considered, there is wide potential 
variability in their acquisition, analysis and interpretation depending on the 
methods used between studies, making direct comparisons often invalid. This is 
particularly the case for MRI measurements of atrophy. 
Indeed, combined outcome measures are now suggested in order to capture all 
known disease activity. The concept of ‘No Evidence of Disease Activity’ (NEDA) 
assumes we know and can measure all MS-related sequelae but generally 
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describes no evidence of relapses, progression or MRI changes (NEDA-3); this can 
be extended to include MRI-estimated brain atrophy (NEDA-4) and neurofilament 
levels (NEDA-5) and could likely be extended further to include cognition and the 
myriad of other factors considered relevant. Similarly, No Evidence of 
Progression or Active Disease (NEPAD) extends to include upper limb function 
(9HPT) and Progression Independent of Relapse Activity (PIRA) aims to identify 
non-inflammatory disease worsening thereby potentially identifying the true 
neurodegenerative aspect. 
However, in lieu of either a multi-arm randomised trial of DMTs or a well-
established observational registry with long-term follow-up and sample sizes to 
make conclusive comparisons, patients and clinicians can only rely on the 
evidence available and must make pragmatic decisions based on this. The pivotal 
DMT trials and attempts to extrapolate valid comparisons between them are 
considered in detail below. 
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DMT Trials 
In the era of evidence-based medicine, the gold standard for disease 
intervention is demonstration of efficacy in an agreed outcome measure against 
either placebo or an active comparison treatment in a randomised, double-blind 
controlled trial. Tables 0-3, 0-4 and 0-5 outline the pivotal trials for currently 
licensed RRMS DMTs and Table 0-6 lists emerging therapies which have been 
studied but not necessarily licensed for use yet. Most of these qualify as Class I 
evidence for the efficacy of the intervention being studied, save for the 
Alemtuzumab and Ocrelizumab trials where blinding was not realistically 
practicable or ethically defensible with the availability of proven therapies. That 
said, these data summarise the best available evidence for DMTs in RRMS. It is 
widely agreed that cross-trial comparisons are not valid, and the variation in 
numbers, cohort characteristics, definitions and outcome measures described 
here reinforce this point, as discussed previously. Additionally, the trials 
outlined have been undertaken between the early 1990s and late 2010s i.e. over 
a 20-year period during which a multitude of other societal and medical changes 
have occurred. Indeed, the diagnosis of MS has notably changed over time, with 
each iteration of diagnostic criteria generally allowing inclusion of patients with 
earlier (milder) disease than previously. There have been comparator trials, as 
outlined in the subsequent table, allowing clear statements about the 
superiority of some DMTs over others, but most DMTs have not been compared in 
head-to-head trials.  
Inevitably placebo-controlled trials are compared in practice, in the absence of 
other evidence. The raw outcome comparisons, comparing relative ARR 
reduction as the typical primary outcome measure, are usually used and quoted, 
but some argue that this inflates apparent efficacy outcomes and absolute 
differences should be used55. Relative ARR risk reduction figures suggest 
natalizumab as the most effective DMT (68% reduction) versus placebo followed 
by cladribine (57.6%). DMF and Fingolimod had similar relapse rate reductions, 
as did Teriflunomide and Plegridy®. The other interferons and Copaxone® have 
relapse reduction rates of around 30%, other than Avonex® for which this was 
only demonstrated in the per-protocol analysis. Clearly, as stated, this is an 
artificial and simplistic view, and relapse reduction is not the only measure of 
disease activity and, arguably, not the most relevant to patients or society. 
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Additionally, tolerability and safety are important issues for patients and hence 
real-world concordance. From these pivotal trials, Copaxone® has the best 
tolerability profile (1.6% discontinued) and the oral treatments the worst.  
The comparator trials (Table 0-7) provide the best evidence as to the efficacy of 
one DMT versus the other but, again, cross-trial comparisons are not valid. From 
these we can however conclude that: 
• Alemtuzumab is more effective than Rebif® (Further details in Table 0-5) 
• Rebif® is more effective than Avonex® 
• Betaferon® is more effective than Avonex® 
• Fingolimod is more effective than Avonex® 
• Ocrelizumab is more effective than Rebif® (Further details in Table 0-6) 
• Copaxone®, Betaferon®, Rebif®, Teriflunomide and DMF are of 
comparable efficacy 
• Natalizumab in addition to Avonex® is more effective than Avonex® alone 
• Natalizumab in addition to Copaxone® is not more effective than 
Copaxone® alone 
There are clearly caveats to the above which is an over-simplification, and there 
are some obvious potential contradictions with the placebo-controlled trial 
outcomes e.g. the addition of Natalizumab to Copaxone not improving efficacy. 
There may be reasons for this which are not yet understood, in addition to the 
small study sample size, and these data, despite their problems, represent the 
gold standard available. 
Interestingly, despite the caveats discussed, meta-analysis of all available trial 
data seem to bear out the ‘league’ of efficacy suggested by crude comparisons 
of the pivotal trials56. From this analysis, Alemtuzumab and Natalizumab appear 
most effective in most measures, followed by Fingolimod and DMF, and then the 
injectable therapies. Teriflunomide is of mid-range efficacy in terms of 3-month 
disability progression, but similar to the injectables in terms of relapse activity. 
Ocrelizumab and cladribine were not included in this analysis. 
In summary, a number of factors function in patients’ treatment choices but the 
available data provides clinicians with some guidance on the most appropriate 
treatment advice for an individual. Both efficacy and safety/tolerability are 
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relevant in deciding on which DMT to use, with the frequency of discontinuation 
very relevant given the impossibility of effectiveness if patients choose not to 
use the treatment. Table 0-8 outlines a summary of efficacy and discontinuation 
rates from the pivotal trials and suggests favourability on this measure for the 
most efficacious treatments, in terms of relapse reduction, as they are also well 
tolerated, often as a result of the short courses of treatment required (in the 
case of Cladribine and Alemtuzumab for example).
Table 0-3: Pivotal DMT trials - First-line Injectable treatments 
 Avonex® Betaferon® Rebif® Plegridy® Copaxone® 
DMT/Comparator 
Avonex® Placebo 
Betaferon® 
(8MIUs) 
Placebo Rebif44 Placebo 125µg 
2weekly 
Placebo Copaxone 
20mg/day 
Placebo 
Trial (Year) 1996 (MSCRG)57 199358 1998 (PRISMS)59 2014 (ADVANCE)60 1995 (MSSG)61 
Trial details 
N [analysed] 85 87 115 [58] 112 [56] 184 187 438 456 125 126 
Primary outcome Time to ↑EDSS≥1 
ARR / Proportion 
relapse-free 
MRI: %Δlesion area 
Relapse count ARR Relapse rate 
Duration 104 weeks 2yrs [5yrs Follow-up] 2yrs 48 weeks 2yrs 
Inclusion Criteria 
CDMS>1yr 
EDSS 1-3.5 
18-55yrs 
≥2 relapses in 3yrs 
CDMS or ‘lab 
supported’>1yr 
EDSS 0-5.5 
18-50yrs 
≥2 relapses in 2yrs 
CDMS or ‘lab 
supported’>1yr 
EDSS 0-5 
≥2 relapses in past 
1yr 
McDonald criteria 
(2005) 
EDSS ≤5 
18-65yrs 
≥2 relapses in 3yrs, 
at least 1 in last yr 
EDSS 0-5 
18-45yrs 
≥2 relapses in 2yrs 
 
Exclusion Criteria 
‘Any disease 
compromising organ 
function’ 
Pregnancy or 
‘unwillingness to 
practice 
contraception’ 
Prev. 
immunosuppression 
AZA or 
Cyclophosphamide use 
previously 
Any previous 
immunotherapy in 
past 1yr 
Previous IFN use 
No relapse/steroids 30 
days before study 
Diabetes 
Pregnancy/lactation 
No Aspirin/NSAIDs 
during trial 
EDSS frequency 6-monthly 3-monthly 3-monthly 3-monthly 3-monthly 
 
 
 Avonex® Betaferon® Rebif® Plegridy® Copaxone® 
DMT/Comparator 
Avonex® Placebo 
Betaferon® 
(8MIUs) 
Placebo Rebif44 Placebo 125µg 
2weekly 
Placebo Copaxone 
20mg/day 
Placebo 
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MRI frequency Annual 
Annual (52 pts had 6-
weekly for 2yrs) 
Every 6/12 (205 pts 
had monthly scans 
for first 9/12) 
6/12 N/A 
ITT Design? Yes Yes Yes Yes ? 
Relapse definition ≥48hrs and EDSS↑ ≥24hrs and new sign 
≥24hrs, stable for 
30/7 before 
≥24hrs, stable for 
30/7 before and 
signs 
≥48hrs and EDSS↑, 
stable for 30/7 
Progression 
definition 
↑EDSS ≥1 @ 6/12 ↑EDSS>1 @90days ↑EDSS>1 @3/12 
EDSS ↑>1 if baseline 
EDSS >1 or ↑>1.5 if 
baseline EDSS 0 
 
 
↑EDSS>1 @3/12 
 
 
 
Baseline Characteristics 
Mean age 36 35.5 
35.6 
(Median) 
34.6 
(Median) 
36.9 36.3 34.6 34.3 
% Female 72-75 68-72 66 75 71 72 70.4 76.2 
%White 92-93 93-94 N/A N/A 81 82 93.6 94.4 
Mean ARR 1.2 
Relapses in past 2yrs 
Mean 3 relapses in 
previous 2 yrs: ARR 
=1.5 
Mean relapses in 
past 1yr (3yrs) 
Mean relapses in 2yrs 
2.9 (1.8) 2.9 (1.8) 
3.3 3.6 1.6 (2.6) 
Mean EDSS 2.3 3.0 2.8 2.5 2.4 2.5 2.4 2.8 2.4 
 
 
 Avonex® Betaferon® Rebif® Plegridy® Copaxone® 
DMT/Comparator 
Avonex® Placebo 
Betaferon® 
(8MIUs) 
Placebo Rebif44 Placebo 125µg 
2weekly 
Placebo Copaxone 
20mg/day 
Placebo 
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Disease duration 
(years) 
6.5 4.7 3.9 6.4 5.3 6.9 6.3 7.3 6.6 
MRI Brain T2 data N/A N/A N/A 
Mean No. T2 
N/A 
48.7 50.6 
 MRI Brain Gd+ 
data 
0 Gd+ lesions 
N/A N/A 
% with Gd+ lesions 
N/A 
47% 46% 
>4Gd+ lesions 35 41 
20% 18% 
Mean No. Gd+ 
lesions 
1.2 1.6 
Efficacy Outcomes 
Relapses 
ARR (95%CIs) 0.61 (ITT) 0.9 (ITT) 0.84 1.27 
Mean relapses/pt 0.256* 
(0.206-
0.318) 
0.397 
(0.328-
0.481) 
0.59* 0.84 
1.73 2.56 
Time to 1st relapse Not significant 295days* 153days 
Prolonged by 5/12 
vs. placebo 
N/A 287 (NS) 198 
ARR Reduction 
32%* (completers) 
[18% whole group] 
33.9%* 33%* (21-44) 35.5% 
29.7% 
33% in EDSS 0-
2@baseline 
% relapse free N/A 36* 18 32* 16 81* 71 33.6 (NS) 27 
Severity N/A 
Mod/Severe relapses 
(mean) 
Mod/Severe relapses 
(mean) 
 
N/A 
 
 
 
 
 Avonex® Betaferon® Rebif® Plegridy® Copaxone® 
DMT/Comparator 
Avonex® Placebo 
Betaferon® 
(8MIUs) 
Placebo Rebif44 Placebo 125µg 
2weekly 
Placebo Copaxone 
20mg/day 
Placebo 
 
 
58 
0.23* 0.45 0.62* 0.99 
N/A 
 
Disability 
% progression-free 
78.8 66.6 
5yr data (n=114) 
N/A 99.93* 90 78.4 (NS) 75.4 
65 54 
Change in EDSS 
↑EDSS>2.5 
No difference after 2 
and 3 yrs 
↑0.24* ↑0.46 
N/A 
% improved (EDSS↓≥1) 
24.8* 15.2 
2.4% 11.4% 95% CIs include 0 
% no change 
54.4 56 
% worse (EDSS↑≥1) 
20.8* 28.8 
MRI 
Gd+ 
0 Gd+ lesions 
N/A N/A 
Mean no. lesions 
N/A 
71% 57% 
>4Gd+ lesions 
0.2* 1.4 
6% 11% 
T2 
%Δ lesion vol. %Δ lesion area yr 2/3 ‘Burden of disease’ 
Mean no. new or 
enlarging 
-13.2% -6.5% 
↓0.1% 
↓6.2% 
↑20% 
↑17.1% 
↓3.8%* ↑10.9% 3.6* 10.9 
6/52 MRI (n=52) ‘Active lesions’ Lesion volume Δ 
Median new/yr 
↓by 78%* vs placebo ↓0.26%* ↑0.77% 
0.5 2 
 
 
 Avonex® Betaferon® Rebif® Plegridy® Copaxone® 
DMT/Comparator 
Avonex® Placebo 
Betaferon® 
(8MIUs) 
Placebo Rebif44 Placebo 125µg 
2weekly 
Placebo Copaxone 
20mg/day 
Placebo 
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T1 N/A N/A N/A 
Mean no. lesions 
1.8* 3.8 
Atrophy N/A N/A N/A N/A 
Safety Outcomes 
% Discontinued Rx 
4 1 
21 21 
Withdrew due to AEs 
4.7 1 1.6 ? Withdrew due to SEs 
8.7% 0.8% 4.9% 1% 
Common AEs with 
Rx 
Flu Sx (61%) 
Myalgia (34%) 
Fever (34%) 
Fever (58%) 
Myalgia (41%) 
↑LFTs (3pts withdrew) 
Injection pain 
Flu Sx esp. small pts 
Injection site 
reactions 
Depression (2.7%) 
↑LFTs (1%) 
 
Injection erythema 
(62%) 
Flu Sx (47%) 
Pyrexia (45%) 
Headache (44%) 
Injection site reaction 
(90%) 
Transient systemic 
reaction (15.2%) – can 
occur late 
Generalised 
lymphadenopathy 
(0.8%) 
% SAE 
No difference 
 
Nil 
 
N/A 5% both groups 
Nil 
 
Malignancy Colon x1(?group) Nil 
Infection N/A No difference 
Death 1 IFN pt - PTE 1 suicide ?group 1 suicide(placebo) 1 2 
Autoimmunity N/A Nil N/A Nil 
Pregnancy 
N/A N/A N/A N/A 
3 in total: 1 elective 
abortion / 2 stopped 
trial 
 
 
 Avonex® Betaferon® Rebif® Plegridy® Copaxone® 
DMT/Comparator 
Avonex® Placebo 
Betaferon® 
(8MIUs) 
Placebo Rebif44 Placebo 125µg 
2weekly 
Placebo Copaxone 
20mg/day 
Placebo 
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Labs Anaemia Lymphopaenia 
‘Asymptomatic ↓in 
WCC/lymph /neut 
and ↑LFTs in Rx vs 
placebo but 
lessened in Yr 2’ 
WCC <3 
No difference in 
blood/urine/ECGs btw 
groups 
3 1 80 65 7% 1% 
LFTs/WCC/Plts N 
Mild neutropaenia Lymph <0.8 
17 4 5% 3% 
↓Hb / ↓Plts in Rx group 
but ‘clinically 
insignificant’ 
No difference ↓Hb / 
↓Plts btw groups 
ALT>5xULN 
2% 1% 
Neutralising 
Antibodies (NAbs) 22% N/A 45% 11% 
12.5% N/A 
<1% <1% N/A Nab +: no effect on 
relapse count 
Notes 
 1.5T MRI used 
Depression scores 
equal; 1 patient in 
PBO cohort attempted 
suicide 
Only 5 pts completed 5 
yrs of study 
ARR reduction not 
significant after 2yrs 
1mg=32MIUs 
MRI 0.15-1.5T: 
reviewed by 2 
radiologists 
5yr data: 
↓ARR>50% in Nab-ve Rx 
group for last 2yrs 
 Dose titration – 20% 
total dose for 2-
4wks, 50% for 2-
4wks 
No difference in 
depression scores at 
any time between 
Rx and PBO 
Manufacturer 
(Biogen®) 
collected, analysed 
and contributed to 
the interpretation 
of the data 
2yr trial  
Benefit was greatest if 
baseline EDSS<2 
 
 
 Avonex® Betaferon® Rebif® Plegridy® Copaxone® 
DMT/Comparator 
Avonex® Placebo 
Betaferon® 
(8MIUs) 
Placebo Rebif44 Placebo 125µg 
2weekly 
Placebo Copaxone 
20mg/day 
Placebo 
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 Table 0-4: Pivotal DMT trials - First-line oral treatments 
 Teriflunomide Dimethyl Fumarate 
DMT/ 
Comparator 
Teriflunomide 
14mg 
Placebo 
Teriflunomide 
14mg 
Placebo 
DMF 
240bd 
Placebo 
DMF 
240bd 
Placebo 
Trial (Year) TEMSO (2011)62 TOWER (2014)63 DEFINE (2012)64 CONFIRM (2012)65 
Trial details 
N (analysed) 
358 
(333 RRMS) 
363  
(329 
RRMS) 
370 
(366 RRMS) 
388 
(366 RRMS) 
410 408 359 363 
Primary 
outcome 
ARR ARR % relapsed by 2yrs ARR 
Duration 108 wks 108wks (but see Notes) 2yrs 2 yrs (96 weeks) 
Inclusion 
Criteria 
McDonald criteria (2001) 
EDSS 0-5.5 
18-55yrs 
≥1 relapse in 1 yr or 
≥2relapses in 2yrs 
RRMS with or without 
progression 
McDonald criteria (2005) 
EDSS0-5.5 
18-55yrs 
≥1 relapse in 1 yr OR ≥2 
relapses in 2 years – no 
relapses 30 days before trial 
 
McDonald criteria (2010) 
EDSS 0-5 
18-55yrs 
 ≥1 relapse in 12 months OR ≥1 Gd+ within 6wks 
of randomisation 
Exclusion 
Criteria 
Relapse within 60 days 
‘Other systemic diseases’ 
Pregnancy or planning to 
conceive 
Previous cytokine therapy, 
pregnancy/breast-
feeding/planning to conceive 
Previous IFN or GA within 
3months or ever had 
Natalizumab or other 
immunosuppressants 
‘another major 
disease’ 
LFTs >2x ULN, 
WCC<3.5, 
Eosinophils >0.7 
Any Rx w 
monoclonal (except 
Natalizumab), IFN or 
GA Rx within 
3months 
As DEFINE except NO 
prev Rx with 
Natalizumab/IVIgs or 
Plex within 6months 
 
 
 
 Teriflunomide Dimethyl Fumarate 
DMT/ 
Comparator 
Teriflunomide 
14mg 
Placebo 
Teriflunomide 
14mg 
Placebo 
DMF 
240bd 
Placebo 
DMF 
240bd 
Placebo 
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EDSS 
frequency 
After 3 months then 6-
monthly thereafter 
3-monthly 3-monthly 3-monthly 
MRI frequency 6-monthly N/A 
‘MRI cohort’  ‘MRI cohort’ 
N=184 N=180 N=169 N=167 
6-monthly 
ITT Design Yes Yes ? Yes 
Relapse 
definition 
≥24hrs, stable for 30/7 
before and ↑EDSS 
≥24hrs AND ↑EDSS by 1 in 2 
FSs or 2 in 1 FS 
(bowel/bladder/cognitive 
excluded)  
OR ↑EDSS >0.5 
≥24hrs & examination findings (‘according to 
examining neurologist’s evaluation’) 
Progression 
definition 
↑EDSS ≥1if baseline ≤5.5; ↑EDSS ≥0.5if baseline >5.5 at 
3months 
↑EDSS≥1 if baseline EDSS ≥1;  
↑EDSS ≥1.5 if baseline EDSS 0 
Baseline Characteristics 
Mean age 37.8 38.4 38.2 38.1 38.1 38.5 37.8 36.9 
% Female 71 75.8 69 70 72 75 68 69 
%White 96.9 98.3 84 82 78 78 85 84 
Mean ARR 
Relapses in past 1yr (2yrs) Relapses in past 2yrs Relapses in past 1yr 
1.3 (2.2) 1.4 (2.2) 2.1 (1.05) 1.3 1.3 1.4 
Mean EDSS 2.67 2.68 2.71 2.69 2.4 2.48 2.6 2.6 
Disease 
duration 
(Years) 
8.7 8.6 8.18 7.64 
Time since diagnosis 
5.6 5.8 4.9 4.8 
 
 
 
 Teriflunomide Dimethyl Fumarate 
DMT/ 
Comparator 
Teriflunomide 
14mg 
Placebo 
Teriflunomide 
14mg 
Placebo 
DMF 
240bd 
Placebo 
DMF 
240bd 
Placebo 
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MRI Brain T2 
data 
Total lesion vol. (ml) 
N/A 
Mean No. T2 Mean lesion vol (mm3) 
18.08 19.34 47.6 49.2 13,876 14,595 
 MRI Brain Gd+ 
data 
% with Gd+ lesions 
N/A 
Mean No. Gd+ 
lesions 
Mean No. Gd+ lesions 
35.2 38.2 
1.2 1.6 
2.7 2.7 
Mean No. Gd+ lesions % with Gd+ lesions 
1.81 1.66 
 
13 
 
 
14 
 
Efficacy Outcomes 
Relapses 
ARR (95%CIs) 
0.37*  
(0.31-0.44) 
0.54  
(0.47-
0.62) 
0.32*  
(0.27-0.38) 
0.5 
(0.43-0.58) 
0.19* 
(0.15-
0.23) 
0.36 
(0.3-
0.44) 
0.22* 
(0.18-0.28) 
0.4 (0.33-
0.49) 
Time to 1st 
relapse 
N/A 
369 days 
(282-485) 
188 days 
(142-249) 
637 266 
25th centile 
504 210 
ARR Reduction 
31.5%*  
(includes non-RRMS 
patients) 
36%* 
(34.5-37.2) 
53% 44% 
% relapse free 
56.5 
 (51-62) 
45.6  
(50.2 -51) 
@ 48 weeks 
73* 54 71* 59 76.3  
(71.7-81) 
60.6 
(55.5-65.6) 
 
 
 
 Teriflunomide Dimethyl Fumarate 
DMT/ 
Comparator 
Teriflunomide 
14mg 
Placebo 
Teriflunomide 
14mg 
Placebo 
DMF 
240bd 
Placebo 
DMF 
240bd 
Placebo 
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Disability 
% progression-
free 
79.8 (75.3-
84.4) 
72.7 
(67.7-
77.7) 
@ 48 weeks 
84* 73 87 82 
92.2  
(89.2-95.1) 
[n=267] 
85.8 
 (82.1-89.4) 
[n=271] 
@ 108 weeks 
84.2 
(79.6-88.8)  
[n=87] 
80.3 
(75.9-84.8) 
[n=83] 
 
MRI 
Gd+ 
Mean No. lesions 
N/A 
 
Mean No. lesions 
Mean No. lesions 
0.5*  
(-1.2 to 
2.2) 
[N=147] 
2 
(-3.6 to 7.6) 
[N=144] 0.26* 1.33 
0.1* 
(-0.5 to 
0.7) 
1.8  
(-2.4 to 
6) 
 
% free of Gd+ 
93* 62 
T2 
%Δ lesion vol. No. new/enlarging No. new/enlarging 
↑0.39%* 
(-6.51 to 7.29) 
↑1.67%  
(-4.8 to 
8.14) 
2.6* 
(2-3.5) 
17 
(12.9-
22.4) 
5.1* 
(3.9-6.6) 
[N=140] 
17.4 
(13.3-22.4) 
[N=139] 
 
 
 
 Teriflunomide Dimethyl Fumarate 
DMT/ 
Comparator 
Teriflunomide 
14mg 
Placebo 
Teriflunomide 
14mg 
Placebo 
DMF 
240bd 
Placebo 
DMF 
240bd 
Placebo 
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%free of new/enlarging 
27* 12 
T1 
%Δ lesion vol 
N/A 
No. new lesions 
↑0.33%*  
(-0.68 to 1.34) 
↑1.67% 
(-4.8 to 
8.14) 
3 
(2.3-4) 
[N=140] 
7 
(5.3-9.2) 
[N=139] 
Atrophy 
BPF Δ from baseline 
N/A 
N/A 
 
 
 
-0.003 -0.004 
Safety Outcomes 
% Discontinued 
Rx 
10.9 8.1 16 6 
16 13 
12 10 Due to flushing 
2 <1 
Common AEs 
with Rx 
Diarrhoea (17.9%) 
Nausea (13.7%) 
Hair thinning (13.1%) 
Headache (18.7%) 
HTN (5%) 
Skin reactions (11.2%) 
Pyelonephritis 
 
↑ALT (14%) 
Hair thinning (13%) 
Headache (12%) 
Neutropaenia (9%) 
Diarrhoea (11%) 
HTN: 2 serious events in 
Teri14 group 
Mean↑BP=2.7/2.2mmHg 
Peripheral neuropathy (0.8%) 
Flushing (38%) 
Diarrhoea (15%) 
Abdo pain (10%) 
Nausea (13%) 
Lymphopaenia 
Proteinuria 
Pruritis 
↑AST 
Flushing (35%) 
GI Sx (36%) 
Proteinuria (8%) [7% 
placebo group/9% GA 
group] 
 
 
 
 
 Teriflunomide Dimethyl Fumarate 
DMT/ 
Comparator 
Teriflunomide 
14mg 
Placebo 
Teriflunomide 
14mg 
Placebo 
DMF 
240bd 
Placebo 
DMF 
240bd 
Placebo 
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% SAE 15.9 12.8 12 18 21 17 22 
Malignancy 1 (Cervical) 3 Nil <1% 
Nil in DMF groups [1 
placebo, 4 GA] 
Infection 
1.6 -2.5% (NS) 
No serious opportunistic 
infections 
Any infection Any infection Any infection 
44% 51% 64% 65% 56% 50% 
Opportunistic infections (<1%) 
Serious infection 2% 
both groups 
No opportunistic 
infections 
1 pt intestinal 
TB  
1 pt Hep 
C/CMV 
No opportunistic 
infections 
 
Death No deaths 
3 (suicide / 
septicaemia / 
RTA) 
1 
2: RTAs (both in Rx 
arms) 
Nil 
Autoimmunity Nil 
1 pt Teri7mg had ITP – 
stopped Rx → steroids / 
Rituximab 
Proteinuria Nil 
9% 8%  
 
 
 
 Teriflunomide Dimethyl Fumarate 
DMT/ 
Comparator 
Teriflunomide 
14mg 
Placebo 
Teriflunomide 
14mg 
Placebo 
DMF 
240bd 
Placebo 
DMF 
240bd 
Placebo 
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Pregnancy 
11: 4 spont abortions 
(1PBO/3Rx); 6 elective 
abortions (1 Teri14mg / 5 
Teri 7mg) 
1 healthy baby @2yrs, 
after 31 days Teri 14mg in 
pregnancy 
18  
14 : 10 elective abortions; 4 
healthy births (1 Teri 14mg) 
4 partners: 1 elective 
abortion; 3 healthy babies 
(Teri 7mg) 
Nil Nil 
Labs 
Neutropaenia Neutropaenia 
Lymph <0.5 
WCC<3 
<1% 0 3pts (<1%) 0 10% 1% 
↑ALT >1xULN ALT>1xULN 
4% <1% 
Lymph<0.5 
57.3% 35.9% 55% 39% 5% <1% 
↑ALT>3xULN 
ALT>3xULN 
No serious infections 
in those with 
lymph<0.5 
None stopped Rx due to 
lymphopaenia 
8% 6% ALT>1xULN 
6.7% 6.7% 
Lymph<0.5 ALT>3xULN 47% 41% 
3% <1%  ALT>3xULN 
Lymph<0.2 
6% 3% 6% 6% 
Nil 
NAbs N/A N/A 
Notes 
 TEMSO 
CIs cross for % relapse free, % with disability progression 
and MRI outcomes 
DEFINE 
SD cross for Gd+ lesions 
No significant neutropaenia 
 
 
 
 Teriflunomide Dimethyl Fumarate 
DMT/ 
Comparator 
Teriflunomide 
14mg 
Placebo 
Teriflunomide 
14mg 
Placebo 
DMF 
240bd 
Placebo 
DMF 
240bd 
Placebo 
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Leflunomide used in RA since 1998: 2 PML cases  
No difference in fatigue questionnaires between groups 
Bloods every 2wks for 6months then every 6weeks 
Abdo USS for pancreatitis (associated with Leflunomide) at 
baseline and every 6/12 
LFTs↑ months 1-6 (largest difference with 
placebo at 4/52) 
ECGs: No abnormalities detected 
No renal/liver failure 
TOWER 
821 Completed study: placebo=274; Teri7mg=289; 
Teri14mg=258 
Median duration of Rx (weeks): placebo=83; Teri7mg=79; 
Teri14mg=84 
CIs cross for disability 
No significant difference between placebo and Rx for 
change in EDSS from baseline to week 48 or changes in 
physical health summary score, mental health summary 
score or fatigue score at 48 weeks or at end of trial but 
was significant difference (p=0.02) between mental health 
summary score and fatigue score (p=0.042) at baseline and 
end of study between placebo and Teri14mg, but no 
significant difference at week 48 
Most cases of hair thinning resolved on Rx – 2% patients in 
Teri14mg group stopped Rx due to hair thinning 
 
 
 
 
 
 Teriflunomide Dimethyl Fumarate 
DMT/ 
Comparator 
Teriflunomide 
14mg 
Placebo 
Teriflunomide 
14mg 
Placebo 
DMF 
240bd 
Placebo 
DMF 
240bd 
Placebo 
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 Table 0-5: Pivotal DMT trials - Second-line treatments 
 Fingolimod Natalizumab Alemtuzumab 
DMT/ 
Comparator 
Fingo 
0.5 
Placebo Fingo 0.5 Placebo Nat Placebo 
Alem12 Rebif® Alem12 Rebif® 
Trial (Year) 
FREEDOMS I 
(2010)66 
FREEDOMS II (2014)67 
AFFIRM (2006)68 CARE-MS I (2012)69 CARE-MS II 
(2012)70 
Trial details 
N 425 418 358 355 627 315 376 187 426 202 
Primary outcome ARR ARR 
Relapse rate at 1yr 
Sustained disability 
progression at 2yrs 
Relapse rate 
Time to 6-month sustained disability 
Duration 2 yrs 2 yrs 2yrs (120wks) 2 yrs 2 yrs 
Inclusion Criteria 
McDonald criteria (2010) 
EDSS 0-5.5 
Age 18-55 
McDonald Criteria 
(2001) 
EDSS 0-5 
≥1 relapse in past 
year 
Age 18-50 
Untreated RRMS 
McDonald criteria 
(2005) 
EDSS≤3 
Disease duration <5yrs 
≥2 relapses in past 2yrs 
(≥1 relapse in past 1yr) 
Age 18-50 
Relapse despite 
1st line Rx 
McDonald criteria 
(2005) 
EDSS≤5.0 
Disease duration 
<10yrs 
≥2 relapses in 
past 2yrs / ≥1 
relapse in past 
1yr 
Age 18-55 
Exclusion 
Criteria 
Active infection 
Recent steroids (30/7) 
Macular oedema 
Diabetes 
PPMS and SPMS 
Relapse within 50 
days 
Progressive MS 
Previous DMTs 
Prev monoclonal Abs 
As CARE-MS I 
PLUS Rx with 
Natalizumab 
 
 
 Fingolimod Natalizumab Alemtuzumab 
DMT/ 
Comparator 
Fingo 
0.5 
Placebo Fingo 0.5 Placebo Nat Placebo 
Alem12 Rebif® Alem12 Rebif® 
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Immunosuppression 
‘clinically significant systemic disease’ 
Cyclophos or Mitox 
in previous year 
IFN, GA, 
cyclosporine, AZA, 
MTX, IVIgs in prev 
6months (or had IFN 
or GA for >6/12 at 
any time) 
‘clinically significant 
autoimmunity other 
than MS’ 
within 6/12 [all 
had prev DMTs¶] 
EDSS frequency 3-monthly 
MRI frequency 6-monthly 12-monthly 
ITT Design? Yes Yes Yes Yes Yes 
Relapse 
definition 
≥24hrs, stable for 30/7 and ↑EDSS ≥0.5 
(excluding bowel, bladder or cognition) 
>24hrs AND signs 
>48hrs after 30/7 stability and new signs 
(↑EDSS) 
Progression 
definition 
Baseline EDSS<5.5: ↑>1 
Baseline EDSS≥5.5: ↑>0.5  
Confirmed at 3-months outwith relapse 
Baseline EDSS≥1: 
↑>1 
Baseline EDSS 0: 
↑>1.5  
Confirmed at 3-
months outwith 
relapse 
Baseline EDSS≥1: ↑>1 
Baseline EDSS 0: ↑>1.5  
Confirmed at 6-months 
Baseline Characteristics 
Mean age 36.6 37.2 40.6 40.1 35.6 36.7 33.9 33.2 34.8 35.8 
% Female 69.6 71.3 77 81 72 67 65 65 66 65 
 
 
 Fingolimod Natalizumab Alemtuzumab 
DMT/ 
Comparator 
Fingo 
0.5 
Placebo Fingo 0.5 Placebo Nat Placebo 
Alem12 Rebif® Alem12 Rebif® 
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%White N/A N/A 96 94 94 96 90 93 
Mean ARR 
No. relapses in past 1yr (2yrs) Mean relapses in past 1yr 
1.5 
(2.1) 
1.4 
(2.2) 
1.4 (2.2) 1.5 (2.2) 1.53 1.50 1.8 1.8 1.7 1.5 
Mean EDSS 2.3 2.5 2.4 2.4 2.3 2.3 2.0 2.0 2.7 2.7 
Disease duration 
Time since 1st Symptoms 
5 6 2.1 2 
Time since first 
clinical event 
8 8.1 10.4 10.6 4.5 4.7 
MRI Brain T2 
data 
Vol. of lesions (mm3) % pts <9 T2 lesions Vol of lesions (mm3) 
6128 6162 5484 5553 5 5 7400 7300 9040 9940 
  
MRI Brain Gd+ 
data 
% with Gd+ lesions 
Mean no. Gd+ 
lesions Mean no. Gd+ lesions 
37 38 
39 36 
2.2 2.0 Mean No. Gd+ lesions 
2.3 2.1 2.28 2.3 
1.3 1.2 
Efficacy Outcomes 
Relapses 
ARR (95%CIs) 
0.18* 
(0.15-
0.22) 
0.4 
(0.34-
0.47) 
0.21* 
(0.17-
0.25) 
0.4 
(0.34-0.48) 
ARR @ 1yr 
0.18* 
(0.13-
0.23) 
0.39 
(0.29-0.53) 
0.26* 
(0.21-
0.33) 
0.52 
(0.41-
0.66) 
0.26* 
(0.21-
0.32) 
0.82 
(0.67-
0.97) 
 
 
 Fingolimod Natalizumab Alemtuzumab 
DMT/ 
Comparator 
Fingo 
0.5 
Placebo Fingo 0.5 Placebo Nat Placebo 
Alem12 Rebif® Alem12 Rebif® 
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ARR @ 2yrs 
0.23* 0.73 
Time to 1st 
relapse 
N/A 
Hazard ratio 0.5 (0.4-
0.67) delayed time to 
1st relapse 
N/A N/A N/A 
ARR Reduction 55% 
48% 
(47-50) 
68% 
54% 
(55-56.6) 
50% 
% relapse free 
70.4* 
(66-
77.8) 
45.6 
(40.7-
50.6) 
71.5* 
(66.6-
76.4) 
52.7 
(47.2-58.2) 
67* 41 77.6* 58.7 65.4* 46.7 
Severity N/A 
% Mod/Severe relapses 
N/A N/A N/A 
70 77 
Disability 
% progression-
free 
Confirmed @ 3/12 Confirmed @ 6/12 Hazard ratio 0.46 
(0.33-0.64) for risk 
of progression 
sustained at 6/12 
vs. placebo [54% ↓] 
92% 
[NS]¶ 
89% 
87 80 
82.3 
(78.6-
86.1) 
75.9 
(71.7-
80.2) 
86.2 
(77.9-
86.4) 
[NS] 
83.2 
(77.9-86.4) 
Confirmed @ 6/12 
Cumulative 
probability of 
progression 
HR 0.58 in favour 
of Alem: 42% risk 
reduction* 
87.5 81 17%* 29% 
 
 
 Fingolimod Natalizumab Alemtuzumab 
DMT/ 
Comparator 
Fingo 
0.5 
Placebo Fingo 0.5 Placebo Nat Placebo 
Alem12 Rebif® Alem12 Rebif® 
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(84.3-
90.7) 
(77.1-
84.9) 
Change in EDSS 
0 
(-0.88 
to 0.88) 
↑0.13 
(-0.81 
to 1.07) 
0.046 
[NS] 
0.055 N/A 
-0.14 
[NS] 
-0.14 
↓0.17* 
(-0.29 
to -0.05 
↑0.24 
(0.007 
to 0.41) 
 
MRI 
Gd+ 
Mean No. Gd+ lesions (SD) 
% with no Gd+ lesions @ 2yrs 
0.2* 
(-0.6 to 
1) 
1.1 
(-1.3 to 
3.5) 
0.4* 
(-1.44 to 
2.24) 
1.2 
(-1.77 to 
4.17) 
0.1* 
(-1.3 to 
1.5) 
1.2 
(-2.7 to 
5.1 
% with no Gd+ @2yrs 
93* 81 91* 77 89.7* 
[N=369] 
65.1 
[N=332] 
87 
[N=269] 
65 
[N=256] 
97* 72 
T2 
Mean % Δ Vol. Mean No. new  Median % Δ Vol. 
↑10.6* 
(-92.9-
114.1) 
↑33.8 
(-73.1 
to 
140.7) 
↑13.74* ↑25.06% 
1.9* 11 
-9.3 
(-19.6 to 
-0.2) 
[NS] 
-6.5 
(-20.7 to 
2.5) 
-1.27 
(-12.7 
to 7.78) 
[NS] 
-1.73 
(-11.1 
to 
11.39 
Mean no. new or enlarging % pts with new/enlarging 
 
 
 Fingolimod Natalizumab Alemtuzumab 
DMT/ 
Comparator 
Fingo 
0.5 
Placebo Fingo 0.5 Placebo Nat Placebo 
Alem12 Rebif® Alem12 Rebif® 
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2.5* 
(-4.7 to 
9.9) 
[N=370] 
9.8 
(-3.4 to 
23) 
[N=339
] 
2.3* 
(-4.96 to 
9.56) 
[N=264] 
8.9 
(-4.96 to 
22.7) 
[N=251] 
48* 58 46* 68 
T1 
Mean % Δ Vol. 
N/A N/A N/A 
↑8.8 
(-67.5 
to 85.1) 
[N=346] 
↑50.7 
(-337.6 
to 439) 
[N=305] 
↑12.6 
(-198.47 
to 
223.67) 
[N=225] 
[NS] 
↑26.4 
(-122.4 to 
175.2) 
[N=209] 
Atrophy 
Mean % Δ Brain Vol. (SD) 
N/A 
Median Δ BPF 
-0.84* 
(-2.15 
to 0.47) 
[N=357] 
-1.31 
(-2.81 to 
0.19) 
[N=331] 
-0.86* 
(-2.08 to 
0.36) 
[N=266] 
-1.28 
(-0.22 to 
2.78) 
[N=249] 
 
 
 
 
-0.87%* 
(-1.5 to -
0.254) 
-1.48% 
(-2.3 to -
0.5) 
-0.62%* 
(-1.3 to 
0.006) 
-0.81% 
(-1.5 to 
0.2) 
Safety Outcomes 
% Discontinued 
Rx  
Due to AEs 
7.5 7.7 18 10 6 4 1 6 3 7 
 
 
 Fingolimod Natalizumab Alemtuzumab 
DMT/ 
Comparator 
Fingo 
0.5 
Placebo Fingo 0.5 Placebo Nat Placebo 
Alem12 Rebif® Alem12 Rebif® 
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Due to abnormal 
labs 
6.8 1.4 
Due to lack of 
efficacy 
3.3 14.6 
Common AEs 
with Rx 
↑LFTs (15.8%) 
Influenza infection 
(12.9%) 
Back pain (11.8%) 
Diarrhoea (11.8%) 
LRTI (9.6%) 
Herpesvirus 
infection (8.7%) 
Dizziness (7.3%) 
HTN (6.1%) 
Lymphopaenia 
(3.5%) 
Bradycardia (2.1%) 
LRTI (11%) 
Herpesvirus (8%) 
HTN (9%) 
↑ALT (8%) 
Lymphopaenia (8%) 
Insomnia (9%) 
1st dose 1° AV block 
(5%) 
1st dose 2° AV block 
(Wenckebach) (4%) 
Fatigue (27%) 
Hypersensitivity 
reaction (4%) 
 
Infusion reaction 
(headache, rash, fever) 
[90%] 
UTI (17%) 
Herpesvirus infection 
(16%) 
Fatigue (13%) 
Rash (12%) 
Infusion reaction 
(90%) 
Fatigue (19%) 
Chest discomfort 
(8%) 
Headache (53%) 
Dizziness (11%) 
Rash (44%) 
Pruritis (15%) 
% SAE 10.1 13.4 15 13 19 24 14 7 13 13 
Malignancy 
<1% in all groups  
[BCC 0.9% Fingo0.5 
vs 0.2% placebo] 
4% 
(10 pts 
BCC) 
2% 
(2 pts BCC) 
<1% in both groups: 
5 in Rx group [3 
breast, 1 cervical, 1 
melanoma] 
2 (1%) thyroid cancers 
in Alem group (None in 
Rebif) 
2 
(BCC, 
Thyroid) 
2 
(BCC, 
AML) 
 
 
 
 Fingolimod Natalizumab Alemtuzumab 
DMT/ 
Comparator 
Fingo 
0.5 
Placebo Fingo 0.5 Placebo Nat Placebo 
Alem12 Rebif® Alem12 Rebif® 
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Infection 
69-72% across all 
groups 
1.6-2.6% serious 
infections 
Any infection 
3% 1% 79% both groups 67% 45% 77% 6% 
VZV infection Serious infection 
3% 1% 3.2% 2.6% 2% 1% 4% 1% 
Death 0 2 No deaths 
2 deaths: both in Rx 
group [melanoma, 
alcohol XS] 
2 deaths: both in Alem 
group [RTA, sepsis] 
2 deaths in 
Alem12 group 
(RTA, aspiration 
after relapse) 
Autoimmunity N/A N/A N/A 
Thyroid Thyroid 
18% 6% 16% 5% 
3 pts ITP, 1pt each: 
haemolytic anaemia, 
glomerulonephritis, 
neonatal 
thyrotoxicosis, 
pancytopaenia 
7 pts ITP, 1 pt 
glomerulonephriti
s 
Pregnancy Nil Nil Nil Nil in Alem group? Nil 
Labs 
Mean 73% ↓Lymph 
after 1/12 in Rx 
group 
Lymphopaenia (%pts) 
↑lymph/mono/eosin 
in Rx group (not 
neut) 
Lymphopaenia transiently after Alem 
infusions: B cells recovered within 6 
months; T cells after ≈1 year 
ALT>3xULN 8 0 ‘Liver toxicity’ 
8.5% 1.7% ↑ALT (%pts) 17% 4% 4% 6% 
 
 
 Fingolimod Natalizumab Alemtuzumab 
DMT/ 
Comparator 
Fingo 
0.5 
Placebo Fingo 0.5 Placebo Nat Placebo 
Alem12 Rebif® Alem12 Rebif® 
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8 2 
↑ nucleated red 
cells in few Rx 
group 
ALT>5xULN Recovery of mean 
lymphocyte count 
occurred within 45 
days of drug 
discontinuation 
Changes were 
reversible, without 
clinical sequelae 
+ returned to 
baseline approx. 
4/12 after last dose 
1.9% 1% 
NAbs N/A N/A 
9% - 
29% before 2nd course 
Alem; 86% 1/12 after 
2nd course 
29% before 2nd 
course Alem; 81% 
1/12 after 2nd 
course 
6% persistent – 
associated with 
hypersensitivity and 
↓efficacy 
Did not influence efficacy or safety 
Notes 
 Bradycardia 
8 patients had 
bradycardia as SAE 
(7 in Fingolimod 
groups – 
No differences in HRCT 
between groups; PFTs 
slightly reduced in 
Fingolimod groups 
 
MRI 3mm cuts 
 
No evidence of 
‘rebound’: 51 Nat 
patients and 27 
Placebo patients 
Monthly 
questionnaires, bloods, 
urinalysis and 
microscopy (every 3/12 
in Rebif group) 
TFTs every 3/12 
¶ No. previous 
DMTs tried 
(mean): Rebif 
=Alem=1; Drugs 
used (both 
groups): Rebif 
 
 
 Fingolimod Natalizumab Alemtuzumab 
DMT/ 
Comparator 
Fingo 
0.5 
Placebo Fingo 0.5 Placebo Nat Placebo 
Alem12 Rebif® Alem12 Rebif® 
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Fingo0.5=4; 
Fingo1.25=3) [<1%] 
 
6 were 
asymptomatic: all 
continued 
Fingolimod 
 
Total no. 
bradycardia 
events: Placebo = 
3, Fingo 0.5=9; 
Fingo1.25=14 
6 were 
symptomatic 
(dizziness, chest 
discomfort, 
palpitations) 
All resolved within 
24hrs; 2 patients 
required Rx 
HR decreases 
started within 2 
hrs; nadir after 4-
No difference in LV 
ejection fraction 
between groups (echo 
at baseline, 3 mo, 
12mo and 24mo) 
 
Bradycardia requiring 
overnight admission: 
2% Fing1.25, none in 
other groups 
Most first-dose 
monitoring events 
were asymptomatic, 
did not require Rx and 
resolved within 24hrs 
of onset. 
 
Max decrease in mean 
HR in Fingo0.5 group 
was 8.5bpm 
Holter ECG findings at 
3 months were similar 
between groups 
who stopped Rx 
returned to baseline 
disease activity 
% having relapses 
after stopping Rx: 
Nat=29; Placebo=30 
 
Lymphocyte subsets 
every 3/12 and at 1/12 
after Alem infusion 
Screening for Alem 
Nabs at baseline, 1,3 
and 12 months after 
each dose 
IFN Nabs at baseline 
and 2yrs 
 
¶ authors expected 20% 
in Rebif group hence 
perhaps not powered 
to detect a difference 
given the low rate in 
Rebif group 
 
%patients MRI and 
clinically disease free 
(?at 2yrs): Rebif =27; 
Alem = 39 
Odds ratio = 1.5 (1.2-
2.6) [p=0.006] 
 
(≈35%), Avonex 
(≈25%), Betaferon 
(≈30%), GA 
(≈35%), 
Natalizumab 
(≈3%), AZA (≈1%) 
 
Herpes and fungal 
infections more 
common with 
Alem 
1 case VZV 
requiring hosp 
admission in 
Alem12 group (2 
in Alem24) 
 
Prophylactic 
Aciclovir reduced 
herpetic 
infections 
(approx. 0.5% 
with cover, 
 
 
 Fingolimod Natalizumab Alemtuzumab 
DMT/ 
Comparator 
Fingo 
0.5 
Placebo Fingo 0.5 Placebo Nat Placebo 
Alem12 Rebif® Alem12 Rebif® 
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5hrs, with 
attenuation 
beginning at 6hrs 
Max drop in mean 
resting HR (from 
baseline) was 
8bpm, 5hrs after 
Fingo0.5 (10bpm 
4hrs after 
Fingo1.25) 
1st degree AV block 
(no. patients): 
Placebo = 6, 
Fingo0.5=20 [on 
day 1 Rx] 
2nd degree AV block 
(Mobitz 1): 
Placebo=0; 
Fingo0.5=1, 
Fing1.25=4 
Symptomatic in 1 
patient – SOB and 
palpitations 
approx. 2% 
without) 
1 patient 
pulmonary TB 
 
‘No opportunistic 
infections’ 
 
 
 
 Fingolimod Natalizumab Alemtuzumab 
DMT/ 
Comparator 
Fingo 
0.5 
Placebo Fingo 0.5 Placebo Nat Placebo 
Alem12 Rebif® Alem12 Rebif® 
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No effects were 
seen with 
continued use of 
Fingolimod 
 
Macular oedema 
Macular oedema: 7 
Fingo1.25 patients 
(0 in other groups): 
5 occurred within 3 
months of Rx; 6 
resolved in 1-
6months after Rx 
was discontinued 
 
  
 Table 0-6: Pivotal DMT trials - Emerging Therapies 
 Ocrelizumab Cladribine Laquinimod 
DMT/ 
Comparator 
OCR 600mg  
6-monthly 
Rebif 
44 
OCR 600mg 
6-monthly 
Rebif 44 
Cladribine 
3.5mg/kg 
Placebo 
Laquinimod 
0.6mg 
Placebo 
Trial (Year) 2017 (OPERA I)71 2017 (OPERA II)71 2010 (CLARITY)72 2012 (ALLEGRO)73 
Trial details 
N (analysed) 410 411 417 418 433 437 550 556 
Primary outcome ARR ARR ARR 
Duration 96 weeks 96 weeks 24 months 
Inclusion 
Age 18-55 
2010 revised McDonald criteria 
EDSS 0-5.5 at screening 
2 clinical relapses in past 2 years OR 1 clinical 
relapse within 1 year 
MRI with typical MS changes 
No neurological worsening for 30 days before 
screening and baseline visits 
McDonald 2001 criteria 
MRI with typical MS 
changes 
≥1 relapse in past 1 yr 
EDSS≤5.5 
3/12 washout if had DMTs 
before 
Age 18-55 
McDonald 2005 criteria 
EDSS ≤5.5 
Disease duration ≥6 months 
≥1 relapse in past 1yr or 2 within 
2yrs 
≥1 Gd+ lesion in previous year 
 
Exclusion 
PPMS 
Previous B-cell therapy / other 
immunosuppressants (Alem / Mitox / Teri / 
Nat >1yr / Cyclophos / MMF / Fingo / DMF) 
Disease duration > 10 years with EDSS ≤ 2 
Failed ≥2 previous DMTs 
Previous 
immunosuppressants 
Abnormal FBC 
‘Disorder that could 
compromise immune 
function’ 
Relapse within 28 days 
before study 
Progressive MS 
Relapse between screening and 
baseline 
Clinically significant or unstable 
medical or surgical conditions 
Immunosuppressants in last 6 
months 
Use of IFN/GA in last 2 months 
Natalizumab ever 
EDSS frequency 3-monthly  3-monthly 3-monthly 
 
 
 Ocrelizumab Cladribine Laquinimod 
DMT/ 
Comparator 
OCR 600mg  
6-monthly 
Rebif 
44 
OCR 600mg 
6-monthly 
Rebif 44 
Cladribine 
3.5mg/kg 
Placebo 
Laquinimod 
0.6mg 
Placebo 
 
 
84 
(not stated but 12wk confirmed disability 
progression rates reported) 
MRI frequency 6-monthly 6-monthly 12-monthly 
ITT Design Yes (except NEDA – ‘modified ITT’) Yes Unclear  
Relapse 
definition 
>24hrs and ↑EDSS; stable for 30 days before 
>24hrs and ↑EDSS; stable 
for 30 days before 
>48hrs and ↑EDSS; stable for 30 
days before 
Progression 
definition 
Increased EDSS 
Baseline <5.5: ↑ ≥ 1 
Baseline >5.5: ↑ ≥ 0.5 
Sustained for 3 months 
Increased EDSS 
Baseline 0: ↑ ≥ 1.5 
Baseline ≥0.5: ↑ ≥ 1 
Sustained for 3 months 
Increased EDSS 
Baseline 0-5: ↑ ≥ 1 
Baseline >5.5: ↑ ≥ 0.5 
Sustained for 3 months 
Baseline Characteristics 
Mean age 37.1 36.9 37.2 37.4 37.9 38.7 38.9 38.5 
% Female 65.9 66.2 65.0 67.0 68.8 65.9 71.1 66.2 
%White N/D N/D 98.2 98.2 N/D N/D 
Mean ARR 
Number of relapses in past 12 months 
N/D 
Relapses in past 12 months 
1.31 1.33 1.32 1.34 1.2 1.3 
Mean EDSS 2.86 2.75 2.78 2.84 2.8 2.9 2.6 2.6 
Disease duration 
Time since symptoms onset (yrs) 
7.9yrs* 8.9yrs 
Time since first MS symptom (yrs) 
6.74 6.25 6.72 6.68 8.7 8.7 
T2 
Number of T2 lesions (volume, cm3) Volume of T2 lesions (mm3) Volume of T2 lesions (cm3) 
51.04 
(10.84) 
51.06 
(9.74) 
49.26 
(10.73) 
51.01 
(10.61) 
14828 14287 9.8 9.7 
 
 
 Ocrelizumab Cladribine Laquinimod 
DMT/ 
Comparator 
OCR 600mg  
6-monthly 
Rebif 
44 
OCR 600mg 
6-monthly 
Rebif 44 
Cladribine 
3.5mg/kg 
Placebo 
Laquinimod 
0.6mg 
Placebo 
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 Gd+ 
% with NO Gd +ve lesions (% with ≥4) % with lesions 
Number of Gd +ve lesions 
57.5 (14.3) 
61.9 
(14.0) 
61.0 (13.3) 58.6 (14.0) 
31.9 29.3 
Mean number 
1.7 
2.0 
 
 
1.0 0.8 
Efficacy Outcomes 
Relapses 
ARR (95%CIs) 
0.16* 
(0.12-0.2) 
0.29 
(0.24-
0.36) 
0.16* 
(0.12-0.2) 
0.29 (0.23-
0.36) 
0.14* (0.12-
0.17) 
0.33 (0.29-
0.38) 
0.3* (±0.02) 0.39 (± 0.03) 
Time to 1st 
relapse 
N/D N/D 13.4* months 4.6 months N/D N/D 
ARR Reduction 46% 47% 57.6% N/D 
% relapse free 
NEDA (%) NEDA (%) 
79.7* 60.9 62.9* 52.2 
47.9* 29.2 47.5* 25.1 
Severity N/D N/D N/D N/D N/D 
Disability 
% progression-
free 
Confirmed at 3 months 
Confirmed at 6 months Confirmed at 3 months 
92.4* 87.8 90.9* 86.4 
Confirmed at 6 months 
85.7* 79.4 88.9* 84.3  
94.1* 
90.5 93.1* 89.5 
 
 
 Ocrelizumab Cladribine Laquinimod 
DMT/ 
Comparator 
OCR 600mg  
6-monthly 
Rebif 
44 
OCR 600mg 
6-monthly 
Rebif 44 
Cladribine 
3.5mg/kg 
Placebo 
Laquinimod 
0.6mg 
Placebo 
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Change in EDSS N/D N/D N/D 
Mean final EDSS 
2.68 2.79 
MRI 
Gd+ 
% patients with new lesions 
Mean number 
Mean number 
8.3* 30.2 9.8* 36.1 
1.33* 2.12 Mean number of lesions/scan 
0.12* 0.91 
0.02* 0.29 0.02* 0.42 
T2 
(New or enlarging) % patients Mean number Mean new or enlarged 
38.3* 61.3 39.1* 62.0 
0.38* 1.43 5.03* 7.14 Mean number of lesions / scan 
0.32* 1.41 0.33* 1.9 
T1 
Mean number of lesions / scan 
N/D N/D 
0.42* 0.98 0.45* 1.26 
Atrophy 
Brain volume change week 24-96 (% change) 
N/D 
% Change brain vol from baseline 
-0.57* 
(-0.66 to -
0.49) 
-0.74 
(-0.83 
to -
0.65) 
-0.64* 
(-0.73 to -
0.54) 
-0.75 
(-0.85 to -
0.65) 
-0.87* -1.3 
Patient Reported 
Outcome / QOL 
SF-36 mean score change 
N/D N/D 
0.04 -0.66 0.33 
Safety Outcomes 
Due to AEs Any reason 
 
 
 Ocrelizumab Cladribine Laquinimod 
DMT/ 
Comparator 
OCR 600mg  
6-monthly 
Rebif 
44 
OCR 600mg 
6-monthly 
Rebif 44 
Cladribine 
3.5mg/kg 
Placebo 
Laquinimod 
0.6mg 
Placebo 
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% Discontinued 
Rx  
3.2 6.4 3.8 6.0 3.5 2.1 
Year 1 
12% 15.2% 
Year 2 
8.5% 7.9% 
Due to AEs 
3% 1% 
Common AEs 
with Rx 
Infusion reaction (30-37%) 
Nasopharyngitis (15%) 
URTI (15%) 
Headache (11%) 
Headache (24%) 
Lymphopaenia (22%) 
Nasopharyngitis (14%) 
URTI (13%) 
Nausea (10%) 
ALT (30%) 
Abdominal pain (6%) 
Back pain (16%) 
Cough (8%) 
 
 
 
 
 
% SAE 1.2 2.9 1.4 2.9 8.4 6.4 3.9 0.8 
Malignancy 
3 (0.7%) 
Ductal 
breast ca. 
Renal ca. 
1 
(0.7%) 
Lymph
oma 
1 (0.2%) 
Melanoma 
1 (0.2%) 
Squamous 
cell ca 
6 (1.4%) 
5 benign 
uterine 
leiomyoma, 1 
cervical ca, 1 
melanoma, 1 
ovarian ca, 1 
0 
8 (1.5%) 
Breast ca (3) 
Lung ca, BCC, 
Oesophageal, 
GBM, 
Lymphoma (1 
each) 
6 (1.1%) 
Ovarian ca (2), 
Breast ca, BCC, 
Rectal ca, Prostate 
ca (1 each) 
 
 
 Ocrelizumab Cladribine Laquinimod 
DMT/ 
Comparator 
OCR 600mg  
6-monthly 
Rebif 
44 
OCR 600mg 
6-monthly 
Rebif 44 
Cladribine 
3.5mg/kg 
Placebo 
Laquinimod 
0.6mg 
Placebo 
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pancreatic 
ca, 1 
myelodysplas
ia (inc 
5.25mg/kg 
group also) 
 
Infection 
Any infection (%) Serious infection (%) UTI (7.3%) 
Sinusitis (5.3%) 
UTI (4.5%) 
Sinusitis (4.5%) 56.9 54.3 60.2 52.5 2.3 1.6 
Herpes infections (oral / zoster) (%) Herpes zoster SAE 
4.4 3 5.5 3.2 1 patient 0 
0 
 3 (injury, suicide, 
pneumonia) Death 0 
1 
(0.2%) 
Suicid
e 
1 (0.2%) 
Suicide 
1 (0.2%) 
Bowel 
obstructio
n 
2 (0.5%) 
MI, 
pancreatic ca 
2 (0.5%) 
Suicide, ICH 
Autoimmunity Nil Nil Nil Nil 
Pregnancy Nil documented 1 1 Nil documented 
Labs Nil documented 
Lymphopaenia <0.2 (%) ALT > 3x ULN 
0.7 0 4.8% 1.6% 
Any thrombocytopaenia (%) 
No liver failure / Bilirubinaemia 10.9 4.6 
Neutrophils <1 (%) 
 
 
 Ocrelizumab Cladribine Laquinimod 
DMT/ 
Comparator 
OCR 600mg  
6-monthly 
Rebif 
44 
OCR 600mg 
6-monthly 
Rebif 44 
Cladribine 
3.5mg/kg 
Placebo 
Laquinimod 
0.6mg 
Placebo 
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1.4 1.6 
NAbs 
3 patients (0.4%) developed antidrug-binding 
Abs with Ocrelizumab across both trials 
1 developed Nabs 
21.3% Rebif patients developed NAbs 
Nil documented Nil documented 
Notes 
 Approx. 25% in each cohort had previous DMTs 
(IFN>GA>Nat>Fingo>DMF) 
As a result of the failure in the statistical 
hierarchical testing, all the P values for the 
subsequent secondary efficacy end points, 
including the change in the SF-36 quality-of-
life physical-component summary and the 
measure of no evidence of disease activity, 
were considered to be nonconfirmatory: 
applies to SF-36, NEDA, Brain volume change 
 
Most of the new or newly enlarged lesion 
activity on T2-weighted MRI in the 
ocrelizumab groups occurred between baseline 
and week 24 (Fig. S8 in the Supplementary 
Appendix). From week 24 to week 48, the 
number of lesions was 94% lower in the 
ocrelizumab group than in the interferon 
Severe neutropenia (as 
rated by the investigators) 
was reported in three 
patients receiving 
cladribine (one in the 3.5-
mg group and two in the 
5.25-mg group), with 
severe thrombocytopenia 
and pancytopenia in one of 
the patients in the latter 
group, who also had an 
exacerbation of latent 
tuberculosis 
 
Herpes zoster infections 
therefore developed in 
3.18% of cladribine tablet 
treated patients 
*P values calculated based on 
adjustments for baseline MRI, 
disability and/or relapses using 
regression analyses 
 
No significant difference in MSFC 
scores between LAQ and PBO 
 
Safety concerns previously seen 
with roquinimex, such as serositis, 
cardiovascular events, and 
thrombosis, did not emerge as 
signals in the current study 
 
 
 Ocrelizumab Cladribine Laquinimod 
DMT/ 
Comparator 
OCR 600mg  
6-monthly 
Rebif 
44 
OCR 600mg 
6-monthly 
Rebif 44 
Cladribine 
3.5mg/kg 
Placebo 
Laquinimod 
0.6mg 
Placebo 
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beta1a group in the OPERA I trial and 96% 
lower in the ocrelizumab group than in the 
interferon beta1a group in the OPERA II trial. 
From week 48 to week 96 the number of 
lesions was 98% lower and 97% lower in the 
ocrelizumab group than in the interferon beta-
1a group in the OPERA I trial and the OPERA II 
trial, respectively. 
 
In the OPERA I trial, a patient treated with 
ocrelizumab for 1.6 years was hospitalized for 
a severe genital herpes simplex infection, 
which resolved with treatment 
 
CD19+ cells represent a measure of B-cell 
counts in anti-CD20–treated patients. The 
level of CD19+ cells decreased to negligible 
levels with ocrelizumab treatment by week 2. 
 
experiencing grade 3 or 4 
lymphopenia at any time 
during study compared with 
development in 1.75% of 
cladribine tablet treated 
patients that did not 
experience grade 3 or 4 
lymphopenia during the 
study 
 
The most commonly 
reported adverse event was 
lymphocytopenia. There 
was an inverse correlation 
between the incidence of 
infection and a patient’s 
lowest absolute lymphocyte 
count in the combined 
cladribine groups. 
Activation of latent herpes 
zoster occurred in 20 
cladribine-treated patients. 
One patient who was 
treated with cladribine had 
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DMT/ 
Comparator 
OCR 600mg  
6-monthly 
Rebif 
44 
OCR 600mg 
6-monthly 
Rebif 44 
Cladribine 
3.5mg/kg 
Placebo 
Laquinimod 
0.6mg 
Placebo 
 
 
91 
reactivation of latent 
tuberculosis and died. The 
use of cladribine may have 
contributed to this 
reactivation, and 
tuberculosis screening 
measures were 
subsequently implemented 
in ongoing clinical trials to 
rule out latent or active 
infection before treatment 
or retreatment. 
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Comparator 
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 Table 0-7: DMT Comparator trials 
Trial* N Duration 
Baseline characteristics Efficacy Outcomes 
Age ARR EDSS 
Disease 
duration 
(yrs) 
Proportion 
Relapse-free 
EDSS MRI 
Rebif® vs. Avonex® (EVIDENCE) 
Proportion 6-month 
progression 
Proportion no new 
lesions 
Rebif® 
339 
48 
weeks 
38.3 1 2 4 62% (p=0.003) 
12.7% (HR 0.87, 
p=0.51) 
63% (p<0.001) 
Avonex® 338 37.4 1 2 4.1 52% 14.5% 43% 
Betaferon® vs. Avonex® (INCOMIN) 
Proportion 6-month 
progression 
Proportion no new 
lesions 
Betaferon® 96 24 
months 
38.8 1.52 1.97 5.9 51% (p=0.03) 13% (p=0.005) 51% (p=0.001) 
Avonex® 92 34.9 1.38 1.96 6.7 36% 30% 25% 
Copaxone® vs Rebif® (REGARD) 
Proportion 6-month 
progression 
Proportion no new 
lesions** 
Copaxone® 
378 
96 
weeks 
36.8 - 2.33 6.55 62% 8.7% (p=0.117) 
31% (p=0.125) 
[n=230] 
Rebif® 386 36.7 - 2.35 5.93 62% 11.7% 38% [n=230] 
Copaxone® vs. Betaferon® (BEYOND) 
Proportion 3m-
month progression 
Number of new T2 
lesions 
Copaxone 448 
24 
months 
35.2 1.6 2.28 5.1 59% (p=0.72) 20% (p=0.68) 4.6 (p=0.011) 
Betaferon® 
(250µg) 
897 
35.8 1.6 2.35 5.3 58% 21% 
 
3.3 
 
 
 
 
 
Trial* N Duration 
Baseline characteristics Efficacy Outcomes 
Age ARR EDSS 
Disease 
duration 
(yrs) 
Proportion 
Relapse-free 
EDSS MRI 
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Teriflunomide vs Rebif® (TENERE)   
Teriflunomide 
(14mg) 
111 
48 
weeks 
36.8 1.4 2.3 6.6 76.6% (NS) - - 
Rebif® 104 37.0 1.2 2.0 7.7 84.6% - - 
DMF vs Copaxone® (CONFIRM) 
Proportion 3mo 
progression 
Number of new T2 
lesions 
DMF (240mg bd) 359 24 
months 
37.8 1.3 2.6 4.9 71% (p=0.58) 16% (NS) 5.1 (p=0.007) 
Copaxone® 350 36.7 1.4 2.6 4.4 68% 13% 8.0 
Fingolimod vs Avonex® (TRANSFORMS) 
Proportion 3mo 
progression 
Number of new T2 
lesions¶ 
Fingolimod 
(0.5mg) 
431 
12 
months 
36.7 1.5 2.24 7.5 82.6 (p<0.001) 6.7% (p=0.25) 1.5 (p=0.004) 
Avonex® 435 36.0 1.5 2.19 7.4 69.3 7.9% 2.6 
Natalizumab plus Avonex® vs. Avonex® alone (SENTINEL) 
Proportion 3mo 
progression 
Number of new T2 
lesions 
Natalizumab + 
Avonex® 
589 
24 
months 
38.8 1.44 2.4 7.0 61% (p=0.001) 23% (p=0.02) 0.9 (p=0.001) 
Avonex® 582 39.1 1.49 2.5 8.0 37% 29% 5.4 
Natalizumab plus Copaxone® vs. Copaxone® and PBO (GLANCE) 
Median EDSS Number of new T2 
lesions 
Natalizumab + 
Copaxone® 
55 24 
weeks 
40.2 1.4 2.6 8 78% (p=0.658) 2.5 0.5 (p=0.029) 
 
 
Trial* N Duration 
Baseline characteristics Efficacy Outcomes 
Age ARR EDSS 
Disease 
duration 
(yrs) 
Proportion 
Relapse-free 
EDSS MRI 
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PBO + Copaxone® 55 42.5 1.3 2.7 8 73% 2.5 1.3 
Alemtuzumab vs Rebif® [Treatment-naïve] (CARE-MS I) 
Proportion 6mo 
progression 
Proportion no new 
T2 lesions 
Alemtuzumab 
376 
24 
months 
33.9 1.8 2.0 2.1 
77.6% 
(p<0.00001) 
8% (p=0.22) 52% (p=0.04) 
Rebif® 187 33.2 1.8 2.0 2.0 58.7% 11% 42% 
Alemtuzumab vs Rebif® [Failed 1st DMT] (CARE-MS II) 
Proportion 6mo 
progression 
Proportion no new 
T2 lesions 
Alemtuzumab 
(12mg) 
426 
24 
months 
34.8 1.7 2.7 4.5 65.4% (p<0.0001) 13% (p=0.0084) 54% (p<0.0001) 
Rebif® 202 35.8 1.5 2.7 4.7 46.7% 20% 32% 
*Superior DMT in bold 
**Less brain volume loss with Copaxone vs. Rebif (-1.24% vs 1.073%, p=0.018)  
¶Less brain volume loss with Fingo vs. Avonex (-0.3 vs -0.45, p<0.001)  
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Table 0-8: Summary of efficacy and safety outcomes from pivotal trials for 
available DMTs  
DMT ARR Reduction vs PBO % discontinued 
Rx 
Avonex® 32% [18% (NS) in non-
completers] 
4% 
Betaferon® 33.9% 8.7% 
Rebif® 33% 4.9% 
Plegridy® 35.5% 4.7% 
Copaxone® 29.7% 1.6% 
Teriflunomide 31.5-36% 10.9-16% 
DMF 44-53% 12-16% 
Fingolimod 48-55% 7.5-18% 
Natalizumab 68% 6% 
Cladribine 57.6% 3.5% 
Alemtuzumab - 1-3% 
 
Emerging therapies and future trial considerations 
A number of potential disease-modifying therapies are emerging for both 
relapsing and progressive forms of MS. The DMTs described so far were 
developed largely with the aim of immunomodulation or selective 
immunosuppression, which is reflected in the outcome measures of the pivotal 
trials – therapies are largely deemed effective due to their impact on relapse 
rates and MRI inflammatory activity. With time, the focus of therapeutic efficacy 
has moved back towards preventing established disability, which was in fact the 
aim of the early IFN trials. The translation into long-term impact from proven 
(short-term) beneficial effects on measures of inflammatory disease activity 
remains uncertain, as discussed in our MODERATE study, and so there is a move 
toward measurable short-term trial outcomes with greater longitudinal 
relevance.  
Essentially, this means better measures of neurodegeneration, the likely 
mechanism by which long-term disability occurs in MS, though it seems unlikely 
that this is independent of inflammation and a role for anti-inflammatory 
treatments will therefore remain. The mechanisms of neurodegeneration in MS 
and other neurological conditions have not yet been fully elucidated, but loss of 
neural tissue (as measured radiologically by brain or spinal cord atrophy) likely 
represents a final common pathway, and so is a potentially useful biomarker to 
evaluate this. Neural breakdown products such as neurofilaments are another 
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way in which tissue (axonal) loss can be measured. In terms of clinical outcomes 
of neurodegeneration, cognitive measures are likely to be important given the 
multifocal network anatomy involved in higher functions, therefore also 
providing a final common pathway in grey and white matter loss. Lastly, patient 
reported outcome measures (PROMs) are now being considered robust enough to 
base efficacy results upon and of course provide a patient-centred measure of 
treatment which has long been absent from clinical trials in MS. The move 
towards this is exemplified by the recent Ocrelizumab studies which have 
included quality of life measures as a pre-defined outcome for analysis. 
With these factors in mind, a role for DMTs targeted at neuroprotection and 
immunomodulation is suggested but further iterations of established DMTs are 
likely to be the next available wave of treatments. More selective sphingosine-1-
receptor modulators such as Ponesimod [NCT02425644] and Ozanimod 
[NCT02047734] aim to reduce potential side effects of fingolimod whilst 
retaining its efficacy. The fully humanised anti-CD20 monoclonal antibody 
Ofatumumab [NCT02792218] has similar aims as a ‘next generation 
Ocrelizumab’. Novel anti-inflammatory mechanisms have also been explored, 
such as the anti-CD25 monoclonal antibody Daclizumab which acts through 
interleukin-2 inhibition, but this has currently been removed from the market 
because of safety concerns despite having been licensed initially74,75. A number 
of neuroprotective agents have been studied, with varied results, but none have 
yet reached licensed therapy status76. A specific approach is promotion of 
remyelination, Opicinumab being an example which is currently being tested in a 
Phase II/III study [NCT03222973]. Opicinumab actively binds Nogo receptor-
interacting protein-1 (LINGO-1) which otherwise negatively regulates 
myelination and inhibits neurite outgrowth. A Phase II study did not meet its 
primary endpoint but this may also reflect the challenge of demonstrating 
effects on neurodegeneration given the likely longer trial durations required to 
do so77. Additionally, phenytoin, through its sodium-channel stabilisation effects, 
has been shown to reduce retinal neural loss when used early in optic neuritis78 
but further study is needed to confirm the utility of this in larger cohorts.  
Indeed, the repurposing of drugs licensed for other indications has become a 
strategy for drug discovery in MS, obviating the need for time-consuming and 
expensive development programmes essentially available only to large 
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multinational pharmaceutical companies. Minocycline79 and clemastine80 are 
examples of this for RRMS but this approach has been used for progressive MS 
given the accessibility of these to smaller institutions where the financial burden 
of drug discovery would otherwise preclude this. 
The focus of this thesis is on RRMS and a detailed discussion on treatment of 
progressive MS is beyond its scope. That said, the development of DMTs for 
progressive forms of MS, both SPMS and PPMS, bears mentioning given the 
therapeutic nihilism that has existed until now. The FDA has approved 
Ocrelizumab for use in PPMS following a successful demonstration of benefit in a 
placebo-controlled Phase III study81. This is the first licensed therapy for PPMS. 
Similarly, Siponimod (another S1P-modulator) has been shown efficacious in 
SPMS82 and high dose Biotin, an endogenous co-factor (‘Vitamin H’), also appears 
promising and remains under evaluation as a neuroprotective agent thought to 
act through promotion of remyelination, amongst other mechanisms83. The 
effectiveness of immunomodulatory therapy serves as evidence for the 
hypothesis that the progressive forms of MS are simply a different stage of the 
disease rather than a separate entity to RRMS, and that DMTs are likely to be 
effective for both if outcome measures are appropriately applied over the 
correct duration of time84. 
Lastly, the focus on MS in isolation has recently been questioned by evidence 
supporting the role of co-morbidities in detrimental outcomes for people with 
MS85. Clearly this is particularly relevant for progressive phenotypes due to 
advanced age but is also relevant in RRMS where present. The trials presented 
here generally exclude significant co-morbidities in order to demonstrate 
efficacy in the absence of significant confounders but in real-world practice this 
does not apply. This, firstly, calls into question the applicability of the stated 
results to populations who were not included in the trials and, secondly, the 
unmeasured impact of non-MS diagnoses on their outcomes. Whilst younger 
patients with RRMS may have few, if any, co-morbidities at diagnosis these will 
inevitably accumulate as per the usual epidemiology of their location, genetic 
background and lifestyle factors common to all in society. Remaining cognisant 
of other co-morbidities is therefore vital is considering the role of MS as perhaps 
only one facet in a holistic care model. 
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In conclusion, the natural history of RRMS is well established from work in the 
pre-treatment era and there are now numerous treatments with demonstrable 
disease-modifying capabilities which have been studied in large randomised 
controlled trials. There remain issues in extrapolating natural history data to the 
modern era, not least because of changing definitions of MS over time, and one 
must be aware of the limitations of trial data. However, the growing number of 
treatment options for patients with MS, including progressive forms, is welcomed 
and provides choice to clinicians and patients which was not available in the 
past. The following chapter reviews the literature on the use of DMTs in practice 
and summarises some of our own experience with recently-introduced oral 
agents.
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Chapter 1: DMT initiation and escalation in RRMS 
Introduction 
Literature Review 
At present, there are over ten licensed disease-modifying therapies (DMTs) for 
RRMS, with more expected in the near future, as described earlier. This chapter 
evaluates the literature regarding DMT initiation and escalation in general and 
the use of Dimethyl Fumarate (DMF) and Fingolimod in our centre in particular as 
examples of the role of real-world evidence supplementing randomised trials.  
DMT initiation 
Evidence of asymptomatic radiological and pathological CNS changes suggest 
that by the time first symptoms occur in MS the disease process is often already 
well established. There is a spectrum of disease from asymptomatic microscopic 
pathological abnormalities to macroscopic radiological changes (RIS) and 
symptomatic clinical events which can be isolated (CIS), recurrent (RRMS) or 
progressive (PPMS). The best point at which to initiate DMTs along this timeline 
must therefore be considered, in the knowledge that not all those with 
asymptomatic lesions will be affected and that the prognosis is highly variable 
even in those who develop symptoms. There remains significant variation in the 
practice of clinicians and the guidance of national advisory bodies worldwide as 
to when DMTs should be instituted, or offered at least, and the evidence often 
appears contradictory. Similar to the apparent dissociation between 
inflammatory and degenerative processes from an immunopathological view in 
MS, there appears to be disparity between short-term beneficial effects of DMT 
initiation early in the disease course and long-term outcomes. This evidence 
largely comes from trials of IFNs however, and so may have limited applicability 
to newer DMTs that have demonstrably more powerful anti-inflammatory 
effects. Additionally, the role of induction therapies at an early stage shows 
promise in modulating both inflammatory and degenerative activity but their 
relatively recent development limits conclusions about long-term outcomes.  
Notably, all of the studies cited to demonstrate benefits of early treatment, or 
not, suffer from methodological limitations, not least the use of the EDSS as an 
outcome measure. This largely relies on motor disability to demonstrate 
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symptomatic worsening, when non-motor symptoms can often be just as 
disabling.  
 
Timing of treatment in Multiple Sclerosis 
By definition, patients must have had clinical symptoms to meet diagnostic 
criteria for MS86. Further, these must be ‘typical of an acute inflammatory 
demyelinating event in the CNS’ with non-focal, but arguably CNS-related, 
symptoms such as fatigue or depression not included. For a CIS, a single clinical 
demyelinating event has occurred; this can also be the case for RRMS if 
dissemination in time and space can be otherwise demonstrated. With the 
advent of MRI for investigation of a wide range of neurological presentations, 
radiological changes typical of MS, including dissemination in time and space, 
have been seen in patients with no clinical history of typical demyelinating 
events. This has been termed the Radiologically Isolated Syndrome (RIS)87. This 
is currently the earliest in vivo manifestation of subclinical demyelination 
available to clinicians and researchers. Importantly, this does appear to be a 
prelude to MS development as the majority develop further radiological disease 
activity within 2-5 years and around a third have a clinical demyelinating event 
during this time88. There have been no attempts at systematic treatment trials 
in RIS, but rather single-figure cases of treated patients included in MS study 
cohorts with off-label DMT use. There is therefore no robust data on treatment 
outcomes in RIS and the focus remains on delineating its natural history. 
Given the relatively recent discovery of RIS and uncertainty as to its natural 
history, CIS is currently the earliest stage of CNS demyelination where the utility 
of DMTs has been evaluated in a systematic way. There have been a number of 
clinical trials of DMTs in CIS, as described below, but there are other data which 
support the consideration of treating demyelination at the earliest opportunity89 
and these are considered first. 
‘Epitope spreading’ describes the propagation of immunological self-recognition 
with recurrent exposure of a single antigenic stimulus. This was described in the 
animal model of MS, Extrinsic allergic encephalomyelitis (EAE), and purports to 
explain, in part at least, the increasing complexity of the immune response with 
time. Using T-cells activated against a single epitope in proteolipid protein 
   
 
102 
(PLP), an abundant myelin component, the EAE mouse model was created. Yet, 
after recurrent relapses in the animal, T-cells reactive against another epitope 
were demonstrated90. This appears to be a fundamental immunological 
phenomenon and suggests that autoimmunity begets autoimmunity such that the 
host response multiplies its defence against a single antigen to include other 
(potential) antigens, increasing the likelihood of erroneous self-attack. It 
follows, therefore, that if the immune response can be halted before the 
propagation of self-recognising epitope spreading, perhaps this will limit the 
damage caused by any multiplied response. The counter to this is the known 
limitations of animal models in general, and EAE in particular, in replicating the 
human situation. 
Early treatment can also be considered in order to prevent the axonal loss 
thought to underlie persistent disability in MS. Since the first pathological 
diagnosis of multiple sclerosis, axonal damage has been known to occur38 and 
this has been confirmed in modern studies, where axonal transection was seen in 
lesions from patients with disease duration from two weeks to 27 years91. Of 
course, the availability of biopsy tissue marks these cases out as unusual, but it 
is generally accepted that this is a feature of all MS lesions. In early disease, 
compensatory factors may prevent irreversible axonal loss, particularly via the 
integrity of the oligodendrocyte-axonal unit. With recurrent injury however, 
compensatory mechanisms such as remyelination may fail. This, along with the 
apparent reduction in axonal loss over the course of the disease92, suggests that 
early treatment before irreversible axonal loss occurs and during the period of 
maximal loss may be the best approach to reduce long-term disability. 
Imaging studies provide in vivo evidence of the impact of MS even at the earliest 
stages and, hence, potential treatment targets. MRI correlates of volume have 
been used to estimate atrophy within CNS structures over time and are thought 
to reflect the sum total of both neurons and axons - lower volumes result from 
the loss of both. Whilst volume loss is not necessarily apparent in all patients 
with CIS, it occurs at a higher rate in those who go on to develop RRMS, as 
measured by ventricular enlargement93 and corpus callosum atrophy94. Similarly, 
comparing patients with MS to age-matched healthy controls, there are 
significant reductions of brain and spinal cord volume measured on MRI95. 
Additionally, those with SPMS (and longer disease duration) have significantly 
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lower brain and spinal cord volumes than those with RRMS, suggesting the 
atrophy continues to progress over the disease course. Further, it has been 
established that MRI measures of atrophy, particularly spinal cord grey matter 
atrophy96, correlate with measures of disability97,95 and that the treatment 
effect of DMTs on disability independently correlates with their effects on MRI 
brain atrophy measures98. These data suggest that CNS atrophy occurs at the 
earliest stage of MS and could be used as a treatment target biomarker to assess 
the efficacy of DMTs in relation to disability progression. It should be 
remembered, however, that the ‘disability’ with which atrophy was correlated 
by Sormani et al.98 was the short-term disability progression at 3- or 6-months 
from large clinical trials which has since been demonstrated as frequently 
reversible35 and perhaps relapse-related, rather than indicative of relentless 
disability worsening.  
The concept of a ‘window of opportunity’ for treatment, that there is a 
timepoint after which treatment will be less or ineffective in MS, derives from 
the use of Alemtuzumab in patients with RRMS and SPMS. The first use of 
Alemtuzumab in MS included 58 patients with relapsing-remitting and secondary 
progressive disease. This was an open-label study conducted between 1991 and 
2002 with a mean follow-up of 29 months99. In patients with established 
secondary progressive disease (n=36), a significantly reduced relapse rate 
[0.7/yr to 0.001/yr (p<0.001)] and absence of new lesions on MRI was 
accompanied by progressively worsening disability of the group over the study 
period, as measured by the Expanded Disability Status Scale (EDSS). When used 
in patients with RRMS (n=22), in whom licensed treatment had failed or who had 
a high early relapse rate suggesting poor prognosis, the annualised relapse rate 
(ARR) improved by 94% in comparison to the year before treatment, and, unlike 
the SPMS cohort, EDSS improved - by a mean of 1.2 points 2 years after a five-
day course of 20mg Alemtuzumab/day intravenously. Following this, a ‘window 
of opportunity’ to slow disease progression was suggested in order to explain the 
difference in the outcomes between patients with early versus established 
disease, despite similar reductions in inflammatory clinicoradiological activity. 
The presence of secondary axonal damage was the postulated mechanism for the 
lack of effectiveness in patients with progressive disease. This hypothesis, with 
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rational clinical and pathological evidence to support it, provides further weight 
to the argument that early treatment is likely more beneficial.  
What is not clear, however, is when this window of opportunity ‘closes’. Those 
with established SPMS and resultant disability did not appear to benefit, but at 
what point does SPMS become ‘established’ and ‘untreatable’? There are no 
accepted clinical criteria and there is no diagnostic test that demarcates when a 
patient enters the secondary progressive phase. A standardised definition has 
been recently proposed100. A pragmatic consensus opinion generally defines SPMS 
as the time-point when disability worsens in the absence of (explanatory) 
relapses and usually the disability progression must be confirmed after 1 year. 
Both the relapsing-remitting and progressive phases can be further categorised 
as ‘active’ or not and ‘progressive’ or not, depending on the occurrence of 
subsequent clinico-radiological disease activity or worsening disability on an 
annual basis101. Providing more clarity on the definitions of the dynamic disease 
course of MS may assist in more robust ‘cut-offs’ for the therapeutic window and 
ensure those most likely to benefit receive appropriate treatment at the right 
time. Despite these clinical findings, however, patients with progressive MS 
continue to have evidence of CNS inflammatory activity102, suggesting there 
remains an inflammatory target in the progressive phase which may be amenable 
to treatment. The uncertainties underlying this may, however, contribute to 
therapeutic inertia in MS whereby potentially disease-modifying therapies are 
not instituted or considered despite evidence of disease worsening. 
 
Trials of DMTs in early MS and predictors of treatment response 
Trials of DMTs at the earliest clinical stage of MS, Clinically Isolated Syndromes 
(CIS), suggest there is a short-term benefit but this does not appear sustained in 
long-term extension studies. There have been 4 large trials of DMTs in CIS103–106. 
These have all shown significant reductions in conversion to MS from CIS in the 
treated cohorts in comparison to placebo. Between 43 and 50% of the untreated 
CIS cohort converted to MS in comparison to between 25 and 35% of the treated 
patients over 2-3 years.  
Kappos et al. describe benefits of early treatment in terms of disability levels, 
relapse rates and MRI burden of disease after 8 years of follow-up comparing 
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those commenced on IFN (Rebif®) immediately or delayed (after 2 years) as part 
of a RCT, but also outline the issues inherent in long-term follow-up studies to 
which theirs and others are subject107: 
1) Patient ascertainment – those remaining under long-term follow-up will 
tend to be tolerating the treatment and perceiving it as beneficial more 
so than those who are lost to follow-up as they choose to stop treatment, 
pursue alternatives or simply cannot participate in the study requirements 
due to accumulated disability i.e. these studies will favour treatment-
responders 
2) Lack of long-term parallel placebo control group 
3) Changing (improved) MRI technologies which may affect data 
4) Retrospective assessment of relapses and adverse events may result in 
recall bias 
5) Difficulties confirming EDSS progression 
6) Unblinded assessment of patients no longer on study treatment 
7) Treatment interruptions and conversion to non-study medications 
In terms of disability outcomes, they found that 23.9% (32/134) of those initially 
randomised to Rebif® 44mcg TIW reached EDSS 4.0 by 8 years in comparison to 
27.6% (37/134) in the delayed treatment group. They could not make 
comparisons of SPMS development as this was not collected in the original study. 
Goodin et al108 found that long-term physical and cognitive outcomes were not 
significantly affected by whether patients were randomised to Betaferon® or not 
within the first 2 years. Assessing patients 16 years after their involvement in a 
pivotal IFN trial, the authors sought to identify which factors in that early course 
of their disease related to long-term outcomes. Reflecting that this study is 
similarly subject to the methodological flaws outlined above, only 260 (69.8%) of 
those involved in the original trial were included in this analysis. Those who 
participated in the long-term follow-up were largely comparable to those who 
did not however, other than the proportion that received active treatment 
(IFNβ-1b 250µg) during the 2-year trial was higher in those included in the long-
term follow-up in comparison to those who were not (37% vs 25%, p=0.0178). 
Using univariate regression, a number of variables were assessed for their 
correlation with physical (EDSS or SPMS conversion) and cognitive (summary of 
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PASAT, SDMT, CVLT-II, COWAT and D-KEFS tests) outcomes. Physical outcomes 
were statistically significantly correlated with baseline EDSS, relapses during the 
trial and EDSS change over the course of the trial. However, the correlations 
were fairly weak (R2 0.22 for baseline EDSS and 0.12 for on-trial ARR). Similarly, 
baseline EDSS, baseline MRI T2 lesion volume, third ventricular width (baseline 
and change during trial) and premorbid IQ had weak (but statistically significant) 
correlation with cognitive outcomes at 16 years. Notably, being on treatment 
during the 2-year trial period did not correlate significantly with either physical 
or cognitive outcomes at 16 years. Similarly, the on-trial change in T2 MRI brain 
lesion volume, a common short-term outcome measure, did not correlate with 
either physical or cognitive outcomes. The authors conclude that long-term 
outcome in MS may be largely determined early in the disease course and that 
baseline characteristics, before treatment, appear more important than the 
treatment thereafter. Again, this may suggest that treating those with the most 
severe disease earlier is optimal and that patients presenting with more 
established disability will benefit less from treatment in the long-term.  
Interestingly, the same group evaluated this cohort at 21 years with regards to 
overall survival109. In this study, they were able to determine the relevant data 
for 366 (98.4%) of the original trial cohort (121 original PBO arm; 245 original IFN 
arm) and found that all-cause mortality was significantly lower in those included 
in the original treatment arm (mean 21.1 years previously) in comparison to 
those randomised to placebo. This was in spite of the fact that all were then 
offered open-label treatment and did not differ systematically (although the 
treatments used after the 2-year trial are not presented). A total of 81 (22.1%) 
deaths occurred over the follow-up period, 37 who had originally been in the 
placebo arm (30.6%) and 44 who had been in the treatment arm (18%). Those in 
the high-dose treatment arm had a reduced hazard of death during follow-up in 
comparison to the placebo group (HR=0.532, 95%CIs 0.314-0.902, p=0.0173) 
hence there was almost a 50% relative reduction in mortality in the treatment 
group. The groups were randomised, hence, whilst co-morbidities and other 
confounders for all-cause mortality are not presented, it would be assumed they 
were balanced on such measures. Additionally, of those whose cause of death is 
reported, the majority were considered MS-related, raising the possibility that 
early treatment may have prevented these. This finding has not been evaluated 
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in a prospective, systematic way, however, therefore it is difficult to form firm 
conclusions regarding the impact of early treatment on longer-term mortality 
from this analysis alone, but a recent study of the Danish MS register also found 
evidence for a shortened time to death for patients starting DMTs 2 years after 
their first symptom in comparison to those starting sooner, after over 10 years of 
follow-up110. 
In an attempt to overcome some of the systematic methodological flaws 
common to long-term follow-up studies, Trojano et al. used statistical matching 
in order to compare contemporary treated and untreated cohorts followed for a 
median of 5.7 years and found significant benefits in the treated group111.  
Patients with RRMS (Poser and McDonald criteria) were recruited from 2 Italian 
centres and treatment with IFN assigned at the discretion of the treating 
physician and patient as part of usual clinical practice. Those treated with IFN 
(n=1103) were then compared with those not treated (n=401).  Obviously, the 
cohorts differed due to indication bias, amongst other variables, hence were not 
comparable. The cohorts were therefore matched statistically by including a 
propensity score within Cox proportional hazards regression models. Whilst 23% 
of the untreated cohort did not receive treatment because their disease was 
considered too mild (no relapses in past 2 years and EDSS<3), a number of other 
factors were relevant to this group: refused treatment (19%), planning 
pregnancy (15%), discontinuation of DMTs within 3-6 weeks due to adverse 
events and significant concomitant disease preventing the use of IFN (23%). Time 
to SPMS and disability milestones EDSS 4 and 6 were the endpoints compared in 
the matched samples. The cohort size was reduced in the matching process (as 
not all participants had a comparable match), such that n=1328 for the SPMS 
endpoint, 1246 for EDSS 4 and 1378 for EDSS 6. Using these matched cohorts, 
there was a significant reduction in the risk of developing SPMS [HR 0.38 (95%CIs 
0.24-0.58) p<0.0001] in the IFN-treated group in comparison to the untreated 
group. For EDSS 4 and 6, there was also a lower risk in reaching these endpoints 
in the treated versus untreated patients [HR 0.7 (0.53-0.94), p=0.0174 and HR 
0.6 (0.38-0.95), p=0.0304 respectively]. The percentage of patients that reached 
SPMS after 7 years of follow-up was 20.2% for the untreated group versus 8% for 
IFN-treated patients. Similarly, in terms of proportions, 28% of untreated 
patients had reached EDSS 4 by 7 years and 12.4% EDSS 6; for IFN-treated 
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patients, 20.5% and 7.7% reached these endpoints respectively. Sensitivity 
analyses were undertaken which suggested only an unmeasured confounder 
between the groups with a hazard ratio of ≥2 would be required to lose the 
observed significant effect of IFN on the measured outcomes. The authors 
conclude that this study suggests that IFN-β delays the inevitable and 
irreversible clinical worsening seen in pre-treatment era natural history cohorts, 
which the untreated group was comparable with in terms of outcomes. They 
concede the usual biases associated with observational studies but contend that 
the statistical matching process at least accounts for overt confounders and the 
sensitivity analyses, whilst suggesting an unknown confounder could invalidate 
the results, do not imply a confounder necessarily exists. The study was heavily 
criticised as it was thought to specifically suffer from immortal time bias 
(described earlier), and when it was reanalysed taking this into account the 
positive results did not persist. 
These data provide some support for the early use of DMTs in RRMS, but once 
the decision to embark upon DMTs has been made, a number of questions 
naturally follow. Firstly, with numerous licensed therapies, which one to choose 
can be somewhat daunting for both patients and clinicians given the differing 
properties of each in terms of efficacy, safety, administration and monitoring. 
Cost is certainly a consideration for patients in fee-paying healthcare services 
and obviously impacts upon approvals in the UK, but is not considered in detail 
here. The wealth of data from large, high-quality, randomised trials is certainly 
empowering, but can also be potentially overwhelming in treatment decisions 
for patients and non-specialists. The lack of head-to-head trials for most of the 
available DMTs results in an inability to derive fully evidence-based conclusions 
on relative safety and efficacy outcomes between many of the options.  
Certain DMTs have pronounced immunomodulatory effects such that their use 
can be considered to have long-term effects even after treatment is 
discontinued. The majority of licensed therapies, however, are seen as 
maintenance therapies that lose their efficacy when stopped, albeit some 
appear more effective in reducing disease activity than others. These two 
classes of DMT belie the treatment paradigms of induction and escalation in MS 
respectively. The decision to use a high-efficacy broad immunomodulator at the 
outset is tempered by the higher risks associated with such treatment and the 
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difficulty in accurately prognosticating long-term outcomes in MS at an early 
stage and, hence, who is likely to benefit most. Equally, high-efficacy 
maintenance therapies have significant associated risks and the escalation 
approach demands failure of initial treatment(s), exposing the patient to a 
sequence of immunomodulating therapies, the long-term safety of which is not 
established. Further DMT use may be necessary in patients despite an induction 
approach and of course the same concerns apply but it appears the frequency of 
this is significantly lower. 
Escalation and Switching 
It is clear that MS disease activity continues in a significant proportion of 
patients after DMTs are started and deciding if and when to change treatment 
remains a common clinical problem. This is largely informed by perceived 
benefits of reducing overt clinical or radiological disease activity in the short-
term although the level of disease activity which is reasonable to tolerate (if 
any), what therapy should be offered as an alternative, and the impact on long-
term outcomes remains controversial.  
 
DMT therapeutic paradigms 
Induction 
The concepts of induction and escalation in MS therapeutics result from the 
growing number of DMT options over recent years, with differing mechanisms of 
action and efficacy. Thus, when IFN and GA were the only licensed options, 
there were obvious limits in the therapeutic strategy. Freedman defined 
induction as moving either transiently or completely to a 2nd-line drug before 
ever attempting first-line therapy112, whilst Rieckmann described it in terms of 
the goal of ‘resetting’ the immune system to avoid epitope spreading and 
prevent early structural damage113. The latter mechanistic description seems 
most appropriate as 2nd-line therapies are often designated so due to safety, and 
possibly economic, issues rather than their mechanism of action: hence, 
Fingolimod and Natalizumab are considered 2nd-line therapies but not with the 
aim of inducing a permanent alteration of the immune system. Additionally, the 
understood mechanisms of action of these agents and the apparent reversibility 
of their pharmacodynamic effects on discontinuation suggest there is no 
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fundamental change to the immune system with their use. In contrast, 
Mitoxantrone impacts upon DNA and hence protein synthesis upstream of 
circulating immune cells, suggesting a basic alteration in immune (and other) 
cell-lines.  
Alemtuzumab is perhaps the clearest example of an induction agent given its 
demonstrable CD52-mediated depletion of lymphocytes and resultant subsequent 
switch from a pro-inflammatory Th1 lymphocytic phenotype to anti-
inflammatory Th2 after treatment114. This measurable re-population of 
lymphocytes over years after a short course of Alemtuzumab treatment implies a 
fundamental change in the immune repertoire, but whether this is maintained 
thereafter is not known. So-called induction agents can be used first-line if 
induction is the goal and this would appear to be the logical time for greatest 
benefit, but the inherent adverse safety profile associated with broad 
immunosuppression limits their use in this way. For this reason, induction is 
generally reserved for those with active, aggressive disease where the balance 
of risks can be considered to favour treatment risks over disease risks. The 
difficulty remains, however, on an individual patient basis, in predicting whether 
their early active disease will undoubtedly result in long-term disability. Equally, 
reserving induction therapies for those with highly active disease implies 
reassurance for those with less disease activity who may actually have 
comparatively worse long-term outcomes, perceived or actual, depending on 
their lifestyle, the future characteristics of their disease or their goals. 
There is precedent in the induction approach in other conditions. Use of 
Cyclophosphamide followed by maintenance steroids is the standard approach in 
ANCA-associated systemic vasculitis115 and bone marrow transplant in 
conjunction with cytotoxic chemotherapy has resulted in drastic disease-free 
survival benefits in haematological malignancies which were previously fatal116. 
Of course, MS is not a life-threatening illness hence the aggressive approach in 
other conditions is not comparable, given the treatment risks, but the model is 
applicable.  
The focus on MS as a T-cell dependent autoimmune condition has been 
challenged in the last decade, not least by the efficacy of Alemtuzumab which 
depletes B- and T-lymphocytes. This recognition has led to investigation of a 
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number of B-cell depleting agents in recent years, with positive results in both 
relapsing and progressive MS phenotypes71,117–119. Rituximab and its humanised 
analogues Ocrelizumab and Ofatumumab are anti-CD20 monoclonal antibodies 
which target circulating B-cells but, importantly, do not affect long-term 
memory and early progenitor cells and so have more predictable and less 
widespread deleterious effects: this seems borne out by favourable safety 
profiles from trial experience thus far. It is proposed that the benefits of B-cell 
depletion include T-cell effects given the loss of antigen presentation and 
secondary effects, rather than purely through B-cell loss, retaining the role of T-
cells in the immunopathogenesis of MS. Whilst there is lymphocyte depletion 
however, typical of an induction agent, this does not appear sustained in the 
same way as Alemtuzumab’s effects, so long-term dosing is advocated for these 
agents. This is perhaps a benefit, given the ability to discontinue treatment and, 
presumably, reverse or reduce deleterious effects, but requires long-term 
financial expenditure. In this sense, it is proposed that B-cell depleting agents 
are used as a maintenance therapy despite their induction qualities.  
The common theme to these agents is their ability to deplete immune cells, 
resulting in necessary re-population, rather than simply reducing cell trafficking 
or modulating their function. This non-targeted approach clearly has undesirable 
wider effects and has limited the use of the induction approach from a practical 
point of view as much as any theoretical debate over MS treatment paradigms. 
Alemtuzumab and Cladribine are licensed induction agents in the UK presently 
but only Alemtuzumab can be used as a first-line therapy although this is not the 
case globally. The expected introduction of DMTs with induction properties yet 
more favourable safety profiles is likely to result in more widespread use of this 
approach. 
Escalation 
The current standard treatment paradigm for RRMS remains escalation. In this 
approach, the safest treatment is used first and switching to higher risk DMTs is 
only considered if this fails. The higher risk DMTs generally equate to higher 
efficacy but the lack of head-to-head randomised trials prevents this conclusion 
being definitive. From the available evidence where comparator trials have been 
undertaken, however, some conclusions can be drawn as outlined earlier. 
Alemtuzumab was more effective than Rebif®, whether patients were 
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treatment-naïve69  or had failed previous treatments120. The addition of 
Natalizumab to Avonex®121 or Copaxone®122 results in better efficacy outcomes 
than these agents as monotherapy, although benefits were minimal in the latter. 
Fingolimod had better efficacy outcomes in direct comparison with Avonex®123 
and there was a trend, but non-significant, to Dimethyl Fumarate comparing 
favourably with Copaxone®65. There was no demonstrable difference between 
Teriflunomide and Rebif® in terms of efficacy124 but Rebif®47 and Betaseron®125 
were superior to Avonex®. Copaxone® was equivalent to both Rebif®126 and 
Betaseron®127.  
Blinding is problematic in these trials, given the varied modes and frequency of 
administration. Indeed, the issue with a number of these studies is the lack of 
double-blinding and often short follow-up periods, again, making definitive 
conclusions difficult. That said, the escalation paradigm presupposes superiority 
of some DMTs over others in this way. Given the lack of randomised and double-
blinded trials with adequate follow-up, post-hoc re-analyses of the data have 
been undertaken, for example, as network meta-analyses52,53. Of course, these 
are based on the flawed data described and placebo-controlled trials, meaning 
that conclusions are not equivalent to a prospective, multi-arm randomised, 
blinded trial. However, a 3-tier efficacy ladder is generally accepted, with the 
monoclonal antibodies Natalizumab and Alemtuzumab likely most efficacious 
and the injectable therapies (IFN/GA – ‘BRACE’ – an acronym of their trade-
names used above) least effective. Fingolimod is considered more effective than 
Dimethyl Fumarate and Teriflunomide, which are considered either equivalent 
or Dimethyl Fumarate possibly superior. However, Teriflunomide is the only oral 
DMT associated with reduced risk of sustained progression of disability 
(confirmed at 3 months) in both its pivotal placebo-controlled trials62,63. This 
applies to the hazard ratio of sustained disability progression [0.7 (95%CIs 0.51-
0.97, p=0.03)] and time to sustained progression [0.68 (0.47-1.0, p=0.0442)] but 
the proportion of patients free from sustained progression, as reported in the 
other oral DMT trials, was not significantly different to placebo, as the 95% CIs 
cross.   
From the head-to-head studies cited, this ‘order’ of DMT efficacy seems 
credible, with all agents comparing favourably to Avonex® where tested; 
Copaxone®, Rebif®, Betaseron® and Teriflunomide appearing equivalent to each 
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other; Dimethyl Fumarate trending towards superiority against Copaxone® and 
Alemtuzumab clearly superior to Rebif® (in an unblinded trial). The magnitude 
of Fingolimod’s efficacy over Avonex® compares favourably with Avonex’s 
comparisons to other injectable treatments, again, suggesting a degree of 
superiority above these. Natalizumab is the slight outlier, given its lack of direct 
comparison to the other DMTs or trial evidence of use in patients failing previous 
treatment. Again, though, the magnitude of its efficacy over placebo belies its 
position as a higher-efficacy agent in comparison to placebo-controlled trials of 
the other DMTs. Indeed, this order is borne out in the network meta-analyses 
cited above and the real-world observational studies discussed below.  
Of course, a major flaw in all of these apparent comparisons is the outcome 
measure used to compare them. The above descriptions are largely based on 
relapse rates, which have previously been discussed as of potentially limited 
value as an outcome measure, particularly if long-term disability prevention is 
the goal. Short-term (3- or 6-month) disability worsening and MRI lesions and/or 
atrophy are alternatives but also have flaws in their predictive value of long-
term disability. The ‘efficacy ladder’ is therefore based on short-term outcomes 
and weighted towards relapse rates as this has been the primary outcome for the 
majority of DMT trials. Quality of Life and other PROMs are not assessed in a way 
which permits comparison of DMTs based on these important outcomes either, 
for example. In TENERE, however, scores on the Treatment Satisfaction 
Questionnaire for Medication (TSQM) were a secondary endpoint, with 
significantly higher scores for Teriflunomide over Rebif® (68.82 vs 60.98, p=0.02) 
despite no demonstrable efficacy difference124. The role of PROMs as an 
outcome measure is likely to increase over time, particularly if efficacy and 
safety are comparable between agents: this would require a paradigm-shift in MS 
trials, however, and necessitate much improved understanding of the 
interpretation and limitations of such measures, including their validity and 
precision, within the global MS community. Certainly, robust (ideally short-term) 
outcome measures which predict long-term disability accurately remain elusive 
but are necessary for future DMT comparator studies to allow accurate ordering 
of their efficacy. Serum, CSF and MRI biomarkers are postulated as potential 
outcome measures to address this, but are not yet validated in this way. 
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Safety considerations are of course paramount in the minds of clinicians and 
patients when comparing DMT options. The majority of adverse events are 
usually recognised during Phase 2 and 3 studies, permitting their anticipation 
(and therefore mitigation) once drugs are in clinical use. However, the 
development of PML in 2 patients involved in the SENTINEL study (combining 
Natalizumab and Avonex®), after the study in one case, raised major concerns 
about the risks of DMTs which may not be apparent from a 1-2 year trial. These 
events led to the withdrawal of Natalizumab from the market and its re-
introduction only after a strict risk mitigation scheme was developed and long-
term pharmacovigilance agreed. Phase 4 post-marketing studies have become 
pivotal to the monitoring of DMTs outwith clinical trials and offer the only 
reasonable method of identifying unanticipated long-term safety issues. In 
TRANSFORMS (comparing Fingolimod with Avonex®), for example, there were 2 
cases of breast cancer and 3 cases of melanoma in the 0.5mg Fingolimod group 
and none in the Avonex® group. The authors conclude that the numbers are too 
small to draw definitive conclusions about causality, hence raising the concern 
of RCTs being underpowered to demonstrate differences between cohorts when 
rare, but serious, events are considered. In this study, there were also 3 cases of 
Basal Cell Carcinoma (BCC) in the Fingolimod cohort versus 1 in the interferon 
group: since Fingolimod has been licensed, it has become apparent that BCC 
occurs at a higher rate with Fingolimod use than would be expected and, hence 
should be actively monitored for in treated patients. Similarly, the development 
of PML in patients using Fingolimod and Dimethyl Fumarate, after their 
licensing, in patients never treated with Natalizumab provides further evidence 
of the need for post-marketing safety monitoring and should be borne in mind by 
clinicians discussing newer DMT options128,129. The apparent parallel increase in 
efficacy and safety issues is noted and some suggest that risk of adverse events 
is a proxy for efficacy, for the currently licensed treatments at least. As 
understanding of the cause(s) of MS improves and treatments become more 
targeted, it could be anticipated that unexpected adverse events become less 
prevalent. 
Treatment failure definitions 
A model for escalation of treatment to more efficacious, higher risk treatments 
is only rational if treatment failure can be defined. However, there remains 
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uncertainty as to what constitutes a failure of treatment in terms of efficacy 
and, therefore, when escalation of treatment should be considered130,131. There 
are a number of studies which have aimed to determine prognostic factors based 
on early clinico-radiological outcomes in treatment trials and, hence, identify 
which patients are likely to benefit from a change in treatment.   
The decision to change DMT is based on the balance of tolerability and efficacy. 
Intolerable side effects may lead to a ‘horizontal’ switch to a DMT of similar 
efficacy and safety profile; lack of efficacy would suggest the need to introduce 
a higher efficacy treatment (‘vertical’ switch), albeit with a potentially less 
favourable safety profile. It is the ‘vertical’ switch to higher efficacy DMTs that 
is a particular subject under review here, but ‘horizontal’ switching to an agent 
with a different mechanism of action has a biological basis and is employed by 
some clinicians. 
The difficulty in quantifying the number of relapses or new MRI lesions ‘allowed’ 
before escalating treatment (in other words, defining ‘treatment failure’), is 
borne of the fact that no DMT is completely successful in suppressing such 
measures of disease activity, and RRMS symptoms are episodic by definition. In a 
given individual the assumption that that individual would have more 
lesions/relapses/disability were they not on treatment may be entirely 
incorrect. Further difficulties arise from the time course and individual nature of 
the history during DMT treatment – for example when a DMT is well tolerated 
and perceived to have been relatively efficacious prior to a change in disease 
status (such as a patient relapsing after 4 years of relapse-free therapy), 
whether to switch, and what to switch to, can present particular challenges. 
In clinical practice a number of clinical and radiological factors govern the 
decision about whether to escalate to higher efficacy treatments – these 
‘markers of disease activity’ are imperfect and limited, but are the best guide 
available in routine practice currently. A number of groups have attempted to 
provide specific guidance on the level of worsening that suggests treatment 
failure and a need to switch, based on post-hoc analysis clinical trial data 
132,133134, observational studies135,136 or expert opinion137. All agree that 
development of new relapses and MRI lesions are markers of treatment failure, 
but there is no clear consensus on how to quantify these. The Canadian group137 
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also include disability progression (as measured by EDSS) in their decision-making 
model, but this necessitates detailed objective examinations at two time-points, 
which is not always undertaken in routine clinical practice.  
The Rio score138 was based on an observational cohort of 222 RRMS patients and 
used 1-year data to predict outcome at 2 years, including MRI, relapse and 
disability criteria. The Modified Rio Score (MRS) was adapted from this to include 
only relapses and MRI, using 4-year data from a pivotal trial of IFNβ-1a139. MRI 
findings after 1 year of treatment are dichotomised into either ≤4 new T2 lesions 
or more. Scores of 0-2 were given for 0, 1 or 2 relapses respectively and, 
combined with the MRI score, had prognostic value for disability progression 
within the next 3 years. Hence, it was argued that >4 new T2 lesions and 1 or 
more relapses after 1 year of treatment would suggest the need for an 
alternative strategy where possible, as these patients could be considered ‘non-
responders’. 
Bermel et al.132 assessed patients from another pivotal placebo-controlled IFN 
trial140, 15 years after their participation in the 2-year randomised phase, in a 
bid to identify predictors of long-term outcome for those in the treatment arm. 
Disease activity whilst on treatment, as measured by MRI and clinical relapses 
during the 2 year-trial, predicted the severity of disability 15 years after 
completion, despite the fact that treatments differed among patients after the 
trial. These data suggested that >3 new T2 lesions, ≥2 clinical relapses and ≥2 
Gd-enhancing lesions during the 2 –year treatment phase predicted 
incrementally higher odds of severe disability after 15 years. This reinforced the 
importance of disease control in the early stages, as well as suggesting potential 
parameters to guide treatment response (or lack of it). 
Using data from the Avonex-Steroids-Azathioprine (ASA) Study, completed in 
2003, Horakova et al. sought to identify responders and non-responders to IFN 
treatment based on the relationship between year 1 events and outcomes 2-6 
years later134. Of the original 181 patients included in the trial, 172 had 
complete datasets for this post-hoc analysis. All patients had been treated with 
Avonex® but were subdivided such that 56 (32.5%) had no other treatment, 55 
(32%) took Avonex® in combination with azathioprine (50mg od) and 61 (35%) 
took Avonex® combined with azathioprine and prednisolone (10mg alternate 
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days). Since completion of the original study, 126 (73%) had treatment changes 
either during the 1st year of the study (n=3) or in the intervening 6 years 
(n=123). The majority discontinued treatment it seems, with others having 
treatment added or switching to an alternative first-line therapy, but the raw 
numbers quoted in the paper do not tally with the total cohort who changed. 
Median time on any DMT during the 6-year follow-up was 6 years (IQR 62-72 
months) i.e. the population was largely treated for the majority of follow-up 
analysed. Notably, the study was ultimately negative in that the addition of 
azathioprine or prednisolone was not associated with different efficacy in 
comparison to IFN alone141 – therefore, this population can be considered 
comparable to IFN-only treated patients it seems. The authors retrospectively 
divided the follow-up period into a ‘Prediction Phase’ (Year 1 of the study) and a 
‘Response Phase’ (Years 2-6 thereafter) in order to identify early predictive 
factors, in treated patients, which result in poorer outcomes i.e. non-
responders. An Annualised Relapse Score was calculated based on the number 
and severity (based on impact on ADLs) of relapses occurring during follow-up. 
Patients were initially defined as non-responders if EDSS increased from 
baseline, sustained until the entire duration of follow-up, and the Annualised 
Relapse score was >1 on average during follow-up occurred. A 2-stepped EDSS 
increase was used for this definition i.e. increased by >1 if baseline EDSS ≥1 or 
by1.5 if baseline EDSS=0. Thirty-six patients (21%) met both criteria for non-
response, but the analysis is based on 90 patients (52%) who only fulfilled one of 
the pre-defined criteria. From these patients, the number of new MRI T2 lesions 
and Annualised Relapse Score within the first year were predictive of non-
response to IFN treatment. EDSS change was not a statistically significant 
predictor of non-response. Relapse score and the number of T2 lesions were 
further analysed to provide odds ratio for each new T2 lesion or 1-point increase 
in Relapse Score in the first year. Greater than or equal to 1 new T2 lesion 
during the first year of IFN was associated with a 3.3 times higher risk of being a 
non-responder [OR 3.3 (95% CIs 1.6-6.6)] in comparison to no new lesions. 
Interestingly, ≥3 new T2 lesions was associated with a lower, but still increased, 
risk of being defined as a non-responder [OR 2.8 (1.4-5.5)]. Greater than or 
equal to 1 relapse was associated with a higher risk of non-response [OR 2.7 
(1.5-5.0)] and this increased with the number of relapses [OR 3.4 (1.4-8) for ≥3 
relapses]. Combined MRI and relapse activity was strongly predictive of being a 
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non-responder: a relapse score of ≥2 and ≥2 new T2 lesions provided an Odds 
Ratio of 18 (5-67)]. In terms of MRI changes alone, patients with ≥3 new T2 
lesions within the first year of treatment were at higher risk of non-response 
(OR=3) regardless of relapse activity. This study therefore provides evidence 
that combined relapse and MRI activity within the first year of IFN treatment 
predicts future relapses and sustained disability in the medium-term. 
Additionally, it provides useful numerical cut-offs, similarly to Rio and Bermel, 
for the number of MRI lesions which may be tolerable in the first year of 
treatment. Notably, patients with relapse activity but no new T2 MRI lesions in 
the first year were not at increased risk of future relapses or disability in this 
study. Of course, it may be the case that these clinico-radiological events 
predict disability in the long-term, which is not assessed by this analysis. The 
authors also note that, in keeping with other studies, a lower EDSS at baseline 
(≤2) was associated with better outcomes overall. Again, this suggests that 
treatment earlier in the course of disease (or at least before disability is 
established) is likely to be beneficial. 
In a prospective observational study based at a single Italian centre Prosperini et 
al. also found that MRI changes within the first year of IFN treatment were 
predictive of later disability but the magnitude differed135. The aim was to 
compare MRI criteria alone with the guidance issued by the European Medicines 
Agency (EMA), which requires at least one relapse and ≥9 T2 lesions or ≥1 
contrast-enhancing lesion in order to pursue escalation to 2nd-lne treatments. A 
total of 370 patients were followed-up for 4 years from an initial cohort of 445. 
Patients who received IFN for <1year (n=65, 14.6%) were excluded: 38 (8.5%) 
discontinued treatment for lack of efficacy. All available IFN preparations were 
included and analysed as a single cohort. In this analysis, the number of relapses 
(not including severity) and the 2-step EDSS worsening used by Horakova et al. 
were the primary outcome measures upon which treatment failure was based. 
Overall, the EMA guidelines and MRI changes within the first year both similarly 
predicted higher relapse rate and disability worsening in comparison to patients 
without disease activity. One or more new contrast-enhancing lesion or ≥2 T2 
lesions were more sensitive [61% (95%CIs 54-67) vs. 34% (27-41)] and accurate 
[70% (65-74) vs. 57% (51-62)] than the EMA guidelines, but both were similarly 
associated with a higher risk of relapse and disability worsening in the following 
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4 years (EMA guidelines: HR=3.69 for relapses, HR=6.02 for disability worsening; 
MRI criteria: HR 3.15 and 5.31 respectively). These data suggest that MRI activity 
alone is a reasonable proxy for the EMA criteria and, hence, escalating in the 
absence of relapses, when there is ≥1 new contrast-enhancing or ≥2 new T2 
lesions within the first year of IFN treatment, could be considered. Notably, the 
specificity increases with increasing numbers of new T2 lesions [specificity 96% 
(92-98) for ≥3 new T2 lesions] but sensitivity is reduced [31% (24-37)], meaning a 
higher number of new T2 lesions is unlikely in those who will have better 
outcomes, but does not definitely predict a worse outcome in those in which this 
occurs. Similarly, the combined predictive value of relapses and MRI activity 
improves specificity but not sensitivity. It can therefore be fairly reassuring that 
those without MRI or relapse activity in the first year of IFN will have relatively 
better outcomes over the next 4 years but that, whilst more likely, it does not 
necessarily follow those with clinico-radiological activity are destined to 
disability. MRI disease activity should, however, certainly be considered when 
escalation decisions are being made. 
The largest, and most recent, dataset employed to define treatment failure 
using IFN comes from the multicentre European MRI in MS (MAGNIMS) network136. 
This included 1280 patients with RRMS from 9 European centres with 
prospectively collected data but retrospective analysis. Again, clinico-
radiological events during the first year of treatment with any IFN were analysed 
for their association with treatment failure. This study included just 2 years of 
follow-up, however. Treatment failure was also defined as EDSS worsening, 
confirmed at 6 or 12 months, again using a 2-step paradigm based on the 
baseline EDSS as in previous studies. Additionally, treatment was considered to 
have failed if the patient had been escalated to a second-line therapy (because 
of lack of efficacy, not tolerability) within the following 2 years, at the 
discretion of the treating physician and their patient. Time-to-treatment-failure 
was then used as the outcome variable for a multivariate Cox model where the 
number of relapses and new T2 lesions in the first year were assessed for their 
relative contribution to the outcome. This then allowed estimation of the 
average effect of the number of new T2 lesions and relapses during the first year 
on the risk of treatment failure in the subsequent 2 years. The authors found 
that there was significant heterogeneity between centres with regard to T2 
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lesions resulting in a treatment failure but that this did not appear to invalidate 
their results. However, one of the centres was excluded as a result of its 
different approach to the others in this respect. Unfortunately, the proportion of 
patients who were deemed treatment failures due to EDSS worsening and 
(physician-directed) treatment escalation are not provided. The factors upon 
which treatment escalation were based were not standardised, or reported, 
therefore the inclusion of this as a definition of treatment failure suggests a 
circular analysis. However, analysis of EDSS worsening as an outcome measure 
mirrors that of treatment failure suggesting it is robust. Patients were grouped 
into 3 tiers of increasing disease activity, from no relapses and <3 new T2 lesions 
in the first year to 1 relapse and ≥3 new T2 lesions or ≥2 relapses. In this way, it 
was demonstrated that those with the most clinical and/or radiological disease 
activity had significantly shortened time to treatment failure and EDSS 
worsening. Additionally, multivariate Cox modelling permitted Hazard Ratio 
calculations for the effect of each incremental T2 lesion or relapse in the first 
year on the risk of treatment failure at 3 years. Patients with no new T2 lesions 
or relapses in the first year respectively were used as the reference point for 
comparison. The number of new T2 lesions at which the increased risk of 
treatment failure at year 3 became significant was 4 [HR 2.36 (95%CIs 1.35-
4.16)]. A single relapse was associated with a HR of 1.84 (1.39-2.44) for 
treatment failure at 3 years and ≥2 relapses 3.03 (2.06-4.45) in comparison to no 
relapses. Again, this reiterates the predictive value of MRI in isolation but the 
occurrence of early relapses is also predictive of more future disease activity 
and that the combination of both is even more likely to predict treatment failure 
as defined here. 
 
The Canadian Treatment Optimisation model137 grades disease activity based on 
relapses, MRI activity and disability, and defines 3 levels of ‘concern’. As well as 
including disability measures, this guidance also categorises relapse severity, 
rather than the absolute number alone, and the year of treatment in which they 
occur. A single attack in the 2nd year of treatment with minimal effect on ADL, 
no motor or cerebellar involvement and prompt recovery without the need for 
steroids would suggest a ‘low’ level of concern with regards to disease activity; 
more than 1 attack in the first year of treatment, with severe motor 
involvement and incomplete recovery at 6 months would be of ‘high’ concern. 
Similarly, EDSS changes are graded and the Timed 25-Foot Walk (T25FW) is 
included, in contrast to the other scoring systems. A single new Gd-enhancing or 
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T2 lesion (per year) on MRI is considered ‘low’ concern but ≥3 of either suggest a 
‘high’ concern. A cumulative level of concern is then reached based on these 
findings and the higher the level of concern, the stronger the rationale to 
escalate therapy. 
Overall, then, the definition of treatment failure is largely based on evidence 
from IFN use and suggests that early relapses and MRI activity beget short- and 
medium-term poorer disease outcomes, generally suggestive of the need to 
escalate treatment. The cut-offs differ slightly but most studies suggest any 
relapse activity within the first year of treatment and >3-4 new T2 lesions (even 
in the absence of relapse activity) or >1 new contrast-enhancing lesion are 
associated with more disease activity in the following 2-6 years, in terms of 
relapses and disability worsening. The desire to define non-responders early (i.e. 
within the first year of treatment) results in a more limited role for EDSS change 
given the small proportion of patients having a significant change over this 
relatively short period – but its presence is rightly concerning and may inform 
escalation decisions, particularly if thought to be part of an inflammatory 
phenotype.  
A practical point which is not considered in these studies is the time to 
effectiveness of the agents involved. Pivotal DMT trials generally show a 
separation of the treatment and control arms at 3-6 months, in terms of clinical 
efficacy outcomes, hence it is generally agreed that clinical or radiological 
disease activity within the first 3-6 months of treatment does not necessarily 
reflect a lack of efficacy of the treatment but, rather, it has simply not reached 
full efficacy in this time. Of course, it is the case that the purported time to 
efficacy of DMTs simply reflects the fact that clinical and radiological 
assessments first occur at these timepoints, rather than this being a 
pharmacodynamic fundamental. Indeed, it has been postulated that Copaxone® 
specifically has a longer latency to effectiveness (up to 9 months) but this is 
challenged by a recent pharmaceutical-sponsored post-hoc analysis of a GA 
placebo-controlled trial, which suggests treatment efficacy is evident even at 2 
months142. Similarly, patients may mount an antibody-response to treatment 
which, if transient, delays onset of full efficacy but does not appear to have an 
ongoing impact unless the neutralising antibodies are persistent143. 
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‘Real-world’ studies are the primary (Class IV) evidence of various escalation 
options available with the increasing development of DMTs in the past decade. 
Prosperini et al. evaluated 285 patients with RRMS from 2 Italian centres who 
had failed treatment with IFN or Copaxone and were escalated to Natalizumab 
or switched to another IFN/Copaxone®144. Treatment failure was defined as ≥2 
relapses or 1 relapse with residual disability after at least 1 year of treatment. 
Although the study was prospective, over 2 years, patients were not randomly 
assigned to each treatment cohort: ‘the choice of second-line treatment 
depended on the availability of Natalizumab or was a patient choice due to 
safety concerns regarding PML’. After patients and their physicians had chosen 
whether to pursue escalation or a switch to an alternative 1st-line DMT, a 
propensity score-adjusted Cox regression model was used to balance the groups. 
There were significant differences between the unmatched groups, the 
escalation cohort having higher relapse rates and EDSS at baseline. Additionally, 
a higher proportion of the escalation group had failed on high-dose IFN or 
Copaxone® whereas the switch group had more patients failing on low-dose IFN. 
These factors suggest the group which ultimately escalated had worse disease, 
as would be expected. Most of the switch group (62.6%) actually simply 
increased their dose of IFN, rather than changing to a new DMT, however. In 
total, 106 (93%) of patients in the escalation group and 161 (94%) in the switch 
group completed 2 years of follow-up. In the non-adjusted analysis, the 
escalation group had significantly higher proportions of patients with absence of 
relapse activity, EDSS progression and MRI activity at 24 months (but there was 
no difference at 12 months). This could reflect regression to the mean, given 
their higher baseline disease activity, but the statistically matched patients also 
showed lower hazard ratios for disease activity in the escalation group, including 
No Evidence of Disease Activity (NEDA, defined as no relapses, progression or MRI 
inflammatory lesions) in comparison to those who switched between 
immunomodulators [HR 0.51 (95%CIs 0.35-0.74), p=0.001].   
Using the MSBase and Tysabri Observational Program (TOP) datasets, Spelman et 
al. also reported improved outcomes for patients escalating to Natalizumab, 
after relapse on 1st-line DMTs, in comparison to those who did not145. MSBase is a 
large prospectively collected dataset from 73 countries, largely European, 
currently with almost 50000 patients included. The TOP dataset includes 
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longitudinal follow-up of Natalizumab-treated patients, mainly for 
pharmacovigilance. Interrogating these databases, the authors identified 
patients who had relapsed on first-line treatments (‘BRACE’) in the 12 months 
prior to switching to either an alternative BRACE treatment or Natalizumab. 
Over 4500 patients available within these databases met inclusion criteria: 
propensity-matching was undertaken to improve comparability between the 
cohorts, including indication bias, resulting in 869 matched pairs of patients. 
Covariates used to generate propensity scores and, hence, cohorts comparable 
on known confounders, included gender, age, disease duration, baseline EDSS, 
number of DMT initiations, duration of DMT use (as a proportion of disease 
duration) and relapse rates in the past 12-24 months at baseline. The matching 
process was successful at balancing known confounders between the cohorts. 
Mean follow-up was longer (2.24 years) in the BRACE group than in those 
escalating to Natalizumab (1.95 years), but duration between follow-up visits 
was comparable. Overall, annualised relapse rate was significantly lower for 4 
years in patients switched from BRACE treatments to Natalizumab rather than 
another BRACE treatment (0.14 vs 0.36, p=0.0002) but the difference was 
greatest and most sustained in those switching from IFN than with Copaxone (or 
both). After year 1, for example, there was no significant difference in those 
who switched to Natalizumab from Copaxone®, in terms of ARR but the numbers 
available for these sub-group analyses are notably smaller. Disability outcomes 
were based on 374 patients continuing BRACE treatments after relapse and 514 
escalated to Natalizumab with 3 EDSS scores available. Patients who escalated 
to Natalizumab had a 26% reduction in the risk of 3-month confirmed disability 
progression [HR 0.74 (95%CIs 0.55-0.97, p=0.036] but there was no significant 
difference in time to disability progression within the first 12 months. Using the 
area under the curve method, to capture EDSS changes over time, the escalated 
group had significantly lower levels of disability over 24 months of follow-up 
overall, however. Additionally, patients escalating to Natalizumab were 
significantly less likely to discontinue treatment in comparison to those 
remaining on BRACE treatments [HR 0.26 (0.2-0.34), p<0.001]. This study did not 
evaluate safety outcomes but it is well established that PML risk is significantly 
higher with Natalizumab use and has not been reported with any of the BRACE 
treatments. These data therefore, again, support the conclusion that escalating 
to Natalizumab, after disease activity on first-line treatments, is superior in 
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terms of efficacy outcomes than switching amongst first-line treatments but 
with higher associated risk. 
The benefit of escalation has not been demonstrated in all studies however. In a 
recent single-centre Italian study, no significant difference was found in the 
proportion of patients reaching NEDA at 24 months, whether they switched to 
another first-line DMT or a second-line DMT after clinical disease activity on 
first-line therapies146. This retrospective analysis of their local database 
identified patients with RRMS who had a relapse and/or confirmed disability 
progression within 12 months preceding a switch from IFN/Copaxone to 
Copaxone/IFN or a second-line DMT (Fingolimod, Natalizumab, 
Cyclophosphamide) and with subsequent 12 months of follow-up available. 
Treatment use was based on prescriptions dispensed but drug use was not 
confirmed or measured over time. The study included 91 patients, 48 of who 
performed a ‘lateral’ (horizontal) switch and 43 escalated. There were 
significant baseline differences in MRI lesion load between the groups, the 
escalated group having more. Otherwise the groups were comparable but no 
attempts were made to match them further. The primary endpoint was the 
proportion reaching NEDA (no relapses, progression or MRI activity) at 24 months 
and this was not significantly different between the groups (20.8% in switch 
group vs. 18.6% in escalation group). Similarly, time to EDSS 4 and first relapse 
was comparable between the groups. The numbers of patients within the 24-
month analysis small (10 and 8 in escalation and switch NEDA groups 
respectively) and clearly the escalation group had higher MRI disease burden, 
signalling a worse prognosis and preventing statistically-meaningful comparisons 
between the groups.  
Similarly, other data from MSBase suggests that switching to purported higher 
efficacy oral DMTs from first-line treatments does not improve efficacy 
outcomes when the switch is made for reasons of tolerability, rather than 
efficacy147. This retrospective study used propensity-score matching to identify 
396 comparable pairs of patients (N=792) with stable RRMS for 12 months who 
switched to either an alternative injectable or oral DMT largely due to side 
effects or inconvenience from an initial IFN/Copaxone. The cohorts were well 
matched using propensity scores and most switched to Fingolimod (71.2%) over 
DMF (16.2%) or Teriflunomide (12.6%) in the oral switch group. Despite this, 
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there was no difference within the first 6-months between the groups in terms 
of relapse rates or disability progression whether patients switched to an oral or 
alternative injectable DMT. Additionally, there was no significant difference 
between relapse rates between the three available oral agents when adjusted 
for baseline differences. Concluding that switching to oral DMTs in the setting of 
poor tolerability of injectable treatments does not improve efficacy is mitigated 
by the short follow-up in this study and the acknowledgement that the reason 
for switching was not documented in over half of the patients included. 
 
Overall then, the benefits of an induction approach are favourable against the 
risks when used at an early stage of disease when there is significant disease 
activity and patients may wish to accept higher risks for the purported benefits. 
An escalation approach remains the prevailing paradigm in MS therapeutics and 
the first-line injectable agents have a long-standing proven safety record, albeit 
with a higher risk of MS disease activity. Treatment failure should be considered 
when any relapse activity occurs within the first year of treatment or >3-4 new 
T2 lesions (even in the absence of relapse activity) or >1 new contrast-enhancing 
lesion as these are associated with more disease activity in the following 2-6 
years in terms of relapses and disability worsening. Clinical and MRI activity 
within the first 3-6 months of treatment may simply reflect subtherapeutic 
pharmacodynamics of the agent used and hence caution should be exercised in 
considering this a treatment failure. The available evidence suggests that 
escalating to a second-line DMT is more effective than switching between first-
line DMTs if treatment failure occurs, but there is no evidence of an efficacy 
benefit in switching to oral DMTs from injectable DMTs for tolerability reasons 
alone. In choosing the escalation agent after first-line treatment failure, 
Alemtuzumab is more effective than Rebif® and Natalizumab appears more 
efficacious than Fingolimod but individual patient risk-factors, such as co-
morbidities and JCV status, should of course be considered carefully when such 
choices are being made. 
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1st- and 2nd-line DMTs in Clinical Practice: Real-world data 
Dimethyl Fumarate and Fingolimod 
The merit of randomised controlled trials (RCTs) is obviously well-founded, but 
the artificial nature of cohort selection, concordance and follow-up reflects the 
efficacy of an intervention under ideal conditions and hence outcomes cannot 
necessarily be extrapolated directly to real-world practice148. Similarly, the 
chronic nature of MS requiring decades of follow-up to demonstrate long-term 
benefits or safety issues does not lend itself to a RCT model given both the 
practical and ethical issues around blinding, as well as the financial costs and 
inevitable attrition of participants over such long periods. That said, the RCT is 
undoubtedly the least biased approach given its ability to balance both known 
and unknown confounders such that any difference observed between cohorts 
can be attributed to treatment effects with greater confidence. There is clearly 
a role for both methods in reaching conclusions about the safety and efficacy of 
DMTs in RRMS as long as the limitations of both are understood. Considering 
these limitations in the design of treatment studies in MS, as well as analysis, 
can minimise their impact or at least rationalise any conclusions.  With this in 
mind, we sought to describe the efficacy and safety of DMF when used in our 
centre and specifically considering post-marketing safety concerns. 
Dimethyl Fumarate (DMF) is an immunomodulatory treatment for RRMS which 
demonstrated efficacy in two placebo-controlled randomised trials64,65. Its 
therapeutic effect is thought to be related to activation of the nuclear factor 
(erythroid-derived2)-like (Nrf2) pathway, with beneficial modulation of pro- and 
anti-inflammatory cytokines. It was the second licensed oral treatment for RRMS 
and the first available for use as a first-line treatment. After its approval in April 
2014, our centre became one of the leading users of DMF in Europe.  
Fingolimod is a first-in-class, sphingosine-1 phosphate (S1P) receptor modulator, 
and was the first oral disease modifying treatment (DMT) licensed for use in 
multiple sclerosis (MS)149. Fingolimod alters trafficking of both naïve and 
antigen-activated lymphocytes from secondary lymphoid tissue, thymus and 
bone marrow to produce a relative lymphopaenia. It does this via two non-
specific mechanisms - an agonistic action on S1P receptors 1,3,4 and 5, and a 
functional antagonistic action against the SIP1 receptor. The cumulative effect 
   
 
127 
of these actions is the internalisation of the S1P1 receptor within lymphocytes, 
thereby resulting in the transient retention in lymph nodes. The non-selective 
mode of action of fingolimod may produce unwanted additional effects, for 
example bradycardia. Combined analysis of FREEDOMS and TRANSFORMS showed 
a mean decrease in heart rate by 8 beats per minute, and an incidence of 1st 
degree AV block of 4.7%. This is thought to occur as a consequence of 
fingolimod’s transient agonistic effects on S1P1 receptors within atrial 
myocytes150. Originally evaluated as a treatment for renal transplant rejection, 
at doses 10 times higher than now prescribed in MS, in renal transplant trials 
macular oedema was noted to be twice as prevalent in patients receiving 
fingolimod compared to those on placebo (28% in diabetic patients and 4% in 
non-diabetic patients). All subsequent clinical trials involving fingolimod have 
therefore implemented screening for macular oedema151. The incidence of 
macular oedema from the TRANSFORMS and FREEDOMs trials was 0.3% for 0.5mg 
Fingolimod, and 1.2% for the 1.25mg dose, and the vast majority of cases 
occurred within 3-4 months of starting the study drug66,123. The manufacturer of 
fingolimod (Gilenya®) has recommended ophthalmological evaluation is 
undertaken at 3-4 months after treatment initiation152. Further, it is 
recommended that multiple sclerosis patients with diabetes mellitus or a history 
of uveitis undergo an ophthalmological evaluation prior to initiating therapy and 
have follow-up evaluations while receiving therapy. It is recommended that 
Gilenya be discontinued if a patient develops macular oedema. Fingolimod has 
been available for use in the UK since 2012. In Scotland, it is licensed for use as 
a first-line DMT in patients with highly active relapsing remitting MS (RRMS) or 
failing a 1st-line therapy due to ongoing disease activity. 153 
As outlined previously, clinical trials do not provide efficacy and safety results 
which are necessarily comparable to real-world outcomes once the drug is used 
in a wider population, and this was the case for both DMF and Fingolimod with 
regards to progressive multifocal leukoencephalopathy (PML)154,155. PML had 
been associated with Fumaderm, the parent drug of DMF used mainly for 
psoriasis in Europe, but no cases occurred during the DMF or Fingolimod clinical 
trials for RRMS. The importance of post-marketing data was illustrated by the 
subsequent diagnosis of PML in a patient receiving DMF with notably prolonged 
lymphopaenia and further case reports have since also suggested a link between 
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prolonged lymphopaenia and risk of PML with DMF154. Lymphopaenia occurred in 
approximately 37% of patients in the pivotal trials of DMF, around 7% having 
Grade 3 [ALC (Absolute Lymphocyte Count) <0.5x109/l ] at least once during 
follow-up156. As a result of the association between lymphopaenia and PML with 
DMF from these post-trial events, European guidelines now recommend 
considering DMF discontinuation if grade III lymphopaenia is present for 6 
months. On stopping DMF, however, lymphopaenia can persist and global data on 
the expected recovery of ALC following DMF discontinuation due to lymphopenia 
is limited to a small number of patients from pivotal trials showing that, whilst 
lymphocyte counts generally increase on discontinuation, levels had not 
returned to pre-treatment levels after 4 weeks. Risk factors for Fingolimod-
associated PML have not been defined. 
With these issues in mind, we undertook firstly an analysis of the overall utility 
(real world effectiveness) of DMF and Fingolimod in our centre. Additionally, we 
wished to evaluate real world safety outcomes relevant to each product, 
specifically lymphopaenia and lymphocyte recovery with DMF since this is the 
chief identifiable PML risk factor, and has major implications for the 
introduction of subsequent therapy. Speed and level of lymphocyte recovery (in 
any population) was unknown from trial data available at the time, and so the 
analysis of this particular safety aspect represented data particularly pertinent 
to contemporary practice. We also wished to evaluate rates of macular oedema 
with Fingolimod in a real-world population, rather than the artificial trial 
populations studies in the pivotal studies – again vital data for practising 
clinicians. 
Methods 
Retrospective analyses of electronic medical records were undertaken in our 
regional tertiary Neurology centre. The Institute of Neurological Sciences in 
Glasgow is the neurosciences referral centre for the West of Scotland, covering a 
catchment area of 2.5 million people. Each NHS patient in Scotland is assigned a 
unique identifier, the Community Health Index (CHI) number, which is included 
in admissions records and hence permits access to their electronic medical 
records including GP referrals, laboratory results and all secondary care 
correspondence. Additionally, the electronic portals are linked in the West of 
Scotland such that regional records are available centrally and vice versa, 
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permitting access to all follow-up correspondence even for patents located out 
with our tertiary centre. A contemporary electronic prescription, from GP 
records, is also accessible to view current and recent medications which patients 
have been prescribed.  
Patients treated with DMF were identified through local prescription records. 
Firstly, all patients who commenced DMF during its first year of availability were 
identified and, secondly, all patients who had discontinued DMF due to 
lymphopaenia between December 2014 and March 2016.  
 
All patients commencing Fingolimod are admitted to our day investigation unit 
for first-dose cardiac monitoring. Patients were identified using local 
prescription and admission records. In the first analysis, all patients treated with 
fingolimod in our centre by April 2015 were identified and their clinical records 
used for retrospective analysis of tolerability and efficacy. Later, we identified 
all patients commenced on fingolimod in our centre between May 2016 and May 
2017 specifically evaluating screening for, and occurrence of, fingolimod-
associated macular oedema. Patients admitted for re-initiation of fingolimod 
after a break in treatment were not included in the evaluation of macular 
oedema.  
 
Demographic, clinical, radiological and laboratory data were collected and 
analysed using Microsoft Excel® and XLSTAT®. Descriptive statistics were 
compiled. Parametric data were compared using a 2-tailed t-test, non-
parametric data with the Mann-Whitney test and proportions were compared 
using z-scores. 
This work includes data collection and analyses completed by Frederick Winslow 
(University of Glasgow), Kieran Fitzpatrick (Pharmacist, NHS GGC) and Sarah-
Jane Martin (Neurology Registrar, NHS GGC). 
Results 
Dimethyl Fumarate  
A total of 156 patients (74% female) commenced DMF within its first year of availability 
in our centre. Table 1-1 summarises the demographic, clinical, radiological and 
laboratory results for the cohort. There were no significant differences in radiological or 
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laboratory outcomes between those starting DMF first-line or having had previous 
treatment(s). As expected, those starting DMF first-line had a shorter disease duration 
in comparison to those having had other previous treatments but time to first relapse on 
treatment was significantly shorter for treatment-naïve patients.  
Lymphopaenia and discontinuation due to side effects were higher than in the pivotal 
clinical trials. In our cohort, 46% (66/143) developed a lymphocyte count less than 0.8 
x109/l on at least one occasion during the first year of treatment. Additionally, 20.5% 
(32/156) of our cohort discontinued DMF due to side effects. No renal impairment, 
proteinuria or opportunistic infections were documented in our cohort. 
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Table 1-1: DMF cohort characteristics and outcomes 
 Whole 
Cohort 
(N=156) 
DMF 1st 
Treatmen
t (N=36) 
DMF not 1st 
Treatment 
(N=120) 
n (%) Female 116 (74) 25 (69) 91 (76) 
Mean Age (SD) [years] 39.5 (8.9) 38.3 
(11.8) 
39.8 (7.9) 
Mean time since diagnosis (SD) 
(years) 
5.6 (6.2) 
(n=131) 
3.5 (8.0) 
(n=36) 
6.5* (4.9) 
(n=95) 
 
Number of DMTs tried before DMF [n (%)]                         
1 72 (60) 
31 (26) 
17 (14) 
2
3 
RELAPSES 
Relapse occurred [n (%)] 21 (13.5) 8 (22.2) 13 (10.8) 
Disabling relapse occurred 
[n(%)] 
7 (4.5) 3 (8.3) 4 (3.3) 
Steroids used [n(%)] 5 (3.2) 1 (2.8) 4 (3.3) 
Mean duration to 1st relapse 
after starting DMF (SD) 
[months] 
6.3 (3.7) 4.4 (3.7) 7.5* (3.3) 
MRI FINDINGS 
MRI undertaken [n(%)] 54 (34.6) 16 (44.4) 38 (31.7) 
Reason for MRI 
Re-baseline [n(%)] 
Interval [n(%)] 
Following Relapse [n(%)] 
   
24 (44) 4 (25) 20 (52.6) 
14 (26) 4 (25) 9 (23.7) 
16 (30) 8 (50) 8 (21.1) 
Mean duration since starting 
DMF (SD) [months] 
8.4 (3.5) 8.3 (4.1) 8.5 (3.6) 
Median time since comparison 
MRI (IQR) [years] 
1.4 (2.0) 1.3 (0.8) 1.7 (3.2) 
Patients with new T2 lesions 
[n(%)] 
Re-baseline [n(%)] 
Interval [n(%)] 
Following Relapse [n(%)] 
23 (42.6) 
10 (41.6) 
3 (21.4) 
10 (62.5) 
8 (50) 
0 
2 (50) 
6 (75) 
15 (39.5) 
8 (40) 
3 (33.3) 
4 (50) 
Patients with new Gd-
enhancing lesions [n(%)] 
7 (13) 4 (25) 3 (7.9) 
LYMPHOCYTE NADIR 
FBC checked at least once 
[n(%)] 
143 (91.7) 34 (94.4) 109 (90.8) 
No lymphopaenia [n(%)] 32 (22.4) 5 (13.9) 25 (22.9) 
1.1-1.5 x109/l  [n(%)] 45 (31.5) 13 (36.1) 32 (29.4) 
0.8-1.0 x109/l  [n(%)] 29 (20.3) 6 (16.7) 23 (21.1) 
0.5-0.7 x109/l  [n(%)] 31 (21.7) 5 (13.9) 26 (23.9) 
<0.5 x109/l  [n(%)] 6 (4.2) 3 (8.3) 3 (2.8) 
CONTINUED ON TREATMENT AT TIME OF ANALYSIS 
n (%) 109 (69.9) 23 (63.9) 86 (71.7) 
Mean duration of DMF 
treatment (SD) [months] 
14.1 (1.5) 13.9 (1.4) 14.2 (1.5) 
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DISCONTINUED TREATMENT BY TIME OF ANALYSIS 
n (%) 47 (30.1) 13 (36.1) 34 (28.3) 
Mean duration of DMF 
treatment (SD) [months] 
6.2 (4.2) 8.4 (3.8) 5.3 (4.1) 
Reason for stopping 
Side effects [n(%)] 
Lymphopaenia [n(%)] 
Treatment failure [n(%)] 
   
32 (20.5) 7 (19.4) 25 (20.8) 
9 (5.8) 2 (5.6) 7 (5.8) 
4 (2.6) 3 (8.3) 1 (0.8%) 
*p<0.05 
 
The majority of patients (75.8%) commenced DMF having failed at least one 
previous DMT. Table 1-2 shows the number of patients using each DMT and the 
sequence used. The majority (n=72, 60%) had been initiated onto an injectable 
treatment before being switched to DMF. Indeed, where DMTs were sequenced 
before switching to DMF, the injectable therapies were mostly used. A smaller 
proportion of patients switched from 2nd-line therapies (Fingolimod / 
Natalizumab), largely having failed other DMTs first. Table 1-3 outlines the 
reasons for switching to DMF from the various DMTs. Side effects were the main 
reason to switch from all treatments except Natalizumab, where, of the 6 
patients switching from this, half were due to treatment failure and half due to 
PML concerns because of JCV antibody positivity.  Additionally, a significant 
proportion of patients using Rebif switched because of concerns regarding 
thrombotic microangiopathy (TMA) which had occurred in patients in Scotland 
around this time 157 and all patients were counselled on the risks and offered the 
option to switch. 
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Table 1-2: DMTs used prior to DMF (N=120) 
 1 DMT 
tried 
(n=72)* 
2 DMTs tried 
(n=31) 
3 DMTs tried (n=17) 
1st DMT** 2nd DMT 1st DMT 2nd DMT 3rd DMT 
Avonex® 
24 (34.2%) 12 (40%) 
4 
(12.9%) 
5 
(29.4%) 
5 
(29.4%) 
4 
(23.5%) 
Betaferon® 0 0 0 1 (5.9%) 1 (5.9%) 0 
Extavia® 0 0 0 0 1 (5.9%) 0 
Rebif® 
23 (32.9%) 
10 
(33.3%) 
7 
(22.6%) 
5 
(29.4%) 
5 
(29.4%) 
2 
(11.8%) 
Copaxone® 
23 (32.9%) 7 (23.3%) 
12 
(38.7%) 
5 
(29.4%) 
5 
(29.4%) 
5 
(29.5%) 
Fingolimod 
0 0 
4 
(12.9%) 
0 0 
4 
(23.5%) 
Natalizumab 
0 1 (3.3%) 
4 
(12.9%) 
1 (5.9%) 0 
2 
(11.8%) 
*2 unknown 
** 1 unknown 
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Table 1-3: Reasons for switching to DMF from last DMT tried 
DMT 
Reason for switching (to DMF) [n (%)] 
Total Injection 
issues 
Side 
effects 
Preferred 
oral 
treatment 
Treatment 
failure 
Other 
Avonex 
1st DMT 5 10 3 6 0 24 
(75%) 
2nd DMT 0 3 0 1 0 4 
(12.5%) 
3rd DMT 1 0 0 1 2 4 
(12.5%) 
Total 6 (18.8%) 13 
(40.6%) 
3 (9.4%) 8 (25%) 2 (6.3%) 32 
Rebif 
1st DMT 7 5 4 2 5 23 
(71.9%) 
2nd DMT 1 0 1 0 5* 7 
(21.9%) 
3rd DMT 0 1 0 0 1 2 
(6.3%) 
Total 8 (25%) 6 
(18.8%) 
5 (15.6%) 2 (6.3%) 11 
(34.4%) 
32 
Copaxone 
1st DMT 12 4 2 5 0 23 
(57.5%) 
2nd DMT 5 2 2 3 0 12 
(30%) 
3rd DMT 2 1 0 0 2 5 
(12.5%) 
Total 19 
(47.5%) 
7 
(17.5%) 
4 (10%) 8 (20%) 2 (5%) 40 
Natalizumab 
2nd DMT N/A 0 0 1 3** 4 
(66.7%) 
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3rd DMT N/A 0 0 2 0 2 
(33.3%) 
Total N/A 0 0 3 (50%) 3 (50%) 6 
Fingolimod 
2nd DMT N/A 4 N/A 0 0 4 (50%) 
3rd DMT N/A 2 N/A 1 1 4 (50%) 
Total N/A 6 (75%) N/A 1 (12.5%) 1 
(12.5%) 
8 
Overall 
Total 
33 
(28.0%) 
32 
(27.1%) 
12 (10.2%) 22 (18.6%) 
19 
(16.1%) 
118¶ 
*Concerned about TMA 
**JCV positive after > 2yrs Rx 
¶Data missing for 2 patients 
‘Other’ reasons included patient concern about TMA with Rebif (n=4), JCV positivity and lack of 
response to 2 other DMTs (n=1), Natalizumab antibodies positive (n=1) and unknown 
reason/unattainable from available clinical documents (n=5). 
 
 
The second analysis identified all patients who discontinued DMF due to 
lymphopaenia between December 2014 and March 2016. At this time, 594 
patients had been commenced on DMF in our centre. A total of 30 patients 
(5.1%) discontinued DMF due to lymphopaenia. Median age for those 
discontinuing due to lymphopaenia was 44.5 years (range: 31-60), in comparison 
to 39.5 for the entire cohort. Similarly, there was a higher proportion of females 
in the discontinuation group compared with the overall cohort (80 vs 74%). DMF 
was the first DMT for almost half (n=14) but was second- or third-line in 37% 
(n=11) and 16% (n=5) respectively. Median ALC before DMF use was 1.5x109/l 
(range 1-3.1) and 0.6x109/l (range 0.2-0.8) at the time of stopping, with 73% 
(n=22) JC positive. DMF was given for a median of 331 days (Range 169-597). 
Discontinuation occurred with Grades I, II and III lymphopaenia in 2(6%), 23(78%) 
and 5(16%) patients respectively.  
Median follow-up after DMF discontinuation was 3 months (range 0-14). The 
majority of patients (18, 60%) commenced a new DMT. Patients given fingolimod 
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(n=8) and interferons (n=8) after DMF had a subsequent decline in ALC. Six 
patients (20% of those discontinuing and 1% of the entire cohort) had prolonged 
lymphopaenia after DMF discontinuation, defined as ALC ≤0.9x109/l for ≥6 
months, despite no further treatments. Notably, time to lymphopaenia 
development after DMF commencement was shorter in those who subsequently 
developed prolonged lymphopaenia after its discontinuation in comparison to 
patients who did not (median 4 vs. 7 months).  
Therefore, female sex, older age and shorter latency to lymphopaenia after DMF 
initiation appeared associated with prolonged lymphopaenia after DMF 
discontinuation. ALC prior to starting DMF,  number of treatments prior to DMF 
and time on DMF was not. Additionally, in our centre, JC Virus antibody positive 
status appears a factor in the decision to discontinue DMF when lymphopaenia 
occurs during treatment. 
Fingolimod 
Safety 
93 patients had been commenced on fingolimod in our centre by April 2015. The 
mean duration of fingolimod therapy was 415 days (SD 261). All of the patients in 
our cohort used fingolimod as a 2nd-line DMT, whereas this was the case for less 
than half in FREEDOMS (42.6%) and TRANSFORMS (44.8%). Our cohort is compared 
with those in the pivotal fingolimod trials in Table 1-4. Older and with a higher 
proportion of female patients, our cohort also had a shorter disease duration and 
most had used one or more DMT before fingolimod, perhaps suggesting a more 
active disease phenotype than the trial cohorts. In our cohort, 59 patients (63%) 
switched from injectable therapies due to disease activity on treatment and 23 
(25%) switched from natalizumab due to JCV Ab positivity and, hence, PML risk 
with continued natalizumab treatment.  
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Table 1-4: Fingolimod cohort characteristics 
Baseline 
Characteristics 
Study 
Cohort 
(n=93) 
TRANSFORMS 
Cohort 
(n=431) 
FREEDOMS 
Cohort 
(n=425) 
Age (SD) [Years] 38.3 (9.5) 36.7 (8.8) 36.6 (8.8) 
Female (%) 69 (74) 282 (65) 296 (70) 
Time since diagnosis of 
MS (SD) [Years] 
6.7 (5.1) 
[n=84] 
7.5 (6.2) 8.0 (6.6) 
Number of DMTs  
pre-fingolimod (% 
cohort) 
1 55 (59) - 
2 31 (33) - 
3 7 (8) - 
 
Nineteen patients (20.4%) discontinued fingolimod in our cohort, with the majority 
(14/19, 15.1%) due to side effects. Side effects leading to discontinuation were 
headache (4/14), lymphopaenia (3/14), diarrhoea (2/14) and 1 patient each for 
back pain, limb pain, rash. Additionally, 1 patient had bradycardia during 
initiation therefore fingolimod was not continued and 1 patient was found to have 
macular oedema during follow-up screening hence fingolimod was discontinued. 
In comparison, 80/425 (19%) discontinued fingolimod in total, but with just 35 (8%) 
due to an adverse event or abnormal laboratory results in FREEDOMS and 6% in 
TRANSFORMS. 
The overall occurrence of side effects in our cohort are outlined in the Table 1-
5. Again, headache was the most common and comparable to the frequency seen 
in the pivotal trials. 
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Table 1-5: All documented side effects related to Fingolimod 
Side effect 
Study 
cohort 
(n=93) 
 
 
% 
FREEDOMS 
Population 
(n=425) 
 
 
% 
TRANSFORMS 
Population 
(n=429) 
 
 
% 
Headache 25 26.9 107 25.2 99 23.1 
Infections 22 23.7 - - - - 
UTI 10 10.8 34 8.0 26 6.1 
LRTI 6 6.4 41 9.6 - - 
URTI 3 3.2     
Herpes virus  2 2.2 37 8.7 9 2.1 
Dental 1 1.1 - - - - 
Vaginal Thrush 1 1.1 - - - - 
Raised GGT  21 22.6 67* 15.8 - - 
Depressed 
mood 
12 12.9 33 7.8 21 4.9 
Palpitations 9 9.7 - - - - 
Diarrhoea 8 8.6 50 11.8 32 7.5 
Reported 
worsening 
vision 
7 7.5 - - - - 
Transient 
chest Pain 
4 4.3 4 0.9 - - 
Dizziness 4 4.3 31 7.3 24 5.6 
Dyspepsia 4 4.3 38 8.9 40 9.3 
Itch 3 3.2 - - - - 
Constipation 3 3.2 - - - - 
Back pain 3 3.2 50 11.8 26 6.1 
Breakthrough 
bleeding 
2 2.2 - - - - 
Reduced 
appetite 
2 2.2 - - - - 
Rash 2 2.2 - - - - 
Macular 
oedema** 
1 1.1 0 0 - - 
Bradycardia** 1 1.1 9 2.1 2 0.5 
Tachycardia** 1 1.1 - - - - 
Aching limbs** 1 1.1 - - 21 4.9 
*FREEDOMS reports ANY “abnormal liver function tests”  
** Side effect reported by a single patient only reported if leading to 
discontinuation of therapy or admission/medical  
review of fingolimod treatment 
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Fingolimod-associated macular oedema 
In the first analysis of those starting fingolimod before April 2015, only 1 patient 
developed macular oedema as outlined above. Subsequent further analysis of 
patients who commenced on fingolimod in our centre between May 2016 and May 
2017 was undertaken to investigate the ongoing evaluation and occurrence of 
fingolimod-associated macular oedema (FAME) in more detail. This identified 40 
patients who had initiated onto fingolimod in this time. The mean age for this 
cohort was 39 years (SD 10.9) with a range between 19 and 60 years. The 
majority were female (32, 80%). No patients were on medications predisposing 
to macular oedema but 1 patient (2.5%) had diabetes. Duration of available 
follow-up correspondence was at least 6 months from fingolimod initiation, with 
a mean treatment duration of 351.8 days (SD 98.2). 
 
All patients were referred and seen by ophthalmology to screen for macular 
oedema. The patient with diabetes was referred and appropriately screened 
prior to commencement of fingolimod. All patients underwent OCT as part of the 
ophthalmological assessment.  
 
Mean time from fingolimod initiation to ophthalmology assessment was 124.8 
days (SD 46.8), range 28-238]. Two patients did not attend their first appointed 
ophthalmology assessment: excluding these patients (duration from fingolimod 
initiation to ophthalmology assessment 182 and 199 days respectively) reduced 
the mean duration of the cohort to 121.4 days (SD 45.4). Overall, however, 25 
patients (62.5%) waited more than the advised 120 days between fingolimod 
initiation and ophthalmology screening for macular oedema. 
In considering reasons for delays, the mean duration between fingolimod 
initiation and ophthalmology referral was 15.6 days (SD 15.8) but up to 50 days 
in one case. Two patients were ‘pre-referred’ prior to fingolimod dosing notably, 
although one still waited beyond 120 days. Generally, however, the greatest 
delay was awaiting the ophthalmology appointment, with mean 109.3 days (SD 
41.6) from referral, but up to 230 days in one case and 17 patients (42.5%) 
waiting more than 120 days for this alone, as outlined in Figure 1-1. 
Macular oedema was found in 2 patients (5%), neither of whom had a 
predisposing condition or drug therapy. These patients were older than the 
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cohort average (44 and 53 years), with one male and one female, but the limited 
numbers preclude any inferences about this. Both had switched from a previous 
DMT (Glatiramer Acetate and Dimethyl Fumarate) but both screened after the 
target 120 days (129 and 136 days respectively). Neither patient had visual 
symptoms. In one case, there was minimal intraretinal fluid and no discernible 
visual impact hence this was managed expectantly with continuation of 
Fingolimod and had resolved spontaneously during follow-up over 2 months. 
There have been no visual sequelae documented since but, interestingly, the 
patient was diagnosed with Type 2 diabetes within 6 months after this finding. 
The second patient had significant unilateral macular oedema and measurable 
acuity reduction (6/12+2) despite a lack of visual symptoms. Fingolimod was 
stopped immediately and the OCT changes had resolved within 3 months. 
The majority of patients were switching to fingolimod from natalizumab, due to 
PML risk with the latter, but fingolimod was being used first-line in a significant 
proportion as outlined in Figure 1-2. This suggests a trend toward using 
fingolimod first-line, which was not the case in the earlier cohort. 
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Figure 1-1: Duration between fingolimod initiation and ophthalmology review 
for FAME 
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Figure 1-2: DMT use prior to fingolimod (N=40) 
 
 
Efficacy 
Efficacy of fingolimod in real-world practice was assessed using basic outcomes 
for the 93 patients started on fingolimod by April 2015 in our centre. The cohort 
was split into 3 groups: 
• A: switchers from BIFN/GA (n=56) 
• B: switchers from natalizumab (n=24) 
• C: other circumstances (for example, those starting fingolimod after 
treatment interruption) 
 
In terms of clinical efficacy, 73 patients (78.5%) remained relapse-free overall, 
after a mean treatment duration of 407 days (SD 257), and this was similar whether 
switching from an injectable DMT or natalizumab. This was within the range seen 
in TRANSFORMS (82.5% after mean 360 days) and FREEDOMS (70.4% at mean 720 
days).  The ARR for all fingolimod patients was 0.27 (SD 0.74, range 0.12-0.42), 
which did not differ significantly whether switching from injectables or 
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natalizumab but was higher than that reported in the pivotal trials and may reflect 
a more active cohort from baseline or simply the real-world use of treatment 
where concordance and monitoring are less vigorous than in a clinical trial setting. 
Table 1-6 tabulates these results.  
 
Table 1-6: Relapse activity with fingolimod use in our centre vs pivotal trials 
 Study Cohort 
TRANSFORMS 
(N=429) 
FREEDOMS 
(N=425) 
 Switching 
from 
injectable 
(n=56) 
Switching 
from Nat 
(n=24) 
Total 
(N=93) 
Relapse-
free (%) 
44 (78.6) 19 (79.2) 73 (78.5) 354 (82.6) 299 (70.4) 
ARR (SD) 
0.22 (0.55) 0.39 (1.1) 
0.27 
(0.74) 
0.16 (0.42) 
0.18 
(0.31) 
 
 
Of the 93 patients studied, 86 had a pre-fingolimod MRI, mean 279 days (95% CIs 
192.7-365.4) prior to drug initiation. The first subsequent follow-up MRI was 
available for 63 patients and occurred after a mean of 329 days (95% CIs 267.9-
389.6). The majority of patients (38/63, 58.7) had no evidence of either increased 
T2 lesion load or contrast-enhancing lesions. Of those who did develop radiological 
disease activity in this time, 22 (34.9%) had new T2 lesions and 4 (6.4%) had new 
contrast-enhancement. This is comparable with the findings from TRANSFORMS, 
where 54.8% of patients had no increased T2 lesion load or new contrast-enhancing 
lesions, 35.3% developed new T2 lesions and 9.9% contrast-enhancement over a 
similar time period. 
 
Discussion 
The available literature pertaining to DMT treatment in RRMS suggests benefits 
in early initiation and escalation with real-world observational studies 
complementing randomised controlled trials. Data from our centre has shown 
some differences in safety and efficacy outcomes with DMF and fingolimod in 
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comparison to published studies, as well as identifying possible predictors of 
prolonged lymphopaenia with DMF. 
Clearly, there is a spectrum of disease at presentation, from RIS to PPMS, and 
the ideal time to start treatment to maximise benefits and minimise risks 
remains debated, with resultant variations in practice. A particular issue is 
identifying an appropriate outcome measure to demonstrate benefit, 
particularly with short-term trials in a lifelong disease, and many agree that the 
past focus on inflammatory activity and motor-heavy disability measures such as 
the EDSS is unsatisfactory. There are sound immunopathological reasons to 
suggest benefit of early treatment and MRI modalities demonstrate the loss of 
brain tissue at even the earliest stages, suggesting a target for end-organ 
damage even at this stage. Clinical trials have shown clear discrepancy in the 
benefits of treatment in early (RR) and late (SP) MS but at what point in an 
individual’s disease course that anti-inflammatory treatment becomes futile 
remains uncertain and is dependent on clear definitions of disease stages and 
agreement on the most valid outcome measures, which remain debated. Indeed, 
global variance in advice from national regulatory bodies on the use of DMTs in 
CIS for example, based on the same evidence, belies the uncertainty within the 
MS community regarding their utility. Despite purported long-term benefits from 
early DMT initiation, much of the evidence is subject to methodological flaws 
and the role of real-world studies to enrich the evidence-base is becoming more 
accepted but have their own limitations too. The reality is that there are a 
number of factors influencing the timing and choice of DMTs, including safety, 
cost, patient factors, clinician factors and the regulatory environment in which 
the decisions are made. 
It is clear, however, that DMTs are not fully effective or always tolerated so 
changing treatments is often necessary. The decision to ‘escalate’ to a different 
DMT presupposes that some therapies are more effective although there is a 
paucity of head-to-head randomised trials comparing many DMTs and even fewer 
evaluating escalation directly in those failing treatment. This approach remains 
the most accepted presently, but early aggressive ‘induction’ therapy is being 
more widely used, particularly in those with highly active disease, and offer the 
possibility of avoiding long-term maintenance treatments and the need to switch 
between them. Again, definitions are important and there remains no single 
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agreed definition on the magnitude of disease activity that should trigger the 
offer of treatment change, but data suggest those who have relapses or new MRI 
lesions early after starting treatment are likely to benefit from a change. The 
introduction of PROMs will help establish whether there are true benefits 
perceived by patients with such approaches, and DMT use in general, and it 
seems likely that a multimodal outcome measure of MS will be most appropriate 
whilst the specific aetiology of MS remains elusive. 
Real-world evidence from observational studies clearly provide insight into 
disease and its management that randomised controlled trials (RCTs) cannot 
always provide44,148. Although RCTs can establish the efficacy of an intervention 
under ideal conditions, they do not necessarily provide the best indication of its 
effectiveness in real-world practice. As explained in the earlier chapter, 
Montalban describes this as the difference between efficacy, treatment 
outcomes under the ideal conditions in a clinical trial setting, and effectiveness, 
the outcomes actually achieved in everyday practice. Patients included in RCTs 
are not necessarily representative of real-world populations and their limited 
follow-up duration make them unsuitable for long-term efficacy and safety 
outcomes. Real-world studies include subgroups not included in RCTs and can 
provide long-term data not otherwise available. Additionally, particularly in 
multicentre observational studies, large populations can be included and 
comparisons between various DMTs can be made. However, real-world studies 
are subject to numerous biases but strategies exist to minimise these as far as 
possible, in both the planning of the study and the statistical analysis. Indeed, 
real-world studies have already provided useful results predictors of treatment 
response158, comparative effectiveness159 of DMTs and long-term effectiveness11. 
With these issues in mind, we evaluated the use of DMF (N=156) and Fingolimod 
(N=93) in patients with RRMS in our centre. Both treatments were typically used 
after the failure of injectable therapies, largely due to side effects for DMF but 
breakthrough disease for fingolimod. In the DMF cohort, time to first relapse on 
treatment was significantly shorter in those using DMF 1st-line in comparison to 
those switching from another therapy (4.4 vs 7.5 months) but there was no 
significant difference in efficacy or safety outcomes between these subgroups 
otherwise. The occurrence of lymphopaenia and treatment discontinuation due 
to side effects in our cohort was higher than that reported in the pivotal trials of 
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DMF. Additionally, we found that increased age, female sex and a shorter 
latency to lymphopaenia onset were associated with prolonged lymphopaenia 
after DMF discontinuation but the sample size is too small to be definitive and 
confirmation of this would be needed in a larger cohort. In our fingolimod 
cohort, safety and efficacy outcomes were largely comparable to that in its 
pivotal trials, but we identified some adverse events which hadn’t been reported 
albeit in small numbers. Additionally, similarly to DMF, the proportion of 
patients discontinuing fingolimod due to adverse events was higher than in the 
trials. ARR was also higher in our real-world cohort than in fingolimod trials but 
this may relate to baseline differences between the cohorts, as much as any 
impact from uncontrolled real-world factors. In a specific evaluation of 
fingolimod-associated macular oedema (N=40) screening, 2 patients (5%) were 
identified during recommended screening which is higher than the 0.7% in 
FREEDOMS and 0.5% in TRANSFORMS but clearly these had a much larger sample 
size. We also identified delays to screening for a majority of patients which may 
be amenable to local remedial measures with time. 
Our local data on DMF and fingolimod use confirm the utility of real-world 
observational data and some of the limitations of randomised trials as outlined 
above. The higher rates of treatment discontinuation due to side effects in our 
real-world cohort than pivotal trials may reflect the different motivation or 
acceptance of patients and clinicians in a clinical trial versus an everyday setting 
where the levels of monitoring, follow-up and time investment differ, for 
example. The identification of rare adverse events will only be identified by 
large real-world, longer term follow-up studies but are extremely important in 
identifying the true benefits and costs of a treatment. Our identification of 
patients potentially at higher risk of prolonged lymphopaenia after DMF 
discontinuation needs further confirmation but could act as a springboard for 
other centres to evaluate this also and speaks to the goal of personalised 
medicine such that the decision to embark upon DMF may be evaluated 
differently in the older female patient who may need further DMTs after DMF, 
were these findings to be replicated on a larger scale. Lastly, the evaluation of 
local factors in implementing the use of a new treatment e.g. fingolimod-
associated macular oedema is crucial to ensure the appropriate framework and 
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infrastructure are in place in order to use treatments safely and effectively in 
the real world. 
 
Conclusions 
The current literature on DMTs in RRMS support the utility of their use early in 
the disease course for maximum benefits and switching to alternatives when 
clinical or radiological disease activity occurs. A number of questions remain as 
to how early in disease DMTs should be introduced, what treatment goals should 
be, what constitutes treatment failure and the comparative efficacy of available 
DMTs, particularly in the long-term. The limitation of randomised clinical trials 
to answer these, and other clinically-relevant questions, is recognised and the 
role of observational real-world studies is expanding, as well as understanding of 
their own limitations and strategies to minimise these.  
We describe outcomes for patients who started DMF during its first year of 
availability in our centre (N=156) and all patients treated by 2016 (N=594). The 
majority of patients commenced DMF due to tolerability issues with injectable 
treatments. The proportion of patients discontinuing DMF due to side effects and 
experiencing lymphopenia was higher than that reported in pivotal trials. There 
was a significantly shorter latency to first relapse on DMF for treatment-naïve 
patients in comparison to those switching from a previous therapy. The 
occurrence of lymphopaenia with DMF was evaluated in the larger cohort after it 
had been used in our centre for a few years (N=594). Of these patients, 5.1% 
discontinued DMF due to lymphopaenia, the majority of these being JCV Ab 
positive. Older female patients were over-represented in the lymphopaenia 
group and 6 patients (20% of the discontinuation cohort, 1% of the total 
treatment group) had prolonged lymphopaenia for 6 months after DMF 
discontinuation despite no further treatments. Shorter latency to lymphopaenia 
after starting DMF was associated with subsequent prolonged lymphopaenia after 
DMF discontinuation. This has potential implications for instituting new DMTs 
after DMF discontinuation, in terms of PML risk for example, hence prolonged 
lymphopenia and its attendant risks should be kept in mind even after DMF is 
stopped. 
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Two cohorts of fingolimod-treated patients were also evaluated – all patients 
commenced on treatment by April 2015 (N=93) and those starting treatment 
between 2016 and 2017 (N=40). Efficacy and safety outcomes were evaluated in 
the former group and the occurrence and screening process for macular oedema 
in the latter. Similarly to DMF, a higher proportion of patients discontinued 
fingolimod due to adverse events than expected from trial data but that efficacy 
results were largely reassuring, although our cohort had generally failed 
injectable therapies (which was not the case for trial patients) and may belie 
more active disease and explain some discrepancies. Patients in our centre often 
waited longer than advised for macular screening after fingolimod initiation and, 
although a higher incidence was found than in the trials, there was no 
deleterious effects where macular oedema was identified. Local practice can be 
reviewed in order to minimise delays in ophthalmological assessment and overall 
these data provide a comprehensive picture of the local experience to help 
inform patients and clinicians as to the reality of DMT use. 
In the end, different study methodologies should be used to complement each 
other and provide a more holistic view of the benefits and costs of MS 
treatments which patients and clinicians can then use to inform decision-making 
in practice. The next chapter considers the approach to the use of DMTs in 
regional MS centres in Scotland and resultant outcomes. 
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Chapter 2: Multiple sclerosis Outcome Determination 
Evaluating Real Differences After TimE (MODERATE) 
Introduction 
Uncertainty regarding the efficacy and safety of DMTs for RRMS, as well as their 
cost, has led to varied practice in their use by clinicians since their introduction 
in the early 1990s. Few would suggest that DMTs have no place in the management 
of RRMS, but the indications for initiation and switching between therapies, and 
timing of their use in the course of the disease, remains contentious. Large 
randomised controlled short-term clinical trials have established a reduction in 
relapse frequency and short-term disease worsening using a variety of DMTs. Long-
term extension studies suggest ongoing effects on disease activity, but are flawed 
by a number of methodological difficulties and cannot properly address the impact 
of treatment initiation and early escalation during the initial phase of the disease 
on longer-term impairments, which are often the main cost to patients and 
society. The extent to which early treatment affects such fixed impairments 
remains the fundamental issue in MS therapeutics. 
The debate about balancing efficacy with safety has intensified with the advent 
of higher efficacy DMTs and their attendant safety concerns, and the identification 
of significant but rare safety concerns with lower efficacy treatments such as 
cases of PML (progressive multifocal leukoencephalopathy) in patients taking 
dimethyl fumarate (DMF). Improved imaging and the establishment of clinical and 
radiological prognostic factors early in the disease course that correlate with long-
term disability help guide clinicians in making difficult treatment choices, but the 
best choice of therapy in the individual remains inexact and uncertain. Long-term 
randomised controlled trials are both impractical and arguably unethical in the 
current climate, and real uncertainty exists regarding whether early treatment 
policies affect the outcomes that really matter to people with MS.  
Within Scotland, different centres and specialists have different approaches to 
the use of DMTs. The purpose of this study is to compare outcomes between 
patients cared for by these clinical teams, who differ only in respect of the 
clinician overseeing their care. We aim to address one of the fundamental 
unanswered questions in MS care: to what extent does a policy of early 
inflammatory disease control influence real clinical outcomes? Notably, the 
   
 
150 
purpose of concentrating on data from the Grampian and Glasgow centres is to 
enrich the sample with prognostically similar but differently managed patients, 
rather than comparing the centres.  
The Scottish MS Register (SMSR) was used to identify patients for this study. The 
SMSR is a national Register within the Scottish Healthcare Audits programme at 
the Information Services Division (ISD) of NHS National Services Scotland (NSS). 
The aim of the SMSR is to improve healthcare for people living with MS in Scotland. 
The SMSR includes all patients newly diagnosed with MS in Scotland since 1st 
January 2010. The inclusion criterion is a new diagnosis of MS, after 1st January 
2010, as defined by Poser (1983) and the Revised McDonald Criteria (2005). 
Patients with 'possible' MS or a clinically isolated syndrome are not included. Data 
is held in accordance with NSS data protection guidelines and includes 
demographic information, date of first symptoms, family history of MS, diagnostic 
categorisation, investigations undertaken and MS nurse involvement after 
diagnosis.  
  
The most recent SMSR report at the time our study began (September 2015), 
includes 2164 patients diagnosed with MS in Scotland since 2010. Case 
ascertainment is thought to be very high, with around 90% of the true number of 
patients diagnosed with MS in Scotland registered. All patients who make contact 
with MS services are included, minimising referral bias. Notably, whilst the 
register itself does not include all clinical data potentially relevant to the patient 
or proposed research questions, all NHS patients in Scotland have a unique 
identifier, the Community Health Index (CHI) number. The SMSR includes the CHI 
number, which is used in all community and hospital health records in Scotland, 
thus opening the potential for a much broader scope of relevant data access and 
collection, both clinical and radiological, for our study. 
There is uncertainty as to the true utility of DMTs in MS, specifically their long-
term benefits, and what constitutes treatment success and failure160–163.  The 
primary outcome measure in pivotal clinical trials is almost uniformly the 
(relative) reduction of relapse frequency in the comparator arm, over a 
relatively short period of time (2-3 years), in a lifelong disease.  
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The rationale for relapse reduction as a treatment goal in RRMS is derived from 
large natural history studies which suggest predictable, irreversible progression 
of disability once a particular level of disability is reached31,164. It is proposed 
that prevention of relapses, and therefore prevention of the accrual of disability 
that occurs as a consequence of each relapse, will prevent or delay the 
development of irreversible fixed disability. The level of disability is described 
by the Expanded Disability Status Scale (EDSS) score, ranging from 0 
(asymptomatic and normal neurological examination) to 10 (death due to MS). 
The scale is non-linear and lower scores may result from examination findings 
alone, in the absence of reported disability, whilst higher scores reflect more 
apparent fixed disability, principally the need for walking aids and mobility 
limitation. Particular ‘milestones’ within this scale are recognised: while the 
time to deteriorate from a score of 0 to 3 is highly variable between individuals, 
once an EDSS score of 3 is reached predictable irreversible progression of 
disability occurs17. For this reason, we have chosen an EDSS score of 3 as our 
primary efficacy endpoint to evaluate the utility of early DMT initiation and 
escalation.  
Whether the reduction of relapses and inflammatory activity prevent the 
occurrence of irreversible disability milestones and irreversible progression is 
uncertain. While many experts share the view that early intervention with DMTs 
will lead to longer term benefits, the ‘causal’ relationship between relapse rate 
and disability progression is easily challenged165 along with DMT trial designs in 
general43,45, leaving clinicians uncertain how to apply trial data in clinical 
practice.  
The degree to which DMTs alter likelihood and severity of permanent disease 
accumulation and progression in MS remains the most clinically important 
question in modern MS practice, and is unlikely to be answered by traditional 
randomised studies, given the impracticalities of designing trials that would have 
to last decades. The typical timescale of a clinical trial does not provide an 
opportunity to assess long-term fixed disability reliably. Reduction in 3- or 6-
month sustained increases in disability scores during 2- year trials are claimed to 
represent long-term positive effects of DMTs from clinical trial data, but their 
validity is highly questionable166. 
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Conflicting evidence suggesting no effect of DMTs (IFN-β) on disability 
progression167 and a significant effect on disease progression168, with similar 
clinical endpoints, has been published. Recent evidence from the DMT risk-
sharing scheme in the UK11 provides some ‘real world’ data as to the merits of 
DMTs in the long-term, but the outcome measures used and the validity of the 
control group lead to real uncertainty and caution regarding a firm conclusion. 
The published data have thus not answered the central question facing clinicians 
dealing with early stage RRMS, and there remains a climate of uncertainty 
regarding the true long-term benefit of early intervention, and whether this is 
outweighed by the inevitable risk of immunomodulatory therapy  
More recently, the concept of a ‘window of opportunity’ for MS treatment has 
emerged following experience with newer DMTs, as discussed earlier, which 
clearly impacts DMT initiation strategies. Trials of the anti-CD52 monoclonal 
antibody Campath (now known as Alemtuzumab) failed to show any significant 
effect on disability progression in patients with established disability in the 
progressive phase of their condition, despite reducing relapses and radiological 
markers of inflammation; the opposite was the case for those with early active 
MS, where a significant reduction in the accumulation of disability was observed 
in treated patients99. Additionally, clinical and imaging studies now support 
longstanding pathological data suggesting that the neurodegenerative aspect of 
multiple sclerosis (as measured by brain atrophy and cognitive dysfunction) 
occurs in parallel with clinico-radiological inflammatory disease169,170 at the 
onset of the disease, is predictive of long-term disability171,96 and may be 
ameliorated by DMT use172,173,174,175. These factors inform the practice of many 
clinicians in advocating the early initiation of DMTs in the disease course; 
indeed, the use of the highest efficacy agents at the earliest stage, ‘induction’ 
(as discussed earlier), follows intuitively from such observations. The highest 
efficacy DMTs (in terms of relapse reduction) are associated with higher risk in 
terms of short- and long-term adverse events. In addition, the limitations in our 
ability to predict disease course on an individual basis, given the heterogeneity 
of MS, result in understandable caution on the part of both clinician and patient 
when considering this strategy.  
The limitations in our ability to predict an individual’s disease course from the 
onset of RRMS has a major impact on both the patient’s and clinician’s 
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willingness to accept risk from early initiation of DMTs. The heterogeneity of 
prognosis for patients with RRMS is well established, with patients having widely 
different levels of disability despite the same duration of disease. Irreversible 
limitation in ambulation, a unilateral aid for walking and becoming wheelchair-
bound  occurred at median times of 8, 20 and 30 years respectively when 
examined in the era before widespread use of DMTs13, but such summary 
statistics do not provide a clear prognosis to the individual. It is becoming 
accepted that the concept of ‘benign’ MS is either a misnomer or rarer than 
previously described176,177, the definition having relied largely on motor 
dysfunction and not accounting for other disabling symptoms suffered by MS 
patients in the long-term, particularly cognition178,179. In instituting DMTs, 
particularly those with significant risk of adverse events, an accurate individual 
prognosis would allow thoughtful patient selection to identify those most likely 
to benefit.  As outlined previously, a number of predictive prognostic factors 
have been identified through natural history studies13,180,181 and all agree that 
the nature of the disease in its earliest stages has profound effects on the 
development of irreversible disability even decades later. A high number of 
relapses in the early years, particularly with motor or sphincter involvement, 
incomplete recovery after the first relapse, early accumulation of disability and 
a short interval between the first and second relapse are recognised as 
predictive of a higher risk of long-term disability. Age, gender, sensory 
symptoms and ataxia at onset are less clearly relevant in predicting long-term 
outcomes 181. 
 
More recently, statistical methods have been employed with the aim of 
developing useful clinical prognostic models to characterise a patient’s likely 
disease course as early as possible182. The BREMSO (Bayesian Risk Estimate for 
Multiple Sclerosis at Onset) score is a composite of some of the prognostic 
factors described above and has been shown to predict MS outcomes 
successfully. Importantly, the BREMSO score has good specificity but poor 
sensitivity – patients with a low BREMSO score are unlikely to develop severe 
disease but high scoring patients may well have a favourable disease course. The 
BREMSO scoring system appears to work best at the extremes, but is less useful 
in predicting those with intermediate risk, which will of course be the majority. 
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The timing of DMT initiation is controversial and practice varies around the 
world. In the United States and Canada, DMTs are typically commenced after a 
clinically isolated syndrome (CIS) of demyelination in the absence of 
dissemination in time to meet the current diagnostic definition for MS183. In 
Europe, and certainly the UK, DMTs would not usually be initiated until 
dissemination in time and space has been confirmed clinically, after a second 
relapse, or radiologically on MRI. The ability to make a diagnosis of MS after a 
single event and a single initial MRI is a relatively recent one, since the updated 
McDonald criteria in 2010183.  
Proponents of DMT initiation after CIS cite the high likelihood of conversion to 
CDMS (the onset of which has been shown to be delayed by DMTs in numerous 
large RCTs), that early treatment of RRMS has been proven to be beneficial, and 
that the 1st line DMTs have an excellent safety profile 184. Conversely, the 
potential of exposing those who would otherwise not have a second event or 
whose disease natural history would have been ‘benign’ to DMTs, the lack of 
proven benefit of DMTs in the longer term, the modest benefits in disability 
outcomes with early treatment (which reduce with time) and the significant 
financial costs of DMTs are reasons that support a ‘watch and wait’ approach185. 
The decision to institute DMTs once the MS diagnosis has been made is standard 
practice in many westernised nations, but the timing of treatment, and the 
effects that early treatment has on real outcome, remain contentious.  
The choice of whether to begin treatment with first- or second-line DMTs is 
largely dictated by the guidance issued by national advisory bodies, following an 
appraisal of the clinical benefits and financial costs of different treatments, 
which determines their ‘cost-effectiveness’, in different clinical groups. In 
Scotland, the Scottish Medicines Consortium (SMC) advises health boards as to 
the cost effectiveness of DMTs and the clinical indications for which they can be 
used. SMC advice takes account of the available evidence and applies to Greater 
Glasgow and Grampian, so providing an equal framework for decision-making in 
both regions. Despite this, great differences exist between different clinicians 
and different departments in their use of DMTs, both in Scotland and in the UK 
as a whole – the guidelines are not prescriptive, do not mandate treatment in 
particular scenarios, and allow for very significant differences in interpretation 
(for example, what constitutes ‘a disabling’ relapse, what constitutes ‘a 
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significant’ increase in scan lesion load). This means that individual clinicians 
have considerable autonomy in prescribing practice, hence real behaviour in the 
prescription of DMTs is dictated by each clinician’s interpretation of the 
conflicting and incomplete data on treated and untreated prognosis as described 
above.  
Whilst attempts to predict the efficacy of DMTs have been the subject of 
numerous randomised controlled studies, predicting their safety in individual 
patients has largely been influenced by initially unforeseen post-marketing 
safety concerns. An example of this has been the development of Progressive 
Multifocal Leukoencephalopathy (PML) in patients treated with Natalizumab for 
RRMS186,187 , which has led to a global surveillance and risk stratification 
programme, based on the JC virus (JCV) exposure of the patient, the duration of 
treatment and previous use of immunosuppressants188. The unanticipated 
occurrence of PML and other serious adverse events informs the decision-making 
process of clinicians and patients in the use and choice of DMTs at the outset 
and throughout the disease course. This is particularly the case for higher 
efficacy and newer treatments with less robust long-term safety profiles, and is 
a factor pertinent to the choice and timing of DMT initiation and escalation in 
the cohorts studied in MODERATE.  
Notably, the options available for DMT initiation changed during the period 
under study. Fingolimod, Teriflunomide, DMF and Alemtuzumab were only 
approved in Scotland by the SMC as first-line therapies in 2014. Prior to this, 
Fingolimod could only be used if a patient had failed on IFN or GA, and the other 
agents were not licensed. Thus, at the time we are assessing DMT initiation in 
our study (2010-11), Natalizumab was the only high efficacy treatment licensed 
and approved for use first-line (in patients with particular disease 
characteristics), and the vast majority of DMTs initiated were either interferons 
or GA.  
 
Methods 
There were 2 parts to this study:  
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1) Identifying whether patients with similar disease (based on PS) are 
treated differently in Scotland in terms of DMT initiation 
 
2) Establishing whether the difference in treatment impacts on clinico-
radiological outcomes 
 
Aim 
To provide evidence for clinicians and patients regarding current practice in 
Scotland and the benefits and risks of early initiation of disease modifying 
treatments (DMTs) in relapsing-remitting multiple sclerosis (RRMS), using real 
world data. 
Primary Objective 
Establish whether patients with similar severity of RRMS are treated differently 
within Scotland and establish a cohort of differently treated patients with 
similar severity of RRMS, for comparison of prospective outcomes after 
diagnosis. 
Primary Endpoint 
1) Mean DMT initiation propensity scores in patients initiated onto a DMT 
within 1 year of diagnosis and those not initiated onto a DMT within 1 year 
of diagnosis 
 
Secondary Objective 
Compare retrospective safety and efficacy outcomes in cohorts generated by the 
calculation of propensity scores 
 
Secondary Endpoints 
Propensity-score matched pairs were categorised into ‘treated’ and ‘not 
treated’ groups and retrospective comparisons of the following were made by 
review of medical records: 
1) Proportion of patients reaching EDSS 3 first 5-6 years after diagnosis in 
each group 
   
 
157 
2) Proportion of patients relapsed in first 5-6 years after diagnosis in each 
group 
3) Annualised relapse rate in first 5-6 years after diagnosis in each group 
4) Proportion experiencing (serious) adverse events in first 5-6 years after 
diagnosis in each group 
 
Cohort identification, and sample size projections 
This was a retrospective observational study using routinely collected clinical 
data. Our original intention had been to identify differently treated patients 
with RRMS, despite similar disease prognosis at diagnosis, and invite them for a 
detailed clinico-radiological assessment to compare outcomes over time 
between those treated and untreated. Unfortunately, funding for the 
prospective phase of the study was not obtained until 2019, and so the methods 
and results presented here pertain only to the completed (retrospective) part of 
the study. 
Prior to data collection, we hypothesised the various patient trajectories from 
diagnosis to treatment in order to define the groups we would compare for 
clinicoradiological outcomes and estimate the likely sample sizes. This was done 
using available SMSR data and review of the relevant literature to estimate 
treatment and disease characteristics. Between 2010 and 2011, there were 292 
patients registered on the SMSR with a new diagnosis of MS from the Greater 
Glasgow and Grampian regions. In Greater Glasgow, there were 98 new 
diagnoses in 2010 and 91 in 2011; in Grampian, there were 54 and 49 diagnoses 
of MS respectively. Around 90% of all MS diagnoses follow a relapsing-remitting 
course4,189 (RRMS), so we estimated a total sample of around 263 patients with 
RRMS from this cohort, which would form our total sample (n=170 from Greater 
Glasgow; n= 93 from Grampian, N=263). 
Available data from a national patient survey190 suggested that patients with 
similar demographic, clinical and radiological characteristics will have been 
managed differently in the two centres. The average of the reported value for 
DMT use in Grampian from this recent survey1 (19.4%) suggested that, for 
Grampian patients diagnosed with RRMS in 2010-11 (n=93), 75 (80.6%) may be 
eligible but not taking DMTs; in Greater Glasgow the survey untreated rate is 
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54%, hence we estimated 92 of the 170 patients diagnosed in 2010-11 would be 
untreated, giving a total of 167 (75 + 92) initially untreated patients. An average 
of 46% of eligible patients were taking DMTs in Greater Glasgow according to the 
survey meaning, of our initial cohort of 170, 78 patients were estimated to be 
taking DMTs in Glasgow, with 19% (18) of the patients in Grampian, giving a total 
of 96 treated patients. Figure 2-1 below illustrates these calculations. For the 
purposes of these calculations, we assumed those starting treatment do so 
within 1 year of diagnosis.   
We used data from the literature to estimate the likely disease course of each 
group over the first 3 years following diagnosis. From pivotal DMT trials, the 
mean proportion of patients having at least one clinical relapse in the first 2 
years ranges from 41-84% (mean 63%) in the placebo arms, to 29-69% (mean 49%) 
in the treatment arms for low efficacy DMTs and 22-33% (mean 28%) for higher 
efficacy DMTs. Averaging these figures, we estimated that approximately 63% of 
the untreated group would have at least 1 relapse in the first 2 years and 28-49% 
of treated patients would have at least 1 relapse in the first 2 years, depending 
on which DMT was initiated. The vast majority of patients in the treated group 
were likely to have been initiated onto platform therapies, and trial populations 
tend to have milder disease and lower relapse rates, so 49% having at least one 
relapse in the first 2 years was likely to be the more accurate figure, hence this 
was used as the estimate and we assumed relapse rates remain relatively 
constant over time37. Trial data over 2 years suggests that 31.5% of patients on 
no treatment will suffer a relapse each year, and 24.5% of patients on 1st-line 
DMT will suffer a relapse each year. Cumulatively therefore, we estimated that 
over a 3-year period approximately 68% of the untreated group (N=167) will have 
had a relapse (n=114) [See Table 2-1 and Figure 2-1]. 
For the estimated treated group (N=96), we projected that approximately 90% 
(n=86) will have been initiated onto a 1st-line DMT than high efficacy treatment 
(natalizumab)191. Approximately 57% (n=49) of the treated group were expected 
to have a relapse over the first 3 years, assuming a constant relapse rate of 
24.5%, and utilising the same calculation process above [See Table 2-1 and 
Figure 2-1]. 
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Table 2-1: Projected relapse rates by treatment category (Years 1-3) 
Patients on No Treatment  
[N=167 (Annual proportion having a relapse = 31.5%)] 
 Baseline Year 1 Year 2 Year 3 Total by year 3 
Number having 
relapse 
0 53 36 25 
114 
Number relapse-free 167 114 78 53 53 
Patients on 1st line DMT  
[N=86 (Annual proportion having a relapse = 24.5%)] 
Number having 
relapse 
0 21 16 12 
49 
Number relapse-free 86 65 49 37 37 
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Figure 2-1: Projected 3-year treatment pathway and relapse activity for 
2010/11 RRMS Cohort 
 
 
The following assumptions were made to generate these predicted figures: 
• Patients who do not suffer relapse activity are unlikely to have any 
change in their initial management 
• Following relapse activity, we estimated 60% of patients on no treatment 
will remain off treatment and 60% on 1st line DMTs will remain on 1st line 
treatments 
• Patients having tolerability issues with a 1st line DMT are likely to switch 
to another 1st line treatment rather than escalate, and so will remain in 
this category 
 
 
To evaluate the impact of early DMT initiation, we compared outcome for Groups 
1 and 2 [(No DMT use (n≈110)] versus Groups 4, 5 and 7 [Early and maintained DMT 
(n≈70)]. See Figure 2-1 and Table 2-2. 
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Table 2-2: Projected Treatment groups after 3 years 
Group 
Estimated 
Total 
1 No DMT & no relapse 53 
2 No DMT despite relapse 68 
3 No initial DMT but escalation to DMT after relapse 46 
4 1st line DMT initiated & no relapse 37 
5 1st line DMT initiated & continued despite relapse 29 
6 
1st line DMT initiated & escalation to 2nd line DMT 
after relapse 
20 
7 2nd line DMT initiated  10 
 263 
 
Using these estimates, a maximum of 70 matched-pairs were therefore possible 
for analysis. Based on other studies using the propensity matching method192–195,  
the propensity-matching process reduces the total cohort number to varying 
degrees, ranging from 73-93% in the studies quoted, because some patients do 
not have an adequate match. Thus, the final sample number for outcome 
comparisons was estimated to be approximately 85% of the cohort, reducing the 
70 pairs to approximately 60 matched-pairs for assessment (n≈120).  
 
Data collection 
Available clinical records were used to evaluate relevant demographic and 
clinicoradiological baseline data for each patient, to allow stratification into 
prognostic groups. Demographic data was available through the SMSR, but 
detailed information was obtained through hospital patient records. The 
Community Hospital Index (CHI) number (a unique identifier used throughout 
Scotland) is stored in the SMSR and provided access to all available clinical data. 
All records are stored electronically. Data in Greater Glasgow and Clyde were 
accessed via the Clinical Portal application, whilst records from Grampian were 
accessed via SciStore©. Formal agreement between NHS GGC and NHS Grampian 
was provided in order that Grampian records could be accessed remotely for this 
study. 
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Each patient’s disease course and management were recorded - relapses, 
disability, DMT use and safety issues, from diagnosis until the present time. 
Similarly, radiological results are included within the electronic records and used 
to document MRI findings over time.  This established the clinical and 
radiological baseline status and retrospective disease course profile for all 
patients. 
The OPTIMISE portal was used to capture long-term follow-up data for PS-
matched patients. OPTIMISE is a database tool under development in Imperial 
College London that aims to provide a secure IT framework to capture patient-
centred data in MS research and clinical practice.  Its aim is to facilitate the 
capture of prospective longitudinal, standardised clinical and patient-centred 
data, ideally with an ease that would allow it to be used as an adjunct to routine 
clinical practice.  It will ultimately provide open-source software for 
management of MS data, integrating anonymised information from multiple 
centres. This study used the OPTIMISE portal for data capture to pilot the 
platform before its implementation on a wider scale. The OPTIMISE portal was 
hosted as an online stand-alone application by NHS Scotland (‘Scotland’s Health 
On the Web’), allowing online data entry. The utilisation of OPTIMISE in this way 
was subject to approval from the Public Benefit and Privacy Panel for Scotland, 
as outlined in the Ethical Requirements section. 
 
Statistical Analysis 
Statistical analysis was undertaken in conjunction with Mario Hair, independent 
statistics consultant, who calculated the Propensity Scores, generated the 
matched pairs, produced the population pyramids and undertook outcome 
analysis for 3-year data using Microsoft Excel® and SPSS®. This section includes 
some methods which he has written. Longer-term outcome data were analysed 
using XLStat®. 
Hypotheses 
Treatment Comparisons  
Patients with RRMS in Scotland are managed differently despite similar disease 
severity (indicated by propensity scoring for DMT initiation).  
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The null hypothesis is that there are significant differences between mean 
propensity scores for DMT initiation in those who were treated /escalated and 
those who were not. 
Tests of statistical significance will be undertaken to compare the mean 
propensity scores, with a p-value of <0.05 considered significant. 
 
Outcome Comparisons 
The proportion of patients reaching EDSS 3, suffering relapses and annualised 
relapse rate will be lower in patients with RRMS initiated onto DMTs, as opposed 
to those not initiated onto DMTs, but with increased (serious) adverse events. 
The null hypothesis is that there is no difference in outcome between patients 
initiated onto DMTs or not. 
 
Propensity Score Matching 
For DMT initiation, we proposed the following factors to estimate the likelihood 
of starting initial treatment, based on known prognostic factors: these were 
used in calculating individual Propensity Scores: 
• Age 
• Gender 
• Ethnicity 
o Non-Caucasian 
o Caucasian 
• Duration of disease (years since first symptom) 
• Type of initial relapse (the presence of each considered ‘high risk’) 
o Motor 
o Sphincter 
o Motor and sensory 
o Polysymptomatology/Multiple neurological systems involved 
• Recovery from first relapse 
o Incomplete 
o Complete 
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• Time from 1st to second relapse (years) 
• Number of clinical relapses prior to diagnosis 
• MRI at diagnosis 
o Number of T2 lesions 
o Number of Gd-enhancing lesions 
 
Ultimately, the missing data for recovery from first relapse and number of Gd-
enhancing lesions at diagnosis was too large to be included in the propensity 
score matching procedure. In addition, both duration of disease and time from 
1st to 2nd relapse were heavily positively skewed so natural log transformations 
were used on each variable.  
The logistic regression model used to estimate the likelihood of starting 
treatment within the first year (propensity score) therefore used the following 
covariates: 
• Age (in decades) at first diagnosis 
• Gender 
• Ethnicity 
• Natural log of duration of disease 
• Initial relapse symptoms 
• Natural log of time (years) from 1st to 2nd relapse 
• Total number of relapses prior to diagnosis 
• Number of MRI brain T2 lesions at diagnosis 
Baseline categories for the categorical variables were female, white, zero T2 
lesions and sensory only initial relapse. 
These were the covariates for the calculation of each patient’s Propensity Score 
(PS) to stratify their likelihood to be prescribed DMTs: those with PSs in the 
higher strata were also analysed for the frequency of second-line DMTs used 
initially. 
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Treatment Comparisons 
For comparisons of initial treatment, all available patients with propensity 
scores for initiation were included in order to provide matches for patients who 
did or did not start on a DMT within 1 year of diagnosis. The 225 cases with 
propensity scores were matched using the MatchIt package using a calliper of 
0.2. This provided 62 cases from each category matched on propensity score 
[N=124] (60% of those with no treatment & 51% of those with DMT).  The Cohen’s 
d value for standardised difference was used in addition to p-value calculations 
as a measure of the difference between stated means for some variables. A 
Cohen’s d value of 1 would indicate the two groups differ by 1 standard 
deviation, a d of 2 indicates 2 standard deviations, etc. As a general guide the 
difference in means is considered small for Cohen’s d values ≤0.2, medium 
between 0.2 and 0.8 and large if greater than 0.8. 
 
Outcome Comparisons 
For outcome comparisons, the trajectory of patients over time had to be known, 
to ensure only patients who were treated or untreated for the duration were 
compared, in a bid to replicate treatment and placebo arms in a randomised 
trial comparing early DMT initiation versus no treatment. Overall, there were 79 
patients who had no treatment at all in the first 3 years and 89 patients who had 
treatment initiated but had no escalation, whether relapses occurred or not. Of 
these 70/79 and 83/89 had sufficient data to generate a propensity score 
respectively. The 153 cases with propensity scores were matched using the 
MatchIt package using a calliper of 0.2. This provided 39 cases from each 
category matched on propensity score [N=78] (56% of those with no treatment & 
47% of those with DMT).   
 
 
Power calculations  
Given the original plan for prospective clinicoradiological review of matched 
patients, power calculations for demonstrable effect size in the available cohort 
were made to ensure utility of participant involvement. The estimated sample 
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sizes are based on the above calculations, reduced by 20% to reflect our 
estimate that 80% of those patients identified would agree to participate. 
 
Estimated sample size of 96 (48 matched pairs)  
Interval level data: A sample size of 48 matched pairs would be sufficient to 
find a moderate effect size of 0.41 with a power of 0.80. For data such as the 
mean number of MRI lesions after 6 years an effect size of 0.41 corresponds to a 
difference of 8 in mean lesions between the treated and untreated groups 
(assuming the standard deviation of lesions at 6 years is approximately 20).  
 
Categorical data: A sample size of 48 matched pairs would be sufficient to find 
an odds ratio of 4 with a power of 0.80.  
For data such as the proportion reaching EDSS 3.0 over 5/6 years this translates 
to 20% of the treatment group reaching EDSS 3.0 compared to 50% of the 
untreated group (assuming half of the matched pairs have different endpoints).  
 
Inclusion Criteria 
Adult patients (>16 years) 
Diagnosed with RRMS in the Greater Glasgow or Grampian regions between 2010 
and 2011 
Registered on the SMSR 
 
Exclusion Criteria 
PPMS 
SPMS 
Treatment category definitions 
Low efficacy DMTs 
• All IFNs 
• Glatiramer Acetate (GA) 
   
 
167 
• Teriflunomide 
Moderate efficacy DMTs  
• Fingolimod 
• Dimethyl Fumarate (DMF) 
 
High efficacy DMTs / treatments 
• Natalizumab 
• Alemtuzumab 
• HSCT (haematopoetic stem cell transplantation) 
 
Efficacy definitions 
Relapse 
A relapse was defined as the onset of new symptoms or the worsening of pre-
existing symptoms attributable to demyelinating disease lasting for more than 24 
hours and preceded by improving or stable neurological status for at least 30 
days from the onset of the previous relapse, in the absence of infection, fever or 
significant metabolic disturbance. Objective change on neurological examination 
was not necessary to fulfill relapse criteria – the occurrence of relapse was at 
the investigators’ (PG) judgment, but where the treating clinician at the time 
felt a relapse had occurred, this was documented whether meeting the above 
definition or not. 
 
Relapse severity was judged by a severity score, dividing relapses into the 
following categories during data collection: 
 
a) Moderate - a relapse lasting more than 48 hours, fulfilling one of 
the criteria below: 
• Any motor relapse   
• Any brainstem relapse   
• A sensory relapse if it leads to functional impairment   
• Optic neuritis   
• Intrusive pain  
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b) Severe - A disabling relapse is defined as any relapse which fulfils 
one or more of the following criteria:  
• Affects the patient’s ability to work   
• Affects the patient’s activities of daily living as assessed 
by an appropriate method   
• Affects motor or sensory function sufficiently to impair 
the capacity or reserve to care for themselves or others 
as assessed by an appropriate method  
• Needs treatment (inc. steroids)/hospital admission 
 
Relapses which did not fulfill either of the above criteria were classified as 
‘Mild’. A severity score for each relapse was calculated as outlined below also. 
 
Disability 
EDSS, where not documented, was estimated from clinical notes using 
Neurostatus® Version 4.0 as a guide. The OPTIMISE database generates an 
estimated EDSS score based on examination findings at each clinic visit but this 
was subject to approval during data entry.  
 
Ethical Considerations 
MODERATE was approved by the West of Scotland Research Ethics Committee 
(Ref 16/WS/0017). Two further substantial amendments were also approved, the 
second being approval of the retrospective phase of the original study as a 
stand-alone project, as presented here, following the funding issues outlined 
above. The study was ultimately funded via a local NHS Endowment Fund. 
The study was a retrospective, observational assessment of clinical records in 
two regional MS centres in Scotland and did not require subject participation. 
Access to clinical records for the purposes of this study was entirely limited to 
the study team. Cross-board patient data access was required and was agreed 
across sites and in line with national regulations, as per centre-specific IT/data 
access guidelines. Data was entered on NHS-networked devices on NHS premises 
in Glasgow. ‘Scotland’s Health On the Web’ (www.show.scot.nhs.uk) hosted the 
OPTIMISE database on a secure NHS server in order to permit remote data entry 
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and storage from each site. This required password-protected access in order to 
enter data. There was no transfer of data outwith the two regions involved, but 
storage was centralised. Data were stored anonymously, using unique identifiers, 
on NHS-approved storage devices and backed up on local servers.  
An Information Request Form was submitted to Scottish Healthcare Audits, part 
of the Information Services Division of NHS Scotland, to access the SMSR data. 
The decision to release the data was made by the Research Subgroup of the 
SMSR Steering Group, of which Dr Overell is a member. Approval to access 
patient data, using the CHI number stored on the SMSR, was sought from both 
Caldicott Guardians in Glasgow and Grampian and the study was approved by the 
Public Benefit and Privacy Panel for Scotland, with regards to information 
governance. 
 
Results 
Cohort Characteristics 
A total of 397 patients were registered on the SMSR with a new diagnosis of MS 
from the Greater Glasgow and Grampian regions between 2010 and 2011. 
Clinical records were available for 375 patients, 301 (80.3%) of which were 
diagnosed with RRMS, 57 (15.2%) PPMS and 17 (4.5%) SPMS (See Figure 2-2, 
Tables 2-3 and 2-4). 
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Figure 2-2: MODERATE cohort disposition from SMSR 
 
 
Table 2-3: Number of patients registered and MS subtype on SMSR 2010-2011 
Diagnosis N (%) 
Year Location 
2010 2011 Grampian GGC 
RRMS 301 (80.3) 163 138 86 215 
PPMS 57 (15.2) 32 25 15 42 
SPMS 17 (4.5) 14 3 8 9 
Total 375 222 175 119 278 
 
 
   
 
171 
Table 2-4: Number of patients on SMSR 2010-2011 - details 
Region No. of patients 
 Total* RRMS PPMS SPMS Other 
2010a 2011b Totalc 2010 2011 Total 2010 2011 Total 2010 2011 Total 2010 2011 Total 
GGC 102 88 190 76 73 149 19 10 29 6 2 8 1 3 4 
Lanarkshire 43 26 69 37 18 55 5 7 12 1 0 1 0 1 (No 
info) 
1 
Ayrshire 5 1 6 4 1 5 1 0 1 0 0 0 0 0 0 
Western 
Isles 
4 2 6 4 2 6 0 0 0 0 0 0 0 0 0 
Grampian 63 56 119 42 44 86 7 8 15 7 1 8 7  
 
3 10 
Total 217 173 390 163 138 301 31 25 57 14 3 17 8 7 15 
*Patients excluded as no information available (Non-Grampian patients only) 
a = 5 (4 invalid CHI provided, 1 no information on Portal)  
b = 2 (Invalid CHI)  
c = 7 
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Of the 301 patients with RRMS, 245 patients had appropriate data available 
within their clinical records on DMT initiation and escalation to be included in 
the final cohort. Of the 53 patients excluded due to missing data, 28 were from 
Grampian [19% of the total (N=147) Grampian cohort] and 25 [8.3% of the total 
(N=303) Glasgow cohort] hence proportionally more Grampian patients were 
excluded. Of the 3 patients excluded due to diagnostic uncertainty, 2 were from 
Glasgow and 1 from Grampian. 
The cohort was fairly typical for a population of patients with RRMS (See Table 
2-5). Predominantly female, the cohort was also almost entirely Caucasian, and 
mean 36 years of age at diagnosis.  The median duration since first symptom at 
diagnosis was 1.8 years but there was a wide range from weeks to decades; 
similarly, this was also the case for the duration between first and second 
relapses, but on average this was just over a year. Notably, given the 
retrospective nature of the analysis, relapses which occurred after diagnosis 
were included in calculating the duration between first and second relapses as 
not all patients had had 2 relapses at diagnosis. The vast majority (223/245, 
91%) had at least 2 relapses prior to diagnosis, however. Data was incomplete for 
recovery from first relapse but, of those with data available, the majority 
recovered completely although over a fifth of patients had incomplete recovery 
even after 6 months. Baseline MRI brain data were available for the majority of 
patients and most (64.5%) had at least 9 T2 lesions. 
Of the 245 patients included, 130 (53%) had a DMT initiated within one year of 
diagnosis while 115 (47%) did not. The proportion of patients treated with a DMT 
at diagnosis was notably lower than we had predicted prior to the study, as we 
anticipated over 60% of the cohort would be treated within 1 year (See Figure 2-
1). Indeed, it is immediately surprising that the chance of starting on a DMT in 
this cohort was almost 50:50 at the outset, implying virtually random chance of 
being treated or not irrespective of disease status. However, 53% of patients 
receiving a DMT in our cohort is higher than the average overall treatment rates 
in Scotland purported in the survey upon which we based our projections (36%)190 
and the international MS atlas estimates for the UK as a whole (11%)196. More 
recent analysis suggests that around 59% of eligible patients in the UK have 
access to DMTs however197. Importantly, we did not analyse differences between 
the two regional centres directly.  
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The vast majority of patients started on DMTs within 1 year of diagnosis used 
injectable therapies, as shown in Figure 2-3. Overall, 118/130 (91%) used either 
IFN or GA first-line. One patient was started on Azathioprine as a dual treatment 
for MS and retinal vasculitis. Just 11 patients (8.5%) started directly on 2nd-line 
therapy, the majority of which used natalizumab (9/11), with alemtuzumab and 
mitoxantrone used by the others. 
More detailed comparisons of those initiated onto a DMT after diagnosis or not 
will be presented but there are notable differences at the outset. Treated 
patients were more likely to be female and were, on average, significantly 
younger than those who did not receive treatment (See Table 2-5). Duration of 
disease at diagnosis and the time between first and second relapses was also 
notably shorter in the treated group. Additionally, a higher proportion had had 4 
or more relapses prior to diagnosis in those who went on to have treatment but, 
notably, this was also the case for 4 patients (3.5%) within the untreated group. 
Indeed, almost a quarter of the untreated group had 3 or more relapses prior to 
diagnosis, albeit these were more likely to be spread over a longer time. 
Recovery from first relapse and MRI lesion load does not appear to have been a 
major factor in treatment decisions, but a higher proportion of the treated 
group had ≥9 MRI brain T2 lesions in comparison to those who did not start 
treatment. Together, these data suggest that young female patients with short 
disease duration and frequent relapses close together were prioritised for DMT 
initiation in our cohort. 
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Table 2-5: MODERATE Cohort characteristics  
 
Total cohort 
DMT started 
<1yr 
DMT not started 
<1yr 
N (%) 245 (100) 130 (53) 115 (47) 
Female (%) 168 (69) 92 (71) 76 (66) 
Mean age at diagnosis 
(SD) [years] 
36 (9.8) 33 (9.2)* 39 (9.6) 
Median duration of 
disease at diagnosis 
(Range) [years] 
1.80 (0.05-
29.7) 
1.32 (0.05-
21.3)* 
3.10 (0.15-29.7) 
Median duration 
between 1st and 2nd 
relapses (range) [years] 
1.19 (0.04-
20.29) [n=238] 
0.66 (0.04-
20.29)* 
[n=128] 
2.87 (0.08-19.55) 
[n=110] 
Relapses before diagnosis 
Mean (SD) 2.28 (0.75) 2.35 (0.83) 2.20 (0.64) 
Number n (%) 
1 
2 
3 
4 
5 
N/D 
21 (8.6) 
154 (62.9) 
51(20.8) 
16 (6.5) 
2 (0.8) 
1 (0.4) 
11 (8.5) 
78 (60) 
26 (20) 
12 (9.2) 
2 (1.5) 
1 (0.8) 
10 (8.7) 
76 (66.1) 
25 (21.7) 
4 (3.5) 
0 
0 
Recovery from 1st 
relapse 
n (%) 
Complete at <3/12 
Incomplete at 3/12 
Incomplete at 6/12 
N/D 
93 (38.0) 
33 (13.5) 
50 (20.4) 
69 (28.2) 
53 (40.8) 
21 (16.2) 
27 (20.8) 
29 (22.3) 
40 (34.8) 
12 (10.4) 
23 (20) 
40 (34.8) 
Number of MRI Brain T2 lesions at diagnosis 
0 
<9 
≥9 
N/D 
8 (3.3) 
69 (28.2) 
158 (64.5) 
10 (4.1) 
4 (3.1) 
34 (26.2) 
89 (68.5) 
3 (2.3) 
4 (3.5) 
35 (30.4) 
69 (60) 
7 (6.1) 
*p<0.05 
 
 
 
 
 
 
 
 
 
 
   
 
175 
Figure 2-3: DMTs used at initiation of treatment (n=130) 
 
 
 
Treatment comparisons 
The following primary endpoints will be addressed in this section 
• Mean DMT initiation propensity scores in patients initiated onto a DMT 
within 1 year of diagnosis and those not initiated onto a DMT within 1 
year of diagnosis 
 
There was a total of 20 missing cases so the model estimated propensity scores 
for 225 patients (103/115, 90% of those with no DMT & 122/130, 94% of those 
with DMT). The Cox & Snell r2 for the model was a modest 0.212 and only age, 
time between relapses and number of relapses had p values of less than 0.2; this 
suggests the model was relatively weak at predicting the outcome variable but 
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these factors were most important. However, analysis comparing actual 
outcomes with the propensity scores i.e. likelihood of being in the chosen 
treatment group based on the propensity score calculated. 
 
 
The mean propensity score (SD) for treatment was significantly higher in 
patients initiated onto a DMT within 1 year of diagnosis [0.64 (±0.19)], in 
comparison to those who did not start on a DMT [0.42 (±0.23), p<0.001]. This 
reflects patient and clinician decisions to start treatment in those with more 
severe disease. However, Figure 2-4 shows the propensity scores for treatment 
distributed across the entire cohort and, whilst those who started treatment 
within a year generally had higher scores than those who did not, there is 
considerable overlap. Table 2-6 shows DMT initiation by propensity score 
quartile, with 42% (43/103) of those having no treatment and 57% (70/122) of 
those starting treatment in the middle two quartiles and hence likely 
comparable baseline disease. These data suggest that, whilst on average 
patients with worse prognostic factors at diagnosis are more likely to receive 
treatment, a significant proportion of patients are being treated differently 
despite comparable disease severity.  
It is also notable that patients with propensity scores at the extremes of the 
cohort were not necessarily managed as might be expected. For example, 12/56 
(21%) of the patients in the highest PS quartile for DMT initiation did not start on 
a DMT within 1 year and, of those in the lowest PS quartile for DMT initiation 
(n=56), 9 (16%) were commenced on a DMT within 1 year of diagnosis. This 
suggests that more patients are being under- rather than over-treated, perhaps. 
Interestingly, of those initiated directly onto a 2nd line DMT (natalizumab) 
[Group 7, n=11], 6 (55%) were in the highest quartile (4), 3 were in the 3rd 
quartile and 1 was in the second quartile (1 did not have enough available data 
to calculate a PS) and none from the first quartile, suggesting this group of 
patients were appropriately initiated onto high efficacy treatment from the 
outset. 
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Figure 2-4: Population pyramid showing distribution of propensity scores by 
group 
 
 
Table 2-6: Proportion of DMT category by propensity score quartile 
Propensity score quartiles 
DMT started <1yr? 
Total 
No Yes 
1 (lowest likelihood of 
receiving treatment) 
47 (46%) 9 (7%) 56 
2 26 (25%) 30 (25%) 56 
3 17 (16%) 40 (33%) 57 
4 (highest likelihood of 
receiving treatment) 
13 (13%) 43 (35%) 56 
Total 103 122 225 
 
Using PSM, we were able to match 124 (55%) of the 225 patients on prognostic 
factors at diagnosis and there was no longer a significant difference in the mean 
propensity score for treatment despite half the group being treated and half not 
(62 matched pairs). Table 2-7 shows the cohort characteristics before and after 
the matching process. In the unmatched cohorts, patients receiving a DMT within 
1 year were significantly younger at diagnosis, with a shorter duration of disease 
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and inter-relapse interval. The cohorts were otherwise comparable but those 
starting a DMT within 1 year had a significantly higher mean PS for treatment. 
After matching, there was no significant difference in disease characteristics, as 
reflected in the comparable mean PS for treatment, yet they were treated 
differently. This suggests factors other than the disease characteristics included 
in our propensity score are influencing treatment decisions. These may be 
patient- or clinician-related but, notably, only 8 (7%) of the 115 patients who 
didn’t start a DMT within 1 year of diagnosis were documented to have refused 
treatment for imminent pregnancy plans (6, 5%) or other reasons (2, 2%). As 
outlined below, however, follow-up information was limited for many patients 
and incomplete documentation may result in this being an underestimate, but it 
does not appear to be the case that the vast majority of patients refused 
treatment where it was offered or suggested.  
The propensity score using prognostic factors at baseline was notably predictive 
of treatment within the first 3 years, being lowest in those receiving no DMTs 
and having no subsequent relapses and highest in those initiated directly onto 
2nd-line therapy, as shown in Table 2-8 and Figure 2-5. Using a Tukey B post-hoc 
test, mean PS was significantly higher in those starting and escalating DMTs in 
comparison to those who remained untreated in the first three years. This 
validates the predictive value of our model although the confidence intervals 
overlap outwith the extremes.   
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Table 2-7: Baseline characteristics of patients before and after matching 
 Unmatched  Matched 
DMT started <1yr  DMT started <1yr 
No Yes d† No Yes d† 
N (% female) 103 (65%) 122 (70%)  62 (71%) 62 (66%)  
Age at 
diagnosis 
(mean±SD) 
38.3±9.6 33.5±9.2 0.51* 
35.1±9.
2 
35.8±9.1 0.08 
Duration of 
disease (years) 
5.7±5.7 2.7±4.1 0.60* 3.5±4.5 3.7±4.7 0.06 
Years between 
relapse 
4.3±4.3 1.6±2.7 0.76* 2.4±3.3 2.4±3.5 0.001 
Number of 
relapses prior 
to diagnosis 
2.2±0.7 2.4±0.8 0.21 2.2±0.7 2.5±0.9 0.32 
White 
ethnicity (%) 
102 (99%) 118 (97%)  61 (99%) 62(100%)  
Initial relapse symptoms 
Sensory only 68 (66%) 77 (63%)  42 (68%) 43 (69%)  
Motor 15 (14%) 16 (13%)  6 (10%) 6 (10%)  
Sensorimotor 12 (12%) 15 (12%)  8 (13%) 5 (8%)  
Polysymptoms 7 (7%) 12 (10%)  5 (8%) 8 (13%)  
Sphincter 
involvement 
1 (1%) 2 (2%)  1 (1%) 0 (0%)  
Number of T2 lesions on Baseline MRI Brain 
0 4 (4%) 3 (3%)  3 (5%) 1 (2%)  
<9 33 (32%) 33 (27%)  21 (34%) 21 (34%)  
≥9 66 (64%) 86 (70%)  38 (61%) 40 (64%)  
Propensity 
score 
0.42±0.23 0.64±0.19 1.07* 
0.54±0.
21 
0.57±0.20 
0.13 
p=0.46 
Recovery 
from 1st 
relapse 
n=72 n=97  n=46 n=49  
Complete 39 (54%) 51 (53%)  24 (52%) 21 (43%)  
Partial 
(incomplete at 
3/12) 
11 (15%) 20 (20%)  8 (17%) 10 (20%)  
None 
(incomplete at 
6/12) 
22 (31%) 26 (27%)  14 (30%) 18 (37%)  
†Standardised difference (Cohen’s d) for continuous variables.  
*p < 0.001 
 
 
Table 2-8: Patient groupings after 3 years from diagnosis 
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Group 
Outcome at 3 
years 
DMT started <1yr Mean Propensity Score 
Total 
No Yes 
DMT 
initiation 
(n) 
DMT 
escalation 
(n) 
1 
No DMT & no 
relapse 
42 
(37%) 
0 0.38 (38) 0.21 (41) 42 
2 
No DMT despite 
relapse 
37 
(32%) 
0 0.39 (32) 0.27 (34) 37 
3 
No initial DMT 
but escalation to 
DMT after relapse 
31 
(27%) 
0 0.50 (28) 0.37 (28) 31 
4 
1st line DMT 
initiated & no 
relapse 
0 
30 
(23%) 
0.59 (28) 0.26 (27) 30 
5 
1st line DMT 
initiated & 
continued 
despite relapse 
0 
48 
(37%) 
0.64 (45) 0.33 (46) 48 
6 
1st line DMT 
initiated & 
escalation to 2nd 
line DMT after 
relapse 
0 
37 
(29%) 
0.65 (35) 0.54 (34) 37 
7 
2nd line DMT 
initiated 
0 11 (9%) 0.76 (10) 0.48 (10) 11 
8 
Escalation after 
MRI not relapse 
5 (4%) 4 (3%) 0.56 (9) 0.23 (9) 9 
 Total 115 130 
0.54 
(216) 
0.33 (229) 245 
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Figure 2-5: Mean propensity score (95% CIs) at diagnosis and treatment group 
after 3 years 
 
Matched cohort outcome comparisons 
The following secondary endpoints will be addressed in this section: 
• Proportion of patients reaching EDSS 3 in first 5-6 years after diagnosis in 
each group 
• Proportion of patients relapsed in first 5-6 years after diagnosis in each 
group 
• Annualised relapse rate in first 5-6 years after diagnosis in each group 
• Proportion experiencing (serious) adverse events in first 5-6 years after 
diagnosis in each group 
 
In order to make meaningful outcome comparisons, we evaluated treated and 
untreated PS-matched cohorts over time. This included analysis of both 3- and 6-
year outcomes where available. However, there was significantly less available 
follow-up data available for the untreated cohorts who were often discharged 
from clinic, meaning longer-term outcomes are skewed towards identifying 
events in treated patients, simply because they were being evaluated whilst 
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untreated patients were not. This is a significant bias that has to be borne in 
mind when interpreting comparative outcomes. 
The following sections describe early (3-year) and longer-term (6-year) clinical 
outcomes comparing treated and untreated patients. The patients were grouped 
by treatment and clinical outcome at the end of available follow-up as outlined 
in Table 2-8 and Figure 2-6 for the entire cohort. 
 
Figure 2-6: Patient disposition in first 3 years after diagnosis  
 
 
• Group 1: No DMT initiation and no relapse activity during follow-up 
 
• Group 2: No DMT initiation despite relapse activity during follow-up 
 
• Group 3: No DMT initiation in <1 year from diagnosis but escalated to 
treatment after relapse activity during follow-up 
 
(43.5%) 
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• Group 4: 1st-line DMT initiated in <1 year from diagnosis and no relapse 
activity during follow-up 
 
• Group 5: 1st-line DMT initiated in <1 year from diagnosis and continued 
despite relapse activity during follow-up 
 
• Group 6: 1st-line DMT initiated and escalated to 2nd-line DMT after relapse 
during follow-up 
 
• Group 7: 2nd-line DMT initiated in <1 year from diagnosis 
 
• Group 8: Escalation from no DMT or 1st-line DMT to 1st- or 2nd-line DMT 
respectively after MRI activity alone 
 
There were 39 matched pairs (N=78) of patients either treated with a DMT <1 
year after diagnosis or not. The untreated patients included Groups 1 & 2 (no 
DMT ever whether relapsed or not) and the treated patients comprised Groups 4, 
5 & 7 (started DMT <1 year after diagnosis and continued whether relapses or not 
but not escalated). Table 2-9 shows the baseline characteristics for the cohorts 
before and after matching. Similar to the overall cohort, the treated group were 
significantly younger, with shorter duration of disease and inter-relapse interval 
in comparison to untreated patients in the unmatched cohorts. There were no 
other statistically significant differences. The higher levels of disease activity 
are reflected in the significantly higher PS for initiation in treated patients. 
However, there is no significant differences in the baseline characteristics after 
matching, including PS for initiation, implying that, while this subgroup reflects 
the overall cohort where patients with similar disease activity are managed 
differently, these cohorts had comparable prognosis at diagnosis hence 
differences in outcome are considered related to treatment effects. 
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Table 2-9: Baseline characteristics of DMT initiation patients for 3-year outcome 
comparisons (before and after matching) 
 Unmatched  Matched 
DMT started <1yr  DMT started <1yr 
No Yes d† No Yes d† 
N (% female) 70 (64%) 83 (69%)  39 (72%) 39 (62%)  
Age at 
diagnosis 
(mean±SD) 
39.6±9.1 34.9±8.4 0.54* 36.5±9.5 36.9±8.7 0.04 
Duration of 
disease 
6.0±6.0 2.3±3.4 0.77* 3.5±4.1 3.4±4.4 0.01 
Years between 
relapse 
4.7±4.6 1.2±1.5 1.05* 2.2±2.5 1.8±1.9 0.19 
No of relapses 2.1±0.6 2.3±0.8 0.17 2.2±0.6 2.1±0.7 0.08 
Ethnicity (% 
white) 
70 (100%) 81 (98%)  39(100%) 39(100%)  
Initial relapse symptoms 
Sensory only 47 (67%) 56 (68%)  28 (72%) 25 (64%)  
Motor 10 (14%) 10 (12%)  5 (13%) 6 (15%)  
Sensorimotor 9 (13%) 9 (11%)  4 (10%) 4 (10%)  
Polysymptoms 3 (4%) 7 (8%)  1 (3%) 4 (10%)  
Sphincter 
involvement 
1 (1%) 1 (1%)  1 (3%) 0 (0%)  
Number T2 lesions on Baseline MRI Brain 
0 3 (4%) 2 (2%)  1 (3%) 1 (3%)  
< 9 24 (34%) 22 (27%)  16 (41%) 10 (26%)  
≥9 43 (61%) 59 (71%)  22 (56%) 28 (72%)  
Propensity 
score 0.38±0.22 0.64±0.19 1.26* 0.51±0.21 0.54±0.20 
0.13 
p=0.
58 
Recovery 
from 1st 
relapse 
n=50 n=66  n=31 n=32  
Complete 27 (54%) 32 (49%)  17 (55%) 15 (47%)  
Partial 
(incomplete at 
3/12) 
5 (10%) 15 (23%)  3 (10%) 5 (16%)  
None 
(incomplete at 
6/12) 
18 (36%) 19 (29%)  11 (35%) 12 (37%)  
 †Standardised difference (Cohen’s d) for continuous variables.  
*p < 0.001 
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Clinicoradiological outcome measures were evaluated retrospectively using 
medical records from 2010-2017. Notably, these patients were matched on their 
propensity score for DMT initiation but in the knowledge of their outcomes at 3 
years from diagnosis, allowing their allocation into Groups 1-7 and, hence, 
meaningful group comparisons (See Figure 2-6). For 6-year outcomes, patient 
disposition was similarly categorised after 6 years, as shown in Figure 2-7.  
Three analyses of outcomes at 6 years from diagnosis are presented (Groupings 
refer to Figure 2-7): 
• Entire matched cohort: DMT started < 1yr or not (irrespective of DMT use 
after 3 years) 
o N =78 (39 started DMT <1year vs 39 no DMT in first 3 years) 
o Groups 4-8 vs Groups 1-3 
 
• Early DMT initiation versus late DMT initiation 
o N = 36 (23 started DMT <1year vs 13 started DMT after 3 years, 
after relapse) 
o Groups 4,5 & 7 vs Group 3 
 
• Early DMT initiation (+/- escalation) vs. No DMT 
o N = 65 (39 started DMT <1year vs 26 no DMT) 
o Groups 4-8 vs Groups 1&2 
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Figure 2-7: Patient disposition in first 6 years after diagnosis [N=78] 
 
 
Entire Matched Cohort 
Firstly, outcomes after approximately 6 years for the entire matched cohort 
(N=78) are presented in Table 2-10. This represents the effects of early (<1 
year) DMT initiation where patients were treated or untreated for the first 3 
years. A third of the untreated group were however treated with DMTs after 3 
years (Group 3), but started treatment a median of over 4 years after diagnosis 
and the proportion of time spent on a DMT was, on average, less than 1 year 
over the follow-up period. Figures 2-8 and 2-10 summarise all DMTs to which 
the cohorts were exposed over the study period, whilst Figures 2-3 and 2-9 
outline the initial DMTs used in each cohort: notably, the oral therapies were not 
available at the time the early treatment group started treatments and non-MS 
immunomodulatory therapies [e.g. Mycophenylate (MMF) and Tacrolimus] were 
used in some patients with additional non-MS autoimmune diseases as dual 
therapy. These data demonstrate that injectable therapies were the most 
frequent 1st-line DMTs used and remained the most widely used throughout 
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follow-up. There is notable use of oral therapies though (teriflunomide, dimethyl 
fumarate and fingolimod), with a higher proportion of these used by those 
starting treatment after 3 years. However, high efficacy treatments 
(natalizumab, alemtuzumab and mitoxantrone) were only used in patients 
starting treatment early. Figure 2-11 illustrates the differences in DMTs used by 
patients initiated onto treatment earlier or later. These data establish that, 
when DMTs were used, most patients were exposed to injectable therapies 
whether treatment was started early or late but oral DMTs were used 
proportionally more in those starting treatment later and high efficacy infusion 
therapies only in those starting earlier, albeit in small numbers. 
The outcomes for the entire matched cohort outlined in Table 2-10 were 
intended to reflect the impact of early DMT initiation, but, in practice, the 
follow-up duration was significantly longer in treated than untreated patients 
which biases the results towards capturing increased events in the treated 
cohort. Whilst on average patients were diagnosed over 6 years before the end 
of data collection, potentially allowing 6-year outcome comparisons as planned a 
priori, treated patients had available follow-up correspondence for 5.2 years on 
average and untreated patients just 3.3 years. Additionally, the treated cohort 
had a higher number of visits, documented EDSS scores and MRI scans 
undertaken over this longer period, permitting increased capture of events in 
comparison to the untreated group. It is also notable that baseline EDSS score 
was significantly higher in the treated group. This was not a covariate in the 
propensity score for DMT initiation and hasn’t been balanced in the matching 
process, but implies the treated group were more disabled at the outset and this 
may also impact on outcomes, unrelated to treatment decisions, as higher 
baseline EDSS is known to be a strong predictor of worse outcome.  
With these caveats in mind, efficacy and safety outcomes can be considered. By 
definition, the treated group had a longer duration of DMT treatment during 
follow-up in comparison to the initially untreated group (4.2 vs 0.6 years). 
Additionally, the treated group used over 2 DMTs on average during follow-up 
and were initiated onto a DMT within approximately 4 months of diagnosis. 
Outwith DMTs, the earlier treated group also used more symptomatic therapies 
than those not using DMTs initially (2.5 vs 1.1 treatments per patient). This 
likely simply reflects the longer follow-up and, hence, access to symptomatic 
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treatments, but may also represent a higher burden of symptoms. The category 
of symptomatic treatments used is outlined in Figure 2-12. Analgesia, 
predominantly neuropathic, was the most frequent indication for symptomatic 
therapy and in all categories except (male) sexual dysfunction, patients starting 
a DMT earlier had more treatments. 
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Table 2-10: Entire matched cohort 6-year outcomes for DMT initiation 
 DMT started 
<1yr 
No DMT started 
<1yr 
p 
Baseline characteristics 
N (% female) 39 (62) 39 (72)  
Mean age at 
diagnosis (SD) 
36.9 (8.7) 36.5 (9.5) 
0.99 
% Female 62 72 0.5 (z-test) 
Mean no. Co-
morbidities 
1.33 1.46 
0.69 
Mean disease 
duration at 
diagnosis (SD) 
[years] 
3.4 (4.4) 3.5 (4.1) 
0.8 
Mean Baseline 
EDSS 2.7* 
(Median 2.5) 
1.7 
(Median 1.5) 
0.01 
(Mann-
Whitney 
0.026) 
Baseline number 
of T2 lesions (%) 
<9 
>9 
0 
 
(n=34) 
31.3 
65.6 
3.1 
 
(n=36) 
41.7 
55.6 
2.8 
 
z-tests 
0.4 
0.77 
1 
Follow-up  
Mean duration of 
follow-up (yrs) 
5.2* 3.3 
0.0004 
Mean Number of 
visits per patient 
7.7* 4.4 
0.0001 
Mean duration 
from diagnosis to 
end of data 
collection 
6.3 6.3 
 
Number of visits 
per year of study 
1.2* 0.7 
0.7x10-5 
Mean number of 
visits per year of 
follow-up 
1.7 2.1 
0.5 
Treatments 
Mean duration on 
any DMT (years) 
4.2* 
0.6  
(n=13) 
0.48x10-14 
Mean number of 
DMTs used 
2.1* 0.6 
0.95x10-8 
Mean duration 
from diagnosis to 
DMT 
commencement 
(years) 
0.3* 
(median 0.3) 
3.6 
(median 4.4) 
 
 
0.00015 
Total number of 
symptomatic 
treatments used 
96 44 
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Mean number of 
symptomatic 
treatments used 
per patient 
2.5* 1.1 
 
 
0.004 
Relapses 
Total number of 
relapses recorded 
after diagnosis 
62 51 
 
Proportion with 0 
relapses after 
diagnosis 
12/39 13/39 
 
1.0 
Mean total number 
of relapses per 
patient after 
diagnosis 
1.6 1.3 
 
0.4 
Mean duration to 
1st relapse after 
diagnosis (years) 
1.8 1.5 
0.6 
Mean ARR during 
follow-up 
0.3 0.7 
0.09 
Mean ARR 
(excluding 
relapses <1yr after 
diagnosis) 
0.3 0.4 
0.17 
Severity of relapses (%) 
Mild 34.9 52.9 0.08 (z) 
Moderate 38.7* 11.8 0.001 
Severe 6.6 2.0 0.449 
Unknown 19.8 33.3 0.159 
Steroids used 35.5 9.8 0.001 
EDSS 
Total EDSS scores 
recorded 
158 
(n=37) 
89 
(n=37) 
 
EDSS scores 
documented per 
patient 
4.3 2.4 
 
Mean EDSS scores 
per patient per 
year of follow-up 
0.9 
(Median 0.8) 
1.7 
(Median 0.6) 
0.2 
Mean change from 
Baseline EDSS to 
final EDSS 
+1.1 +0.86 
0.75 
Mean duration 
between baseline 
and final EDSS 
(years) 
5.2 
(Median 6.0) 
3.9 
(Median 4.4) 
 
0.054 
Proportion 
developing SPMS 
8/39 2/39 
0.08 (z-
score) 
Proportion 
reaching EDSS 3 
(maintained until 
17/33 9/23 
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last available 
EDSS) 
[denominator is 
number with ≥2 
EDSS scores] 
0.5 (z-
score) 
MRI 
Total number of 
MRIs undertaken 
[inc contrast] 
141 [79] 
(n=34) 
84 [21] 
(n=36) 
 
Number of 
patients having ≥1 
MRIs with contrast 
30 11 
 
Mean number of 
MRIs per patient 
3.6* 2.2 
0.004 
Mean MRIs per 
patient per year of 
follow-up 
0.8 
(Median 0.6) 
1.3 
(Median 0.6) 
 
0.385 
Patients 
developing new or 
enlarging T2 
lesions 
19/34 13/36 
 
0.15 (z-test) 
Patients 
developing new 
Gd lesions 
11/30 (37%) 5/11 (45%) 
0.65 (z-test) 
Treatment-related 
adverse events 
  
 
Number of 
patients having AE 
leading to Rx 
discontinuation 
21 (53.8%) 8/13 (61.5%) 
 
DMT-related AEs - 
total 
34 10 
 
Mean number of 
AEs leading to Rx 
discontinuation 
per patient 
0.9* 0.3 
0.014 
SAEs 
Death from 
PML 
 
 
*p<0.05 
 
Relapses 
There was no statistically significant difference in relapse frequency but steroid 
use and severity significantly favoured the initially untreated group. Despite the 
difference in duration of follow-up, the number of relapses recorded in total was 
similar for both groups. However, relapses had occurred in around two thirds of 
each group, which favours the early treated group given the longer follow-up, 
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assuming more events would have occurred in the untreated group had they 
been evaluated. Additionally, the number of relapses per patient (1.6 vs 1.3), 
time to 1st relapse (1.8 vs 1.5 years) and ARR (0.3 vs 0.7) all favoured the early 
treatment group numerically but there was no statistically significant difference 
in these outcomes. In an attempt to account for immortal time bias with 
relapses, only those occurring after at least 1 year after diagnosis in both groups 
were also evaluated and this resulted in more comparable absolute ARRs but 
remained no statistically significant difference. A significantly higher proportion 
of the untreated group had milder relapses and less need for steroids but there 
was missing data in both cohorts for these measures and proportionally more in 
the untreated group although this difference was not statistically significant. 
Overall, these data may suggest favouring early treatment for relapse outcomes 
in terms of absolute numbers and given the longer follow-up, but the lack of 
statistical significance does not permit this as a conclusion. 
 
Disability 
As outlined above, the earlier treated group had a significantly higher baseline 
EDSS and longer follow-up but there was no statistically significant difference in 
disability outcomes between the groups. EDSS scores were documented in 37/39 
patients from each cohort, but only 33 from the early treatment group and 23 
from the later/no treatment group had more than two scores documented to 
allow comparisons over time. The number of EDSS scores documented was higher 
in the early treatment group but the untreated group had a higher frequency of 
recordings during their shorter follow-up. The early treated group had 
approximately 1 EDSS score documented per year of follow-up whilst the 
untreated group had almost 2 per year. There was a higher absolute increase 
from baseline to final EDSS score in the early treated group (+1.1 vs +0.86) but 
this was not statistically significant and, again, the final EDSS was recorded with 
over a year of additional disease duration in the early treated group in 
comparison to the initially untreated cohort. Proportionally, more patients in 
the early treated group were documented as developing SPMS (8/39 vs 2/39) and 
reached EDSS 3 (17/33 vs 9/23) but these differences were not statistically 
significant. These data suggest the early treated group developed more disability 
over time but this is not statistically significant and likely influenced by factors 
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other than DMT use, namely the higher baseline EDSS and longer duration of 
follow-up. 
 
MRI 
As with the outcomes above, the early treatment group had more MRI evaluation 
over a longer period but no statistically significant differences occurred in terms 
of lesion development between the two cohorts. In the early treatment group, 
34 patients had at least 1 MRI brain and a total of 141 scans were undertaken. 
Intravenous contrast was used in 79/141 MRIs and 30 patients (77%) had at least 
one contrast-enhanced scan. In the untreated group, however, only 84 MRI brain 
scans were undertaken in 36 patients and 21 of the scans included contrast-
enhancement, undertaken in just 11 patients (28%). This meant patients in the 
early treatment group had almost twice as many scans in total (p=0.004), albeit 
the frequency of scanning was higher in the untreated group during their shorter 
follow-up, but this difference was not statistically significant. There was no 
statistically significant difference in lesion load at baseline between the groups 
but a higher proportion of the early treated group [19/32 (56%)] developed new 
or enlarging T2 MRI brain lesions in comparison to the untreated group [13/36 
(36%)] although this is likely explained by the increased monitoring in this group. 
The opposite was the case for contrast-enhancing lesions, where these occurred 
in a higher proportion of the untreated group [5/11 (45%)] than the early treated 
group [11/30 (37%)] despite differences in scanning frequency, but this was also 
not statistically significant. Drawing conclusions from these data is impossible 
owing to the higher frequency of scans undertaken in the early treatment group 
over a longer period of time but the fact there is no significant difference 
between cohorts despite this may favour the early treatment group but clearly 
this cannot be concluded from these data. 
 
Safety 
Given the increased use of DMTs in the early treatment group, more treatment-
related AEs occurred in comparison to those who started treatment later. Most 
importantly, in the early treatment group, a patient died from natalizumab-
associated PML. This occurred in a 35-year-old male diagnosed with Rapidly 
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Evolving Severe MS in 2011, aged 31, who was initially JCV antibody negative but 
seroconverted in late 2014 after approximately 3 years of natalizumab 
treatment. He had been relapse-free since natalizumab was started but 
presented in 2015 with a progressive brainstem syndrome and an enlarging 
pontine lesion on MRI brain. CSF was positive for JCV PCR and, despite plasma 
exchange and active management of his condition including ventilator support, 
he did not survive and was ultimately managed palliatively. No other SAEs were 
identified in the cohort. In terms of AEs leading to treatment discontinuation, 
this occurred in over half of DMT-treated patients in both groups, although was 
proportionally higher in the late treatment subgroup. Indeed, AEs were the most 
common reason for DMT discontinuation in both cohorts, more so than efficacy 
or disease progression as outlined in Figure 2-13. The early treated group had 
significantly more AEs per patient however (0.9 vs 0.3, p=0.014). These data are 
in keeping with the expectation that DMT-related AEs are the counterbalance to 
any efficacy benefits. However, only DMT-related AEs were identified as this was 
a retrospective analysis hence not all AEs would be recorded in routine clinical 
follow-up. This likely underestimates the incidence of AEs in both cohorts but, 
obviously, will only capture AEs in treated patients. MS-related disease activity 
and disability are the adverse outcome of no treatment and this has to be 
balanced with the risks of DMTs identified in pivotal trials and real-world follow-
up such as this. 
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Figure 2-8: DMTs used years 1-6 in early treated cohort [n=39] 
 
 
Figure 2-9: 1st DMTs used after 3 years in delayed initiation cohort [n=13] 
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Figure 2-10: All DMTs used years 3-6 years in the initially untreated cohort 
[n=13] 
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Figure 2-11: Comparison of DMTs used in early (<1yr) and late (>3yrs) initiation 
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Figure 2-12: Symptomatic therapies used by each cohort 
 
 
Figure 2-13: Reasons for stopping DMTs 
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Early vs late DMT initiation 
• Early DMT initiation versus late DMT initiation 
o N = 36 (23 started DMT <1year vs 13 started DMT after 3 years, 
after relapse) 
o Groups 4,5 & 7 vs Group 3 
In order to compare outcomes for early and late DMT initiation, we compared 
those who had started a DMT within 1 year from diagnosis and continued on 
treatment during follow-up but not escalated [Groups 4, 5 and 7 (N=23)] with 
those starting a DMT at least 3 years after diagnosis following relapse activity 
[Group 3 (N=13)]. Table 2-11 outlines the comparisons between these cohorts. 
There was no statistically significant difference between the cohorts at baseline 
although the early treated group had a higher absolute baseline EDSS score on 
average. The cohort sizes obviously differ however and the small numbers, 
particularly in the late treated group, reduce power to detect significant 
differences. Follow-up frequency and duration is much more comparable though 
as untreated patients have been excluded. Indeed, these cohorts have annual 
data available for around 5 years following diagnosis which resolves the issues in 
the entire cohort comparisons related to unequal follow-up and monitoring. 
Outcome comparisons between these cohorts would therefore be expected to 
more closely represent a true reflection of the intervention of early versus late 
DMT initiation. Of course, the earlier treated group had significantly longer 
exposure to DMTs than the later group (3.8 vs 1.7 yrs, p=0.002) and started 
treatments earlier following diagnosis (0.3 vs 3.6 yrs, p<0.0001) but there was no 
significant difference in the number of DMTs or symptomatic therapies used 
between the cohorts. Figure 2-14 shows the DMTs used 1st-line in the early 
treatment group, with 1 patient receiving alemtuzumab (4%), 1 receiving 
mitoxantrone (4%) and 4 natalizumab (18%), hence around a quarter of this 
cohort used highly effective DMTs 1st-line and three-quarters injectable 
therapies. The vast majority of the early treated group were treated with a 
single DMT (17/23, 74%) but some patients switched to other therapies during 
follow-up, as outlined in Figure 2-15. 
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Relapses 
The earlier treated group had significantly fewer relapses during follow-up in 
comparison to the later treated group. By definition, the later treated group 
were only escalated (from no treatment) following relapse however. This likely 
explains the absence of relapse-free patients in the later treated group but, 
additionally, ARR was significantly lower in the early treated group over time 
(0.23 vs 0.49, p=0.03). This remained the case when only relapses occurring at 
least 1 year after diagnosis were included in the analysis, in order to exclude 
immortal time bias. That said, as seen in the overall cohort not treated with 
DMTs within 1 year of diagnosis, the delayed treatment cohort had milder 
relapses and used steroids significantly less often for these.  
 
Disability 
There was no significant difference in disability outcomes between early and 
delayed DMT initiation groups. The frequency of EDSS monitoring was 
comparable between the groups, albeit the early treatment group had roughly 
annual documented scores whilst the later treated group had EDSSs available 
closer to a bi-annual basis but this was not significantly different. There was no 
significant difference in EDSS change from baseline to final EDSS, approximately 
5 years apart on average for both groups, although the absolute numerical 
increase was higher in the later treated group (+1 vs +0.63, p=0.76). Notably, 
only 1 of the 13 later treated patients (8%) was considered to have developed 
SPMS during follow-up by the treating team, in comparison to 6 of the 23 early 
treated patients (26%) but the difference was not statistically significant. 
Similarly, a higher proportion of the early treatment group reached EDSS 3 which 
persisted until the end of follow-up but this was also not a significant difference. 
 
MRI 
The frequency of MRI monitoring was comparable between the early and later 
treated cohorts overall and no significant differences in disease activity were 
seen. A higher proportion of the early treated group had contrast-enhanced MRIs 
but there was no significant difference in the proportion developing new T2 or 
contrast-enhancing brain MRI lesions between the two cohorts. 
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Safety 
DMT-related AEs were comparable between early and later treated patients but 
one patient in the early treatment group died from Natalizumab-associated PML, 
as discussed previously. 
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Table 2-11: Early vs late DMT initiation (N=36) 
 DMT started < 1year 
and continued  
(Groups 4, 5 & 7) 
DMT started 
after 3 years 
(Group 3) 
p 
Baseline characteristics 
N (% female) 23 (61) 13 (54)  
Mean age at 
diagnosis (SD) 
36.8 
35.6 
 
Mean no. Co-
morbidities 
1.2 
1.8 
0.255 
Mean disease 
duration at diagnosis 
(SD) [years] 
3.1  
(n=22) 
(median 1.9) 
2.8 
(n=12) 
(median 2.3) 
0.8 (t-test) 
0.9 (Mann-
Whitney) 
Mean Baseline EDSS 
3.5 
(Median 3.5) 
2.2 
(Median 2.0) 
0.050 (t-test) 
0.052 (Mann-
Whitney) 
Baseline number of 
MRI brain T2 lesions 
(%) 
<9 
>9 
0 
 
 
(n=19) 
6 
13 
0 
 
 
(n=12) 
4 
8 
0 
 
 
>1 
Follow-up  
Mean duration of 
follow-up (yrs) 
5.0 
5.5 
 
Mean Number of 
visits per patient 
7.6 
7.3 
 
Mean duration from 
diagnosis to end of 
data collection 
6.4 
6.4 
 
Number of visits per 
year of study 
1.2 
1.2 
 
Mean number of 
visits per year of 
follow-up 
1.9 
1.3 
0.24 
Treatments 
Mean duration on any 
DMT (years) 
3.8* 1.7 
 
0.002 (t-
test) 
Mean number of 
DMTs used 
1.4 
1.8 
0.36 
Mean duration from 
diagnosis to DMT 
commencement 
(years) 
0.3* 3.6 
<0.0001 (t-
test) 
 
 
Mean number of 
symptomatic 
treatments used per 
patient 
 
2.9 1.7 0.14 
Relapses 
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Total number of 
relapses recorded 
after diagnosis 
32 32 
 
Proportion with 0 
relapses after 
diagnosis 
10/23* (43.5%) 
0 
<0.0001 (z-
test) 
Mean total number of 
relapses per patient 
after diagnosis 
1.4 
2.5 
0.08 (t-test) 
Mean duration to 1st 
relapse after 
diagnosis (years) 
1.5  
(n=13) 1.4 
0.9 but 
missing data 
Mean ARR during 
follow-up 
0.23* 
0.49 
p=0.03 
Mean ARR exc. 
Relapses <1yr after 
diagnosis 
0.24* 
0.49 
Severity of relapses (%) 
Mild 31.3* 
65.6 
p=0.008 (z-
tests) 
Moderate 46.9* 12.5 p=0.003 
Severe 6.3 3.1 0.9 
Unknown 15.6 18.8  
Steroids used 43.8* 11.5 p=0.005 
EDSS 
Total EDSS scores 
recorded 
95 45 
 
Mean EDSS scores 
documented per 
patient 
4.2 3.5 
0.45 
Mean EDSS scores per 
patient per year of 
follow-up 
1.0 
(Median 0.8) 
0.65 
(Median 0.54) 
0.22 
Mean change from 
Baseline EDSS to final 
EDSS 
+0.63 
(Median 0) 
[n=19] 
+1.0 
(Median +0.25) 
[n=10] 
0.76 
Mean duration 
between baseline 
and final EDSS 
(years) 
5.0 
(Median 5.3) 
[n=19] 
5.0 
(Median 5.4) 
[n=10] 
 
Proportion 
developing SPMS 
6/23 
(26%) 
1/13 
(8%) 
0.29 
Proportion reaching 
EDSS 3 (maintained 
until last available 
EDSS) [denominator 
is number with ≥2 
EDSS scores] 
 
11/19 
(58%) 
4/10  
(40%) 
0.59 
MRI 
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Total number of MRIs 
undertaken [inc 
contrast] 
84 [46] 
(n=19) 
36 [9] 
(n=12) 
 
Number of patients 
having ≥1 MRIs with 
contrast 
16 7 
 
Mean number of MRIs 
per patient 
3.7 2.8 
0.36 
Mean MRIs per 
patient per year of 
follow-up 
0.9 
(Median 0.6) 
0.5 
(Median 0.6) 
 
0.16 
Patients developing 
new or enlarging T2 
lesions 
13/19 (68%) 
7/12 (58%) 
 
 
Patients developing 
new Gd lesions 
7/16 (44%) 
3/7 (43%) 
 
Treatment-related 
adverse events 
  
 
Number of patients 
having AE leading to 
Rx discontinuation 
7 6 
 
DMT-related AEs - 
total 
10 9 
 
Mean number of AEs 
leading to Rx 
discontinuation per 
patient 
0.6 0.7 
 
SAEs Death from PML   
*p<0.05 
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Figure 2-14: First-line DMTs used in Early treatment cohort (Groups 4,5 & 7) 
 
 
Figure 2-15: All DMTs used in early treated cohort (Groups 4,5 & 7) 
 
 
Avonex
31%
Rebif
35%
GA
4%
Extavia
4%
Natalizumab
18%
Alemtuzumab
4%
Mitox
4%
1st-line DMT
Avonex
23%
Rebif
26%
GA
13%
Extavia
3%
Natalizumab
16%
Alemtuzumab
3%
Mitox
3%
Fingolimod
7%
Teriflunomide
3%
DMF
3%
All DMTs used in early treated cohort
   
 
206 
Early DMT initiation (+/- escalation) vs. No DMT 
Overall, there was no difference between the early DMT initiation with 
escalation cohort and the untreated cohort which was likely explained by the 
lack of follow-up of untreated patients, making longer-term comparisons 
impossible. Table 2-12 outlines the comparisons between the two groups and 
highlights the significantly shorter follow-up of untreated patients than those 
receiving treatment (mean 2.2 vs 5.2 years, p<0.0001). Consequently, the 
number of clinic visits over the 6 years of potential follow-up was also 
significantly lower in the untreated cohort. The DMTs used in the treated cohort 
have been described previously and this group also used more symptomatic 
treatments on average than those not receiving a DMT although, again, this may 
simply be due to reduced access given the lack of follow-up. 
Given these methodological issues, interpretation of clinicoradiological outcome 
comparisons cannot be conclusive. Longitudinal relapse outcomes clearly cannot 
be compared.  The treated group had lower ARR than the untreated group but 
this was not statistically significant (0.3 vs 0.8, p=0.052) and disappeared when 
only relapses occurring at least 1 year after diagnosis were included. Conversely, 
but similar to other results, DMT-treated patients generally had more severe 
relapses but only the higher use of steroids was statistically significant. Baseline 
EDSS was notably higher in the early treated group but there was no significant 
difference in disability outcomes between the groups. Again, the treated group 
had proportionally higher rates of SPMS development and reaching EDSS 3 but 
this was not statistically significant. Similarly, there were no significant 
differences in MRI activity but the treated group had more recognition of new 
lesions likely as a result of the higher use of imaging in this cohort. The 
treatment-related AEs in the treated group have been described previously and 
clearly the untreated group was not subject to these. 
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Table 2-12: Early DMT and escalation vs no DMT (N=65) 
 
DMT started <1yr 
(Groups 4-8) 
No DMT at last 
review / ever 
(Groups 1 & 2) 
p 
Baseline characteristics 
N (% female) 39 (62) 26 (81)  
Mean age at diagnosis 
(SD) 
36.9 (8.7) 37.9 
 
Mean no. Co-
morbidities 
1.33 1.27 
 
Mean disease duration 
at diagnosis (SD) 
[years] 
3.4 (4.4) 
4.4 
(n=22) 
0.5 
Mean Baseline EDSS 2.7* 
(Median 2.5) 
1.4 
(Median 1) 
p=0.009 
Follow-up  
Mean duration of 
follow-up (yrs) 
5.2* 2.2 
<0.0001 
(t-test) 
Mean Number of visits 
per patient 
7.7* 3.0 
<0.0001 
Mean duration from 
diagnosis to end of 
data collection 
6.3 6.3 
 
Number of visits per 
year of study 
1.2* 0.5 
<0.0001 
Mean number of visits 
per year of follow-up 
1.7 2.6 
0.13 
Treatments 
Mean duration on any 
DMT (years) 
4.2 
 
 
Mean number of DMTs 
used 
2.1 
 
Mean duration from 
diagnosis to DMT 
commencement 
(years) 
0.3 
(median 0.3) 
 
 
 
Total number of 
symptomatic 
treatments used 
96 18 
 
Mean number of 
symptomatic 
treatments used per 
patient 
2.5* 0.7 
 
p=0.001 
Relapses 
Total number of 
relapses recorded 
after diagnosis 
62 19 
 
Proportion with 0 
relapses after 
diagnosis 
12/39 (31%) 13/26 (50%) 
0.19 (z-
test) 
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Mean total number of 
relapses per patient 
after diagnosis 1.6* 0.7 
p=0.014 
(t-test) 
p=0.02 
(Mann-
Whitney) 
Mean duration to 1st 
relapse after diagnosis 
(years) 
1.8 
(n=27) 
1.6 
(n=13) 
0.83 but 
missing 
data 
Mean ARR during 
follow-up 
0.3 0.8 
0.052 
Mean ARR exc relapses 
<1yr after diagnosis 
0.3 0.3 (n=14) 
 
Severity of relapses (%) 
Mild 34.9* 63.2 0.049 
Moderate 38.7 15.8 0.06 
Severe 6.6 0 0.3 
Unknown 19.8 21.0  
Steroids used 
35.5* 10.5 
p=0.02 (z-
test) 
EDSS 
Total EDSS scores 
recorded 
158 
(n=37) 
44 
(n=24) 
 
EDSS scores 
documented per 
patient 
4.3* 1.7 
<0.0001 
Mean EDSS scores per 
patient per year of 
follow-up 
0.9* 
(Median 0.8) 
2.6 
(Median 0.6) 
0.043 (t-
test) 
0.719 
(Mann-
Whitney 
Mean change from 
Baseline EDSS to final 
EDSS 
+1.1 
+0.75 
(Median +0.25) 
[n=12] 
0.7 
Mean duration 
between baseline and 
final EDSS (years) 5.2* 
(Median 6.0) 
4.1 
(Median 2.2) 
[n=12] 
 
p=0.013 
(Mann-
Whitney) 
p=0.009 
(t-test) 
Proportion developing 
SPMS 
8/39 (21%) 1/26 (4%) 
0.32 
Proportion reaching 
EDSS 3 (maintained 
until last available 
EDSS) [denominator is 
number with ≥2 EDSS 
scores] 
17/33 (52%) 
5/12  
(42%) 
0.8 
MRI 
Total number of MRIs 
undertaken [inc 
contrast] 
141 [79] 
(n=34) 
48 [12] 
(n=24) 
 
   
 
209 
Number of patients 
having ≥1 MRIs with 
contrast 
30 6 
 
Mean number of MRIs 
per patient 
3.6* 1.8 
p=0.003 
(t-test) 
Mean MRIs per patient 
per year of follow-up 
0.8 
(Median 0.6) 
1.9 
(Median 0.9) 
p=0.123 
 
Baseline number of T2 
lesions (%) 
<9 
>9 
0 
 
(n=34) 
31.3 
65.6 
3.1 
 
(n=24) 
45.8 
50.0 
4.2 
 
>0.05 
Patients developing 
new or enlarging T2 
lesions 
19/34 7/24 
0.066 
 
Patients developing 
new Gd lesions 
11/30 (37%) 1/6 0.57 
Treatment-related 
adverse events 
  
 
Number of patients 
having AE leading to 
Rx discontinuation 
21 (53.8%)  
 
DMT-related AEs - 
total 
34  
 
Mean number of AEs 
leading to Rx 
discontinuation per 
patient 
0.9  
 
SAEs Death from PML   
*p<0.05 
 
Discussion 
This observational study has identified a cohort of patients with RRMS in 
Scotland with comparable inflammatory disease activity at baseline who were or 
were not treated with a DMT within 1 year of diagnosis. Overall, of 245 patients 
diagnosed with RRMS in Greater Glasgow and Grampian between 2010 and 2011, 
130 patients (53%) were initiated onto a DMT within 1 year of diagnosis. PSM was 
used to generate pairs of patients from the treated and untreated cohorts with 
comparable disease activity at diagnosis based on established prognostic factors 
in order to identify treatment differences. In the unmatched cohorts, patients 
with poorer prognostic factors were significantly more likely to be treated. 
However, of the 225 patients with data available to calculate a PS, 124 (55%) 
were equally treated or not despite comparable PSs, suggesting factors other 
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than inflammatory disease activity and known clinical prognostic markers were 
driving the decision-making process. In this cohort of 62 matched pairs, it 
appears ‘non-disease’ patient and clinician factors are relevant to the decision 
to start a DMT. Notably, however, baseline EDSS was not a covariate in the PSM 
process and, when matched treated and untreated patients were evaluated for 
long-term outcomes, the treated group had a higher mean baseline EDSS. 
Therefore, although this was not evaluated in all 225 patients, this may be an 
additional disease factor which contributed to treatment decisions for both 
patients and doctors. Outcome comparisons between the treated and untreated 
cohorts were subject to detection bias as the treated patients had significantly 
more monitoring and longer follow-up. However, this was not an issue in 
comparing treated patients either staring DMTs early (<1 year after diagnosis) or 
later (>3 years), with over 5 years of follow-up available on average for both 
cohorts. The earlier treated group had significantly fewer relapses and lower 
ARR, although the later treated group had milder relapses when they occurred 
and there was no difference in imaging or disability outcomes. 
Treatment variation in RRMS appears widespread globally but this has not been 
studied directly in the UK before. We used a survey of patients with MS in order 
to estimate DMT use in Scotland as there is no other systematic evidence of DMT 
prescription practices or access available190. Within Europe there are differences 
in the timing of DMT initiation and escalation but much of this can be explained 
by national prescribing guidelines198: there is a notable difference between 
treatment guidelines even within the UK, for example, with NHS England having 
a generally proscriptive approach. Prescribing differences within a single 
country, operating under the same national guidance, must be driven by 
different factors but also exists. In Sweden, for example, regional variations in 
healthcare, including the use of DMTs in RRMS, are evaluated regularly by the 
central government. In 2012, 46.6% of patients with RRMS in Sweden were 
treated with DMTs on average, but this varied from 25.8% in Varmland in the 
South to 79.4% in the Northern county of Vasterbotten199. Establishing treatment 
variation beyond regional differences, for single centres or prescribers for 
example, is obviously more challenging and has not been evaluated 
systematically. However, it is clear that DMT prescription practices in RRMS can 
vary for a number of potential reasons. 
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The reasons for discrepancies in the use of DMTs in similarly-affected patients 
with RRMS will be a summation of both clinician and patient factors. As we have 
shown, patients with more active disease will tend to use DMTs but the 
interaction between clinician and patient beliefs as to their relative benefits and 
costs likely results in varied use otherwise. In structured interviews with 
healthcare professionals involved in MS in the UK, a number of themes were 
identified which influence prescribing decisions200. Within the UK there are 
differing national guidelines which explain some of the variation between 
countries but other factors appear equally important. Variations in the definition 
of relapses impact upon the use of DMTs which are prescribed based on relapse 
frequency. The distinction between a true relapse and pseudorelapse can be 
difficult and severity is open to interpretation. Perceptions of the risks and 
benefits of DMTs in the mind of a treating physician and their familiarity with 
the drug in question was also highlighted as a factor in DMT utilisation in RRMS. 
Additionally, as most UK Neurologists don’t work in isolation, the ‘culture’ and 
prescribing practice within their peer network also influences their individual 
decisions in discussions with patients. These two factors, prescribing experience 
and local culture, are established pivotal factors in variations in medical 
practice generally, summarised as ‘geography and specialty are destiny’ by 
some201.  
The discussion with the patient is also likely key to their ultimate decision on 
using DMTs or not. Very few patients wish to entirely devolve decision-making to 
their doctor, in a paternalistic model, and most appear to prefer a shared-
decision model where patient and doctor agree on the strategy after considering 
the options202–204. The level of involvement in decision-making is variable 
amongst patients, however, with a passive role often preferred by older patients 
and those with lower educational attainment. Additionally, the level of risk 
associated with DMTs which patients will accept for any purported benefit is 
higher in males and those with established disability. However, the preferences 
and goals of patients may be at odds with their doctor203,205,206 hence the final 
decision made will simply reflect that of the party with most influence if a truly 
shared-decision model is not used. Improved understanding and engagement of 
patients in treatment decisions is not only preferred by patients generally but 
also improves concordance. Risk-adversity is typically higher in clinicians than 
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patients, but disease-specialists and patients tend to overestimate the benefits 
of treatment and underestimate side effects which may reflect the reporting of 
misleading statistics in published trials201. Ultimately, however, it should be the 
case that patients have access to treatments for which they fulfil prescribing 
criteria and their doctors facilitate discussion as to the relative risks and 
benefits pertinent to the individual as far as possible before agreeing on a 
management strategy. The relative influence of these patient and clinician 
factors in our cohorts is not known, but recognising them is important if access 
to treatments is to be equitable. 
Our study was limited in drawing conclusions about the impact of early DMT 
initiation on relevant clinical outcomes, but a recent study has attempted to 
answer this question using a similar approach but a much larger dataset207. Using 
the MSBase database to identify matched treated and untreated cohorts of 
patients with RRMS, Brown et al. also used PSM to compare treated and 
untreated patients, but with conversion to SPMS as the primary outcome. A 
standardised definition of SPMS was used, based on EDSS progression, which the 
group had previously published as highly correlating with irreversible subsequent 
disability worsening and identified half of a contemporary cohort of over 17000 
patients as developing SPMS within 32 years from disease onset100. Similar to our 
study, treatment versus no treatment and early vs late treatment cohorts were 
compared. Whilst the treated patients were derived from multiple global centres 
(N=3960), the untreated control cohort was from a single UK centre (N=275) but 
all had at least 4 years of follow-up data. Also, in contrast to our study, PSM 
included baseline EDSS as a covariate and multiple matching (up to 10:1) was 
permitted such that a single patient could be matched multiple times in the 
analyses. Additionally, follow-up was censored to the shortest of the two follow-
up times in matched patients, meaning an identical follow-up duration for each 
cohort.  Overall, treatment with any DMT led to a significantly lower proportion 
developing SPMS in comparison to no treatment, with the greatest benefit using 
high efficacy treatment from the outset. For example, 11 years after diagnosis 
47% of the IFN/GA-treated group had developed SPMS in comparison to 57% of 
the untreated group; at 8 years, 21% of the alemtuzumab-treated group had 
converted versus 41% of the untreated group and 7% versus 39% at 6 years in 
natalizumab-treated patients versus no treatment. Starting treatment earlier 
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(within 5 years of onset) rather than later was also beneficial, with 29% of the 
earlier treated group developing SPMS at 17 years in comparison to 47% of the 
later treated group. There was no significant difference in conversion rates to 
SPMS between untreated patients and those starting a DMT after 5 years when 
followed-up beyond 8 years however. Those who escalated from 1st- to 2nd-line 
DMTs in less than 5 years did benefit though, in comparison to later escalation, 
with 14% and 28% developing SPMS respectively after 7 years. The authors 
comment on the limitations of this study, however, which we could potentially 
help address in the prospective phase of MODERATE. Using our cohorts, we 
would have patients from a geographically comparable location, treated in the 
same era and ensure reliable clinical outcome measures undertaken specifically 
for the purpose of the study. Additionally, we would hope to include more 
extensive phenotyping of disease including cognitive and radiological outcome 
measures. We have also attempted to evaluate the risks of DMTs in our study, 
which was not addressed in the MSBase cohort. 
Indeed, our current study has a number of strengths but its value lies mainly as a 
precursor to detailed evaluation of the treated and untreated cohorts in a 
prospective phase. The nature of the cohorts, diagnosed at the same time in a 
single country and healthcare system with identical prescription frameworks, 
excludes many confounding factors. A limitation of PSM is the reliance on known 
prognostic factors for inclusion in a treatment group, meaning unknown 
confounders may bias results in contrast to true randomisation, but our study 
minimises the chance of much of these. In observational studies, it is suggested 
that PSM is advantageous over other statistical models and caliper matching is 
robust when the sample size is small208,209. Additionally, with patients diagnosed 
in 2010-2011, we have significant duration of follow-up retrospectively for 
treated patients and can extend this to include all patients in a prospective 
study potentially. 
Our study has a number of limitations, however, limiting any conclusions as to 
the risks and benefits of early DMT initiation from these results alone. From the 
outset, patients were drawn from only two centres and exclusions occurred due 
to lack of available medical records and missing data at all stages, given the 
reliance of routinely collected data accessed retrospectively. This had less of an 
impact on deriving the matched patients but highly influences conclusions 
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regarding clinical outcomes. The major issue was lack of follow-up of untreated 
patients in comparison to treated patients. Additionally, numbers are relatively 
small, although were robust enough to provide clinically and statistically 
significant results such as the lower rate of relapses in earlier treated patients. 
The lack of statistical significance in other clinicoradiological outcome measures 
likely belies the cohort size as much as any true difference between the cohorts. 
The flaws of PSM are well established, not least the possibility of unmeasured 
confounders210–212. Additionally, although sometimes considered a method of 
‘pseudorandomisation’ the process is retrospective here and the choice of 
treatment was actually made by the patient and their treating physician and not 
by chance, which limits interpretation of the true effects of a treatment 
intervention in isolation. Patients in our study also did not have access to first-
line oral DMTs at initiation, which differs from current practice, and diagnostic 
criteria have since been updated. Additionally, for outcome measures at least, 
our model did not balance for baseline EDSS between the cohorts and this is a 
known factor in disability over time. In any future prospective study, it would be 
critical to ensure the treated and untreated cohorts are balanced as far as 
possible on all known measures which may influence outcome and therefore this 
should be included as a covariate for PSM. The role of RCTs is not intended to be 
replaced by observational studies using PSM but is simply an attempt to provide 
some level of evidence, rather than none, where more robust trial designs are 
not available to answer clinically-relevant questions such as we have posed here. 
 
Conclusions 
We have identified treatment variation in patients with RRMS despite 
comparable disease characteristics in Scotland. Conclusions regarding the 
clinical impact of early DMT initiation were hampered by unequal follow-up and 
monitoring, with treated patients more closely followed, but evidence of benefit 
on relapse activity was seen in the early treated group. This is to be expected, 
in keeping with the results of short-term clinical trials, but the main focus of 
outcome evaluation in this study was long-term disability and no difference was 
found using the available retrospective data. Detailed evaluation of this and 
other clinicoradiological outcomes is planned in a prospective study of the 
patients identified in this pilot phase. 
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Chapter 3: Alemtuzumab after Natalizumab Switch in 
Evolving Rapidly Severe Multiple Sclerosis (ANSWERS MS) 
Introduction 
Natalizumab is a very effective monoclonal antibody approved in the UK & 
Ireland for use in rapidly evolving severe multiple sclerosis (RES MS), 
characterised by two or more disabling relapses in one year with signs of disease 
activity on MRI scanning. Although usually effective in this group of patients, a 
small proportion of patients fail natalizumab therapy, due to allergic or 
hypersensitivity reaction to the first few infusions, persistent disease activity 
(either clinical or radiological) on therapy, or adverse effects. Neutralising 
antibodies to natalizumab are often detected in patients hypersensitive to 
natalizumab, or who fail therapy due to persistent disease activity. 
 
In clinical practice, natalizumab failure is a challenging dilemma. First-line 
disease modifying therapies (interferons and glatiramer acetate) are less 
effective than natalizumab and often patients who start natalizumab will have 
already failed such agents. Fingolimod is now an option for natalizumab failure 
in the UK, but its effectiveness in highly active disease is uncertain and based on 
limited data from clinical trials.  
 
Alemtuzumab has been used ‘off label’ in the UK and Ireland for more than a 
decade in patients with highly active RRMS, both prior to and during the 
implementation of the pivotal phase 3 program (Comparison of Alemtuzumab 
and Rebif Efficacy (CARE) MS 1 and 2 trials). This ‘real-life’ clinical experience 
with alemtuzumab is unique to the UK and Ireland and relates to the fact that 
the drug was discovered and developed in Cambridge, where it has been used 
regularly as a treatment for RRMS since 1999. The CARE MS 1 and 2 studies have 
proven the effectiveness of alemtuzumab in RRMS, but long-term clinical 
experience outwith the UK and Ireland is limited to trialists and trial centres.  
 
Both natalizumab and alemtuzumab are associated with significant safety 
concerns that limit their use, particularly in patients whose disease prognosis is 
potentially more favourable. Any additive effect and the risk of sequencing such 
therapies one after the other are unknown.  
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Alemtuzumab is now widely approved as a treatment for adults with active 
RRMS, defined by clinical or MRI features, but its use is often restricted either to 
patients failing first-line therapies or to patients with features of disease 
activity broadly similar to those currently characterised by the approved 
indication for natalizumab. In the absence of direct trial comparisons, data on 
response to alemtuzumab in patients with RES MS deemed suitable (in everyday 
clinical practice) for natalizumab, which has now been used in over 160,000 
patients worldwide, will be very helpful for practicing clinicians.  
 
Background 
There has been considerable progress in the development of new DMTs for RRMS 
in the last 2 decades, hence the options for patients and treating clinicians have 
expanded significantly. Despite the use of such medications there remains a 
cohort of patients whose disease worsens and evolves. DMTs are generally used 
sequentially on a first, second or third-line basis when previous treatments have 
failed, with the least efficacious but safest treatments used first and the most 
efficacious but higher-risk treatments used last. This policy is known as 
‘escalation therapy’ and is generally adopted after detailed risk / benefit 
discussions with individual patients. The recent emergence of oral agents for 
RRMS65,123,213,214 with superior outcomes compared to injectable first-line 
therapies is currently changing the landscape of MS management, but the 
concept of ‘escalation’ remains accepted practice in most centres.  
The experience of patients and treating clinicians in the UK and Ireland is 
currently unique in terms of data relating to the long-term real-world efficacy 
and safety of alemtuzumab. The place of alemtuzumab in the current complex 
therapeutic landscape of RRMS is uncertain and is strongly influenced by real-
world experience of its efficacy and risk profile. In the ANSWERS study, we 
collected and analysed data on patients from the UK and Ireland who have been 
treated with alemtuzumab after natalizumab failure to control rapidly evolving 
severe RRMS.  
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Alemtuzumab 
Alemtuzumab was developed in 1983 in the labs of Cambridge pathology, hence 
its original name of Campath. It was the first therapeutic humanised monoclonal 
antibody to be made and is directed against CD52, a surface glycoprotein of 
unknown function expressed on all mature lymphocytes. Its administration 
results in profound B- and T-cell lymphopaenia, resulting from antibody-
dependent cell-mediated lysis. It is given as an intravenous infusion of 12mg/day 
for 5 consecutive days in the first cycle and for 3 consecutive days in the second 
cycle 12 months later. Recovery of B- and T-lymphocytes to the lower limit of 
normal takes 8 months and 3 years respectively215. Originally developed to treat 
B-cell chronic lymphocytic leukaemia, it has also shown efficacy when used (off-
licence) in a number of autoimmune conditions216–218. Its therapeutic effect in MS 
is postulated to result from the complex reorganisation of the immune system 
which follows homeostatic reconstitution of lymphocytes after depletion, rather 
than the depletion itself219. 
Three open-label, one Phase 2 and two Phase 3 trials have studied the use of 
alemtuzumab in MS since 199149,99,120,220–222. Four of these have been co-
ordinated from Cambridge, UK where all patients continue to be followed up 
within an extension study.  
The first use of alemtuzumab in MS included 58 patients with relapsing-remitting 
and secondary progressive disease. This was an open-label study conducted 
between 1991 and 2002 with a mean follow-up of 29 months99. In patients with 
established secondary progressive disease (n=36), a significantly reduced relapse 
rate [0.7/yr to 0.001/yr (p<0.001)] and absence of new lesions on MRI was 
accompanied by progressively worsening disability of the group over the study 
period, as measured by the Expanded Disability Status Scale (EDSS). When used 
in patients with RRMS (n=22), in whom licensed treatment had failed or who had 
a high early relapse rate suggesting poor prognosis, the annualised relapse rate 
(ARR) improved by 94% in comparison to the year before treatment, and mean 
EDSS improved by 1.2 points 2 years after a five-day course of 20mg 
Alemtuzumab/day intravenously. Following this, the concept of a treatment 
‘window of opportunity’ to affect disease progression was suggested to explain 
the difference in the outcomes between patients with early versus established 
disease, the presence of secondary axonal damage being the postulated 
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mechanism for the lack of effectiveness in patients with progressive disease.  
Two further small open-label studies220,221 (n=39 and 45 respectively) have since 
been published and showed similar reductions in ARR (-92% and -94% 
respectively), but more modest improvements in EDSS (0.36 and 0.38 
respectively), albeit with shorter follow-up (mean 21 and 24 months 
respectively). Hirst et al220 included a majority of drug-naïve patients (82%), 
whereas Fox et al221 included only patients who had relapsed despite interferon 
therapy.  
The emergence of autoimmune conditions in patients treated with alemtuzumab 
was apparent during these studies, as had been previously reported114, with 
almost a third of patients developing autoimmune conditions following 
treatment. This was predominantly thyroid-related autoimmunity (Graves’ 
disease most commonly), but one patient in the original series became dialysis-
dependent after developing Goodpasture’s syndrome99. 
The CAMMS223 trial was a multicentre phase 2 rater-blinded study, published in 
2008, which randomised 334 treatment-naïve patients with RRMS to receive 
treatment with alemtuzumab or interferon beta 1a (INF-β1a)222. This trial 
examined patients with active, early disease of less than 3 years duration, a 
baseline EDSS of ≤3 and at least two relapses in the previous 2 years. In terms of 
clinical response, this trial was successful in establishing alemtuzumab as 
superior to INF-β1a in the prevention of relapse (relapse rates 0.11/year vs. 
0.36/year) and the development of sustained disability measured by mean EDSS 
after 36 months follow-up. After 36 months, 80% of patients in the alemtuzumab 
group were relapse-free in comparison to 52% in the interferon group. 
Concerningly, the trial had to be suspended after 3 years due to the emergence 
of immune thrombocytopenic purpura (ITP) in three patients in the 
alemtuzumab group, one of whom died due to intracranial haemorrhage. 
However, five-year follow-up data of those who participated before the 
suspension has shown continued clinically significant benefits in the 
Alemtuzumab group despite the administration of only 1 cycle of treatment in 
the vast majority223. 
The Phase 3 Comparison of Alemtuzumab and Rebif Efficacy in MS trials (CARE-
MS1 and CARE-MS2) were rater-blinded active comparator trials assessing the 
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effectiveness of alemtuzumab against INF-β1a, published in 201249,120. CARE-MS1 
analysed 563 previously treatment-naïve patients, while CARE-MS2 included 798 
patients who had relapsed despite standard treatments. Both trials were 
conducted over 2 years. Given the different cohorts, the mean duration of 
disease was different (2.1 years in CARE-MS1 and 4.5 years in CARE-MS2). In both 
studies the ARR was reduced significantly in comparison to the INF-β1a groups: 
patients were roughly half as likely to relapse on Alemtuzumab compared with 
INF-β1a over the 2 years (CARE-MS1 hazard ratio = 0.45, CARE-MS2 hazard ratio = 
0.51). In CARE-MS2 there was an overall improvement in EDSS worsening in the 
alemtuzumab group in comparison to interferon, though this was not seen in 
CARE-MS1. It was postulated that the lack of expected disease worsening in the 
INF-β1a group (perhaps as a consequence of relatively mild RRMS) made the 
study underpowered to detect a difference in effect on EDSS worsening between 
the treatments.  
In all the comparator studies, the occurrence of any infection, serious infection, 
malignancy and autoimmune disease was higher in the alemtuzumab groups in 
comparison to IFN-β1a. Over 90% of patients receiving alemtuzumab experienced 
an infusion reaction, but these were largely mild, and prophylactic use of 
methylprednisolone and antihistamines was instituted for management of this 
complication. In the CARE-MS trials, 17.4% of patients randomised to 
alemtuzumab developed autoimmune thyroid disease compared to 5.3% of those 
taking IFN-β1a, and 0.8% (8 patients) developed ITP, with one patient requiring 
splenectomy49,120. Recent data have suggested that rates of autoimmune thyroid 
disease may rise with longer term follow up224. Three patients died in the 
alemtuzumab groups during the study period in total: two patients were involved 
in fatal road traffic accidents and one suffered a fatal aspiration pneumonia 
following a brainstem relapse of their MS. In addition, one patient died from 
sepsis after the study. Herpetic infections occurred in 16% of patients in the 
alemtuzumab group in CARE-MS1, a rate that was unchanged despite the use of 
prophylactic antivirals in CARE-MS2. This compared with a 2.4% rate of herpetic 
infection in the IFN-β1a groups across both studies. In CARE-MS1, two patients 
required hospital admission for herpes zoster infections. In the alemtuzumab 
arms of both CARE-MS trials a patient from an endemic region developed 
pulmonary tuberculosis during the trial period. In CARE-MS1, five patients (0.8%) 
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in the alemtuzumab group developed malignancy (basal cell, thyroid, vulval and 
colon carcinomas) while 2 patients (0.9%) developed malignancy in the IFN-β1a 
group (basal cell carcinoma, acute myeloid leukaemia). Two patients (0.5%) in 
the alemtuzumab arm of CARE-MS2 developed thyroid papillary carcinoma with 
no malignancies in the IFN-β1a arm.  Drug discontinuation due to side effects 
was consistently lower in the alemtuzumab groups in comparison to interferon 
(1-3.3% vs. 6-12.1%)225.  
Following the European licensing of alemtuzumab (Lemtrada®), a standardized 
Risk Management Plan has been developed to monitor for adverse events 
encountered in clinical trials226. Baseline and subsequent monthly full blood 
count (with differential), serum creatinine and urinalysis with microscopy are 
required to screen for ITP and nephropathies respectively. These should 
continue until 48 months after the last infusion. Similarly, baseline and 3-
monthly thyroid function tests should be monitored for this period to screen for 
potential thyroid dysfunction. Patients must be advised to comply with periodic 
tests and report possible adverse event symptoms early. 
 
Natalizumab 
Natalizumab is a humanised monoclonal antibody (IgG4) directed against 
transmembrane receptors (integrins) and prevents diapedesis of activated 
leucocytes across the blood-brain barrier, which limits the inflammatory 
response within the CNS227. Very late antigen 4 (VLA-4) is a critical adhesion 
molecule that regulates the translocation of leucocytes from the peripheral 
circulation to sites of inflammation. In binding to the α4 chain of integrins, 
natalizumab prevents its association with β1 integrins to form VLA-4. In contrast 
to alemtuzumab, its pharmacodynamic action is short-lived as, upon 
discontinuation of treatment, VLA-4 returns to baseline levels within 4 
months227. 
Natalizumab is currently licensed worldwide as a first or second-line therapy for 
active RRMS although, in practice, it is most often used in patients who fail to 
respond adequately to first-line treatments such as interferon-beta or glatiramer 
acetate. The AFFIRM study68 compared natalizumab to placebo and showed a 
significant effect of natalizumab on relapse rate, progression and MRI lesions. 
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Similarly SENTINEL228 showed that adding natalizumab therapy to INF-β1a 
resulted in better outcomes compared to the combination of natalizumab and 
placebo. 
In the AFFIRM trial, 627 patients were randomised to natalizumab treatment and 
315 to placebo. The mean ARR at 1 and 2 years were the primary clinical 
endpoints: this was 0.26 and 0.23 at 1 and 2 years respectively in the 
natalizumab group, in comparison to 0.81 and 0.73 in the placebo group 
(p<0.001). In SENTINEL, the mean ARR was 0.38 and 0.34 in the natalizumab plus 
IFN-β1a group (n=589) at 1 year and 2 years, in comparison to 0.82 and 0.75 in 
the placebo plus IFN-β1a group (n=582). The cumulative probability of sustained 
progression of disability at 2 years was 17% and 23% in the active arms of AFFIRM 
and SENTINEL respectively, in comparison to 29% in both the comparator groups 
(p<0.001 for AFFIRM, p<0.05 for SENTINEL). At 2 years, 72% of patients in the 
natalizumab arm of AFFIRM and 61% in the natalizumab plus IFN-β1a arm of 
SENTINEL were relapse-free; this was significantly higher than the comparator 
groups [46% and 37% respectively (p<0.001)]. Notably, post-hoc analysis of 
AFFIRM229  showed that, when stratified by baseline disease activity, those with 
highly active disease seemed to gain particular benefit from natalizumab 
therapy, as the proportion of patients free of both clinical and radiological 
disease was similar (65 vs. 69.5%) whether the disease was highly active or not 
at baseline. Overall, relapses were reduced by 81% and disease progression was 
reduced by 53% in patients with highly active disease at baseline230. These 
observations have informed the decision of the National Institute of Clinical 
Health and Excellence (NICE) in the UK to license natalizumab for RES MS231. 
The most concerning adverse outcome related to natalizumab is the risk of 
progressive multifocal leukoencephalopathy (PML). In AFFIRM, the only adverse 
events that were significantly more frequent with natalizumab than with 
placebo were fatigue and allergic reactions. There were 5 cases (0.8%) of 
anaphylaxis in the natalizumab arm. In SENTINEL, anxiety, pharyngitis, sinus 
congestion and peripheral oedema occurred more frequently with natalizumab in 
comparison to IFN-β1a, and one case of PML emerged. JC virus is the human 
polyomavirus responsible for PML and leads to lysis of oligodendrocytes, 
resulting in rapid nerve demyelination232. The case of PML in SENTINEL occurred 
after 29 doses of natalizumab in a patient also using IFN-β1a, which led to the 
   
 
222 
recommendation that dual therapy should no longer be used. Unfortunately, 
cases of PML have continued to develop in patients on natalizumab monotherapy 
since it was licensed for use. As of 31st August 2017, there have been 749 cases 
of PML from over 174 000 natalizumab-treated patients, with mortality between 
20-25% and the majority of symptomatic survivors having a poor functional 
outcome233. Patients treated for 2 years or more, with prior exposure to 
immunosuppressants and positive anti-JC virus antibodies are at the highest risk 
(11.1. cases per 1000 patients), while patients with none of these factors have 
the lowest risk (0.09 cases per 1000)188. 
The risk of PML is dictated by a number of predisposing factors including prior 
use of immunosuppressants, increasing length of natalizumab treatment and JC 
virus seropositivity and serum JC antibody titre. Using these parameters, risk 
mitigation strategies are now employed to identify and counsel patients 
regarding their risk of PML. To date, PML has not been reported in alemtuzumab-
treated RRMS patients although did occur when alemtuzumab was used for 
haematological neoplasia234. 
These extensive clinical development programs have demonstrated that both 
natalizumab and alemtuzumab are extremely effective in controlling RRMS, but 
that both are limited by their risk of serious adverse events. The mechanism of 
action and dosing schedules for each drug is notably different, and the risk-
benefit equation for individual patients is dictated by the severity and prognosis 
of their disease, the likely benefits of each drug, and the risks and toxicity 
associated with each drug.  
 
Study Rationale 
In the coming years, the current staged ‘escalation’ approach to early 
management of RRMS may be challenged if long-term follow-up studies 
strengthen the ‘window of opportunity’ concept and suggest that early effective 
DMT use can prevent or delay the development of persistent or progressive 
disability. There may be a move to an induction therapy approach using the most 
efficacious treatments early, particularly in patients with clinical or radiological 
evidence of active disease. With either strategy the decision about when, how 
and why to use each drug will evolve as experience of newer drugs grows in the 
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global MS community. The optimal sequencing of the vast array of treatments 
now available is unknown and various therapeutic paradigms have been 
suggested, including sequential monotherapy, induction and maintenance 
therapies, combination therapy or highly personalised individual treatment plans 
if an accurate prognosis can be predicted235. Multiple pharmacological 
(mechanism of action, pharmacodynamic effects), clinical (safety profiles, 
teratogenicity and pregnancy risk, method of administration, need for 
monitoring, overall efficacy) and non-clinical (cost, availability, licensing) 
factors will influence this, in addition to the individual assessment of benefit 
and risk that must be made by each patient.  
The ANSWERS study provides real-life clinical data on the use of alemtuzumab 
after natalizumab failure in patients with rapidly evolving severe relapsing 
remitting multiple sclerosis. Head-to-head studies of disease modifying agents 
are unlikely to be conducted in the current climate, and observational studies of 
effectiveness in distinct clinical scenarios currently provide the best data for 
practising clinicians to make complex decisions about both the initial choice and 
sequence of MS disease modifying therapies. 
 
Aims 
Describe the real-world use of alemtuzumab after natalizumab in rapidly 
evolving severe RRMS and the safety and efficacy of this treatment sequence.  
 
Primary objectives 
1) To evaluate the safety and tolerability of using alemtuzumab after 
natalizumab failure 
 
2) To describe the occurrence of relapses, the occurrence of sustained 
accumulation or reduction of disability, and the development of 
significant MRI markers of active inflammatory disease during each of 
five treatment phases (Pre-Natalizumab, Natalizumab treatment, 
Switch phase, Alemtuzumab treatment and Post-Alemtuzumab) 
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3) To assess the number of patients without relapse, significant MRI 
markers of active disease, or sustained accumulation of disability 
(‘freedom from disease activity’) in each phase 
 
Secondary objectives 
1) To evaluate whether there is an optimal time period for the ‘switch’ 
phase between natalizumab and alemtuzumab and the effect of 
alternative DMTs as bridging therapies 
 
2) To describe any effects of natalizumab and alemtuzumab on 
qualitative atrophy and cognition in patients with rapidly evolving 
severe RRMS 
 
Primary endpoints  
1) The incidence of infections (including opportunistic infections) during 
each treatment phase 
2) The incidence of secondary autoimmunity during each treatment phase 
3) The incidence of infusion reactions, hypersensitivity reactions, new 
blood or urine monitoring events or neoplastic events during each 
treatment phase 
4) Annualised relapse rate during each treatment phase 
5) The occurrence of sustained accumulation of disability (defined by an 
increase from baseline of at least one EDSS point or ≥1.5 points if 
baseline EDSS score was 0) confirmed over 6 months in each treatment 
phase 
6) The occurrence of significant MRI evidence of active inflammatory 
disease in each treatment phase 
7) ‘Freedom from disease activity’ in each treatment phase 
 
Secondary endpoints 
1) The incidence of clinically significant or disabling relapses during each 
treatment phase 
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2) The occurrence of worsening or improving T2/FLAIR lesions, new T1 
lesions and changes in qualitative atrophy during each treatment 
phase 
3) The occurrence of new clinical markers of cognitive impairment during 
each treatment phase 
4) Ambulation score in each treatment phase 
5) EDSS change during each treatment phase 
6) Presence of neutralizing antibodies in each treatment phase 
7) Change in any marker of quality of life / employment 
 
Study Population 
All patients treated with alemtuzumab due to natalizumab failure in the UK and 
Ireland, out with clinical trials. 
 
Methods 
This was a retrospective observational study using routinely collected clinical 
and radiological data. Clinicians from 13 MS specialist centres in the UK & 
Ireland, identified as having suitable patients for the study through personal 
communication, entered data into a bespoke online database created by an 
independent software engineer and hosted securely by NHS Scotland. 
 
Data Capture System 
Software Development 
An electronic database was created in conjunction with a software company 
(TechNeoSoftwareSolutions©) in order to capture a standardised dataset for each 
patient, from each centre. The following section, developed in conjunction with 
a software engineer (Mark Adamson) summarises the software methods used to 
develop the database. 
The architecture used for the AnswersMS application is the Model-View-
Controller (MVC).  
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MVC is a model used for application development; it separates the three main 
components of the application into its own isolated environment. These three 
components are the Controller, the View, and the Model 
The Controller manages the requests, determining which view needs to be 
loaded, and interaction with the models. For example, when you go to login to 
AnswersMS, the Controller tells the application that the login View is to be 
loaded. When logging in, the controller loads the Model that handles logins, 
which will check the database that the credentials match. If the login attempt is 
successful, the Controller will redirect the user to the patient screen, the 
patient controller will then handle any further requests. 
The View is the GUI that the user interacts with. The Controller will call the 
View after getting the required information from the Model. Basically, the View 
is what the user will see on the screen (the web page). 
The Model is where data from the controller is actually passed and interacted 
with. The Model, will take the username and password passed from the 
Controller, verify that information against what is stored in the SQL database, 
then communicate with the Controller to display the correct View. For example, 
if an incorrect username or password is entered, the Model will pass this 
information to the Controller that the credentials are incorrect, then the 
Controller will communicate to the View to display an error message e.g. “Your 
username or password is incorrect. 
The Technologies used to create Answers MS consisted of Microsoft SQL Server 
2014 and Visual Studio 2013. To implement a work stream within the application 
the developer should start with creating a database table in SQL Server.  
Upon creation of the patient table (Appendix 1) the developer now has a 
structure for implementing the application stream in Visual studio. 
Following the MVC pattern the developer can select the database table to 
underpin the dataset used in the application. 
Firstly, the developer is required to add a controller to manage request for the 
patient object (Appendix 2). 
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 The model class is selected from the list e.g. patient table and the views for the 
user interface are created. MVC links all the required code together and allows 
the developer to focus on implementing the complex functionality on the 
system. 
Once the developer has a complete work stream, they will repeat the process 
for each table they wish to interact with in the application.  
User management is controlled by aspmemebership. ASP.NET Web Site 
Administration Tool can be accessed by clicking ASP.NET Configuration from the 
Website menu. 
The developer can programmatically access the features provided by the 
ASP.NET Web Site administration tool via the System.Web.Security namespace in 
the application. Membership and Roles are used to store, access and modify user 
information in the application database. The user could be authenticated using 
the Membership.ValidateUser. Page-based user authorization is given by using 
the AuthorizeRequest event in the HttpApplication class.  
 
Clinicoradiological data fields 
The standardised dataset requested from each centre for each patient was based 
on the primary and secondary objectives and endpoints of the study as outlined 
above. These included: 
 
• detailed descriptions of disease activity and severity (relapse rates, EDSS 
scores) during the 2 years prior to natalizumab therapy 
• patient serial JC virus status (seropositive / seronegative / JCV titre) 
• behaviour of patients on natalizumab (relapse rates, EDSS scores, 
presence of hypersensitivity / infusion reaction symptoms, presence of 
natalizumab antibodies) 
• total natalizumab treatment course, as well as the reason for 
discontinuation 
• interval between natalizumab and alemtuzumab 
• infusion reactions to alemtuzumab 
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• disease activity during the years of follow up after alemtuzumab (relapse 
rates, EDSS scores) 
• side effects and complications of alemtuzumab therapy (specifically 
lymphopenia, thrombocytopaenia and organ-specific autoimmune disease) 
• presence of any opportunistic infections, including progressive multifocal 
leukoencephalopathy (PML), during the course of sequential ‘aggressive’ 
monoclonal antibody therapy 
• presence of any other, perhaps previously unreported, complications that 
might be attributable to sequential monoclonal antibody therapy 
• requirement for further alemtuzumab courses 
• requirement for further disease modifying therapy / treatment for RRMS 
 
Where formal EDSS scores were unavailable, these were estimated by the local 
MS specialist clinician using Neurostatus Version 04/10.2 as a reference aid, 
which was incorporated into the online database, along with other prompts 
including the efficacy and safety definitions outlined below. 
 
The clinical and radiological databases were planned and designed using 
Microsoft Powerpoint® as outlined in Appendix 3 and 4. 
 
Longitudinal MRI imaging was obtained for all patients where available. A 
standardised MRI dataset was completed for each patient at each site by a 
blinded neuro-radiologist, using the online database. The (neuro)radiologist 
documented changes in MRI over time (see MRI data section below) using the 
available interval MRI scans that had been conducted for each patient. The 
effect of sequential natalizumab and alemtuzumab therapy on MS radiological 
lesion development and activity could thereby be determined in each patient, 
and summarised for the whole cohort.  
 
Data were anonymised so that no patient identifiable information was provided 
within the online database or accessible by persons outwith the clinical team 
caring for each individual patient.  
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Study Design 
Duration of follow up varied between patients and all data collection was of 
course subject to availability at each centre. Clinical data was collected for 6 
phases as shown in Figure 3-1. Phase 1 (Baseline) was defined by the date of 
diagnosis, with data from that timepoint (or before) included only. Phase 2 (Pre-
natalizumab) was defined as the period between diagnosis and the first dose of 
natalizumab. Phase 3 (Natalizumab treatment) was the period from first 
natalizumab infusion until 4 weeks after the last natalizumab infusion, to 
account for persisting pharmacodynamic effects. Phase 4 (Switch) was the time 
period between the last dose of natalizumab and the first dose of alemtuzumab. 
Phase 5 (Alemtuzumab treatment) was pre-defined as 2 years following the first 
infusion of alemtuzumab. Phase 6 (Post-alemtuzumab) was the time from the 
end of the alemtuzumab treatment phase until the end of data collection 
(31/12/17 for clinical data; 31/1/18 for radiological data).  
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Figure 3-1: Study Design 
 
 
 
The clinicians and neuro-radiologists involved in data entry were provided with a 
centre-specific guide on the use of the online database. Patients with the 
longest follow-up since starting alemtuzumab were prioritised for data entry, 
specifically those with at least 2 years follow-up after alemtuzumab was 
commenced. Whilst centres accumulated new cases as the study progressed, 
with the majority of patients receiving alemtuzumab in the licensed era, those 
with at least 2 years follow-up after alemtuzumab were the focus of this study. 
 
Clinical Data 
The following data were collected for each patient in each phase: 
 
1) Phase 1: Baseline 
a) Patient-specific data* 
i. Demographic data 
ii. Co-morbidities 
iii. Deprivation category (based on postcode) 
iv. Employment status at diagnosis 
v. Pregnancy data 
b) Para-clinical test results 
i. Cerebrospinal fluid results 
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ii. Visual evoked responses results 
c) Disease-specific data 
i. Age /date at MS diagnosis 
ii. Presenting symptom(s) of MS 
iii. Date of first (likely) symptom if remote from presentation 
iv. EDSS / ambulation score at diagnosis 
v. MRI data** 
d) Relapse information *** 
i. Number of relapses prior to diagnosis 
ii. Severity of relapses 
iii. Steroid use 
 
 
 
 
2) Phase 2: Pre-natalizumab 
a) Disease-specific data 
i. EDSS / ambulation score at 6 monthly intervals 
ii. MRI data** 
iii. Symptomatic therapy use 
b) Relapse information *** 
c) Other disease modifying therapy (DMT) use 
i. Date started and duration of first and any subsequent DMT 
ii. Adverse events/serious adverse events/side effects ¶ 
iii. Presence of interferon neutralizing antibodies¶  
d) JC virus status / index¶ 
 
3) Phase 3: Natalizumab Treatment 
a) Date natalizumab started / Age at 1st dose 
b) EDSS /ambulation score on day 1 of natalizumab therapy 
c) EDSS /ambulation score at 6 monthly intervals on natalizumab 
d) Relapse information*** 
e) MRI data** 
f) Cognitive data*** 
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g) Quality of life data***  
h) JC virus status / index¶  
i) Duration of Natalizumab treatment / number of infusions 
j) Adverse events/serious adverse events/side effects¶ 
k) Reason for failure of Natalizumab 
i. Adverse events 
ii. Unsatisfactory efficacy  
iii. Risk mitigation 
l) Presence of neutralising antibodies¶ 
 
4) Phase 4: Switch period 
a) Age / date at start of switch phase 
b) EDSS at 6 monthly intervals during the switch phase  
c) Duration of switch phase  
d) Relapse information*** 
e) MRI data**  
f) JC virus status / index¶ 
g) Symptomatic therapy use 
h) Cognitive data***  
i) Quality of life data***  
j) DMT use 
i. Date started and duration of any DMT 
ii. Adverse events/serious adverse events/side effects¶ 
iii. Presence of interferon neutralizing antibodies¶ 
 
 
 
5) Phase 5: Alemtuzumab treatment period (2 years) 
a) Date of Alemtuzumab treatment / Age at 1st infusion 
b) EDSS / ambulation score at 6 monthly intervals after the first 
Alemtuzumab infusion  
c) Relapse information*** 
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d) MRI data** 
e) Cognitive data***  
f) Quality of life data *** 
g) Symptomatic therapy use 
h) Number of Alemtuzumab infusions / total Alemtuzumab dosage 
i) Adverse events/serious adverse events/side effects¶ 
 
6) Phase 6: Post-alemtuzumab 
a) Age / date at start of post-Alemtuzumab phase 
b) EDSS /ambulation score at 6 monthly intervals during the post-
Alemtuzumab phase  
c) EDSS at the end of the post-Alemtuzumab follow up period (last score)  
d) Number of further Alemtuzumab infusions/ total Alemtuzumab dosage 
e) Relapse information*** 
f) Adverse events/serious adverse events/side effects¶ 
g) MRI data** 
h) Cognitive data*** 
i) Quality of life data***  
j) Symptomatic therapy use 
a) Other disease modifying therapy (DMT) use 
i. Date started and duration of any DMT 
ii. Adverse events/serious adverse events/side effects¶  
iii. Presence of interferon neutralizing antibodies¶ 
 
*These data were collected for each phase and updated accordingly 
**See MRI data section below 
***See Efficacy Definitions below 
¶See Safety Definitions below 
 
MRI data 
A neuroradiologist was identified in each centre by the centre lead. 
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The neuroradiologist was blinded to all clinical data and was provided only with 
the serial images for each patient. They were informed that the study was being 
conducted to assess the serial efficacy and safety of commonly used disease-
modifying therapies in multiple sclerosis but were not informed which drugs or 
sequence of drugs were being assessed or which treatments patients were 
receiving at the time of each scan. 
 
The neuroradiologist was provided with all available MRI brain images for each 
patient from diagnosis through the 6 assessment stages of the study (Baseline, 
Pre-natalizumab, Natalizumab treatment, Switch, Alemtuzumab treatment, 
Post-alemtuzumab). Every effort was made to obtain all films for each 
individual, but some were unavailable. Additionally, as a retrospective study, 
MRI scans were undertaken at different frequencies and intervals depending on 
clinician judgement at the time, likely related to disease activity and/or DMT 
use i.e. higher frequency of imaging in those with more clinically active disease 
or switching DMTs. 
 
The first available scan for each patient was the Baseline scan. The blinded 
neuro-radiologist commented on supra- and infra-tentorial lesion load (minor, 
moderate, marked), the presence of significant atrophy (global / corpus 
callosum) and the number of gadolinium enhancing lesions on the baseline scan. 
 
The following data were entered by the neuro-radiologist into the online 
database for each subsequent scan, making a comparison with the preceding 
scan: 
 
1) Date scan was conducted 
2) Number of new Gadolinium enhancing lesions 
2) Number of new T2/FLAIR lesions 
3) Improved (smaller or less intense) T2/FLAIR lesions 
4) Worsened (larger or more intense) T2/FLAIR lesions 
5) New T1 hypo-intense lesions 
 
Specific MRI brain scans were also compared in a bid to assess the radiological 
efficacy of natalizumab and alemtuzumab. The scans to be compared were 
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identified automatically by the database, if available, once all available scan 
dates were entered by the neuro-radiologist. The database referenced the date 
of each scan with the dates of each treatment phase entered via the clinical 
database, to which the neuro-radiologist had no access. The specific MRI brain 
comparisons were: 
 
1) Latest scan in Natalizumab treatment phase vs. latest scan in Pre-
natalizumab phase [Effect of natalizumab treatment] 
2) Latest scan in Alemtuzumab treatment phase vs. latest scan in Switch 
phase [Effect of alemtuzumab treatment within first 2 years] 
3) Latest scan in Post-alemtuzumab phase vs. latest scan in Switch phase 
[Overall effect of alemtuzumab] 
4) Latest scan in Post-alemtuzumab phase vs. latest scan in Alemtuzumab 
treatment phase [Effect of alemtuzumab in the longer term]  
In these comparisons, the scan listed first is the more recent one, compared 
with (vs.) a previous one, with the following data collected: 
1) Date scan was conducted 
2) Number of new Gadolinium enhancing lesions 
2) Number of new T2/FLAIR lesions 
3) Improved (smaller or less intense) T2/FLAIR lesions 
4) Worsened (larger or more intense) T2/FLAIR lesions 
5) New T1 hypointense lesions 
6) Qualitative Atrophy (Global and corpus callosum): improved, 
unchanged or worsened 
 
The blinded neuroradiologists were additionally provided with free text areas 
within the database to make additional comments if necessary. 
 
Serial MRI imaging of spinal cord was also retrieved where available, both 
cervical and thoracic specifically. Similar comparisons were made between 
baseline scans and all subsequent follow-up scans. For the baseline spinal cord 
(cervical/thoracic), the following data were entered: 
 
1) Number of T2 lesions 
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2) Number of Gadolinium enhancing lesions 
3) Qualitative atrophy assessment (Present or Not) 
 
For subsequent interval spinal cord imaging, the number of new T2 and 
Gadolinium enhancing lesions were documented and whether atrophy had 
changed (‘improved’, ‘unchanged’ or ‘worsened’) in the opinion of the 
neuroradiologist. 
 
Efficacy Definitions 
These definitions were embedded within the online database as a reference for 
clinicians entering data. 
Relapse 
A relapse was defined as the onset of new symptoms or the worsening of pre-
existing symptoms attributable to demyelinating disease lasting for more than 24 
hours and preceded by improving or stable neurological status for at least 30 
days from the onset of the previous relapse in the absence of infection, fever or 
significant metabolic disturbance. Objective change on neurological examination 
was not necessary to fulfill relapse criteria – the occurrence of relapse was 
ultimately up to the investigators’ judgement. 
 
Relapse severity was judged by a relapse severity score, dividing relapses into 
the following categories: 
 
a) Clinically Significant Relapse - a relapse lasting more than 48 hours, 
fulfilling one of the criteria below: 
 
• Any motor relapse   
• Any brainstem relapse   
• A sensory relapse if it leads to functional impairment   
• Optic neuritis   
• Intrusive pain  
 
b) Disabling relapse - any relapse which fulfilled one or more of the 
following criteria:  
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• Affects the patient’s ability to work   
• Affects the patient’s activities of daily living as assessed 
by an appropriate method   
• Affects motor or sensory function sufficiently to impair 
the capacity or reserve to care for themselves or others 
as assessed by an appropriate method  
• Needs treatment (steroids)/hospital admission 
 
The need for steroid therapy was also recorded. 
 
EDSS score 
EDSS scores were variably documented in clinical notes, but all centre leads and 
investigators involved in the project are very familiar with the EDSS score, its 
scope and its limitations. EDSS scores were entered whenever formally stated in 
clinical notes. Additionally, EDSS scores were estimated by clinicians entering 
data if a clinical examination (but not formal EDSS) was documented upon which 
to base this (using Neurostatus EDSS scoring sheet version 04/10.2 as a guide) at 
the following time-points (or more if available): 
 
a) at baseline (date of diagnosis) 
b) at 6 monthly intervals during the Pre-natalizumab period 
c) at 6 monthly intervals during natalizumab treatment 
d) at 6 monthly intervals during the Switch phase 
e) at 6 monthly intervals after the first Alemtuzumab infusion 
f) at 6 monthly intervals during the post-Alemtuzumab phase 
g) at the end of the post-Alemtuzumab follow up period (last score) 
 
Ambulation score was also estimated at each of the above time-points if 
appropriate information was available. 
 
Sustained accumulation of disability (SAD) was defined as an increase in EDSS, 
sustained for at least 6 months, of ≥1.5 EDSS points if the baseline EDSS was 0; 
   
 
238 
≥1.0 point if the baseline EDSS was ≥1 but <5.5; and >0.5 points if the baseline 
EDSS was ≥5.5.  
 
Sustained reduction in disability (SRD) was defined as a reduction in the EDSS 
score of either ≥1.0 or 0.5, for baseline EDSS scores below and above 5.5 
respectively sustained for at least 6 months. Analysis for SRD was restricted to 
those with a baseline EDSS ≥2.0. 
 
MRI assessment definitions 
Significant MRI evidence of active inflammatory disease was defined as 1 new 
gadolinium 
enhancing lesion and / or 2 or more new T2/FLAIR lesions on an interval scan 
compared to the previous scan. 
 
Cognition assessment 
Clinicians were asked to provide the results of any of the following cognitive 
assessments which were documented during each phase: 
• Mini Mental State Examination (MMSE) 
• Addenbrooke’s Cognitive Examination (ACE) 
• Montreal Cognitive Assessment (MOCA) 
• Paced Auditory Serial Assessment Tool (PASAT) 
 
Quality of life assessment 
Formal quality of life measures were not made, but data on employment status, 
driving and changes in deprivation category (based on Postcode) were collected. 
 
Safety Definitions 
Adverse event (AE) 
Any untoward medical occurrence that did not necessarily have a causal 
relationship with natalizumab, alemtuzumab or any other DMT that has been 
used. An AE was therefore any unfavourable and unintended sign (including an 
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abnormal laboratory finding), symptom, or disease occurring during the five 
treatment phases, whether or not related to any medicinal product. 
 
Adverse events were grouped into: 
a) Infusion reaction – any adverse event occurring during or within 24 
hours of natalizumab or alemtuzumab infusions  
b) Hypersensitivity reaction – reports of hypersensitivity, allergic 
reaction, or anaphylactic or anaphylactoid reaction by the 
investigator, as well as any report or urticarial, allergic dermatitis or 
hives 
c) Blood monitoring event – occurrence of renal, liver or thyroid function 
test abnormalities, leucopaenia, lymphopenia, neutropenia, anaemia 
or thrombocytopenia 
d) Urine monitoring event – the presence of proteinuria, haematuria, red 
cell casts or abnormal urine microscopy  
e) Organ specific autoimmune disease – the occurrence of any organ 
specific autoimmune disease, specifically thyroid disease (including its 
nature/extent) and immune thrombocytopenic purpura 
f) Neoplastic event – the occurrence of any neoplasm 
g) Infection event (including opportunistic infection) – any infection 
event, specifically any opportunistic infection, any herpetic infection 
(including shingles), any viral infection or any bacterial infection, 
whether confirmed by diagnostic studies or not 
Serious Adverse Event (SAE) 
An SAE was defined as any untoward medical occurrence that at any dose: 
 
a) Resulted in death 
b) In the view of the centre lead, placed the subject at immediate risk of 
death (a life-threatening event); however, this does not include an 
event that, had it occurred in a more severe form, might have caused 
death 
c) Required inpatient hospitalization or prolongation of existing 
hospitalization 
d) Resulted in persistent or significant disability/incapacity, or 
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e) Resulted in a congenital anomaly/birth defect 
 
An SAE could also be any other medically important event that, in the opinion of 
the centre lead, jeopardised the subject or required intervention to prevent one 
of the other outcomes listed in the definition above. (Examples of such medical 
events include allergic bronchospasm requiring intensive treatment in an 
emergency room or convulsions occurring at home that do not require an 
inpatient hospitalization.) 
 
Again, serious adverse events were grouped into: 
 
a) Infusion reaction – any serious adverse event occurring during or within 
24 hours of natalizumab or alemtuzumab infusions 
b) Hypersensitivity reaction – reports of severe / serious hypersensitivity, 
allergic reaction, or anaphylactic or anaphylactoid reaction 
c) Blood monitoring event – occurrence of severe or significant renal, 
liver or thyroid function test abnormalities, leucopaenia, lymphopenia, 
neutropenia, anaemia or thrombocytopenia 
d) Urine monitoring event – the presence of significant or marked 
proteinuria or haematuria 
e) Organ specific autoimmune disease – the occurrence of any severe or 
significant organ specific autoimmune disease, specifically resistant 
thyroid disease, immune thrombocytopenic purpura, Goodpasture’s 
syndrome and glomerulonephritis 
f) Neoplastic event – the occurrence of any neoplasm 
g) Infection event (including opportunistic infection) – any serious 
infection event, specifically any severe opportunistic infection, any 
evidence of PML (progressive multifocal leukoencephalopathy), any 
severe herpetic infection, any serious viral infection or bacterial 
infection, whether confirmed by diagnostic studies or not.  
 
Neutralising antibodies 
Natalizumab neutralising antibodies generally occur in 5-10% of patients 
receiving natalizumab and are strongly associated with both infusion-related 
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adverse events (including hypersensitivity) and loss of efficacy. The presence of 
neutralising antibodies was documented where undertaken. 
 
The occurrence of natalizumab antibodies was classified into 2 categories: 
 
a) a single abnormal result 
b) persistent antibodies (2 independent antibody samples conducted ≥2 
times more than 14 days apart) 
 
No assessment of neutralising antibodies was undertaken for alemtuzumab. The 
presence of neutralising antibodies in other phases could be entered as freetext 
if this was a reason for treatment discontinuation. 
JC virus status / index 
JC virus serology is a major determinant of PML risk and was documented when 
available during natalizumab treatment, including any titre or index result 
where available.  
 
Statistical Analysis 
Demographic and background information was summarized using frequency 
distributions (for categorical variables) and descriptive statistics of mean, 
standard deviation, minimum, median and maximum (for continuous variables) 
where appropriate. Relevant medical history/current medical conditions were 
summarised. Concomitant medication and non-drug therapy were summarised 
and categorised in each phase. 
 
Duration (months) of exposure to alternative disease modifying therapy (during 
phase 1, 3 or 5), natalizumab (during phase 2) and alemtuzumab (during phase 
4) was also tabulated. 
 
Primary analysis 
Descriptive statistics were used to report the primary and secondary endpoints 
described above.  
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Adverse events and serious adverse events were summarised by presenting the 
number and percentage of patients having any adverse event, and grouped as 
defined above.  
 
Mean annualised relapse rate, number and proportion of patients with sustained 
accumulation (SAD) or reduction (SRD) of disability, and number and proportion 
of patients developing significant MRI markers of active inflammatory disease 
during each of the 5 phases are presented. The number and proportion of 
patients free of relapse, significant MRI markers of active disease, or sustained 
accumulation of disability (‘freedom from disease activity’) was also evaluated 
in each phase. ARR was calculated as the total number of relapses in a phase 
divided by the total number of patient-years in that phase, rather than using 
each individual patient’s ARR, given the variable duration of each phase for each 
patient and the skewing to higher rates which would have occurred in those with 
shorter duration phases. 
 
Disability outcomes (EDSS scores) were also assessed using the area under the 
curve method236 during each treatment phase. The area under the EDSS/follow-
up time curve (AUC) was calculated as per the trapezium method correcting for 
baseline disability and rescaling—with changes of 0.5 for EDSS scores ≥5.5 and 
<7.0 being normalised to a 1.0 point change at all other levels of the scale. 
Individual patients were then categorised as (i) ‘net improved’ for an AUC of 
<−0.5 EDSS-years; (ii) ‘net worse’ for an AUC > +0.5 EDSS-years and (iii) ‘net 
unchanged’ for an AUC between -0.5 and 0.5 EDSS-years237. Patients with 
available data were also categorised into one of six descriptive disease course 
categories from the profile of their plot of EDSS-change versus follow-up time. 
Under this classification system, SRD and SAD become ‘sustained improvement’ 
and ‘sustained progression’ if the disability change is maintained until last 
follow-up or, if not, as ‘erroneous improvement’ and ‘erroneous progression’36. 
‘Minimal change’ indicates an EDSS change ≤0.5 points from baseline at all 
measurements made over the course of follow-up. The remaining profiles that 
do not fit any of the above categories are labelled as ‘fluctuating’. From these 
six categories, three groups were defined: ‘confirmed stable’ (‘sustained 
improvement’ or ‘minimal change’); ‘unsustained change’ (‘erroneous 
progression’, ‘erroneous improvement’ or a ‘fluctuating’ course); and 
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‘confirmed worsening’ comprising those with ‘sustained progression’. The time 
point (treatment phase) at which disability changes occur in each patient 
leading to their classification in this manner is assessed.  
 
Secondary progression is defined as two consecutive SAD events, the second 
from the new EDSS baseline established after the first SAD event, and in which 
the increase in EDSS occurred independent of relapses. 
 
Secondary analysis 
Comparable descriptive statistics will be presented for all secondary variables. 
 
Ethical requirements 
The protocol proposal was assessed by the West of Scotland Research Ethics 
Service (based in the Tennant Institute in Glasgow) as a phase IV study, not 
requiring ethical approval. Discussions with, and approval from, the Caldicott 
Guardian or Clinical Audit Lead (in Ireland) were advised in each centre, 
initiated by the centre lead. Patients were identified by a unique identifier and 
no patient identifiable data was held on the online database. All clinical and 
radiographic data was handled exclusively by the local clinicians (who will 
ordinarily have been the patient’s treating team) and the blinded neuro-
radiologist in each centre. The study posed no clinical risk to patients, and did 
not infringe on their rights or confidentiality as per the approval of the Glasgow 
Caldicott Guardian, for example. No additional data was collected on patients 
over and above the clinical data already in local files.  
Funding 
The study was funded by Sanofi-Genzyme® pharmaceuticals. NHS Greater 
Glasgow & Clyde was the Sponsor and a contract was agreed between both 
parties. Sub-sites were permitted for inclusion by way of agreement to a Letter 
of Comfort by the centre lead. Importantly, data access by Sanofi-Genzyme® and 
TechNeo® is limited to the overall results rather than patient-level data, as 
indicated by the Data Flow Map in Appendix 5. 
 
   
 
244 
Results 
Cohort Characteristics 
A total of 79 patients with RRMS who had switched from natalizumab to 
alemtuzumab were identified from 13 MS centres across the UK and Ireland. The 
number of patients per location is outlined in Table 3-1. 
 
Table 3-1: Location of patient centres 
MS Centre 
Number of 
patients 
Glasgow 5 
Newcastle  1 
Sunderland 5 
Dublin  14 
Leeds 5 
Liverpool 1 
Sheffield 1 
Birmingham 12 
Swansea 1 
Cardiff 1 
Bristol 5 
Charing Cross 19 
Plymouth 9 
Total 79 
 
For safety analysis, the entire cohort was used (N=79) and for efficacy analysis 
the cohort with follow-up for at least 2 years after the first course of 
alemtuzumab was used (N=51). Similarly, MRI data were available for 36 patients 
(MRI Cohort) and 25 patients had both MRI and clinical data (MRI Efficacy 
Cohort). Table 3-2 outlines the characteristics of each cohort relevant to each 
study phase.  
Given the reliance on medical notes, often from some years previously, data 
were not available for all variables, as reflected in Table 3-2: the number of 
patients with available data (n) is included where this was not the entire cohort.  
For example, for CSF and Pre-natalizumab MRI, only 22 patients had available 
data. There were no statistically significant differences between the Baseline 
characteristics of the cohorts, using ANOVA for parametric comparisons, Kruskal-
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Wallis for non-parametric comparisons and chi-square test for comparisons of 
proportions between the 4 cohorts.  
The final date for duration of follow-up was the end of data collection for the 
study: 31/12/17 for clinical data and 31/1/18 for MRI data. Datapoints (and their 
date of collection) were only entered where an event occurred e.g. relapse or 
EDSS, therefore the (final) date of data entry would underestimate follow-up if 
no further events occurred hence the final date of study data collection was 
used. Using the final date of data being entered as the end of follow-up reduced 
the duration of follow-up for the entire cohort (N=79) to median 1.6 years (range 
-2.6 to 7.6), with 19 patients having last data entry before alemtuzumab 
started. In the efficacy group (N=51), using the last date of data entry as the end 
of follow-up, reduced this to median 2.9 years (range 0 to 7.6) with 2 patients 
having no data entered after alemtuzumab treatment. The design of the 
database therefore makes the assumption that patients were followed-up until 
the end of study data collection and that the absence of data entry reflects an 
absence of available data or clinical events. 
The cohorts were predominantly young and female with onset of their first 
demyelinating symptoms within months before diagnosis (Table 3-2). Despite 
this, EDSS was greater than 2 on average at diagnosis, with most having had 2 
relapses prior to diagnosis. Paraclinical results were in keeping with MS, the 
majority having few white cells in CSF with normal protein, unpaired oligoclonal 
bands and most had abnormal VEPs - a small proportion having bilateral delay in 
optic nerve response. In keeping with the working age of the cohort, the vast 
majority were employed and driving at the time of diagnosis. 
Prior to commencing natalizumab, the majority had been treated with one or 
two DMTs, most ultimately failing treatments due to lack of efficacy. That said, 
for over a third of patients natalizumab was their first DMT, suggesting the high 
disease activity of this cohort given its use as a first-line agent only in patients 
with rapidly evolving severe MS. The annualised relapse rate before starting 
natalizumab was relatively low at approximately 0.5 but, by the time the of 
starting (approximately 4 years after diagnosis on average), average EDSS was 
notably elevated at 3.8 in this young cohort. Additionally, the majority had 
developed a moderate or marked supratentorial lesion load in the opinion of our 
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blinded neuroradiologists retrospectively reviewing imaging undertaken before 
natalizumab was started. As expected at this early disease stage, there was not 
significant evidence of brain atrophy on visual inspection of MRI imaging 
however. 
Patients started natalizumab in their early 30s on average, approximately 4.5 
years after their first demyelinating event had occurred. Natalizumab was used 
for 1-2 years for most patients, a median of 14 infusions in total. Unusually, 
given its evidence-based place as a highly effective DMT, the majority of 
patients failed natalizumab due to efficacy but concerns about PML were also 
clearly prevalent and a high proportion were JCV antibody positive. A small 
proportion had neutralising antibodies to natalizumab found but these were not 
routinely measured in all patients. 
The switch period between natalizumab and alemtuzumab lasted 8 months 
overall and almost 6 months for the efficacy cohort on average. The vast 
majority of patients did not use DMTs during the switch period. This was not 
centre-specific, with patients using DMTs during the switch period being from 
one of seven centres in the total cohort and from four different centres in the 
efficacy cohort.  
The efficacy cohort by definition had a longer duration of follow-up data 
available after alemtuzumab was started (mean 4.8 years) in comparison to the 
cohort overall (mean 3.6 years) but the longest follow-up was available for the 
MRI efficacy cohort (mean 5.3 years). The majority of patients had 2 courses of 
alemtuzumab in total, as expected from its dosing guidance. Now in their mid-
30s on average by the time of alemtuzumab initiation, patients had a disease 
duration of around 7 years at the time of starting this treatment.  
The vast majority did not require further DMTs after using alemtuzumab but, in 
those who did, further courses of alemtuzumab were used in most. In the 
efficacy cohort with available follow-up data, 16 patients (31%) had DMTs after 
using Alemtuzumab, most using one only thereafter (n=12, 75%) but 1 patient 
requiring 2 further DMTs and 3 patients (19%) using 3 DMTs after alemtuzumab. 
Further alemtuzumab treatment due to ongoing disease activity after our pre-
defined 2-year treatment phase was required by 14 patients (27.4%). Three 
patients (5.8%) had a further course of alemtuzumab, having had only 1 course 
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of treatment initially, 10 (19.6%) had a 3rd course and 1 patient (1.9%) required 4 
courses in total. Additionally, fingolimod was used in one patient due to ongoing 
disease activity despite 3 courses of alemtuzumab. 
Haematopoietic Stem Cell Transplantation was undertaken for 3 patients with 
ongoing disease activity despite treatment with natalizumab and alemtuzumab. 
Of these, 2 were from a single centre. Disease activity continued despite a 3rd 
course of alemtuzumab in 2 of these patients and one was treated with 
cyclophosphamide for 3 months before HSCT was undertaken. Of these 2 
patients, one actually went on to have a second HSCT 14 months after the first 
and the second patient was treated with rituximab after HSCT but this was for a 
post-transplant lymphoproliferative disorder.  
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Table 3-2: Cohort characteristics 
 Total 
(Safety) 
Cohort 
(N=79) 
Efficacy 
Cohort 
(N=51) 
Total MRI 
Cohort 
(N=36) 
MRI Efficacy 
cohort 
(N=25) 
Baseline characteristics   
% Female 55 (69.6%) 40 (78%) 30 (83%) 21 (84%) 
Mean Age at 
diagnosis (SD) 
31 (9) 29 (8) 29 (8) 28 (7.3) 
Median Disease 
duration at 
diagnosis [Years] 
(IQR) 
0.37 (1.1) 0.34 (1.1) 0.11 (0.61) 0.07 (0.38) 
Mean baseline 
EDSS (SD) 
2.4 (1.7) 
[n=59] 
2.3 (1.7) 2.9 (1.8) 2.8 (1.9) 
Mean number of 
relapses pre-
diagnosis (SD) 
1.8 (1.3) 
[n=61] 
1.9 (1.3) 1.7 (1.0) 1.8 (1.0) 
CSF WCC  
<5 
5-20 
>20 (max 40) 
[n=22] 
13 (59%) 
8 (36%) 
1 (4.5%)  
[n=20] 
12 (60%) 
7 (35%) 
1 (5%) 
[n=7] 
4 (57%) 
2 (29%) 
1 (14%) 
[n=6] 
3 (50%) 
2 (33%) 
1 (17%) 
CSF Protein  
≤0.5 
>0.5 (max 0.77) 
[n=22] 
12 (55%) 
10 (45%) 
[n=20] 
11 (55%) 
9 (45%) 
[n=9] 
5 (56%) 
4 (44%) 
[n=8] 
4 (50%) 
4 (50%) 
CSF OCBs  
Normal 
Unpaired 
Paired 
[n=28] 
1 (4%) 
23 (82%) 
4 (14%) 
[n=21] 
0 
18 (86%) 
3 (14%) 
[n=9] 
0 
9 (100%) 
0 
[n=7] 
0 
7 (100%) 
0 
VEPs  
Normal 
Unilateral delay 
Bilateral delay 
[n=16] 
5 (31%) 
8 (50%) 
3 (19%) 
[n=14] 
5 (36%) 
7 (50%) 
2 (14%) 
[n=5] 
2 (40%) 
3 (60%) 
0 
[n=5] 
2 (40%) 
3 (60%) 
0 
Patients with no 
co-morbidities 
63 (79.7%) 39 (76.5%) 27 (75%) 19 (76%) 
Employed  38 (76%) 
(n=50) 
27 (66%) 
(n=41) 
17 (59%) 
(n=29) 
13 (72%) 
(n=18) 
Driving  32 (78%) 
(n=41) 
18 (78%) 
(n=23) 
13 (68%) 
(n=19) 
6 (75%) 
(n=8) 
Pre-Natalizumab   
Number of DMTs 
used (%) 
0 
1 
2 
3 
4 
5 
 
 
34 (43%) 
29 (37%) 
10 (13%) 
4 (5%) 
1 (1%) 
1 (1%) 
 
 
20 (39%) 
22 (43%) 
4 (8%) 
3 (6%) 
1 (2%) 
1 (2%) 
 
 
15 (42%) 
15 (42%) 
4 (11%) 
1 (3%) 
0 
1 (3%) 
 
 
9 (36%) 
11 (44%) 
3 (12%) 
1 (4%) 
0 
1 (4%) 
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Main reason for 
stopping DMT(s) 
(%) 
Efficacy 
(52%) 
Side effects 
(38%) 
Efficacy (49%) 
Side effects 
(40%) 
Efficacy 
(50%) 
Side effects 
(40%) 
Side effects 
(46%) 
Efficacy 
(42%) 
Mean duration of 
Pre-Natalizumab 
phase [years] (SD) 
4.3 (4.3) 4.2 (4.4) 3.7 (3.3) 3.7 (3.4) 
Mean ARR¶ 0.53 0.57 0.55 0.45 
Mean EDSS before 
Natalizumab 
treatment (last 
available) (SD) 
3.8 (2.0) 3.4 (2.0) 
3.9 (2.2) 
[n=27] 
3.6 (2.2) 
MRI Brain                    (n=22)              (n=15) (n=22) (n=20) 
Mean Gd+ lesions 
(SD) 
 
Supratentorial 
lesion load (%) 
None  
Minor  
Moderate  
Marked  
Infratentorial (%) 
None 
Minor  
Moderate  
Marked  
Global atrophy (%) 
None 
Minor 
Moderate 
Marked 
Callosal atrophy 
(%) 
None 
Minor 
Moderate 
Marked 
4.9 (10.6) 
 
 
 
 
0 
2 (9%) 
2 (9%) 
18 (82%) 
 
4 (18%) 
7 (32%) 
7 (32%) 
4 (18%) 
 
10 (45%) 
10 (45%) 
2 (9%) 
0 
 
 
11 (50%) 
6 (27%) 
3 (14%) 
2 (9%) 
7.3 (13.5) 
 
 
 
 
0 
2 (13%) 
2 (13%) 
11 (73%) 
 
4 (27%) 
2 (13%) 
5 (33%) 
4 (27%) 
 
9 (60%) 
6 (40%) 
0 
0 
 
 
8 (53%) 
4 (27%) 
2 (13%) 
1 (0.7%) 
4.9 (10.6) 
 
 
 
 
0 
2 (9%) 
2 (9%) 
18 (82%) 
 
4 (18%) 
7 (32%) 
7 (32%) 
4 (18%) 
 
10 (45%) 
10 (45%) 
2 (9%) 
0 
 
 
11 (50%) 
6 (27%) 
3 (14%) 
2 (9%) 
6.9 (12.4) 
 
 
 
 
0 
3 (15%) 
2 (10%) 
15 (75%) 
 
4 (20%) 
4 (20%) 
5 (25%) 
7 (35%) 
 
13 (65%) 
3 (15%) 
0 
0 
 
 
12 (60%) 
5 (25%) 
2 (10%) 
1 (5%) 
Natalizumab Treatment   
Mean age at 1st 
Natalizumab 
Treatment (SD) 
33 (9.4) 34 (8.9) 33 (8.6) 32 (8.5) 
Mean disease 
duration at 1st 
Natalizumab 
Treatment* 
[years] (SD)  
4.5 (4) 4.6 (4.4) 4.2 (3.2) 4.2 (3.5) 
Median duration 
Natalizumab 
Treatment [years] 
(IQR) 
1.8 (2.7) 1.2 (2.1) 
0.9 (1.5) 
[n=19] 
0.9 (1.5) 
[n=19] 
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Median number of 
Natalizumab 
infusions (IQR, 
range) 
14 (33, 2-
104) 
(26 missing) 
12 (19, 2-91) 
12 (33, 2-91) 
(n=25) 
12 (19, 2-91) 
(n=19) 
Main reasons for 
stopping 
Natalizumab 
Efficacy 
(38%) 
PML 
concern 
(16%) 
Efficacy (58%) 
Adverse 
events (19%) 
PML Concern 
(19%) 
Efficacy 
(56%) 
PML concern 
(28%) 
(n=25) 
Efficacy 
(56%) 
PML (24%) 
 
Number of JCV 
+ve patients  
23 (72%) 
(n=32) 
16 (70%) 
(n=23) 
10 (71%) 
(n=14) 
10 (71%) 
(n=14) 
Number of 
patients with 
Natalizumab 
Neutralising Abs 
7 (12%) 
(n=59) 
6 (14%) (n=44) 
4 (15%) 
(n=26) 
4 (17%) 
(n=24) 
Switch period   
Mean duration 
Switch period 
[days] (SD) 
241 (231) 
[8 months] 
174 (150) 
[5.8 months] 
238 (219) 
[7.9 months] 
157 (1135) 
[5.2 months] 
Patients using 
DMTs during 
Switch (%) 
18 (23%) 7 (14%) 9 (25%) 4 (16%) 
Alemtuzumab Treatment   
Mean duration of 
follow-up after 1st 
Alemtuzumab 
dose (years) (SD) 
3.6 (2.4) 4.8 (2.1) 4.2 (2.5) 5.3 (2.1) 
Mean number of 
Alemtuzumab 
courses (SD, 
range) 
2 (1, 1-4) 
(n=59) 
2 (1, 1-4) 
(n=45) 
2 (1, 1-4) 
(n=25) 
2.4 (0.6,2-4) 
(n=24) 
Number of 
Alemtuzumab 
Courses 
1 
2 
3 
4 
Unknown 
 
 
 
13 (17%) 
33 (42%) 
12 (15%) 
1 (1%) 
20 (25%) 
 
 
 
2 (4%) 
30 (59%) 
12 (24%) 
1 (2%) 
6 (12%) 
 
 
 
1 (3%) 
16 (44%) 
7 (19%) 
1 (3%) 
11 (31%) 
 
 
 
0 
16 (64%) 
7 (28%) 
1 (4%) 
1 (4%) 
Mean age at first 
Alemtuzumab 
dose (SD) 
35 (9.6) 36 (8.6) 35 (8.7) 33 (8.3) 
Mean disease 
duration at 1st 
Alemtuzumab 
dose* (years) (SD) 
7.2 (4.5) 6.7 (5.2) 7.5 (4.3) 6.7 (4.8) 
Number of 
patients using 
DMTs after 
Alemtuzumab  
16 (32%) 
(n=50) 
16 (31%) 9 (34%) 
[n=26] 
9 (36%) 
¶ARR calculated by total number of relapses in phase / patient-years in phase 
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*Disease duration = since first symptom (not diagnosis) 
 
The nature of the first reported MS-related symptom for the cohorts are outlined 
in Table 3-3. The predominantly sensory relapses or optic neuritis are in keeping 
with typical RRMS populations. 
 
Table 3-3: First Demyelinating event symptoms 
First demyelinating 
event  
N=79 (Total 
cohort) 
N=51 (Efficacy 
Cohort) 
Pure Sensory 18 15 
Optic neuritis 11 9 
Pure motor 7 3 
Cranial nerve 4 4 
Brainstem 4 1 
Spinal 4 3 
Other visual 3 0 
Cerebellar 3 3 
Polysymptomatology 3 2 
Sensorimotor 2 1 
Bulbar 1 1 
Unknown 9 9 
 
Whilst the cohorts described are historical, the majority of patients in the total 
cohort and almost half of the efficacy cohort were treated with alemtuzumab 
during or after 2015, making them relatively contemporary to current 
populations (See Figures 3-2 and 3-3). Most patients were diagnosed with RRMS 
in the mid-2000s however, before the updated McDonald 2010 diagnostic criteria 
(n=57, 72%), and 23 patients (29%) were diagnosed before the 2005 criteria were 
available. Natalizumab was largely used after its UK licensing date in 2006 but, 
as anticipated, a large proportion of patients in this cohort (n=33, 42%) were 
treated with alemtuzumab before its UK licensing date in late 2014, making it 
unique in the worldwide experience.  
Figure 3-2: Year of Diagnosis, Natalizumab and Alemtuzumab initiation in the 
whole cohort 
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Figure 3-3: Year of Diagnosis, Natalizumab and Alemtuzumab initiation in the 
efficacy cohort 
 
 
Co-morbidities 
At the time of diagnosis of RRMS, the majority of patients had no other co-
morbidities. This was the case for 63/79 (80%) of the total cohort and 39/51 
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(77%) of the efficacy cohort. In the whole cohort, 16 (20%) had one, 6 (8%) had 
two and 3 (4%) had three. In the efficacy cohort, 12 (24%) had one, 5 (10%) had 
two and 3 (6%) had three co-morbidities. The co-morbidities are detailed in 
Table 3-4.  
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Table 3-4: Co-morbidities by phase 
Co-morbidity Baseline Pre-Natalizumab Natalizumab 
Treatment 
Switch Period Alemtuzumab 
Treatment 
Post-Alemtuzumab 
Asthma 3      
Hypertension 2      
Hypothyroidism 2   2   
Bipolar disorder 1  1    
Depression  1   1  
Cholecystectomy 1      
Congenital aortic 
stenosis 
1      
Epilepsy 1    1  
IDDM 1      
Irritable Bowel 
Syndrome 
 1     
Joint hypermobility 
syndrome 
1      
Myocardial 
infarction 
1      
Migraine 1      
Parotid swelling 1      
PCOS 1      
Raynaud’s 
phenomenon 
1      
Appendicitis 1  1    
Eczema 1      
Glandular fever 1      
Osteoarthritis 1      
   
 
255 
Obesity 1 1 1    
Herpes Zoster 1 1     
Allergic rhinitis 1      
Labial cyst  1     
Retinal detachment  1     
Urticaria  1 2   1 
Infection NOS  1 1   1 
Eosinophilia   1    
Erectile 
dysfunction 
  1    
Pilondal sinus   1    
UTI   2   2 
Constipation   1    
Abdominal pain 
NOS 
  1    
Neurogenic bowel   1    
Osteoporosis   1    
Unilateral deafness   1    
Shoulder pain   1    
Lichen Simplex   1    
Intertrigo   1    
CMV infection     1  
Gastritis     1  
Rash NOS     1  
Lymphoedema      1 
Post-Tx lymphoma      1 
Hyperthyroidism      1 
Tonsillitis      1 
Norovirus      1 
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None 63 69 64 74 70 68 
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After baseline there were missing co-morbidities data, as outlined in Table 3-5. 
The large amount of missing data makes comparisons in each phase difficult. 
Only 13 patients had co-morbidities listed for all phases and 11 of these had no 
co-morbidities throughout. With this caveat, the mean number of co-morbidities 
per phase is also included in Table 3-5 and appear to increase over time as 
would be expected with age, but the influence of MS and its treatment cannot 
be clarified in the absence of a control group. 
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Table 3-5: Number of co-morbidities by phase in the efficacy cohort 
Phase 
No of 
patients 
with data 
No. Missing 
(%) 
Mean number of 
Co-morbidities 
(±SD) 
Baseline  51 0 0.41±0.85 
Pre 
Natalizumab  
23 28 (55%) 0.65±0.93 
Natalizumab  22 29 (58%) 0.91±1.06 
Switch  16 35 (69%) 0.50±0.89 
Alemtuzumab  19 32 (63%) 0.58±0.84 
Post 
Alemtuzumab  
21 30 (59%) 0.86±1.24 
 
Disease modifying therapies 
The majority of patients used DMTs prior to natalizumab but only a minority used DMTs 
during the Switch period or Post-alemtuzumab. Table 3-6 shows the use of DMTs in 
these phases for the efficacy cohort. The increase in the proportion of patients with no 
DMT from Pre-natalizumab (39%) to Post-alemtuzumab (69%) was significant (p<0.01). 
This suggests that need for DMTs was significantly reduced after patients were treated 
with natalizumab and alemtuzumab.  
The increase in annualised DMT rate (per 100 patient years) between Pre-
natalizumab (22.8) and Switch (35.1) and the fall to Post-alemtuzumab (16.8) 
were not significant.  
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Table 3-6: Disease modifying treatments (DMT) by phase 
Phase (N=51) 
Pre-
Natalizumab  
Switch 
Post-
Alemtuzumab 
No of patients with no 
DMT (%) 
(95% CI††) 
20/51 (39%) 
(27%,53%) 
44/51 (86%) 
(74%,93%) 
35/51 (69%) 
(55%,80%)¶ 
Total number of DMT  
(max per patient) 
49 (5) 8 (2) 24 (3) 
Total patient yrs in 
phase 
215.2 22.8 142.9 
Overall annualised DMT 
rate* (95% CI†) 
22.8 
(16.8,30.1) 
35.1 
(15.1,69.1) 
16.8 (10.8,25.0) 
*Per 100 patient years †Using Byar's method ††Using the Wilson Score method 
¶p<0.01 vs Pre-Natalizumab phase 
 
Pre-Natalizumab phase 
As outlined in Table 3-2, the majority of patients were treated with DMTs 
before starting natalizumab (n=45, 57%). Figures 3-4 and 3-5 outline the 
number and type of DMTs used during this period respectively. Of those treated 
with a DMT, most had one or two, but up to 5 were used in one patient. The 
injectable therapies were used for almost 90% of patients in the cohort and 
typically sequencing between these, rather than escalating to a higher efficacy 
treatment, was undertaken prior to use of natalizumab. 
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Figure 3-4: Number of DMTs used Pre-natalizumab 
 
 
Figure 3-5: DMTs used Pre-natalizumab 
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Natalizumab Treatment Phase 
Most patients switched from natalizumab to alemtuzumab because of treatment 
failure, either clinical, radiological or both. Use of natalizumab in the UK is 
restricted to patients having 2 disabling relapses in the past year and with 
significant increase in MRI disease activity, known as Rapidly Evolving Severe MS 
(RES MS), meaning these patients had active disease in order to receive this 
treatment. One case was documented as switching to alemtuzumab solely for 
increased radiological disease activity but further detail beyond treatment 
failure due to disease activity was not available for all cases. A notable 
proportion of patients did not have a reason recorded in the study/medical 
notes, however, as outlined in Table 3-7 and Figure 3-6. Adverse events were 
predominantly recorded as hypersensitivity reactions, in one case a SAE 
requiring hospital treatment. Notably, this patient had positive natalizumab 
neutralising antibodies but the others with hypersensitivity events did not. Other 
adverse events included one patient with recurrent infections during treatment 
and one with persistent cough. The third patient discontinuing due to an adverse 
event did not have available details on the nature of this. 
Concerns about the development of PML, presumably both patient and clinician, 
also accounted for a significant proportion of patients switching from 
natalizumab to alemtuzumab. Table 3-8 outlines the JCV antibody results for 
the entire cohort, measured only during the natalizumab phase. As expected, all 
patients who switched to alemtuzumab from natalizumab due to concerns about 
PML were JCV positive. JCV titres were documented for just 3 patients positive 
for the antibody: these were 0.44, 0.93 and 4.43 respectively. 
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Table 3-7: Reason for switch from Natalizumab to Alemtuzumab 
 n (N=79) 
Total Cohort 
n (N=51) 
Efficacy Cohort 
Efficacy 30 25 
JC +ve/PML concern 13 8 
Hypersensitivity  6 6 
Adverse event 3 2 
Patient choice* 5 2 
Non-compliance 1 1 
Neutralising Abs 1 0 
Not documented 20 7 
*2 found travelling difficult, others not specified 
 
Figure 3-6: Reasons for stopping Natalizumab (N=51) 
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Table 3-8: JCV antibody results during Natalizumab treatment 
 N=79 
Positive 23 (29%) 
Negative 9 (11%) 
Not checked in clinical 
practice 
6 (8%) 
Not documented in study 41 (52%) 
 
Safety Results 
The following primary endpoints will be addressed in this section: 
1) The incidence of infections (including opportunistic infections) during 
each treatment phase 
2) The incidence of secondary autoimmunity during each treatment phase 
3) The incidence of infusion reactions, hypersensitivity reactions, new 
blood or urine monitoring events or neoplastic events during each 
treatment phase 
 
Safety events related to the use of DMTs and the incidence of adverse events 
leading to treatment discontinuation in each phase will be outlined here. For the 
Alemtuzumab treatment and Post-alemtuzumab phases all adverse events and 
serious adverse events were recorded in order to assess the safety of the 
sequencing of alemtuzumab after natalizumab, the primary objective of this 
study. Indeed, the design of the data entry system, whilst allowing AEs to be 
recorded in all phases, was directed towards capturing adverse events during 
and after alemtuzumab treatment for this reason. In the other phases, only the 
safety reasons for treatment discontinuation were recorded. In this section, the 
whole cohort (N=79) is under evaluation unless otherwise stated. The results are 
summarised in Table 3-9. 
 
 
 
Table 3-9: Safety Results Summary (N=79) 
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 Pre-
Natalizumab 
Natalizumab 
Treatment 
Switch 
Alemtuzumab 
Treatment 
Post-
Alemtuzumab 
Total 
Events leading to treatment 
discontinuation 
All events 
 
Infections 0 1 0 5 8 14 
Opportunistic 
infections 
0 0 0 1 0 1 
Secondary 
autoimmunity 
0 0 0 10 4 14 
Infusion 
reactions 
0 0 0 48 0 48 
Hypersensitivity 
reactions 
2 6 0 1 0 9 
Blood 
monitoring 
event 
   5 0 5 
Urine 
monitoring 
event 
   0 1 1 
Neoplastic 
events 
0 0 0 0 1 1 
Death 0 0 0 0 1 1 
SAE 1 1 0 2 4 8 
Total 3 8 0 72 19 102 
 
Pre-Natalizumab Phase 
No infections or secondary autoimmunity were recorded during the Pre-
natalizumab phase. Efficacy was the main reason for treatment discontinuation 
in this phase but, in those stopping treatment due to adverse events, injection-
site reactions (2, 3%), hypersensitivity reactions (2, 3%) and flu-like symptoms 
(1, <1%) were reported as leading to treatment discontinuation. One SAE 
occurred with Rebif® and was a hypersensitivity reaction. The majority of 
adverse events were not specified in detail however (20, 69%). Tables 3-10 and 
3-11 outline the data obtained from the Pre-natalizumab treatment phase, 
leading to DMT discontinuation, including adverse events. The injectable 
treatments were more frequently stopped due to lack of efficacy rather than 
adverse events but the opposite was true for oral DMTs. 
 
 
Table 3-10: Reasons for stopping DMTs in the Pre-Natalizumab phase - Summary 
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N Efficacy (%) 
Adverse 
Event (%) 
Other (%) 
Avonex® 16 8 (50) 6 (38) 2 (13) 
Rebif® 25 16 (64) 8 (32) 1 (4) 
Betaferon® 9 2 (22) 6 (67) 1 (11) 
Copaxone® 14 9 (64) 3 (21) 2 (14) 
DMF 2 0 2 (100) 0 
Fingolimod 3 1 (33) 2 (66) 0 
Azathioprine 1 1 (100) 0 0 
Mitoxantrone 2 0 0 2 (100) 
Total 72 37 (51) 29 (40) 8 (11) 
 
 
 
Table 3-11: Reasons for stopping DMTs in the Pre-Natalizumab phase - Details 
DMT 1st-
line 
2nd-
line 
3rd-
line 
4th-
line 
5th-
line 
Total 
Avonex® Number of patients 
 12 3 1 0 0 16 
Reason for stopping 
Efficacy 5 2 1 - - 8 
AE NOS 4 1 - - - 5 
Injection-site 
reaction 
1 - - - - 1 
Pregnancy 2 - - - - 2 
Rebif® Number of patients 
 20 3 1 0 1 25 
Reason for stopping 
Injection-site 
reaction 
1 - - - - 1 
Hypersensitivity 
reaction 
1 - - - - 1 
AE NOS 4 - - - - 4 
Flu-like 
symptoms 
- 1 - - - 1 
Efficacy 12 2 1 - 1 16 
Patient 
preference 
1 - - - - 1 
SAE 
(hypersensitivity) 
1 - - - - 1 
Betaferon® Number of patients 
 5 3 1 0 0 9 
Reason for stopping 
AE NOS 3 3 - - - 6 
Pregnancy 1 - - - - 1 
Efficacy 1 - 1 - - 2 
Copaxone® Number of patients 
 7 4 3 0 0 14 
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Reason for stopping 
Efficacy 6 3 - - - 9 
Part of clinical 
trial 
1 - 1 - - 2 
AE NOS - 1 1 - - 2 
Worsening 
mobility 
- - 1 - - 1 
DMF Number of patients 
 0 0 1 1 0 2 
Reason for stopping 
AE NOS - - 1 1 - 2 
Fingolimod Number of patients 
 1 1 0 0 1 3 
Reason for stopping 
AE NOS 1 - - - - 1 
Efficacy - 1 - - - 1 
2nd degree heart 
block 
- - - - 1 1 
Azathioprine Number of patients 
 0 1 0 0 0 1 
Reason for stopping 
Efficacy - 1 - - - 1 
Mitoxantrone Number of patients 
 0 1 0 1 0 2 
Reason for stopping 
Reached max 
dose 
- 1 - - - 1 
Bridging therapy - - - 1 - 1 
 
 
Natalizumab Treatment Phase 
Similar to previously-used DMTs, natalizumab was discontinued in most cases 
because of treatment failure (n=30, 38%) but adverse events (n=9, 11%) were 
also reported as outlined in Table 3-7 and Figure 3-6. A single SAE was reported 
with natalizumab, listed as a hypersensitivity reaction. Hypersensitivity 
reactions were the most common adverse event (n=6, 8%) but one patient 
developed recurrent infections during treatment and one had persistent cough 
which resolved on treatment discontinuation.  
 
Switch Phase 
During the Switch phase only one adverse event, leading to discontinuation of 
fingolimod, was recorded but details not specified. 
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Alemtuzumab Treatment and Post-Alemtuzumab phases 
Following alemtuzumab treatment, 85 AEs occurred in total and 37 patients 
(46.8%) had at least one documented. We estimate that over 575 Alemtuzumab 
infusions are captured in this dataset but this is limited by some missing data 
with regards to the dose of each course given (See Table 3-12). It is assumed, 
where not available, that the first alemtuzumab course included 5 infusions and 
subsequent courses 3 infusions per course.  
In the entire cohort, 13 patients developed infections (16%) after alemtuzumab 
treatment, 3 of which were SAEs (4%) and 1 of which was an opportunistic (CMV) 
infection. Secondary autoimmune disorders (n=14, 17%) were all thyroid-related 
with 5 patients (6%) developing hypothyroidism, 8 hyperthyroidism (10%) and 1 
(1%) not specified. Of the AEs during the Alemtuzumab treatment phase, the 
majority [48 (56%)] were infusion reactions. Thrombocytopaenia occurred in 2 
patients (3%) and proteinuria and (transient) neutropaenia in 1 each (1%) with 
none requiring specific therapy. Importantly, the majority of this cohort will not 
have had the intensive monitoring regime in current practice after alemtuzumab 
so these will be underestimates. 
One patient developed malignancy, related to HSCT following alemtuzumab, and 
one patient died in the Post-alemtuzumab phase. The death was a female aged 
32 with rapidly worsening MS from onset. She was significantly disabled even 
before alemtuzumab, given in 2013, and died 3 years later from urosepsis which 
the treating team felt did not directly relate to her DMT use but rather the 
aggressive course of her disease despite treatment. Secondary autoimmunity 
occurred both during the 2-year Alemtuzumab treatment phase and after but 
infections more commonly occurred in the latter in this cohort. The details are 
outlined in Table 3-13. 
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Table 3-12: Number of Alemtuzumab courses and infusions 
Total number of 
Alemtuzumab courses 
N (patients) Number of infusions  
1 13 65 
2 33 264 
3 12 132 
4 1 14 
Unknown (but at least 1) 20 ≥100 
Total 79 ≥575 
 
 
Table 3-13: Adverse Events in the Alemtuzumab and Post-Alemtuzumab phases 
(N=79) 
AE Details 
Course 
1 
Course 
2 
Course 
3 
Post-
Alemtuzumab 
Total 
Infusion 
reaction 
Headache 3 1   4 
Rash 22 4 2  28 
Arm weakness 1    1 
Nausea 1    1 
Pyrexia 2 1   3 
Tingling in legs 1    1 
Leg bruising 1    1 
Loose stools 1  1  2 
Malaise 1    1 
SOB 1    1 
Wheeze 1    1 
Low back pain  1   1 
Chest pain/ 
tightness 
1 1   2 
Flu-like symptoms  1   1 
    Total 48 
Organ-specific 
autoimmunity 
Hypothyroidism 3 1  1 5 
Hyperthyroidism 4 1  3 8 
Autoimmune 
thyroid NOS 
1    1 
    Total 14 
Hypersensitivity 
reaction 
Urticaria 1    1 
    Total 1 
Blood/urine 
disorders 
Persistent 
lymphopaenia 
2    2 
Thrombocytopaenia 2    2 
Neutropaenia 
(transient) 
1    1 
Proteinuria    1 1 
    Total 6 
Infections Shingles 3    3 
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Oral candida    1 1 
Fungal skin 
infection 
   1 1 
UTIs    2 2 
Tonsillitis    1 1 
Norovirus    1 1 
    Total 9 
Other Lymphoedema    1 1 
     Total 1 
SAEs 
Infection NOS  2 (1 post-
HSCT) 
2 
UTI 1  1 
CMV 1  1 
Malignancy Post-Tx 
lymphoproliferative 
disorder 
 1 (post-
HSCT) 
1 
Death Death from 
urosepsis 
Alemtuzumab first 
dose 18/2/13 age 
29; death Feb 2016 
1 
(‘Unrelated 
to Alem 
Rx’) 
1 
   Total 6 
Total 85 
 
 
 
Adverse events in the efficacy cohort (N=51) 
There was a total of 69 adverse events across 30 patients. Sixteen (35%) had no 
adverse events; 16 (35%) had one event, 9 (20%) had two events, 3 (7%) had 4 
events, one patient had 5 and one patient had 6 adverse events. There were 
more adverse events during the first alemtuzumab course (44 events across 30 
patients) than the second course (13 events across 8 patients). All patients with 
an adverse event during the second course also had an adverse event in the first 
course. The number of adverse events in patients receiving further alemtuzumab 
in the Post-alemtuzumab phase was similar to the second course (12 events 
across 7 patients). 
The most common type of adverse events were infusion reactions which 
accounted for 38/57 (67%) of the events in the Alemtuzumab treatment phase. 
Organ-specific autoimmunity accounted for 12/69 (17%), Infections 10/69 (14%) 
and Blood/urine disorders 6/69 (9%) accounted for most of the other adverse 
events. Tables 3-14 and 3-15 provide a more detailed breakdown. 
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Table 3-14: Adverse Events in the Alemtuzumab and Post-Alemtuzumab phases 
in the efficacy cohort – Summary (N=51) 
 Alemtuzumab 
Course 1 
Alemtuzumab 
Course 2 
Post-
Alemtuzumab 
Total 
No. of patients with 
no adverse events  
16/46 (35%) 36/44 (82%) 44/51 (86%)  
No. of patients with 
adverse events  
30/46 (65%) 8/44 (18%) 7/51 (14%)  
Total adverse 
events 
44 13 12 69 
Categories     
Infusion reaction 29 9 0 38 (55%) 
Organ-specific 
autoimmunity 
6 2 4 12 (17%) 
Infections 3 2 5 10 (14%) 
Blood/urine 
disorders 
5 0 1 6 (9%) 
Other 0 0 2 2 (3%) 
Hypersensitivity 
reaction 
1 0 0 1 (1%) 
 
Three of the serious adverse events outlined in Table 3-13 occurred in patients 
in the efficacy cohort. The patients with urinary tract and CMV infections SAEs 
and the patient who died were included in this cohort.   
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Table 3-15: Adverse Events in the Alemtuzumab and Post-Alemtuzumab phases 
in the efficacy cohort – Details (N=51) 
Adverse events  Alemtuzumab 
Course 1 
Alemtuzumab 
Course 2 
Post-
Alemtuzumab 
Total 
Infusion reaction 29 9 0 38 
Headache 2 1  3 
Rash 17 4  21 
Arm weakness 1   1 
Nausea 1   1 
Pyrexia 2 1  3 
Tingling in legs 1   1 
Leg bruising 1   1 
Loose stools 1   1 
Malaise 1   1 
SOB 1   1 
Wheeze 1   1 
Low back pain  1  1 
Chest tightness  1  1 
Flu-like symptoms  1  1 
     
Organ-specific 
autoimmunity 
6 2 4 12 
Hypothyroidism 2 1 1 4 
Hyperthyroidism 3 1 3 7 
Autoimmune thyroid 
NOS 
1   1 
     
Hypersensitivity 
reaction 
1 0 0 1 
Urticaria 1   1 
     
Blood/urine disorders 5 0 1 6 
Persistent 
lymphopaenia 
2   2 
Thrombocytopaenia 2   2 
Neutropaenia 
(transient) 
1   1 
Proteinuria   1 1 
     
Infections 3 2 5 10 
Shingles 3   3 
Oral candida  1  1 
Fungal skin infection  1 1 2 
UTIs   2 2 
Tonsillitis   1 1 
Norovirus   1 1 
     
Other 0 0 1 1 
Lymphoedema   1 1 
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Efficacy Results 
The efficacy results are based on the cohort with at least 2 years’ follow-up 
after alemtuzumab was started (N=51) and all following results are based on 
these data unless otherwise specified.  
 
Relapses 
The following endpoints are addressed in this section: 
Primary endpoint 
• Annualised relapse rate during each treatment phase 
 
Secondary endpoint 
• The incidence of clinically significant or disabling relapses during each 
treatment phase 
 
The annualised relapse rate significantly reduced when DMTs were started after 
diagnosis and a further significant reduction occurred after alemtuzumab 
treatment, in comparison to all preceding treatment phases, which was 
sustained in the Post-alemtuzumab phase. The percentage of patients with no 
relapses increased significantly in the Alemtuzumab and Post-alemtuzumab 
phases compared to the Pre-natalizumab and Natalizumab treatment phases. 
The proportion of patients with no relapse was also higher in the Switch phase 
but this is likely because it was shorter than the other phases.  
Annualised relapse rates decreased in the Pre-Natalizumab and Natalizumab 
treatment phases compared to Baseline and increased in the Switch phase 
before decreasing again in the Alemtuzumab treatment and Post-alemtuzumab 
phases. The rate in the Alemtuzumab phases was significantly less than in the 
Natalizumab phase, notably. The same was true for the disabling relapse rate, 
which was significantly less in the Alemtuzumab phases compared to all other 
phases, as outlined in Table 3-16 and Figure 3-7. 
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Table 3-16: Relapses by phase 
Phase  
Pre-diagnosis 
(n=44) 
Pre-natalizumab 
(n=51) 
Natalizumab 
treatment 
(n=51) 
Switch 
(n=51) 
Alemtuzumab 
treatment 
(n=51) 
Post-alemtuzumab 
(n=50) 
No. of patients 
with no relapses 
(%) (95%CI††) 
0 
16 (31%) 
(20%,45%) 
25 (49%) 
(36%,62%) 
36 (71%) 
(57%,81%) 
36 (71%) 
(57%,81%) 
36 (72%) 
(58%,82%) 
Total relapses 
(max per patient) 
85 (8) 122 (14) 41 (4) 24 (4) 18 (2) 26 (6) 
Total patient yrs in 
phase 
31.3 215.2 94.5 22.8 101.9 141.7 
Overall annualised 
relapse rate* 
(95% CI†) 
271.6 
(217,336) 
56.7 
(47.1,67.7) 
43.4 
(31.1,58.9) 
105.3 
(67.4,157) 
17.7 
(10.5,27.9) 
18.3 
(12.0,26.9) 
ARR  
(95% CIs) 
2.7 (2.2,3.4) 0.57 (0.47,0.68)  
0.43 
(0.31,0.59) 
1.1 
(0.67,1.6) 
0.18¶ 
(0.11,0.28) 
0.18¶ 
(0.12,0.27) 
Total disabling 
relapses (max per 
patient) 
12 (2) 58 (8) 20 (3) 17 (2) 4 (1) 16 (5) 
Overall annualised 
disabling relapse* 
rate (95% CI†) 
38.3 
(19.8,67.0) 
27.0 
(20.5,34.8) 
21.2 
(12.9,32.7) 
74.6 
(43.4,119) 
3.9 
(1.1,10.1) 
11.3 
(6.5,18.3) 
ARR [Disabling 
Relapses] 
(95% CIs) 
0.38 
(0.2,0.67) 
0.27 
(0.21,0.35) 
0.21 
(0.13,0.33) 
0.75 
(0.43,1.2) 
0.04¶ 
(0.01,0.1) 
0.11¶ 
(0.07,0.18) 
*Per 100 patient years †Using Byar's method. ††Using the Wilson Score method, 
¶p<0.05 (vs other phases) 
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Figure 3-7: Annualised Relapse Rate by Treatment Phase 
 
 
EDSS SAD & SRD analysis 
The following Primary endpoint is addressed in this section: 
• The occurrence of sustained accumulation of disability (defined by an 
increase from baseline of at least one EDSS point or ≥1.5 points if baseline 
EDSS score was 0) confirmed over 6 months in each treatment phase 
 
Sustained accumulation of disability (SAD) was defined as an increase in EDSS, 
sustained for at least 6 months, of ≥1.5 EDSS points if the baseline EDSS was 0; 
≥1.0 point if the baseline EDSS was ≥1 but <5.5; and >0.5 points if the baseline 
EDSS was ≥5.5.  
Secondary progression was defined as two consecutive SAD events within a 
phase, the second from the new EDSS baseline established after the first SAD 
event, and in which the increase in EDSS occurred independent of relapses. In 
the entire cohort, only one patient showed secondary progression by these 
criteria in a single phase, the Pre-natalizumab phase. One patient was classified 
as having SPMS during the Post-alemtuzumab phase by the clinical team. 
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Sustained reduction in disability (SRD) was defined as a reduction in the EDSS 
score of ≥1.0 for EDSS scores below 5.5 or 0.5 for baseline EDSS scores above 5.5 
sustained for at least 6 months. Analysis for SRD was restricted to those with a 
baseline EDSS ≥2.0. 
The analysis was undertaken using a fixed baseline for subsequent EDSS 
comparisons i.e. the first EDSS in each phase for phase comparisons and the EDSS 
at diagnosis for whole study analyses. A re-baselining method was also 
undertaken, where the baseline comparison EDSS was the preceding EDSS rather 
than the first in the phase/at diagnosis i.e. re-baselining after each EDSS 
change. Ultimately the different analyses did not provide significantly different 
results and the former, fixed baseline, correlated better with the area under the 
curve EDSS analysis therefore was thought more likely to reflect reality hence is 
the chosen method for the results presented in this section. 
The majority of patients had no SAD or SRD events during each phase. The 
proportion with no SAD/SRD events was around 70% for all phases except the 
shorter switch phase where it was higher (See Table 3-17). Where SAD did occur, 
it was highest in the Pre-natalizumab and Switch phases and lowest in the 
Alemtuzumab treatment phase, although the difference in annualised SAD rates 
were not statistically significant between phases. Annualised SRD rate was 
highest during the Alemtuzumab phase. This was not statistically significant in 
comparison to preceding phases but the annualised SRD rate did significantly fall 
in the subsequent Post-alemtuzumab phase, as outlined in Table 3-17 and 
illustrated in Figure 3-8. These data suggest a trend toward lower SAD and 
higher SRD rates during the 2-year Alemtuzumab treatment phase but this is not 
sustained beyond this. 
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Table 3-17: SAD/SRD by phase 
Phase (n=51) 
 
Pre-Natalizumab Natalizumab  Switch Alemtuzumab  Post-Alemtuzumab 
Patients with no SAD/SRD (%) (95%CI††) 
26/40 (65%) 
(50%,78%) 
35/45 (78%) 
(64%,88%) 
34/37 (92%) 
(79%,97%) 
30/44 (68%) 
(53%,80%) 
28/37 (76%) 
(60%,87%) 
Total SAD  12 5 2 5 8 
Total SRD 3 5 1 9 1 
Total patient yrs in phase 170.79 82.02 17.84 87.93 121.35 
Overall annualised SAD rate (95% CI†) 
7.0 
(3.6,12.3) 
6.1  
(2.0,14.2) 
11.2 
(1.4,40.5) 
5.7 
(1.8,13.3) 
6.6 
(2.8,13.0) 
Overall annualised SRD rate (95%CI†) 
1.8 
(0.4,5.1) 
6.1  
(2.0,14.2) 
5.6  
(0.1,31.2) 
10.2 
(4.7,19.4) 
0.8¶ 
(0.02,4.6) 
Patients with missing data 11 6 14 7 14 
Per 100 patient years †Using Byar's method. ††Using the Wilson Score method 
¶p<0.05 vs Alemtuzumab phase 
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Fig 3-8: Annualised SAD/SRD rates by phase 
 
 
SAD/SRD categorisation 
There were 35 patients with available EDSS data to permit SAD/SRD analyses 
across all phases. As a method of describing overall cohort outcomes, rather 
than relating to each phase, these patients were categorised into one of six 
descriptive disease course categories from their profile of EDSS-change over the 
entire study. The mean duration of time in the study for these patients was 
11.96 years (SD 4.96). 
Under this classification system: 
1. ‘sustained improvement’ if SRD is maintained until last follow-up 
2. ‘erroneous improvement’ if SRD is not maintained until last follow-up 
3. ‘sustained progression’ if SAD is maintained until last follow-up  
4. ‘erroneous progression’ if SAD is not maintained until last follow-up 
5. ‘Minimal change’ if an EDSS change ≤0.5 points from baseline for all 
measurements 
6. ‘fluctuating’ if the profile does not fit any of the above categories 
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From these six categories, three groups were defined:  
1. ‘confirmed stable’ (‘sustained improvement’ or ‘minimal change’);  
2. ‘unsustained change’ (‘erroneous progression’, ‘erroneous improvement’ 
or ‘fluctuating’ course);  
3. ‘confirmed worsening’ comprising those with ‘sustained progression’  
 
Overall, 20/35 (57%) were confirmed stable, 9/35 (26%) worsened and 9/35 
(26%) improved as outlined in Table 3-18 and Figure 3-9. This analysis was 
dependent on frequently documented EDSS scores in medical notes and the 
patients included were from one of 8 centres. The lack of EDSS scores in all 
patients at the required frequency limits conclusions about these results but it 
would be expected that those with more active disease would have disability 
scores documented more frequently as a result of increased clinical input. The 
possibility that the documentation is simply centre-specific is refuted by the 
number of centres providing these data. With this in mind, the overall SAD/SRD 
analysis over the whole study period suggests that the majority of patients 
treated with alemtuzumab after natalizumab remained stable or improved 
despite being a highly active group with early disability.  
Five patients (14.3%) were classified as having secondary progression using this 
analysis, with two consecutive SAD events over the course of the study 
irrespective of the treatment phase. Data from natural history studies12  suggest 
that by 6-15 years from onset 40% of patients with RRMS will develop SPMS. The 
much lower figure seen in this cohort suggests a long-term disease-modifying 
effect from sequenced DMTs, but comparison to historical controls is limited by 
changing diagnostic guidelines and general progress in healthcare which likely 
favour more recent cohorts toward improved prognosis. Unknown relevant 
socioeconomic and/or environmental factors which differ between generations 
may have either positive of negative effects but also limit such comparisons 
where these cannot be accounted for. 
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Table 3-18: SAD/SRD categorisation over entire study (N=35) 
SAD/SRD six-fold categorisation  SAD/SRD three-fold 
categorisation   
N N  
Sustained improvement 9 
20 Confirmed stable 
Minimal change 11 
Erroneous improvement 2 
6 Unsustained change Erroneous progression 1 
Fluctuating 3 
Sustained progression 9 9 Confirmed worsening 
 
 
Figure 3-9: SRD/SAD categorisation over whole study (N=35) 
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MRI Results 
The following endpoints are addressed in this section: 
Primary endpoint 
• The occurrence of significant MRI evidence of active inflammatory disease 
in each treatment phase 
 
Secondary Endpoints 
• The occurrence of worsening or improving T2/FLAIR lesions, new T1 
lesions and changes in qualitative atrophy during each treatment phase 
 
• To describe any effects of natalizumab and alemtuzumab on qualitative 
atrophy and cognition in patients with rapidly evolving severe RRMS 
 
 
There were 36 patients with completed MRI data. The cohort characteristics are 
outlined in Table 3-2 but there was significant missing clinical data for a 
proportion of patients from one centre in particular. Firstly, the total MRI results 
with all available data will be discussed and then the smaller cohort (N=25) with 
more complete clinical and MRI data with at least 2 years follow-up after the 
first alemtuzumab course. 
 
Baseline MRI Brain 
31 patients had MRI brain scans from the time of diagnosis or prior to 
natalizumab treatment as their first available scan, considered their Baseline 
MRI for this study. The diagnostic scan was available for 9 patients, the other 22 
Baseline MRIs were undertaken during the Pre-natalizumab phase, the latter 
providing the MRI data for Table 3-2. Table 3-19 and Figure 3-10 detail the 
centres from which MRI data were available and the year of the Baseline MRI 
brain scan respectively. Most MRI scans included were from two centres, 
Birmingham and Dublin, and most Baseline scans undertaken in 2008 and 2009. 
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Table 3-19: MRI data available by MS Centre 
Centre n 
Birmingham 12 
Glasgow 4 
Dublin 14 
Cardiff 1 
Leeds 4 
Swansea 1 
Total 36 
 
 
Figure 3-10: Year of MRI Brain Baseline (1st available) scan 
 
 
The reporting blinded neuroradiologist reviewed available scans retrospectively. 
The number of enhancing lesions were counted on the Baseline scan in those 
where contrast was given (n=21). Additionally, a qualitative assessment was 
made on the supratentorial and infratentorial lesion load and degree of both 
global and callosal atrophy. Table 3-20 details the findings. There was an 
average of almost 5 gadolinium-enhancing lesions, but over half of patients had 
no contrast-enhancing lesions in the 21 scans where this could be assessed. The 
majority had a marked supratentorial lesion load but minor infratentorial lesion 
load and minor or no visible atrophy in the opinion of the neuroradiologists. 
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Table 3-20: Baseline MRI Brain Lesion load and atrophy 
Baseline MRI (N=31)  
Mean number of Gd+ lesions* (SD, 
range) 
4.6 (9.7, 0-38) 
Number of patients with no Gd+ 
lesions* (%) 
11 (52%) 
Lesion load qualitative assessment None Minor Moderate Marked 
Supratentorial 0 3 2 25 
Infratentorial 4 12 7 7 
Atrophy qualitative assessment 
Global 16 12 2 0 
Callosal 18 7 3 2 
*n=21 (MRIs where contrast was given) 
 
Interval MRI Brain Comparisons 
Serial MRI brain scans were compared over time from the Pre-natalizumab phase 
to the last available scan in the Post-alemtuzumab phase. Only interval scan 
comparisons which occurred entirely during a phase were included in the final 
analysis to avoid confounding impacts from treatments outwith that phase. For 
example, if an MRI undertaken during the Natalizumab treatment phase was 
compared to a scan undertaken in the Pre-natalizumab phase, based on the 
dates the scans were undertaken and the beginning and end dates of each 
phase, this comparison was not included. In a bid to account for this, however, 
the occurrence of contrast-enhancing lesions was evaluated for each MRI where 
contrast was given in each phase. The occurrence of contrast enhancement is 
considered an acute event and therefore negates the concern regarding the 
impact of previous treatments although we recognise that contrast enhancement 
can persist for months which may result in false positive events during a 
treatment phase, although this is relatively rare238. 
New MRI brain lesions occurred most during the Switch and Pre-natalizumab 
phases, driven mainly by contrast-enhancing lesions in the former and T2/FLAIR 
lesions in the latter (See Table 3-21). The rate of new/worsening lesions was 
highest during the Switch period despite it being the shortest and with the 
fewest scans occurring during this time in comparison to other phases (Figure 3-
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11). The rate of new MRI Brain lesions was lowest in the Natalizumab treatment 
phase and was also relatively low in the Post-alemtuzumab phase.  
The number of improving lesions was highest during the Alemtuzumab treatment 
phase but the rate per year of phase was highest during the Switch (Figure 3-
12). Therefore, the Switch phase had the highest rate of both worsening and 
improving lesions, but the net effect was worsening (Figure 3-13). The Switch 
period also had the highest rate of Gd-enhancing lesions (Figure 3-14) and most 
patients were off DMTs during this phase. From a mechanistic point of view, it 
could be postulated that stopping natalizumab has resulted in a rebound effect 
with an open blood-brain barrier permitting both beneficial and deleterious 
immune activity.  
Natalizumab treatment was associated with the lowest rates of new MRI brain 
lesions and Alemtuzumab with most improved lesions, after the Switch period. 
Considering both new (worsening) and improving lesions, the net effect favoured 
the Alemtuzumab treatment period but, again, this was not sustained after 2 
years (Table 3-21). Figure 3-13 illustrates the cumulative change in MRI brain 
lesions throughout each phase, adjusted for the length of each phase and 
number of scans per phase and is in keeping with low rates of new or worsening 
lesions in all but the Switch phase when the majority of patients were off DMTs, 
albeit for a relatively short period. Figure 3-14 illustrates that this trend 
remains even when only (acute) contrast-enhancing lesions are considered, 
further confirming that the Switch phase was the period with the highest 
inflammatory radiological disease activity. Whilst the number of patients having 
MRI brain scans within the Switch period is lower than the other phases, 
potentially suggesting bias towards those with more active disease, it is notable 
that these MRI results largely mirror the ARR and SAD/SRD profiles seen in 
Figures 3-7 and 3-8 with the Switch phase being an outlier of worsening disease 
activity and disability in comparison to other phases. Given this, however, the 
‘MRI efficacy cohort’ with more complete clinical and radiological data is also 
considered below. 
 
Table 3-21: Interval MRI Brain lesions by Treatment Phase – Full MRI cohort 
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N=36 Pre-
Natalizumab 
Natalizumab 
Treatment 
Switch 
Alemtuzumab 
Treatment 
Post-
Alemtuzumab 
Number of 
patients 
11 (31%) 16 (44%) 
10 
(28%) 
15 (42%) 17 (47%) 
Number of scans 19 71 13 25 48 
Number of Gd 
scans 
18 49 13 19 30 
Mean duration of 
phase (years) 
3.4 2.54 0.61 2 2.22 
Worsening lesions 
Mean New Gd+ 
lesions (SD) 
1.39 (2.1) 1.41 (4.5) 
8.75 
(9.7) 
3.0 (9.6) 1.41 (6.0) 
Mean New T2 
lesions (SD) 
3.21 (4.1) 1.30 (5.4) 
4.53 
(10.1) 
1.35 (2.6) 2.04 (5.3) 
Mean Worse T2 
lesions (SD) 
0.79 (1.3) 1.0 (2.0) 
5.23 
(2.4) 
0.87 (1.8) 0.58 (2.5) 
Mean New FLAIR 
lesions (SD) 
3.63 (5.6) 1.47 (3.8) 
5.75 
(10.5) 
1.65 (3.5) 1.86 (4.9) 
Mean Worse FLAIR 
lesions (SD) 
0.95 (1.8) 1.43 (3.6) 
1.75 
(2.5) 
0.96 (2.1) 0.56 (2.3) 
Mean New T1 
lesions (SD) 
1 (2.2) 0.65 (2.5) 
2.91 
(7.7) 
0.63 (1.4) 1.25 (3.7) 
Mean total any 
new or worse 
lesions* 
9.58 5.85 20.17 5.46 6.29 
Total new or 
worse 
lesions*/scan 
0.50 0.08 1.55 0.22 0.13 
Total new or 
worse 
lesions*/scan/year 
 
0.15 0.03 2.54 0.11 0.06 
Improving lesions 
   
 
285 
Mean Improved T2 
lesions (SD) 
0.79 (1.2) 1.41 (4.1) 
2.69 
(6.0) 
2.91 (5.9) 0.85 (2.9) 
Mean Improved 
FLAIR lesions (SD) 
0.68 (1.1) 1.64 (4.4) 
3.08 
(6.6) 
3.83 (7.5) 1.35 (5.1) 
Mean total any 
improved lesions* 
1.47 3.05 5.77 6.74 2.2 
Total improved 
lesions*/scan 
0.08 0.04 0.44 0.27 0.05 
Total improved 
lesions*/scan/year 
0.02 0.02 0.73 0.13 0.02 
Net effect 
(Worse-
Improving) 
lesions/MRI/year 
0.13 0.01 1.81 -0.02 0.04 
*Excluding Gd+ lesions (denominator is total number of scans in phase) 
 
Figure 3-11: New/Worse MRI Brain lesions by type and treatment phase – Full 
MRI cohort 
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Figure 3-12: Improved MRI Brain lesions by type and treatment phase – Full MRI 
cohort 
 
 
Figure 3-13: Total New/Worse MRI Brain lesions by treatment phase – Full MRI 
cohort 
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Figure 3-14: Number of contrast-enhancing lesions in each treatment phase 
 
 
In addition to MRI Brain imaging, serial spinal cord imaging was assessed by a blinded 
neuroradiologist over the duration of the study where available. Overall, 25 patients from 
6 centres had at least one MRI Cervical spine comparison during a treatment phase, 
totalling 56 MRI Cervical Spine comparisons over the duration of the study. Again, MRI 
disease activity was lowest in the Natalizumab, Alemtuzumab and Post-alemtuzumab 
phases but the number of patients and scans in each phase is small (See Table 3-22). 
Figure 3-15 shows the total number of new T2 and contrast-enhancing lesions per 
treatment phase and in Figure 3-16 this is adjusted for the number of scans undertaken 
and duration of each treatment phase. This corrects for the longer Pre-natalizumab phase 
and, as in previous results, disease activity is highest during the Switch phase, but the 
low number of new lesions in the (longest) Post-alemtuzumab phase suggests a persistent 
effect not seen in other efficacy measures in this study. These data largely concur with 
the previous evidence of high inflammatory disease activity within the Switch phase, low 
during other treatment phases, particularly Natalizumab and Alemtuzumab treatment, 
but also suggest a lasting effect of alemtuzumab not seen in other results. The small 
number of patients and scans limits any specific conclusions other than appearing to 
concur with the previous efficacy results for MRI brain imaging and relapses. 
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Table 3-22: MRI Cervical Spine lesions by treatment phase 
 Pre-
Natalizumab 
Natalizumab 
treatment 
Switch 
Period 
Alemtuzumab 
Treatment 
Post-
Alemtuzumab 
Total 
patients 
18 5 3 5 8 
Total MRI 
scans 
18 15 3 6 14 
Total MRI 
scans with 
contrast 
14 15 3 6 6 
Mean 
duration of 
phase 
[years] 
(SD) 
3.5(2.9) 2.5(2.2) 0.6 (0.6) 2 (0) 4.3 (2.6) 
Mean 
number of 
new T2 
lesions (SD) 
2.7 (2.3) 0.7 (1.0) 1 (1) 0.3 (0.8) 0.1 (0.3) 
Mean 
number of 
new Gd+ 
lesions 
0.5 (1.2) 0.3 (0.5) 0.3 (0.6) 0.2 (0.4) 0 
Mean 
number of 
new T2 
lesions 
/scan/year 
0.04 0.02 0.6 0.03 0.002 
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Figure 3-15: MRI Cervical Spine Total new lesions by treatment phase 
 
 
Figure 3-16: MRI Cervical Spine New T2 lesions / MRI / year of treatment phase 
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scans to assess potential treatment effects. Four comparison were made where 
available: 
• The Latest MRI Brain in the Natalizumab treatment phase was compared 
with the latest MRI scan in the Pre-natalizumab phase to evaluate the 
effect of natalizumab treatment (N=7) [Mean treatment duration =1.6 
years] 
• The latest MRI Brain in the Alemtuzumab treatment phase was compared 
with the latest MRI scan in the Switch phase to evaluate the effect of 
alemtuzumab treatment within the first 2 years (N=18) [Mean treatment 
duration = 2 years] 
• The latest available MRI Brain in the Post-alemtuzumab phase (i.e. most 
recent available) was compared with the latest scan in the Alemtuzumab 
treatment phase to evaluate the effect of alemtuzumab after 2 years 
(N=12) [Mean duration = 3.4 years] 
• The latest available MRI Brain in the Post-alemtuzumab phase (i.e. most 
recent available) was also compared with the latest available scan in the 
Switch period to evaluate the overall effect of alemtuzumab (N=15) [Mean 
duration =5.4 years] 
 
Overall, the number of new MRI Brain lesions was lower with alemtuzumab 
treatment in comparison to natalizumab treatment but the number of 
improved lesions was higher with natalizumab (See Table 3-23 and Figures 
3-17, 3-18 and 3-19). The lower number of new or worsening lesions with 
alemtuzumab was largely driven by effects beyond 2 years of treatment in 
this cohort, suggesting a delayed effect on radiological disease activity. 
Conversely, the rate of improved MRI brain lesions was highest within the 
first 2 years after alemtuzumab treatment. Again, the number of patients is 
small, particularly for natalizumab treatment. 
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Table 3-23: MRI Brain lesions per year of Natalizumab and Alemtuzumab 
Treatment phase 
 Natalizumab 
Treatment 
Alemtuzumab 
Treatment in 
first 2 years 
Alemtuzumab 
Treatment 
after 2 years 
Overall 
Alemtuzumab 
Treatment 
N 7 18 12 15 
Mean New 
Gd+ 
0.88 0.17 0.79 0.51 
Mean New 
T2 
4.0 3.21 1.55 1.91 
Mean New 
FLAIR 
2.31 3.36 1.43 1.83 
Mean Worse 
T2 
0.44 0.34 0.53 0.34 
Mean Worse 
FLAIR 
0.18 0.40 0.41 0.51 
Total 
New/Worse 
7.81 7.48 4.71 5.1 
Mean 
Improved T2 
2.14 1.98 0.18 0.86 
Mean 
Improved 
FLAIR 
1.35 2.23 0.39 0.80 
Total 
Improved 
3.49 4.21 0.57 1.66 
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Figure 3-17: MRI Brain Specific Comparisons per year of Treatment - Mean 
New/Worse lesions 
 
Figure 3-18: MRI Brain Specific Comparisons per year of Treatment - Mean 
Improved lesions 
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Figure 3-19: MRI Brain Specific Comparisons - Overall mean lesion change per 
year of treatment 
 
In addition to changes in MRI brain lesion load, the blinded neuroradiologists also 
evaluated changes in brain atrophy over time during these treatment periods. As 
shown in Figure 3-20, the vast majority of patients had no visible change in 
brain atrophy by visual inspection with both natalizumab and alemtuzumab. 
Callosal atrophy was also assessed and the results mirrored that of global 
atrophy. No patients were deemed to have evidence of improved atrophy. 
Overall, brain atrophy was present in a higher proportion of patients during 
alemtuzumab treatment in comparison to natalizumab treatment. The cohort 
was older by the time of alemtuzumab treatment and had longer follow-up 
which may be relevant to the apparently worse atrophy during alemtuzumab 
treatment but, on average, these patients would still be in their late 30s by the 
end of follow-up making this unlikely to be a significant factor. The difference is 
small and the method non-systematic, but this suggests ongoing brain atrophy 
over time despite sequential treatment with highly effective DMTs. 
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Figure 3-20: Global brain MRI atrophy changes with Natalizumab and 
Alemtuzumab 
 
 
Cervical spinal cord atrophy was visually assessed across all treatment phases in 
patients with available MRI scans. Unlike the above analysis, this was across all 
treatment phases in the study rather than only during the Natalizumab and 
Alemtuzumab treatment phases but, again, the vast majority of patients had no 
evidence of change using this method (See Figure 3-21). As seen with brain 
atrophy evaluations, no patient had evidence of improvement in cervical cord 
atrophy. In contrast to the MRI brain atrophy findings, however, cervical spine 
atrophy was more commonly seen during natalizumab treatment than in the first 
2 years of alemtuzumab treatment but the highest proportion of patients with 
cervical cord atrophy was reported during the Post-alemtuzumab phase. This 
again may suggest a treatment effect of alemtuzumab within the first 2 years 
which is not sustained in the longer term in this cohort. 
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Figure 3-21: Cervical Spine MRI atrophy by treatment phase 
 
 
 
Complete MRI and Clinical Data Cohort (N=25) 
From the efficacy cohort, 25 patients (49%) had both clinical and MRI data 
available, with follow-up greater than 2 years from first alemtuzumab 
treatment, and these are analysed as a subgroup here in order to evaluate MRI 
outcomes in a well-defined clinical population (See Table 3-2). The 
characteristics of the Baseline MRI brain i.e. first available are outlined in Table 
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was comparable but the Switch phase was shorter in the MRI efficacy cohort and 
they had longer available follow-up after alemtuzumab on average (5.3 vs 4.2 
years). The MRI efficacy cohort started alemtuzumab at a younger age (33 vs 35) 
and with a shorter disease duration (6.7 vs 7.5) in comparison to the total MRI 
cohort but over a third required further DMTs after alemtuzumab treatment in 
both cohorts. Overall, the MRI efficacy cohort is comparable to the Total MRI 
cohort on most clinical measures but there is some suggestion of relatively 
milder disease at onset but more active disease despite DMTs prior to 
alemtuzumab. 
The findings of the sequential interval MRI lesions change over time in this 
subgroup of patients with both clinical and MRI data available are largely in 
keeping with Total MRI cohort (See Table 3-25 and Figures 3-22 and 3-23). 
Again, the Switch period is associated with the highest rate of new and 
worsening lesions in comparison to the other phases. In this cohort, however, 
the Alemtuzumab treatment phase is associated with the lowest rate of new or 
worsening MRI brain lesions and the Natalizumab treatment phase with the most 
improving lesions, having been the opposite in the Total MRI cohort. The 
magnitude of the radiological disease activity is also higher in this cohort in 
comparison to the Total MRI cohort, with a particularly significant reduction in 
the Alemtuzumab phase, following very high rates of activity during the Switch.  
Using a two-tailed t-test, the rate of new or worsening lesions per MRI per year 
was significantly lower in the Alemtuzumab treatment period in comparison to 
the Switch period (p=0.013), Natalizumab treatment period (p<0.001) and Post-
alemtuzumab period (p<0.001). There was no significant difference in new or 
worsening lesions between the Post-alemtuzumab and Natalizumab treatment 
periods however (p=0.054) but, similar to the Total MRI cohort, the 
improvements in inflammatory radiological disease activity during the 
Alemtuzumab treatment phase were not sustained in the Post-alemtuzumab 
phase. Indeed, the net effects are much the same per phase as described 
previously save for the fact that all groups had net worsening of their lesion load 
whereas alemtuzumab treatment associated with a (small) net benefit in 
radiological disease activity in the Total MRI cohort.  
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Table 3-24: Baseline MRI Brain scans – MRI Efficacy cohort 
Baseline MRI (N=20)  
Mean number of Gd+ lesions* (SD, 
range) 
6.9 (12.4, 0-38) 
Number of patients with no Gd+ 
lesions* (%) 
6 (55%) 
Lesion load qualitative assessment None Minor Moderate Marked 
Supratentorial 0 3 2 15 
Infratentorial 4 4 2 7 
Atrophy qualitative assessment 
Global 13 7 2 1 
Callosal 12 5 2 1 
*n=11 (MRIs where contrast was given) 
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Table 3-25: Interval MRI Brain lesions by Treatment Phase – MRI Efficacy cohort 
 Pre-
Natalizumab 
Natalizumab 
Treatment 
Switch 
Alemtuzumab 
Treatment 
Post-
Alemtuzumab 
Number of 
patients 
8 (32%) 9 (36%) 
4 
(16%) 
7 (28%) 16 (64%) 
Number of scans 13 31 4 10 39 
Number of Gd 
scans 
12 25 4 7 28 
Mean duration of 
phase (years) 
3.4 1.97 0.37 2 2.94 
Worsening lesions 
Mean New Gd+ 
lesions (SD) 
1.46 (2.3) 1.44 (4.5) 
8.75 
(17.5) 
0 2.23 (7.6) 
Mean New T2 
lesions (SD) 
2.43 (3.7) 1.68 (5.3) 
11.25 
(18.1) 
0.3 (0.7) 2.69 (7.5) 
Mean Worse T2 
lesions (SD) 
0.36 (0.8) 0.58 (2.0) 
0.25 
(0.5) 
0 1.13 (4.1) 
Mean New FLAIR 
lesions (SD) 
2.29 (4.5) 1.27 (3.8) 
10.25 
(18.6) 
0.2 (0.4) 2.51 (7.2) 
Mean Worse FLAIR 
lesions (SD) 
0.21(0.8) 1.0 (3.6) 
0.25 
(0.5) 
0 1 (3.5) 
Mean New T1 
lesions (SD) 
1.31 (2.5) 0.9 (2.5) 
7.5 
(13.1) 
0.2 (0.4) 1.64 (4.6) 
Mean total any 
new or worse 
lesions* 
8.06 6.87 38.25 0.7 11.2 
Total new or 
worse 
lesions*/scan 
0.62 0.22 9.56 0.07 0.29 
Total new or 
worse 
lesions*/scan/year 
0.18 0.11 25.84 0.04 0.10 
Improving lesions 
Mean Improved T2 
lesions (SD) 
0.71 (1.1) 1.23 (4.2) 
4.75 
(8.9) 
0.2 (0.4) 1.13 (3.3) 
Mean Improved 
FLAIR lesions (SD) 
0.57 (0.9) 1.23 (4.4) 
5.0 
(9.4) 
0.4 (1.0) 2.05 (6.2) 
Mean total any 
improved lesions* 
1.28 2.46 9.75 0.6 3.18 
Total improved 
lesions*/scan 
0.10 0.08 2.43 0.06 0.08 
Total improved 
lesions*/scan/year 
0.03 0.04 6.59 0.03 0.03 
Net effect 
(Worsening – 
Improving) 
lesions/ MRI/year 
0.15 0.07 19.25 0.01 0.07 
*Excluding Gd+ lesions (denominator is total number of scans in phase) 
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Figure 3-22: New/Worse MRI Brain lesions by Treatment Phase – MRI Efficacy 
cohort (N=25) 
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Figure 3-23: MRI Brain lesions/scan/year by Treatment Phase – MRI Efficacy 
cohort (N=25) 
 
 
No evidence of Disease Activity (NEDA) by phase 
 
The following Primary endpoint is addressed in this section: 
 
• ‘Freedom from disease activity’ in each treatment phase 
 
NEDA was defined as no relapses, increase in EDSS or MRI activity (T1/T2/FLAIR) 
(‘NEDA-3’). This required patients to have data for all 3 modalities in each phase 
and, as outlined above, was the case for a minority only. Indeed, no patients had 
appropriate serial interval MRI Brain comparisons in every phase to allow 
sequential individual evaluation of lesion changes over the entire study. The data 
presented here are therefore for those patients in each phase where all three 
modalities were available but are not the same patients over time. In total, 19 
patients had 98 interval comparison MRI brain scans available over the course of 
the study. Figure 3-24 shows the proportion of patients in each phase who had 
MRI brain interval comparisons and no evidence of new disease activity. 
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Most of the patients with MRI data available also had relapse and EDSS data for 
the relevant phase but this was not the case for all and further reduces the 
denominator of cases to evaluate NEDA in each phase. Table 3-26 outlines the 
overall proportion of patients with all necessary data available and the proportion 
with NEDA in each phase. The small numbers again limit any conclusions based on 
these data alone but, again in keeping with previous results, disease activity 
appears lowest in the Natalizumab, Alemtuzumab and Post-alemtuzumab phases. 
This is in spite of the variable treatment phase durations, with disease activity 
occurring even during the short Switch phase. Each patient had undergone MRI 
brain more than once in most cases, however, suggesting that these were clinically 
active or deteriorating to merit imaging. This is likely to mean selection bias with 
more active patients having one or more MRI scans but, even with this, some met 
criteria for NEDA-3 and the trends are in keeping with better disease control 
during natalizumab and alemtuzumab treatment. 
 
Figure 3-24: Proportion of patients with no new MRI brain lesions by treatment 
phase 
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Table 3-26: NEDA-3 by phase (N=19) 
 Pre-
Natalizumab 
Natalizumab 
Treatment 
Switch 
Alemtuzumab 
Rx 
Post-
alemtuzumab 
Total 
number of 
patients 
7 10 4 7 15 
Total 
number of 
MRI Brain 
scans 
14 31 4 10 39 
Patients 
with 
NEDA-MRI 
3 (42.8%) 5 (50%) 
2 
(50%) 
5 (71.4%) 10 (58.8%) 
Patients 
with 
NEDA-MRI 
and no 
Relapses 
0 4 1 5 6 
Patients 
with 
NEDA-MRI 
and no 
EDSS 
increase 
0 3 0 3 3 
Patients 
with 
NEDA-3 
(%) 
0 3 (30%) 0 3 (42.8%) 1 (6.7%) 
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EDSS Results 
 
The following Secondary endpoint is addressed in this section:  
 
• EDSS change during each treatment phase 
 
In the whole cohort, mean EDSS scores increased up until the end of the Switch 
phase and then fell after alemtuzumab treatment, but missing data was an issue 
hence focus on the efficacy group here (N=51). Table 3-27 shows data for the 
entire cohort and outlines the limited number of available EDSS scores in each 
phase, particularly at diagnosis (Baseline) and in the Post-alemtuzumab phase. 
Having anticipated the availability of approximately 6-monthly EDSS scores, 
analysis of the total cohort was not possible due to the lack of available data for 
a significant proportion and further analysis on those with the most available 
data is therefore the focus below. With these caveats, Figure 3-25 charts the 
median EDSS and ARR for the whole cohort in each treatment phase and 
demonstrates a reduction in both following alemtuzumab treatment, albeit from 
their highest level during the Switch phase. 
The trends are the same for efficacy cohort (N=51). The frequency of 
documented EDSS scores was higher in this group but the proportion that 
occurred during relapse or were estimated were comparable to that in the entire 
cohort. In contrast to the whole cohort, however, the median EDSS increases 
during the Alemtuzumab treatment phase and falls more modestly in the Post-
alemtuzumab phase, more in keeping with a plateau rather than the reduction 
seen in the whole cohort. These data are represented in Table 3-28 and Figure 
3-26. 
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Table 3-27: EDSS by treatment phase (N=79) 
N=79 Baseline 
Pre-
Natalizumab 
Natalizumab 
Treatment 
Switch 
Alemtuzumab 
Treatment 
Post-
Alemtuzumab 
Mean 2.4 3.4 4.3 4.7 4.4 4.3 
Min 0 0 0 0 0 0 
Max 8 8.5 8.5 8.5 8.5 8 
Median 2 3 4.5 5.5 5 4 
Number of 
patients 
with data 
[at least 1 
EDSS] (%) 
55  
(69.6) 
62 
(78.4) 
68 
(86.1) 
49 
(62.0) 
58 
(73.4) 
36 
(45.6) 
Number of 
documented 
EDSS scores 
55 141 181 65 115 83 
 Duration of Phase (days) 
 n=65      
Mean 6316 1555 876 235 730 599 
Min  4 14 59 28 730 -458* 
Max 41611 8052 3201 1149 730 2421 
Median 192 1159 669 155 730 277 
Total 
patient-days 
404251 122875 69242 18538 57670 47309 
Mean 
frequency 
of EDSS 
recorded 
(EDSSs / 
year) 
0.05 0.42 0.96 1.3 0.73 0.64 
       
Number (%) 
EDSS scores 
during 
relapse 
15 (27%) 31 (22%) 23 (13%) 
15 
(23%) 
8 (7%) 5 (6%) 
Number (%) 
EDSS scores 
estimated 
31 (56%) 21 (15%) 30 (17%) 
14 
(22%) 
19 (17%) 16 (19%) 
Dates of 
recorded 
EDSS scores 
Nov 
1988 – 
Nov 
2016 
March 
2000 – 
Nov 2014 
Jan 2007 
– June 
2015 
March 
2009 – 
Jan 
2017 
Oct 2009 
– Nov 
2017 
Nov 2011 
– Nov 
2017 
*Not all patients had a Post-Alemtuzumab phase i.e. <2yrs since Alemtuzumab 
first started at time of database closure for analysis 
 
   
 
305 
Figure 3-25: EDSS and ARR by treatment phase for whole cohort (N=79)
 
 
Table 3-28: EDSS by treatment phase [Efficacy cohort (N=51)] 
N=51 Baseline 
Pre-
Natalizumab 
Natalizumab 
Treatment 
Switch 
Alemtuzumab 
Treatment 
Post-
Alemtuzumab 
Mean 2.4 3.2 3.9 4.1 4.2 4.2 
Min 0 0 0 0 0 0 
Max 8 8.5 8.0 8.0 7.5 8.0 
Median 1.8 3 3.8 4.0 4.3 4.0 
Number of 
patients 
with data 
[at least 1 
EDSS] (%) 
44 
(86.3) 
45 (88.2) 45 (88.2) 
31 
(60.8) 
46 (90.2) 35 (68.6) 
Number of 
documented 
EDSS scores 
44 105 96 39 96 81 
 Duration of Phase (days) 
 n=41      
Mean 309 1541 666 174 730 1023 
Min  4 14 60 28 730 31 
Max 3439 8052 2805 796 730 2421 
Median 125 1211 423 117 730 1040 
Total 
patient-
days 
12677 78601 33987 8854 37230 52196 
Mean 
frequency 
of EDSS 
recorded 
1.27 0.49 1.03 1.61 0.94 0.57 
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(EDSSs / 
year) 
       
Number (%) 
EDSS scores 
during 
relapse 
11 
(25%) 
23 (22%) 18 (19%) 9 (23%) 5 (5%) 5 (6%) 
Number (%) 
EDSS scores 
estimated 
26 
(59%) 
16 (15%) 19 (20%) 8 (21%) 16 (17%) 16 (20%) 
Dates of 
recorded 
EDSS scores 
Nov 
1988 – 
March 
2014 
March 
2000 – 
Feb 2014 
Jan 2007 
– March 
2015 
March 
2009 – 
October 
2015 
October 
2009 – 
July 2017 
November 
2011 – 
November 
2017 
 
Figure 3-26: EDSS and ARR by treatment phase for Efficacy cohort (N=51) 
 
 
Total study EDSS-years Area Under the Curve (AUC) 
The AUC method was used to assess EDSS change over the whole study and in 
each phase, comparing changes in comparison to the initial baseline EDSS at 
diagnosis. The area under the curve (AUC) was calculated and divided by the 
number of years in the phase to give an annualised baseline-adjusted AUC for 
each patient in each phase where there was sufficient data. Negative values 
indicate better outcomes i.e. reduced disability. 
A total of 35 patients had sufficient EDSS data to calculate their AUC across the 
entire study period. These patients had a median time in the study of 11 years 
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and a total of 356 documented EDSS scores, of which 12% were estimated and 
13% occurred during a relapse. 
Overall, the median annualised baseline-adjusted EDSS AUC was 1.26 EDSS-years. 
Over the median time of 11 years this would give a total AUC of 13.5 EDSS-years. 
There are many profiles that would give this total, for example an increase of 1 
at the start followed by an increase of 0.5 for the last five years. In terms of a 
gradual continuous increase over the study period however, this would equate to 
an increase in EDSS of around 0.25 per year for each patient on average. 
As would be expected in an active cohort, the vast majority of patients had a 
worsening AUC profile over the course of the whole study from diagnosis until 
last follow-up after alemtuzumab i.e. worsening disability. Only 4/35 (11%) 
improved overall compared to their baseline EDSS and a further 6/35 (17%) were 
unchanged but 71% of patients worsened over the study period (See Table 3-29). 
 
Table 3-29: Overall Annualised Total AUC (baseline adjusted) and AUC 
categorisation 
Total study (N=35) 
Time in 
study 
(yrs) 
Max EDSS 
per 
patient 
Annualised Total AUC 
(baseline adjusted) 
Mean±SD 
11.73±4.9
6 
5.46±2.28 1.21±1.95 
Median±IQR 
10.71±4.6
2 
6.5±4.50 1.26±2.06 
Range (min,max) 
(4.84,29.1
6) 
(2,8.5) (-5.39,4.61) 
Net improved (%) 4 (11%) 
Net unchanged (%) 6 (17%) 
Net Worse (%) 25 (71%) 
Number of documented 
EDSS scores 
 
356 
 
Number (%) in relapse  47 (13%) 
Number (%) estimated  44 (12%) 
 
Notably, there was no correlation between annualised total AUC and time in 
study. Those with longer disease duration were no more likely to have a 
different rate of deterioration. 
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EDSS AUC by Treatment Phase 
In the efficacy cohort (N=51), available EDSS scores were plotted against time in 
each phase for each patient with the vertical axis scale starting at the baseline 
EDSS score. Overall, mean annualised EDSS AUC fell from the Pre-natalizumab 
phase (0.5 EDSS-years) to Natalizumab treatment (0.2), rose slightly during the 
Switch phase (0.23), fell considerably during the Alemtuzumab treatment phase 
(-0.39) but rose again to almost Pre-natalizumab levels during the post-
Alemtuzumab phase (0.45) (See Table 3-30). 
Mean annualised EDSS AUC was further categorised as ‘net improved’ (for 
decreases of more than 0.5), ‘net worse’ (for increases of more than 0.5) and 
‘net unchanged’ (for values in between). The proportion of ‘net worse’ 
decreased after the Pre-natalizumab stage but then remained similar for all 
phases except during the Alemtuzumab treatment phase, were there was a fall. 
The proportion of ‘net improved’ remained similar in the Pre-natalizumab, 
Switch and Post-alemtuzumab phases but increased in both the Natalizumab and 
Alemtuzumab treatment phases (See Table 3-30 and Figure 3-27).  
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Table 3-30: EDSS and AUC analysis by phase (N=51) 
Phase (N) Baseline (44) 
Pre Natalizumab 
(45) 
Natalizumab 
(47) 
Switch 
(38) 
Alemtuzumab 
(46) 
Post Alemtuzumab 
(38) 
Maximum EDSS per patient 
Mean (SD) 
2.32 (1.71) 3.68 (2.03) 4.39 (2.23) 
4.38 
(2.17) 
4.37 (2.22) 4.64 (2.22) 
Median (IQR) 1.5 (1.5) 3.5 (3.25) 4.50 (4.5) 4.0 (4.1) 4.5 (4.5) 5.0 (4.1) 
Range (min,max) 0,8 1,8.5 0,8 0,8 0,7.5 0,8 
 
Annualised Total AUC  
(baseline adjusted)  
(39) (45) (37) (38) (37) 
Mean (SD) 
0.50 (1.42) 0.20 (1.26) 
0.23 
(0.64) 
-0.39 (1.07) 0.45 (0.89) 
Median (IQR) 0.44 (1.49) 0 (0.64) 0 (0.53) -0.11 (1.20) 0 (0.71) 
Range (min,max) -4.29,3.64 -3.98,3.22 -1.90,1.99 -3.90,1.37 -0.95,2.55 
AUC categorisation 
Net improved (%) 3 (8%) 9 (20%) 2 (5%) 13 (34%) 3 (8%) 
Net unchanged (%) 18 (46%) 24 (53%) 24 (65%) 19 (50%) 23 (62%) 
Net Worse (%) 18 (46%) 12 (27%) 11 (30%) 6 (16%) 11 (30%) 
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Figure 3-27: EDSS AUC categorisation by phase (only improved or worse shown) 
 
 
There were 35 patients with data for EDSS AUC analysis across all five phases 
[mean (SD) for each phase: 0.49 (1.19), 0.11 (1.25), 0.22 (0.66), -0.42 (1.10), 
0.50 (0.87)]. A repeated measures ANOVA found that there was a significant fall 
in mean EDSS AUC between Switch and Alemtuzumab treatment phases 
(p=0.008) and a significant rise between Alemtuzumab treatment and Post -
alemtuzumab (p=0.002). The changes between Pre-natalizumab and Natalizumab 
treatment and Natalizumab treatment and Switch were not significant (p=0.25 & 
0.72). Non-parametric tests confirmed these results. Figure 3-28 shows the 
mean AUC (& 95% error bars) across phases for this cohort, with the line of no 
change (0) highlighted: values above this reflect net disability worsening and 
values below improvement. Improvement in disability, on average, during the 
Alemtuzumab treatment phase was not maintained in the Post-alemtuzumab 
phase, where there was significant worsening. 
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Fig 3-28: Mean annualised EDSS AUC (baseline adjusted) by phase (N=35) 
 
 
36 patients had EDSS AUC data for both the Natalizumab and Alemtuzumab 
treatment phases. Of these 14/36 (39%) were in the same category for both 
phases (i.e. net better/worse or unchanged suggesting no differing effect of 
either treatment) but 13/36 (36%) were better off in the Alemtuzumab 
treatment phase and 9/36 (25%) were worse off. However, there was no 
statistically significant difference between the Natalizumab and Alemtuzumab 
phases. 
 
Overall, the EDSS AUC analysis is in keeping with our other results in that 
outcomes are generally best during the Natalizumab and Alemtuzumab 
treatment phases. In this analysis, the first 2-year period after alemtuzumab 
treatment was associated with the lowest proprtion of disability worsening of all 
phases and also the highest proprtion of patients with reduced disability. Direct 
comparison of the Natalizumab and Alemtuzumab treatment periods did not find 
a statistically signficant difference in AUC EDSS change however. The highly 
encouraging results obtained during the first 2 years after alemtuzumab 
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treatment were not maintained in the longer term however and, indeed, appear 
to show a return toward Pre-natalizumab rates of disability. 
 
EDSS vs. SAD/SRD analysis 
We have used two methods to analyse disability over time based on EDSS, 
namely SAD/SRD analysis and the EDSS-years AUC method. In comparison of 
these methods in our cohort, there was some agreement between the SAD/SRD 
profile categories and the total AUC categories. However, there were 10 
patients who were recorded as ‘confirmed stable’ by SAD/SRD but were ‘net 
worse’ in the AUC analysis (See Table 3-31). 
 
Table 3-31: SAD/SRD categorisation by AUC categorisation 
SAD/SRD 
categories 
Total AUC categories Total 
Net 
improved 
Net unchanged 
Net 
worse 
 
Confirmed 
stable 
4 6 10 20 
Unsustained 
change 
0 0 6 6 
Confirmed 
worsening 
0 0 9 9 
Total 4 6 25 35 
 
If the AUC criteria were changed so that less than zero (any negative AUC) was 
‘net improved’ (rather than decreases of >0.5) and values between 0 and 1 was 
‘net unchanged’ (rather than changes of <0.5), and only AUC above 1 was 
classified as ‘net worse’ (rather than increase >0.5) then there is slightly better 
agreement, with only 8 patients misclassified but this does not change the 
overall categorisation of net changes over the study, with the majority still ‘net 
worse’ (See Table 3-32). 
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Table 3-32: SAD/SRD categorisation with refined AUC categorisation 
SAD/SRD 
categories 
Total AUC categories Total 
Net 
improved 
Net unchanged 
Net 
worse 
 
Confirmed 
stable 
5 7 8 20 
Unsustained 
change 
0 2 4 6 
Confirmed 
worsening 
0 0 9 9 
Total 5 9 21 35 
 
Overall, it is likely that the AUC method is most accurate in this study as the 
SAD/SRD analysis relies more on frequently measured EDSS scores over time.  
 
Efficacy Results – Summary 
The majority of the clinical and radiological efficacy results suggest the lowest 
levels of most disease activity markers in patients treated with alemtuzumab 
after natalizumab were during the first 2 years after alemtuzumab treatment, 
with lasting positive effects on inflammatory disease activity (relapses / some 
MRI lesions) but not disability or MRI atrophy. A summary of efficacy results are 
illustrtaed in Table 3-33, where the treatment phase with the best performance 
for the outcome is highlighted in green and the least favourable treatment phase 
in red; additionally, whether the beneficial effects of the 2-year Alemtuzumab 
treatment period are maintained into the Post-alemtuzumab phase (or not) are 
highlighted similarly. 
 The highest levels of disease activity across most domains were during the 
Switch period between natalizumab and alemtuzumab. The outcomes during the 
Alemtuzumab and Natalizumab treatment phases were largely comparable in 
most domains, save for MRI atrophy measures and disability worsening using the 
AUC method where the early Alemtuzumab treatment period had the more 
positive effects.  
The small numbers make conclusions less than definitive but there appears to be 
agreement throughout the majority of clinical and radiological outcome 
measures used here that patients failing natalizumab treatment in this cohort 
have the highest levels of disease activity/worsening during the Switch phase 
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but good response to alemtuzumab treatment initially, with sustained reductions 
in some measures of inflammatory disease activity, but benefits on disability and 
MRI atrophy are not maintained. The dissociation between inflammatory and 
‘neurodegenerative’ measures of disease in MS are well-described although it 
seems this is only the case in this cohort once the 2-year treatment phase of 
alemtuzumab is completed.  
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Table 3-33: Clinicoradiological Efficacy Results Summary (N=51 unless otherwise stated)* 
 Pre-
Natalizumab 
Natalizumab 
Treatment 
Switch 
Period 
Alemtuzumab 
Treatment 
Post-
Alemtuzumab 
Alemtuzumab 
Treatment effect 
maintained? 
Clinical outcome measures 
ARR 0.57 0.43 1.1 0.18 0.18 Yes 
Annualised SAD rate 7.0 6.1 11.2 5.7 6.6 No 
Annualised SRD rate 1.8 6.1 5.6 10.2 0.8 No 
Median EDSS 3 3.8 4.0 4.3 4.0 - 
Mean EDSS AUC 0.5 0.2 0.23 -0.39 0.45 No 
AUC Category 
Net improved 
Net Unchanged 
Net Worse 
 
8% 
46% 
46% 
 
20% 
53% 
27% 
 
5% 
65% 
30% 
 
34% 
50% 
16% 
 
8% 
62% 
30% 
 
No 
- 
No 
MRI outcome measures 
Mean net new/worse 
MRI Brain lesions per 
MRI per year (N=36) 
0.13 0.01 1.81 -0.02 0.04 No 
Mean net new/worse 
MRI Brain lesions per 
MRI per year (N=25) 
0.15 0.07 19.25 0.01 0.07 No 
Mean new/worse MRI 
Brain lesions in 
specific MRI 
comparisons 
- 7.81 - 7.48 4.71 Yes 
Mean improved MRI 
Brain lesions in 
- 3.49 - 4.21 0.57 No 
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specific MRI 
comparisons 
Number of new Gd+ 
lesions on MRI brain / 
scan / year 
0.014 0.018 0.18 0.021 0.024 No 
Mean new T2 MRI C-
spine lesions 
0.04 0.02 0.6 0.03 0.002 Yes 
% Worse Global 
Atrophy in Specific 
comparisons 
- 14.3 - 5.6 8.3 No 
% Worse Cervical Spine 
atrophy 
- 40 33 17 71 No 
% No evidence of new 
MRI lesions 
42.8 44.4 50 71.4 58.8 No 
Combined outcome measure 
% NEDA-3 0 30 0 42 6.7 No 
*The treatment phase with the best performance is highlighted in green, the lowest in red 
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DMT-related Neutralising Antibodies 
The following Secondary Endpoint is addressed in this section: 
 
• Presence of neutralizing antibodies in each treatment phase 
 
Neutralising antibodies (Nabs) were only recorded only during the Natalizumab 
treatment phase (See Table 3-2). Natalizumab NAbs were documented in 7 of 79 
patients (8.8%): 5 of these patients stopped natalizumab due to efficacy, 1 due 
to hypersensitivity reaction (SAE) and 1 because of NAbs alone. These data are in 
keeping with the known deleterious effect of NAbs on the efficacy of 
natalizumab.  
 
Quality of Life markers 
The following Secondary Endpoint is addressed in this section: 
 
• Change in any marker of quality of life / employment 
 
Employment 
The majority of patients remained employed throughout each phase of the 
study. The proportion of patients in employment fell with time in the total 
cohort, however. At diagnosis, 64% were in employment but this had fallen to 
53% by last follow-up in the Post-alemtuzumab phase, although the number of 
patients with available data had fallen (See Table 3-34 and Figure 3-29). This 
was not just due to unavailable data however, as the proportion unemployed 
increased with time. Few patients became employed having been unemployed in 
the preceding treatment phase but this appeared to be most common between 
diagnosis and starting DMTs initially. Equally, a small proportion of patients 
became unemployed between phases but this was more consistent over time. 
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Table 3-34: Employment by Treatment Phase 
N=79 
Diagnosis Pre-
Natalizumab 
Natalizumab 
Treatment 
Switch Alemtuzumab 
Treatment 
Post-
Alemtuzumab 
N 59 58 57 57 60 36 
Employed 38 
(64%) 
37 (64%) 33 (58%) 
32 
(56%) 
32 (53%) 19 (53%) 
Unemployed 21 
(36%) 
21 (36%) 24 (42%) 
25 
(44%) 
28 (47%) 17 (47%) 
Unemployed 
to 
Employed 
0 4 (7%) 1 (2%) 
1 
(2%) 
1 (2%) 1 (2%) 
Employed 
to 
Unemployed 
0 4 (7%) 4 (7%) 
2 
(4%) 
3 (5%) 0 
 
 
Figure 3-29: Employment by Treatment Phase 
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(65%)] were employed at diagnosis. Over the study period 11/14 (79%) of those 
unemployed at diagnosis remained unemployed throughout, while 1 person (7%) 
became employed and remained so thereafter. Of those in employment at 
0
10
20
30
40
50
60
70
%
 o
f 
p
at
ie
n
ts
Employment by Treatment Phase (N=79)
% Employed % Unemployed
   
 
319 
diagnosis, 16/26 (62%) remained employed throughout. A large proportion of 
these [6/26 (23%)] became unemployed and did not regain employment 
thereafter, however.  Some patients [6 (15%)] oscillated between employment 
and unemployment over the course of the study. The biggest change was from 
initial employment to unemployment overall, in keeping with results from the 
total cohort.  
 
Driving 
The majority of the cohort were drivers at diagnosis and remained so over time 
although almost half of patients in the total cohort did not have driving data 
available. Similar to employment data, the proportion of drivers fell over time 
although driving appeared to increase back towards baseline in the Post-
alemtuzumab phase but the number of patients with data in this phase was 
again significantly lower. A small proportion of patients stopped driving in each 
treatment phase save for the Post-alemtuzumab phase. These data are 
illustrated in Table 3-35 and Figure 3-30. 
  
  
   
 
320 
Table 3-35: Driving by Treatment phase 
N=79 
Diagnosis Pre-
Natalizumab 
Natalizumab 
Treatment 
Switch Alemtuzumab 
Treatment 
Post-
Alemtuzumab 
N 41 41 39 39 38 20 
Driving 32 
(78%) 
33 (73%) 29 (74%) 
28 
(72%) 
26 (68%) 15 (75%) 
Not 
driving 
9 (22%) 8 (27%) 10 (26%) 
11 
(28%) 
12 (32%) 5 (25%) 
Not 
driving 
to 
driving 
0 1 (2%) 0 0 0 2 (10%) 
Driving 
to not 
driving 
0 1 (2%) 1 (2.5%) 
1 
(2.5%) 
1 (3%) 0 
 
Figure 3-30: Driving by Treatment phase 
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In the efficacy cohort, 21/51 patients (59% missing) had driving data available in 
all phases of the study. Again, the majority [16/21 (76%)] were driving at the 
time of diagnosis and 5/21 (24%) were not. Over the study period 12/16 (75%) 
continued driving while 2 patients stopped driving (one between diagnosis and 
the Pre-natalizumab phase, one after starting natalizumab).  A further 2 
patients oscillated between driving and not driving (one between Natalizumab 
treatment, the Switch period and Post-alemtuzumab; one between the Switch 
period, Alemtuzumab treatment and Post-alemtuzumab). Of those not driving at 
diagnosis, 3/5 (60%) remained not driving throughout but 2/5 (40%) started 
driving and continued thereafter (one between diagnosis and the Pre-
natalizumab phase and one after Alemtuzumab treatment).   
 
Deprivation category 
A Deprivation Index score is available for all patients with a UK postcode (N=65) 
using the Index of Multiple Deprivation (IMD) from the national statistics offices 
of England, Scotland and Wales. This is provided with the decile of the relevant 
area, based on the Lower Layer Super Output Area (LSOA) code for patients in 
England and the postcode for patients in Scotland and Wales. Notably, only the 
Outward Code (Postcode Area and District) were collected to avoid patient-
identifiable level data in the study. This therefore is not entirely accurate to 
small areas but the Outward Code was cross-referenced with the LSOA code and 
the deprivation centile based on this for England. Table 3-36 lists the number of 
patients in each decile, where decile 1 is the most deprived and decile 10 the 
least. The majority of patients [44/65 (68%)] are in the lower half of deprivation 
deciles, suggesting a relatively deprived cohort overall. 
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Table 3-36: Deprivation Category Decile for UK cohort at diagnosis 
Deprivation 
Category Index 
Decile 
N 
1 (most deprived) 7 
2 9 
3 8 
4 9 
5 11 
6 11 
7 3 
8 2 
9 2 
10 (least 
deprived) 
3 
Total 65 
 
Over the period under study only 4 patients changed postcode and one patient 
changed twice. The postcode change was from a lower decile (more deprived) 
area to a higher (less deprived) area for 2 patients although one of these 
patients then returned to the lower decile area. For these patients, the change 
occurred after alemtuzumab for one patient and after natalizumab treatment 
started for the other, who then returned to the lower decile area during the 
Post-alemtuzumab phase. Two patients changed from a higher decile area to 
lower decile areas, both occurring after the Alemtuzumab treatment phase. 
 
Pregnancies 
In total, 26 pregnancies were documented in the entire cohort over the course 
of the study. Only a single complication was recorded and this was outwith any 
DMTs: a retrospectively noted fetal heart condition in a previous pregnancy at 
the time of diagnosis. There was a large amount of missing data for this 
however. The number of pregnancies fell with time but so did the number of 
women with available data as shown in Table 3-37. 
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Table 3-37: Pregnancies by treatment phase 
N=79 Pre-
diagnosis 
Pre-
natalizumab 
Natalizumab 
treatment 
Switch Alemtuzumab 
treatment 
Post-
Alemtuzumab 
Total number 
of women 
with data 
35 13 15 10 12 6 
Number of 
pregnancies 
16 3 4 0 2 1 
Number of 
women 
10 3 4 0 2 1 
Complications Fetal 
heart 
condition 
 
     
 
 
Symptomatic therapy  
The use of symptomatic therapy was recorded in all phases and the results from 
the Efficacy Cohort are presented here (N=51). The highest number of 
symptomatic therapies were used in the Alemtuzumab & Post-alemtuzumab 
phases, which accounted for over half of all symptomatic treatments used over 
the study period [124/239 (52%)]. The other phases had smaller numbers. The 
difference between the Alemtuzumab phases and the other phases was 
significant (chi-square p<0.01). 
Overall, the symptoms most often treated were pain and spasticity, comprising 
61% of all treatments (36% & 25% respectively). Depression and bladder problems 
accounted for another 29% (16% & 13%) while treatments for fatigue, mobility 
and tremor were less common accounting for only 11%.  These category profiles 
were broadly similar in all phases. Whilst there were more treatments in the 
Alemtuzumab phases, the proportions for each treatment category was broadly 
in line with the other phases. Table 3-38 and Figure 3-31 detail these results. 
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Table 3-38: Symptomatic therapies by Treatment phase 
N=51 Pre-
Natalizumab 
Natalizumab 
treatment 
Switch Alemtuzumab treatment Post-Alemtuzumab Overall total 
Number of patients 
with no therapy (%) 
(95%CI†) 
31 (61%) 
(47%,73%) 
28 (55%) 
(41%,63%) 
32 (63%) 
(49%,75%) 
23 (45%) 
(32%,59%) 
29 (57%) 
(43%,69%) 
 
Mean (SD) 0.67 (1.03) 0.88 (1.18) 0.71 (1.10) 1.27 (1.60) 1.16 (1.85)  
Total therapies  
(max per patient) 
34 (4) 45 (4) 36 (4) 65 (4) 59 (8) 239 
Categories       
Pain 13 (38%) 15 (33%) 14 (39%) 23 (35%) 20 (34%) 85 (36%) 
Spasticity 7 (21%) 12 (27%) 9 (25%) 16 (25%) 15 (25%) 59 (25%) 
Depression 8 (24%) 7 (16%) 6 (17%) 11 (17%) 7 (12%) 39 (16%) 
Bladder problems 4 (12%) 6 (16%) 6 (17%) 8 (12%) 6 (10%) 30 13%) 
Fatigue 2 (6%) 2 (4%) 1 (3%) 4 (6%) 7 (12%) 16 (7%) 
Mobility 0 2 (4%) 0 2 (3%) 3 (5%) 7 (3%) 
Tremor 0 1 (2%) 0 1 (2%) 1 (2%) 3 (1%) 
†Using the Wilson Score method 
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Figure 3-31: Symptomatic therapies used by Treatment phase 
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Cognition and ambulation 
Two further secondary endpoints were planned but could not be evaluated due to lack 
of data. No cognitive assessments were documented for any patient during the study 
and the number of ambulation scores was inadequate for any meaningful analysis. The 
occurrence of new clinical markers of cognitive impairment and changes in ambulation 
score are therefore not included. 
 
 
The Switch Period 
The following Secondary endpoint is addressed in this section: 
• To evaluate whether there is an optimal time period for the 
‘switch’ phase between natalizumab and alemtuzumab and the 
effect of alternative DMTs as bridging therapies 
 
 
Cohort characteristics by length of switch period 
In order to evaluate whether there is an optimal time period to switch from 
natalizumab to alemtuzumab, the Efficacy Cohort (N=51) was divided into those 
who switched in less than 4 months and those who took longer. The 4-month cut-
off was to provide similar numbers in each group to evaluate subsequent 
outcomes but also has a basis from other studies suggesting improved outcomes 
in patients switching from natalizumab to fingolimod in less than 16 weeks239. 
The Switch period was defined as the time between the last infusion of 
natalizumab and the first infusion of alemtuzumab. The characteristics of those 
switching from natalizumab to alemtuzumab in less than or greater than 4 
months (120 days) are outlined in Table 3-39 in comparison to the total Efficacy 
Cohort. 
 
There were some notable differences between the patients switching to 
alemtuzumab from natalizumab in less than or greater than 4 months (See Table 
3-39). The difference in duration of the Switch period and the use of DMTs only 
in the longer switch group were statistically significant. Additionally, the higher 
proportion of JCV antibody positive patients in the longer switch group was 
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significantly different in comparison to those switching in less than 4 months, 
even though it appears the proportion in each group stopping natalizumab due to 
concern about PML was comparable but a quarter of the longer switch group did 
not have their reason for stopping natalizumab documented. The longer switch 
group also had shorter follow-up than those who switched in less than 4 months, 
meaning fewer outcomes will be captured in this study. 
 
The relatively small number of patients in the study means that some 
differences may not be statistically significant due to underpowering but other 
potentially relevant differences are noted. The shorter switch group had more 
females and was older on average at diagnosis. They had a shorter disease 
duration at diagnosis on average and shorter duration between diagnosis and 
commencing natalizumab. Despite being older on average at diagnosis, they 
were younger by the time of both natalizumab and alemtuzumab treatment than 
those in the longer switch group. This may suggest an older population with 
more aggressive disease leading to earlier treatments. The higher baseline EDSS 
in the shorter switch group may also suggest this but they had had fewer pre-
diagnosis relapses on average in comparison to the longer switch group. Also, the 
shorter switch group had fewer MRI Brain lesions present during the Pre-
natalizumab phase and lower EDSS before natalizumab treatment. However, the 
relapse rate prior to natalizumab was higher in the shorter switch group and 
natalizumab was more likely to be used as a first-line therapy. The duration of 
natalizumab treatment (and number of infusions) was notably shorter in the 
shorter switch group and more of these patients failed natalizumab due to 
efficacy rather than PML concerns, which was the case for a quarter of patients 
in the longer switch group who also had the statistically significantly higher 
proportion being JCV positive. The shorter switch group were more likely to 
require further courses of alemtuzumab and other DMTs in the Post-
alemtuzumab phase, again suggesting a relatively refractory treatment group. 
Overall, it seems those switching from natalizumab to alemtuzumab in less than 
4 months had more active disease and there was more concern about the risk of 
PML with ongoing use of natalizumab in the longer switch group, both of which 
likely resulted in the shorter and longer switch periods respectively. 
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Notably, there appears also to have been influence on the duration of the switch 
period between natalizumab and alemtuzumab by the year in which it occurred. 
In the whole efficacy cohort, those who started natalizumab before 2010 (23/51) 
had a median switch time of 101 days while those who started after 2010 
(28/51) had a median of 141 days. It is possible this relates to increasing 
concerns about PML in natalizumab-treated patients after 2010 and a desire to 
avoid asymptomatic patients being treated with alemtuzumab. Our study did not 
assess the measures taken during the switch period to exclude PML before 
alemtuzumab was commenced but 23 of the 36 patients (64%) with available MRI 
data had an MRI brain during the Switch period and no cases of PML have been 
reported in this cohort. 
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Table 3-39: Efficacy cohort characteristics by duration of Switch period 
 Total 
(Efficacy) 
cohort (N=51) 
Switch period 
< 4 months 
(N=26) 
Switch period 
> 4 months 
(N=25) 
Baseline characteristics  
% Female 40 (78%) 24 (92%) 16 (64%) 
Mean Age at diagnosis (SD) 29 (8) 30 (10) 28 (6) 
Median Disease duration 
at diagnosis¶ [Years] (IQR) 
0.34 (1.1) 0.29 (1.2) 0.50 (0.7) 
Mean baseline EDSS (SD) 2.3 (1.7) 2.5 (1.9) 2.2 (1.5) 
Mean number of relapses 
pre-diagnosis (SD) 
1.9 (1.3) 1.7 (1.0) 2.1 (1.6) 
Patients with no co-
morbidities 
39 (76.5%) 17 (65%) 22 (88%) 
Employed  27 (66%) 
(n=41) 
14 (67%) 
(n=21) 
13 (65%) 
(n=20) 
Driving  18 (78%) 
(n=23) 
4 (50%) (n=8) 14 (93%) 
(n=15) 
Pre-Natalizumab  
Number of DMTs used (%) 
0 
1 
2 
3 
4 
5 
 
20 (39%) 
22 (43%) 
4 (8%) 
3 (6%) 
1 (2%) 
1 (2%) 
 
11 (42%) 
10 (38%) 
3 (12%) 
2 (8%) 
0 
0 
 
9 (36%) 
12 (48%) 
1 (4%) 
1 (4%) 
1 (4%) 
1 (4%) 
Main reason for stopping 
DMT(s) (%) 
Efficacy (49%) 
Side effects 
(40%) 
Efficacy 
(48%) 
Side effects 
(48%) 
Efficacy (55%) 
Side effects 
(30%) 
Mean duration of Pre-
Natalizumab phase [years] 
(SD) 
4.2 (4.4) 3.5 (3.8) 5.0 (5.0) 
Mean ARR 0.57 
(0.47,0.68 95% 
CIs) 
0.58 0.56 
Mean EDSS before 
Natalizumab treatment 
(last available) (SD) 
3.4 (2.0) 3.0 (1.7) 3.9 (2.4) 
MRI Brain                                         (n=15)                          
(n=8) 
(n=7) 
Mean Gd+ lesions (SD) 
 
Supratentorial lesion load 
(%) 
None  
Minor  
Moderate  
Marked  
Infratentorial (%) 
7.3 (13.5) 
10 Gd scans 
 
 
0 
2 (13%) 
2 (13%) 
11 (73%) 
 
0.2 (0.45) 
5 Gd scans 
 
 
0 
1 (13%) 
2 (25%) 
5 (63%) 
 
14.4 (16.8) 
5 Gd scans 
 
 
0 
1 (14%) 
0 
6 (86%) 
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None 
Minor  
Moderate  
Marked  
Global atrophy (%) 
None 
Minor 
Moderate 
Marked 
Callosal atrophy (%) 
None 
Minor 
Moderate 
Marked 
4 (27%) 
2 (13%) 
5 (33%) 
4 (27%) 
 
9 (60%) 
6 (40%) 
0 
0 
 
8 (53%) 
4 (27%) 
2 (13%) 
1 (0.7%) 
2 (25%) 
1 (13%) 
4 (50%) 
1 (13%) 
 
6 (75%) 
2 (25%) 
0 
0 
 
6 (75%) 
1 (13%) 
1 (13%) 
0 
2 (29%) 
1 (14%) 
1 (14%) 
3 (43%) 
 
3 (43%) 
4 (57%) 
0 
0 
 
2 (29%) 
3 (43%) 
1 (14%) 
1 (14%) 
Natalizumab Treatment  
Mean age at 1st 
Natalizumab Treatment 
(SD) 
34 (8.9) 33 (10.8) 34 (6.1) 
Mean disease duration at 
1st Natalizumab 
Treatment* [years] (SD)  
4.6 (4.4) 4.5 (5.2) 4.7 (3.4) 
Median duration 
Natalizumab Treatment 
[years] (IQR) 
1.2 (2.1) 0.8 (1.6) 1.8 (2.0) 
Median number of 
Natalizumab infusions 
(IQR, range) 
12 (19, 2-91) 11 (17, 2-91) 14 (20, 4-64) 
Main reasons for stopping 
Natalizumab 
Efficacy (58%) 
Adverse events 
(19%) 
PML Concern 
(19%) 
Efficacy 
(67%) 
Adverse 
events (22%) 
Efficacy (29%) 
PML concern 
(25%) 
Not 
documented 
(25%) 
Number of JCV +ve 
patients  
16 (70%) 
(n=23) 
7 (54%) 
(n=13) 
9 (90%)* 
(n=10) 
Number of patients with 
Natalizumab Neutralising 
Abs 
6 (14%) (n=44) 4 (15%) 
(n=26) 
2 (11%) (n=19) 
Switch period  
Mean duration Switch 
period [days] (SD) 
163 (139) 
[5.4 months] 
78 (25) 
[2.6 months] 
273 (162)* 
[9.1 months] 
Patients using DMTs during 
Switch (%) 
7 (14%) 0 7 (28%)* 
Alemtuzumab Treatment  
Mean duration of follow-
up after 1st Alemtuzumab 
dose (years) (SD) 
4.8 (2.1) 5.5 (5.1) 4.1 (1.9)* 
Mean number of 
Alemtuzumab courses (SD, 
range) 
2 (1, 1-4) 
(6 missing) 
2.3 (0.6,2-4) 
(1 missing) 
2.2 (0.6, 1-3) 
(5 missing) 
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Number of Alemtuzumab 
Courses 
1 
2 
3 
4 
Unknown 
 
 
2 (4%) 
30 (59%) 
12 (24%) 
1 (2%) 
6 (12%) 
 
 
0 
18 (67%) 
7 (26%) 
1 (4%) 
1 (4%) 
 
 
2 (8%) 
12 (50%) 
5 (21%) 
0 
5 (21%) 
Mean age at first 
Alemtuzumab dose (SD) 
36 (8.6) 35 (10.9) 37 (4.9) 
Mean disease duration at 
1st Alemtuzumab dose* 
(years) (SD) 
6.7 (5.2) 5.8 (5.3) 8.7 (4.7) 
Number of patients using 
DMTs after Alemtuzumab 
(%) 
16 (31%) 11 (42%) 5 (20%) 
¶ Disease duration = since first symptom (not diagnosis) 
*p<0.05 
 
DMT use during the Switch period 
Only 7 patients (14%) used DMTs during the Switch period in the efficacy cohort 
and all were in the longer switch duration group (>4 months). Fingolimod was 
used in 6 patients and glatiramer acetate in one. Additionally, one patient, 
having used fingolimod, briefly returned to natalizumab for 3 months before 
switching to alemtuzumab within 2 months of stopping. As noted above, there 
was a difference by length of switch and the reasons for stopping natalizumab 
where those with a shorter switch period had more efficacy concerns while those 
with longer switch had more PML concerns. However, this was due to the small 
group of patients with longer switch periods who had been given DMTs, all of 
whom had stopped natalizumab due to PML concern. Once these were removed 
there was no significant difference (fishers exact test p=0.12) between the 
longer and shorter switch groups in terms of the reason for stopping 
natalizumab. 
 
Safety outcomes by Switch duration 
The number of adverse events in the Alemtuzumab treatment phase differed 
significantly by the duration of the Switch period, with a smaller number of 
adverse events among those with the longer duration. There were more adverse 
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events in the Post-alemtuzumab phase among those with the longer switch but 
the difference was not significant. 
 
Table 3-40: Adverse events after Alemtuzumab treatment by switch duration 
Phase 
Total adverse 
events 
Switch 
under 4 
months 
(n=26) 
Switch 
over 4 
months 
(n=14) 
Bridging 
DMT 
(n=6) 
p (two 
switch 
groups) 
Alemtuzumab 
RX 
Mean±SD 1.69±1.64 0.57±0.85 0.83±0.41  
Median±IQR 1.0±1.25 0±1.25 1±0.25 p<0.05* 
Range 
(min,max) 
0,6 0,2 0,1  
Post 
Alemtuzumab 
Mean±SD 0.19±0.40 0.39±1.24 0  
Median±IQR 0.0±0.0 0±0.0 0 p=0.60* 
Range 
(min,max) 
0,1 0,5 0,0  
* Mann Whitney test 
 
Efficacy outcomes by Switch duration 
 
Relapses 
There was a significantly higher relapse rate during the Switch period in patients 
taking more than 4 months to switch between natalizumab and alemtuzumab, 
whether a ‘bridging’ DMT was used during this period or not, compared to 
patients switching in less than 4 months (See Table 3-41 and Figure 3-32). 
Having had a lower ARR during the Natalizumab treatment phase, the longer 
switch groups had a significant increase during the Switch period, whilst this 
actually fell in the shorter switch group. Both groups had lower ARR in the 
Alemtuzumab treatment and Post-alemtuzumab phases, the longer switch group 
now being significantly lower in these phases than the shorter switch group. The 
difference in magnitude in the ARR is most pronounced during the Switch period, 
however. 
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Table 3-41: ARR (95% CIs) in each treatment phase by Switch duration [N=51] 
Switch 
Duration 
Pre-
natalizumab 
Natalizumab 
treatment 
Switch 
period 
Alemtuzumab 
treatment 
Post-
alemtuzumab 
< 120 
days 
(n=26) 
0.57 
(0.56, 0.58) 
0.47 
(0.46 ,0.48) 
0.36 
(0.34, 
0.38) 
0.25 
(0.245, 
0.255) 
0.12 
(0.11, 0.13) 
> 120 
days 
(n=18) 
0.56 
(0.55, 0.57) 
0.41 
(0.40, 
0.42) 
1.12 
(1.08, 
1.16) 
0.10 
(0.09, 0.11) 
0.09 
(0.08, 0.10) 
DMT 
used 
during 
Switch 
[all > 120 
days 
(n=7)] 
0.96 
(0.87, 1.05) 
0.40 
(0.33, 0.47) 
0.98 
(0.87, 
1.09) 
0.07 
(0.05, 0.09) 
0.14 
(0.10, 0.18) 
NB: Significantly lower ARR (<4 months vs >4 months) highlighted in bold 
 
Figure 3-32: Annualised Relapse rate in each phase by Switch duration 
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The shorter switch group had a significantly longer relapse-free period after stopping 
natalizumab than the longer switch group but there was no significant difference in the 
proportion of patients remaining relapse-free until the end of follow-up between the 
groups. Table 3-42 shows that a greater proportion of the shorter switch group 
remained relapse-free until the end of follow-up (50%) compared to the longer switch 
group (33%) but the difference was not statistically significant (fisher’s exact test 
p=0.54). Overall, 22/51 (43%) of the Efficacy cohort had no further relapses after 
switching from natalizumab to alemtuzumab until the end of follow-up, with over 4 
years of follow-up on average in both groups, suggesting a lasting effect of 
alemtuzumab in a significant proportion of patients irrespective of switch length. 
 
Table 3-42: Proportion relapse-free until end of follow-up by Switch duration 
Switch duration 
Number (%) of patients with 
no relapses after 
natalizumab completion until 
end of follow-up 
<120 days (n=26) 13 (50%) 
>120 days (n=18) 6 (33%) 
Bridging DMT used 
[>120 days (n=7)] 
3 (43%) 
Total 22 (43%) 
 
Analysis was undertaken to evaluate time to first relapse after stopping 
natalizumab, comparing the shorter and longer switch groups. Median survival 
time was 740 days overall, but was significantly longer for the <4 months group 
(1146 days) than the >4 months group (537 days) (Mann Whitney p=0.038) as 
shown in Table 3-43. Using a Kaplan-Meier analysis, again the shorter switch 
group had longer relapse-free survival as shown in Figure 3-33, but this was not 
statistically significant (log rank test p=0.120). There was also no significant 
difference when the DMT bridging group was included. 
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Table 3-43: Relapse-free survival after natalizumab by Switch duration 
Survival time 
Overall 
(n=51) 
Switch <4 
months 
(n=26) 
Switch >4 
months 
(n=18) 
Bridging DMT 
(n=7) 
Mean±SD 995±912 1318±1005 693±716 575±575 
Median±IQR 740±1339 1146±1570* 537±831 186±1100 
Range (min,max) 35,3249 35,3249 42,2655 89,1306 
*p<0.05 
 
 
Figure 3-33: Kaplan-Meier relapse-free survival by group switch length  
 
 
Focusing on outcomes after the Alemtuzumab treatment, there was no 
significant difference in the percentage of patients with no relapses by switch 
length in either the Alemtuzumab treatment or Post-alemtuzumab phases (See 
Table 3-44). Both annualised relapse and disabling relapse rates were lower for 
those with longer switch length in both the Alemtuzumab and Post-alemtuzumab 
phases, similar to relapse rates, but none of the differences were significant. 
The group of patients treated with a DMT had the lowest overall annualised 
relapse rate in both the Alemtuzumab treatment and Post-alemtuzumab phases 
Log rank test 
p=0.12 
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but this was based on a small number of patients with a small number of events 
and the confidence intervals are therefore understandably wide, making this 
finding of uncertain significance. The longer switch group had had a higher ARR 
during the Switch period (See Figure 3-32) so the reduced relapses thereafter 
could be regression to the mean or that they had a greater response to 
alemtuzumab treatment than those switching in a shorter period. 
 
EDSS 
There was no significant difference between the two main switch groups in EDSS 
AUC for either the Alemtuzumab treatment or Post-alemtuzumab phases. 
However, disability levels were numerically higher for those with the shorter 
switch period and the absolute values were better for patients with a longer 
switch period and using a bridging DMT but this did not reach significance 
(p=0.06) as shown in Table 3-45. Also shown, there was no significant difference 
by switch duration in the AUC categorisation by switch duration in either the 
Alemtuzumab or Post-alemtuzumab phases (‘improved’, ‘unchanged’, ‘worse’) 
although those with a longer switch duration appeared to have a lower 
proportion with net worsening disability by this method, again this was not 
statistically significant.  
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Table 3-44: Relapse rate after Alemtuzumab treatment by switch duration 
Phase  Alemtuzumab Rx Post-Alemtuzumab 
Length of switch period 
Switch under 4 
months (n=26) 
Switch over 4 
months (n=18) 
DMT used 
(n=7) 
Switch under 4 
months (n=25) 
Switch over 4 
months (n=18) 
DMT used 
(n=7) 
No. of patients with no 
relapses (%) 95%CI††) 
16 (62%) 
(43%,78%) 
14 (78%) 
(55%,91%) 
6 (86%) 
(49%,97%) 
17 (68%) 
(48%,83%) 
13 (72%) 
(49%,88%) 
6 (86%) 
(49%,97%) 
Total number of relapses  
(max per patient) 
13 (2) 4 (1) 1 17 (6) 8 (3) 1 
Total patient yrs in phase 52.0 36.0 14.0 89.1 45.3 7.3 
Overall annualised relapse 
rate* (95% CI†) 
25.0 
(13.3,42.8) 
11.1 
(3.0,28.4) 
7.1 
(0.2,39.8) 
19.1 (11.1,30.5) 17.7 (7.6,34.8) 
13.7 
(0.3,76.3) 
Total number of disabling 
relapses (max per patient) 
3 (1) 1 (1) 0 11 (5) 4 (2) 1 
Overall annualised disabling 
relapse rate* (95% CI†) 
5.8  
(1.2,16.9) 
2.8 (0.1,15.5) 0 12.3 (6.2,22.1) 
8.8 
(2.4,22.6) 
13.7 
(0.3,76.3) 
*Per 100 patient years †Using Byar's method. ††Using the Wilson Score method 
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Table 3-45: Annualised Total AUC (baseline adjusted) and AUC categorisation by 
switch duration 
 Switch 
under 4 
months 
(n=24) 
Switch 
over 4 
months 
(n=16) 
DMT used 
during 
Switch 
(n=7) 
p (two 
switch 
groups) 
Max EDSS per patient     
Pre 
Natalizumab 
Mean±SD 3.2±1.8 4.2±2.4 4.2±2.4  
Median±IQR 
3±2.3 4.3±4 4.3±5 
p=0.25 
NS 
Range 
(min,max) 
(1,7.5) (1,8.5) (2,8)  
Natalizumab 
Treatment 
Mean±SD 4.2±2.1 4.9±2.3 4.0±2.6  
Median±IQR 
4.5±4 6.0±3.5 3.5±4 
p=0.26 
NS 
Range 
(min,max) 
(1,7) (1,8) (0,7)  
Annualised Total AUC (baseline 
adjusted) 
Switch 
under 4 
months 
(n=20) 
Switch 
over 4 
months 
(n=12) 
Fingolimod 
(n=6) 
p (two 
switch 
groups) 
Alemtuzumab 
Treatment 
Mean±SD 
-
0.31±1.24 
-
0.32±0.85 
-0.78±0.91  
Median±IQR 0.0±1.63 
-
0.20±0.55 
-0.78±1.50 
p=0.72 
NS* 
Range 
(min,max) 
-
3.90,1.37 
-
2.35,0.99 
-2.23,0.25  
AUC 
categorisation 
    
Net improved 
(%) 
7 (35%) 3 (25%) 3 (50%) 
p=0.40 
NS* 
Net unchanged 
(%) 
8 (40%) 9 (67%) 3 (50%) 
Net Worse (%) 5 (25%) 1 (8%) 0 
  (n=19) (n=13) (n=5)  
Post 
Alemtuzumab 
Mean±SD 0.67±0.96 0.16±0.74 0.39±0.88  
Median±IQR 0.35±1.36 0±0.46 0±0.98 
p=0.06 
NS† 
Range 
(min,max) 
-
0.73,2.55 
-
0.95,2.14 
0,1.96  
AUC 
categorisation 
    
Net improved 
(%) 
1 (5%) 2 (15%) 0 
p=0.27 
NS† 
Net unchanged 
(%) 
10 (53%) 9 (69%) 4 (80%) 
Net Worse (%) 8 (42%) 2(15%) 1 (20%) 
* Mann Whitney test †Fishers exact test. 
   
 
339 
The analyses above include outcomes after the Switch period but, as shown in 
Figure 3-34, there was no significant difference in EDSS in any treatment phase 
based on Switch duration. There were fewer EDSS scores available in all 
treatment phases in the longer switch group, however, particularly after the 
Switch phase, as shown in Table 3-46. The longer switch group had significantly 
shorter available follow-up [mean 4.1 vs 5.5 years (See Table 3-39)] which likely 
explains this, but the lack of available EDSS data in this group limits conclusions 
regarding comparisons between the groups on all measures of disability using 
EDSS in the study. 
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Figure 3-34: EDSS in each treatment phase by Switch duration (N=51) 
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Table 3-46: Number of available EDSS scores in each treatment phase by Switch 
duration 
 Diagnosis 
Pre-
natalizumab 
Natalizumab 
treatment 
Switch 
Alemtuzumab 
treatment 
Post-
alemtuzumab 
Switch 
<4 
months 
24 55 41 15 51 51 
Switch 
>4 
months 
15 34 37 14 25 24 
 
Combining relapse and EDSS data, 11/51 patients (22%) had no further relapses 
or increases in EDSS after switching from natalizumab to alemtuzumab, defined 
as clinical NEDA. In those where relapses or EDSS increase did occur, relapse was 
the more common disease activity (60% ;24/40) compared to EDSS (40%; 16/40). 
In terms of the effect of switch duration on maintaining clinical NEDA until the 
end of follow-up, again there was no significant difference in the proportions 
from the longer or shorter switch groups but the shorter switch group had 
significantly longer event-free survival.  
Fewer in the over 4-month switch group remained NEDA (11%) compared to the 
other two groups but the difference was not significant (fisher’s exact test p 
=0.51), as shown in Table 3-47. 
 
Table 3-47: Proportion Clinical NEDA until end of follow-up by Switch duration 
Switch duration 
Number (%) of patients with 
Clinical NEDA after natalizumab 
completion until end of follow-up 
<120 days (n=26) 7 (27%) 
>120 days (n=18) 2 (11%) 
Bridging DMT 
used [>120 days 
(n=7)] 
2 (29%) 
Total 11 (22%) 
 
Median survival time with Clinical NEDA after natalizumab discontinuation was 
467 days overall but was significantly longer for the <4 months group (650 days) 
in comparison to the >4 months group (203 days) (Mann Whitney p=0.014) as 
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shown in Table 3-48. There was also a statistically significant difference using 
Kaplan-Meier analysis, illustrated in Figure 3-35, with longer maintenance of 
Clinical NEDA in the shorter switch group. The trend remained the same when 
the bridging DMT group was included but the difference was no longer 
statistically significant (log rank test p = 0.054). 
 
Table 3-48: Clinical NEDA survival by switch duration (N=51) 
Survival time 
Overall 
(n=51) 
Switch <4 
months 
(n=26) 
Switch >4 
months 
(n=18) 
Bridging 
DMT 
(n=7) 
Mean±SD 693±724 953±833 408±448 455±546 
Median±IQR 467±961 650±1009* 203±522 186±1100 
Range (min,max) 29,2871 29,2871 42,1633 89,1306 
*p<0.05 (vs. Switch > 4months group) 
 
Fig 3-35: Kaplan-Meier analysis of Clinical NEDA survival by switch length  
 
 
Log rank test 
p=0.014 
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No Evidence of Disease Activity (NEDA) 
Further Kaplan Meier analysis was conducted to investigate whether the length 
of switch period between natalizumab and alemtuzumab had any effect on the 
amount of time the patient remained free of all measures of disease activity 
available (NEDA), defined as no relapses, new MRI lesions or increase in EDSS. 
Survival was from the date of the last natalizumab infusion to an end date that 
was either the first instance of disease activity or the end data of the study for 
censored cases. 
There were 51 patients in the analysis of which 10 (20%) remained NEDA at the 
end of the study period. The most common disease activity event was relapse 
[59% (24/41)] followed by EDSS increase [29% (12/41)] with only 12% due to new 
MRI lesion (5/41). 
As shown in Table 3-49, fewer in the longer switch duration group remained 
NEDA (11%) compared to the other two groups but the difference was not 
significant (fisher’s exact test p =0.55).  
 
Table 3-49: Proportion NEDA until end of follow-up by Switch duration 
Switch duration 
Number (%) of patients with 
NEDA after natalizumab 
completion until end of 
follow-up 
<120 days (n=26) 6 (23%) 
>120 days (n=18) 2 (11%) 
Bridging DMT used 
[>120 days (n=7)] 
2 (29%) 
Total 10 (20%) 
 
Median survival time was 331 days overall but the <4 months switch group had 
significantly higher median survival than the >4 months switch group (Mann 
Whitney p=0.025) as shown in Table 3-50. 
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Table 3-50: NEDA survival by Switch duration 
Survival time 
Overall 
(n=51) 
Switch <4 
mths (n=26) 
Switch >4 
mths (n=18) 
Bridging 
DMT 
(n=7) 
Mean±SD 595±646 813±766 336±329 455±546 
Median±IQR 331±775 506±962* 203±396 186±1100 
Range (min,max) 29,2854 29,2854 42,1144 89,1306 
 *p<0.05 (vs. >4-month Switch group) 
 
The Kaplan-Meier survival curve shown in Figure 3-36 illustrates that the <4-mth 
switch group had significantly longer NEDA survival times than the >4mth group 
(log rank test p=0.027). Including the Bridging DMT group, the shorter switch 
group still had longer survival but the difference was not statistically significant. 
 
Figure 3-36: Kaplan-Meier analysis of NEDA survival by switch length 
 
 
Symptomatic therapy by Switch duration 
After the Switch phase, there were differences in the number of symptomatic 
treatments in the Alemtuzumab and Post-alemtuzumab treatment phases by 
Log rank test 
P=0.027 
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duration of switch. The mean number of treatments used was lower for those 
with the longer switch duration: this difference was significant for the 
Alemtuzumab treatment phase but not for the Post-alemtuzumab phase (See 
Table 3-51). 
 
Table 3-51: Symptomatic therapy by switch duration 
Phase 
Total 
Symptomatic 
therapies 
Switch under 4 
months (n=27) 
Switch over 4 
months (n=24) 
sig 
Alemtuzumab 
Treatment 
Mean±SD 1.74±1.77 0.75±1.23 p<0.05* 
Median±IQR 1.0±3.0 0±1.75  
Range (min,max) 0,7 0,4  
     
Post 
Alemtuzumab 
Mean±SD 1.48±2.00 0.79±1.62 
p=0.08 
NS* 
Median±IQR 1.0±2.0 0±1.0  
Range (min,max) 0,8 0,6  
* Mann Whitney test 
 
Switch due to Natalizumab efficacy failure only (N=25) 
In the efficacy cohort (N=51), patients were switched from natalizumab to 
alemtuzumab mainly due to safety concerns (PML risk) or lack of efficacy. The 
longer switch group (when those treated with a Bridging DMT during the Switch 
period are included) were more likely to stop natalizumab due to PML concerns 
rather than efficacy and appeared to have a less active disease phenotype on 
some measures, hence long-term outcomes may reflect selection bias rather 
than the effects of the switching process. In order to address this, the cohort of 
patients switching from natalizumab to alemtuzumab because of lack of efficacy 
with natalizumab are evaluated separately here. 
Twenty-five patients switched from natalizumab to alemtuzumab due to lack of 
efficacy. Table 3-52 outlines this cohort and compares those who switched in 
less than or more than approximately 3 months (91 days) and compares their 
subsequent outcomes. The 3-month cut-off was chosen to provide roughly equal 
numbers in each group. 
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Table 3-52: Natalizumab efficacy failure cohort and outcomes by Switch duration 
 
All (N=25) 
Switch period < 3 
months (n=11) 
Switch period > 
3 months (n=14) 
Baseline characteristics 
% Female 20 (80%) 10 (91%) 10 (71%) 
Mean Age at 
diagnosis (SD) 
30 (7.7) 31 (7.6) 29 (7.8) 
Median Disease 
duration at diagnosis* 
[Years] (IQR) 
0.41 (1.2) 0.77 (1.2) 0.39 (0.54) 
Mean baseline EDSS 
(SD) 
2.7 (1.9) 3.1 (2.0) 2.3 (1.8) 
Mean number of 
relapses pre-
diagnosis (SD) 
2.0 (1.0) 1.9 (1.1) 2.0 (1.0) 
Patients with no co-
morbidities 
17 (68%) 7 (64%) 10 (71%) 
Pre-Natalizumab  
Number of DMTs used 
(%) 
0 
1 
2 
3 
 
11 (44%) 
12 (48%) 
1 (4%) 
1 (4%) 
 
3 (27%) 
6 (55%) 
1 (9%) 
1 (9%) 
 
8 (57%) 
6 (43%) 
0 
0 
Main reason for 
stopping DMT(s) (%) 
Efficacy (59%) 
Side effects 
(29%) 
Efficacy (55%) 
Side effects 
(36%) 
Efficacy (67%) 
Side effects 
(17%) 
Mean duration of 
Pre-Natalizumab 
phase [years] (SD) 
4.2 (5.2) 4.9 (4.9) 3.7 (5.6) 
Mean ARR 0.51 0.71 0.29 
Mean EDSS before 
natalizumab 
treatment (last 
available) (SD) 
3.3 (2.0) 3.4 (1.9) 3.2 (2.2) 
Natalizumab Treatment  
Mean age at 1st 
Natalizumab 
Treatment (SD) 
33.9 (8.5) 35.9 (8.4) 32.4 (8.5) 
Median duration 
Natalizumab 
Treatment [years] 
(IQR) 
0.97 (1.79) 1.1 (2.3) 0.84 (1.2) 
Median number of 
Natalizumab 
infusions (IQR, range) 
12 (15) 20 (10.3) 10.5 (6.8) 
Number (%) of JCV 
+ve patients  
6 (55%) 
[n=11] 
5 (71%)  
[n=7] 
1 (25%)  
[n=4] 
Switch period  
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Mean duration Switch 
period [days] (SD) 
117 (93.1) 
[3.9 months] 
67 (15.4) 
[2.2 months] 
155 (110) 
[5.2 months] 
Patients using DMTs 
during Switch (%) 
0 0 0 
Alemtuzumab Treatment  
Mean duration of 
follow-up after 1st 
Alemtuzumab dose 
(years) (SD) 
5.4 (2.0) 4.8 (2.0) 5.8 (2.0) 
Mean number of 
Alemtuzumab 
courses (SD, range) 
2.4 (0.58) 2.4 (0.50) 2.5 (0.66) 
Number of 
Alemtuzumab 
Courses 
2 
3 
4 
Unknown 
 
 
 
15 (60%) 
8 (32%) 
1 (4%) 
1 (4%) 
 
 
 
7 (64%) 
4 (36%) 
0 
0 
 
 
 
8 (57%) 
4 (29%) 
1 (7%) 
1 (7%) 
Mean age at first 
alemtuzumab dose 
(SD) 
36.1 (8.6) 38.1 (8.7) 33.8 (7.9) 
Number of patients 
using DMTs after 
alemtuzumab (%) 
11 (44%) 6 (55%) 5 (36%) 
Post-alemtuzumab Outcomes 
Safety 
Number of patients 
with any AE (%) 
Alem: 18 (72%) 
Post-Alem: 5 
(20%) 
Alem: 8 (73%) 
Post-Alem: 2 
(18%) 
Alem: 10 (71%) 
Post-Alem: 3 
(21%) 
Number of patients 
with autoimmune 
thyroid disease (%) 
 
5 (20%) 
 
2 (18%) 
 
3 (21%) 
Number of patients 
with infection (%) 
5 (20%) 3 (27%) 2 (14%) 
Efficacy 
Alemtuzumab 
Treatment mean ARR 
0.26 0.27 0.21 
Post-alemtuzumab 
mean ARR 
0.13 0.08 0.17 
Alemtuzumab mean 
EDSS (SD) 
4.4 (2.0) 5.3 (1.7) 3.6 (2.0) 
Post-alemtuzumab 
mean EDSS (SD) 
4.1 (2.1) 4.9 (1.6) 3.8 (2.2) 
*Disease duration = since first symptom (not diagnosis) 
Again, overall, the shorter duration switch group appears to have more active 
disease which likely biases longer-term outcomes and may explain the clinical 
reasoning for the shorter switch period. The shorter switch group had 
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proportionally more females, with older age, longer disease duration and higher 
EDSS at diagnosis than the longer switch group. The longer switch group were 
more likely to be treated (younger) with natalizumab as a first-line therapy, yet 
had lower Pre-natalizumab relapse rate and EDSS in comparison to the shorter 
switch group. The shorter switch group had a longer period of natalizumab 
treatment on average, a greater proportion were JCV antibody positive and were 
older at the time of alemtuzumab treatment, but follow-up after alemtuzumab 
was shorter. A greater proportion of the shorter switch cohort required DMTs 
after alemtuzumab treatment in comparison to the longer switch group.  
In terms of outcomes between the groups with longer or shorter switch duration 
who failed natalizumab because of lack of efficacy, there was little difference in 
safety but some (non-statistically-significant) differences in efficacy. The 
proportion of patients having any adverse event or secondary autoimmunity was 
comparable in each group although infections were proportionally higher in the 
shorter switch group. The shorter switch group had a lower relapse rate in the 
Post-alemtuzumab phase but higher mean EDSS in comparison to the longer 
switch group. 
The numbers here are too small to draw conclusions, but this analysis likely 
confirms that of the larger cohort analysis, namely that clinicians switched those 
with more disease activity quicker to maintain ongoing treatment effect. This, in 
turn perhaps explains the generally poorer outcomes in the shorter switch 
period, rather than being able to relate this directly to the duration of the 
switch although this is an alternative explanation. 
 
The Switch period: Conclusions 
Our analysis focused on the duration of the switch period between natalizumab 
and alemtuzumab and its effect on safety and efficacy outcomes. Only 7 of the 
51 patients used a Bridging DMT during the Switch period, making conclusions 
about the effectiveness of this approach limited. We therefore mainly compared 
patients by duration of the switch period, separated into less than or greater 
than 4 months between natalizumab stopping and alemtuzumab starting. 
Overall, the shorter switch group had more aggressive disease before the switch, 
which may explain some of the poorer outcomes during the Alemtuzumab and 
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Post-alemtuzumab phases, but generally the shorter switch group had longer 
disease-free survival on all measures of activity. 
Table 3-53 summarises the differences in outcomes between the shorter and 
longer switch groups, with the statistically significant differences highlighted in 
bold. Efficacy outcomes favour the shorter switch group although there were 
fewer AEs and symptomatic treatments used during alemtuzumab treatment in 
the longer switch group. There was no significant difference in mean EDSS scores 
between groups in any treatment phase, however. The EDSS AUC analyses 
generally favoured the longer switch, including the Bridging DMT group, in the 
Alemtuzumab and Post-alemtuzumab phases but this was not statistically 
significant. When we analysed only patients stopping natalizumab because of 
efficacy failure (N=25), the shorter switch group (<3 months) had lower Post-
alemtuzumab relapse rates but higher mean EDSS scores. The worse disability 
outcomes in the shorter switch groups may reflect the more active disease status 
preceding the switch rather than the characteristics of the switch itself, 
however. There were proportionally more infections during the Alemtuzumab 
treatment phase with the shorter switch group also, but otherwise safety 
outcomes were comparable. 
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Table 3-53: Summary of outcomes between <4months and >4 months switch 
duration groups (statistically significant differences highlighted in bold) 
Favours < 4months switch Favours > 4months switch 
Lower ARR during Switch period 
(0.36 vs 1.12) [See Table 3-41] 
Fewer AEs during the Alemtuzumab 
treatment phase (p<0.05) but no 
difference in Post-alemtuzumab phase 
[See Table 3-40] 
Higher proportion relapse-free after 
natalizumab until end of follow-up 
(50% vs 33%) [See Table 3-42] 
Lower ARR in Alemtuzumab 
treatment phase (0.1 vs 0.25) and 
Post-alemtuzumab phase (0.09 vs 
0.12) [See Table 3-41] 
Longer median duration to any 
relapse (1146 days vs 537 days) 
[See Table 3-43] 
Median EDSS AUC lower for longer 
switch group in Alemtuzumab 
treatment phase (0 vs -0.2) and Post-
alemtuzumab phase (0.35 vs 0) [See 
Table 3-45] 
Proportion ‘net improved’ on EDSS 
AUC categorisation higher in shorter 
switch group (35%) vs longer switch 
group (25%) after Alemtuzumab 
treatment [See Table 3-45] 
Lower proportion ‘net worse’ using 
EDSS AUC categories during 
Alemtuzumab (8% vs 25%) and Post-
alemtuzumab (15% vs 42%) treatment 
phases [See Table 3-45] 
Longer duration of clinical NEDA 
survival after switch: 650 days vs 
203 days in longer switch group 
(p=0.014) [See Table 3-48 and Figure 
3-35] 
Lower number of symptomatic 
treatments used in the 
Alemtuzumab treatment phase (0.75 
vs 1.71) but no significant difference 
in the Post-alemtuzumab treatment 
phase [See Table 3-51] 
Longer survival of NEDA after 
natalizumab stopped – median 506 
days vs 203 days [See Table 3-50 
and Figure 336] 
 
 
Discussion 
This retrospective observational study evaluated the safety and efficacy of 
switching to alemtuzumab after failure of natalizumab in patients with RRMS, 
using routinely collected clinical data. We identified 79 patients from 13 MS 
specialist centres from the UK & Ireland who had made this switch between 
March 2009 and January 2017. This cohort was used for safety analysis and had 
follow-up data for 3.6 years after starting alemtuzumab on average. A subgroup 
of patients (N=51) had at least 2 years’ follow-up data available after starting 
alemtuzumab and were evaluated additionally for efficacy outcomes. In this 
subgroup, the switch occurred between March 2009 and October 2015 and a 
mean of 4.8 years of follow-up data were available from starting alemtuzumab 
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and 11.2 years from diagnosis. MRI data were available for 36 of the 79 patients 
included overall and 25 were within the efficacy subgroup and so had longer 
follow-up data available (mean 5.3 years from first alemtuzumab course). There 
were some differences in the baseline characteristics of the subgroups in 
comparison to the total cohort, but none of these reached statistical 
significance. We assessed patients in 5 retrospectively-defined phases after 
diagnosis and baseline features were characterised; Pre-natalizumab treatment; 
Natalizumab treatment; Switch period; Alemtuzumab treatment and Post-
alemtuzumab treatment. The Alemtuzumab treatment period was defined for 
the purposes of this study as the first 2 years after alemtuzumab was started. All 
other phases were of variable duration and occurred at different time points. 
For example, the earliest diagnosis was made in 1988 and the most recent in 
2016, with natalizumab used between 2005 and 2016 and alemtuzumab between 
2009 and 2017 in the cohort overall. The majority of patients (57%) had been 
treated with DMTs prior to natalizumab but natalizumab was used first-line in 
the remainder, reflecting the highly active nature of the cohort. Almost half of 
patients (49%) stopped natalizumab because of breakthrough disease on 
treatment and 15% due to PML concerns because of positive JCV antibodies. 
The results suggest that that switching to alemtuzumab after failure of 
natalizumab in patients with RRMS is safe and improves inflammatory disease 
control over subsequent years, reducing the need for further DMTs in most, but 
initial benefits on disability are not maintained in the longer term. Overall 
though, despite sequential use of these high-efficacy DMTs, disability worsened 
on average by 0.25 EDSS points per year in this cohort, though there was some 
discrepancy in the overall disability outcomes depending on the analysis used. 
Using patients with longitudinal EDSS scores, 20/35 patients (57%) had either 
minimal change or sustained improvement with SAD/SRD categorisation, whereas 
25/35 (71%) had net worsening disability using the AUC method over the entire 
study period. When the parameters of the AUC evaluation were altered, there 
was closer agreement between these two methods but still the majority had 
worsening disability (21/35, 60%) using the AUC method, which is likely to be the 
more robust option in this study where EDSS values were not systematically 
available at comparable time points for all patients. The largely worsening 
disability occurred despite short-term improvement on all disease activity 
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measures during the 2-year Alemtuzumab treatment phase. However, given the 
selected population of patients with often treatment-refractory RRMS included, 
the rate of disability worsening and development of progressive disease was less 
than might be expected. The lack of a control group means conclusions cannot 
be definitive but using a pre-defined SAD definition, only 5 (14.3%) of the 35 
patients with necessary data available were classified as secondary progressive 
after a mean duration of almost 12 years from diagnosis. This is lower than 
would be expected from natural history studies12 and is lower than the 20-40% 
conversion rate seen with 15 and 16 year follow-up studies respectively with β-
IFN use108,240.  
Safety outcomes after switching to alemtuzumab from natalizumab were 
generally comparable to, or lower than, those described with its use first-line. 
Infections occurred in 13 patients (16%), 3 of which were considered serious 
(4%), and there was a single case of opportunistic CMV infection. There were no 
cases of PML. Autoimmune thyroid disease occurred in 14 patients (17%) but 
there was no other secondary autoimmunity identified. Autoimmune events 
occurred most frequently within the first 2 years after alemtuzumab whilst 
infections occurred later, perhaps counterintuitively. Malignant lymphoma 
occurred in 1 patient after HSCT which post-dated alemtuzumab treatment and 
was successfully managed. A single death from urosepsis occurred 3 years after 
alemtuzumab treatment in an already significantly disabled patient and was not 
thought related to DMT use by the patient’s treating physician. Notably, there 
were no documented cases of stroke or arterial dissection, which is reassuring in 
light of recent concerns, and the safety profile overall provides confidence in 
keeping with the recent EMA licensing decision to re-introduce alemtuzumab 
after a period of re-appraisal of its safety241. 
The 2-year Alemtuzumab treatment phase was associated with the lowest levels 
of disease activity on most measures. ARR, SAD, SRD, EDSS AUC, net 
new/worsening MRI Brain lesions, global and cervical cord atrophy and NEDA-3 
all favoured the Alemtuzumab treatment phase in comparison to all other 
treatment phases. Median EDSS was lowest in the Pre-natalizumab phase and 
generally increased with time despite sequential therapy although there was 
suggestion of plateau after alemtuzumab treatment. Similarly, the rate of new 
contrast-enhancing lesions was lowest before natalizumab treatment and 
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increased with time despite treatments. The reduced measures of disease 
activity during the 2-year Alemtuzumab treatment phase were maintained 
throughout follow-up for relapses and new MRI brain and cervical cord lesions 
but the others were not, including disability outcomes. The disconnect between 
worsening disability despite improved inflammatory disease control is well 
recognised in the literature of DMTs in general and its occurrence here, again, 
suggests that even highly-effective therapies may not prevent this. Overall, 
however, only 16 patients (31%) required further DMTs after treatment with 
alemtuzumab. 
The highest levels of disease activity on almost all measures occurred during the 
Switch period. To evaluate the relationship of switch duration with safety and 
efficacy outcomes, the cohort was separated into those switching between 
natalizumab and alemtuzumab in more or less than 4 months (120 days). There 
were some Pre-alemtuzumab differences in the cohorts of patients switching 
between treatments in less than or greater than 4 months suggesting that the 
shorter switch group had more active disease, but none of these were 
statistically significant. Bridging DMTs were used during the Switch period only in 
7 patients in the longer switch group but these were excluded from efficacy 
analysis in order to evaluate the effects of duration only. There was no 
statistically significant difference in the length of the switch based on whether 
natalizumab was stopped for efficacy or safety reasons but there appeared to be 
non-patient factors involved in decision-making with a trend to increasing switch 
duration after 2010, on average, but this was also not statistically significant.  
Switching from natalizumab to alemtuzumab in less than 4 months was 
associated with greater freedom from inflammatory disease in comparison to a 
longer switch in this cohort. Whilst there were fewer AEs and use of 
symptomatic treatments during the Alemtuzumab treatment phase on average 
for those in the longer switch group, significantly lower relapse rates and 
disease-free survival were seen in the shorter switch group. Lower ARRs in the 
Alemtuzumab and Post-alemtuzumab treatment phases were seen in the longer 
switch group, however, and disability outcomes also favoured this group but 
were not statistically significant and could reflect better prognostic factors 
which may actually explain the length of the switch. It appears that the shorter 
switch in the comparison group may have occurred due to high disease activity 
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preceding the switch and, hence, an attempt to avoid delay in starting effective 
treatment. 
 
Study Limitations 
There is no control group in our study and interventions were non-standardised 
over the study period. The results presented simply reflect the choices of the 
patients and treating clinicians at the time in each patient’s disease course. The 
frequency and extent of clinical, safety and MRI monitoring of each patient was 
variable, as was the duration of each phase other than the Alemtuzumab 
treatment phase (which was set at 2 years to reflect its usual treatment regime 
and initial immunological effects) but this too is relatively arbitrary at the 
individual patient-level. Given the lack of a control group, conclusions regarding 
the outcomes in comparison to another (or no) intervention or treatment 
strategy cannot be drawn. Additionally, patient-level data will have been driven 
by disease activity: that is to say, those with more disease activity are more 
likely to be reviewed in clinic, have an EDSS score documented and MRI 
undertaken than those without. The duration of each phase will also correlate 
with the number of documented events. For example, the number of EDSS scores 
documented in the Post-alemtuzumab phase will relate to the duration of 
follow-up after alemtuzumab: those with shorter follow-up are less likely to 
have a documented EDSS/relapse and those without a relapse are less likely to 
have a documented EDSS score. This is indicative of the necessarily reactive 
nature of clinical healthcare, but may have skewed outcome measures to reflect 
those with more active disease. Indeed, this cohort by definition is somewhat 
unusual in that they are relatively treatment-refractory in order to require 
sequential use of highly active DMTs and therefore do not reflect a typical RRMS 
cohort but should be comparable to cohorts where switching from natalizumab 
to alemtuzumab in real-world practice is considered. 
A particular issue for this study is incomplete data entry. This could be due to 
the lack of availability of (historical) medical records, incomplete 
documentation in source documents or incomplete entries into the online 
database used by each centre. Indeed, the online database used for data entry 
in this study had its own limitations. Where an event was not entered, it was 
   
 
355 
assumed it had not occurred. For example, if no relapse data were entered 
during a phase this was assumed to mean no relapses occurred rather than 
simply incomplete data entry. That said, all centres were provided with detailed 
instructions for data entry, bespoke to their centre, and understood the 
rationale and aims of the study. Additionally, centre leads and/or those entering 
data were asked to confirm when data entry was completed, hence this 
assumption seems reasonable. The lack of any documented infusion reactions 
with the use of alemtuzumab in the Post-alemtuzumab phase, for example, does 
suggest incomplete data entry however, given that the majority of patients have 
such reactions in all published studies.  
Whilst the number of patients included is relatively small, this is the largest 
known longitudinal dataset of patients switching from natalizumab to 
alemtuzumab. The numbers are not adequate to power robust efficacy 
conclusions, even if this was possible in an observational cohort, but these data 
are the largest single-cohort evidence base from which clinicians can base 
decisions in this subgroup of patients with RRMS. The geographically-limited 
patient inclusion may restrict application to comparable populations but the 
number of MS centres involved makes variable local practices less likely to 
explain outcomes. That said, the majority of patients were from two centres 
(Charing Cross and Dublin) and it is possible that centre-specific populations and 
practices were influential in the overall results in these cases. We did not, for 
example, compare local treatment policies including PML exclusion before 
switching and the use of Listeria prophylaxis. As well as location, the era in 
which some of these patients were treated may limit applicability to a 
contemporary cohort. There have been four MS diagnostic criteria updates since 
the earliest diagnosed patients in this cohort were diagnosed. Additionally, 
approaches to treatment and, specifically, the use of alemtuzumab in clinical 
practice has changed. Its use as a 3rd-, 4th-, or 5th-line therapy is less likely in 
current UK practice, with a move to alemtuzumab being first-line in those with 
rapidly evolving disease rather than a late rescue therapy where the benefits are 
less likely to outweigh risks. It could be argued that the safety results from this 
study may be applicable to sequential use of alemtuzumab after other highly 
effective DMTs, but natalizumab’s mechanism of action as modulator of immune 
cell trafficking, rather than immune reconstitution or induction effects, would 
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not support this. Application is more appropriate to the use of other immune 
reconstitution treatments after natalizumab or other cell-trafficking DMTs 
perhaps, but this is entirely speculative and requires separate investigation. 
 
Study Strengths 
This study provides observational evidence on the safety and efficacy of 
switching to alemtuzumab after natalizumab failure in RRMS from the largest 
cohort of patients with the longest follow-up available in the medical literature. 
This is a unique cohort due to the use of alemtuzumab prior to its licensing in 
the UK and Ireland. The data provide real-world evidence for a common clinical 
scenario which is unlikely to be investigated by a randomised controlled trial. 
The collaborative effort of 13 specialist centres across 4 countries is testament 
to the importance of the issue. We have collected a highly detailed dataset and 
evaluated safety and efficacy using a number of outcomes and analyses. The 
AUC method for EDSS evaluation over time, for example, provides the most 
robust and inclusive analysis possible with the available data.  
 
Other studies assessing switching natalizumab to alemtuzumab 
Our study specifically evaluates the safety and efficacy of switching from 
natalizumab to alemtuzumab due to lack of efficacy, tolerability or safety. 
There is very little literature available to provide an evidence-base for this 
switch and no longitudinal data in a significant dataset to inform its safety or 
efficacy. 
The largest reported cohort of patients switching from natalizumab to 
alemtuzumab comes from a single centre in the USA and included 200 patients 
with follow-up over 6 months242. The outcomes are not reported in the abstract 
but have been presented and are taken here from a recent review243. No 
patients experienced a relapse in the first 6 months post-alemtuzumab and 43% 
of patients with EDSS measurements (n=162) showed improvement; 1% had EDSS 
worsening. MRI data was available for 160 patients and only 3 (2%) demonstrated 
new lesions in this time. Adverse events were considered mild and manageable 
overall but one death occurred in the presence of urinary infection and 
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unrecognised non-convulsive status epilepticus. No PML occurred. In this study, 
the average washout period between natalizumab and alemtuzumab was 9 
weeks. 
McGuigan et al. performed a retrospective audit of their patients in Dublin who 
had received alemtuzumab after natalizumab244. This included 11 patients who 
had been treated between 2009 and 2011. The reason for switching to 
alemtuzumab were either allergic reaction to natalizumab (n=3) or lack of 
efficacy (n=8). All patients predictably had lymphopaenia within the first month 
after alemtuzumab treatment. Reduced white cell count persisted for 3 months 
(without neutropaenia) in 4 patients but this had resolved by month 5 post-
alemtuzumab. In terms of safety, no serious infections occurred and 1 patient 
developed hypothyroidism (9 months post-treatment). ARR was reduced from a 
mean of 2.5 on natalizumab to 0.1 in the first year after alemtuzumab 
treatment. There were no new contrast-enhancing or T2 lesions identified within 
the first year of treatment, despite activity whilst on natalizumab (8 had 
increased T2 lesions and 4 had contrast-enhancing lesions). 
A similar evaluation of patients switching from natalizumab to alemtuzumab has 
been undertaken in Canada245. This multicentre retrospective case record-review 
included 13 patients treated with this sequence in Canada since alemtuzumab 
was approved for use there in December 2013. All patients switched to 
alemtuzumab because of inadequate disease control on natalizumab. The 
definition of this treatment failure is not reported. Mean disease duration was 
9.2 years (range 1.5-28) and mean natalizumab treatment duration was 35 
months (7-132) before the switch. On average, there was a gap of 13.2 weeks (4-
72) between therapies as a washout period and patients had follow-up data 
available for 1 year (range 4-18 months). EDSS was reduced from 3.9 (0-6) on 
natalizumab to 3.6 (0-6) after alemtuzumab. Similarly, ARR reduced from 1.8 to 
0.2. There was one case of hypothyroidism, one case of cystitis and one oral 
candida infection. There were no unexpected adverse events and no serious 
infections but almost all patients reported infusion-related reactions. Disability 
progression occurred in one patient within the first year after alemtuzumab 
treatment but the authors note their 22-year disease duration and that this may 
the missed treatment ‘window of opportunity’ in this case. 
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The most recent study evaluating switching from natalizumab to alemtuzumab 
was published after we completed data collection and was single-centre study 
from Italy246. This included only patients switching from natalizumab because of 
PML concern (N=16) and follow-up was less than 6 months for most, but efficacy 
and safety outcomes were also positive. No new MRI lesions, relapses or 
worsening disability occurred during this short follow-up in those with data 
available. In CARE-MS2, approximately 3% of patients in both the alemtuzumab 
and INF-β1agroups had previously had natalizumab (n=20) but the reason for its 
discontinuation is not stated in the publication and discontinuation at least 6 
months before randomisation was an inclusion criterion120. Notably, a 
prospective study on switching from natalizumab to alemtuzumab is underway in 
the United States presently with the aim of completion at the end of 2019 
(NCT03135249). 
There were no cases of PML in our study, but a single fatal case has been 
reported in a patient who switched from natalizumab to alemtuzumab where 
PML MRI lesions were retrospectively identified and, hence, the condition 
predated alemtuzumab use and was attributed to natalizumab243. There have 
been no other cases of PML using alemtuzumab reported otherwise for RRMS.  
The appropriate ‘washout’ period between stopping natalizumab and starting 
alemtuzumab remains controversial. In CARE-MS II, the 3% of patients switching 
from natalizumab to alemtuzumab had a 6-month washout period. Most now 
agree this is likely too long given the risk of disease reactivation on natalizumab 
discontinuation247 and some authors advise no washout period as the risk of PML 
is so much lower than the risk of a severe relapse243. The European Medicines 
Agency (EMA) suggests a 12-week washout between stopping natalizumab and 
starting another DMT, based on its pharmacodynamic effects. A recent 
observational single-centre study from Italy reported a median of 70 days (range 
41-99) between natalizumab and alemtuzumab in their cohort switching 
between the two246. Overall, expert opinion suggests the washout period should 
be no more than 1-2 months but a robust evidence-base for this is lacking. 
Additionally, however, it is suggested that subclinical PML infection is excluded 
in JCV-positive patients (using MRI and CSF for JCV DNA) prior to initiating 
alemtuzumab given the lack of its reversibility once administered243. 
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The issues surrounding switching patients with RRMS, particularly if JCV-positive, 
have been considered by Giovannoni et al. along with practical suggestions for 
approaches to this strategy248. This group advocates a washout period of less 
than 4 weeks between stopping natalizumab and starting a new DMT in general 
but has a different strategy for alemtuzumab given the risk of subclinical PML. 
Using a ‘bridging’ agent is suggested in order to allow the immune system to 
reconstitute after natalizumab discontinuation, and hence detect and manage 
subclinical PML, whilst still providing treatment for the patient’s often active 
MS. Fingolimod is suggested as the bridging agent of choice but MRI and CSF for 
JCV DNA are routinely undertaken in their centre before starting this. If these 
investigations do not suggest PML, fingolimod is commenced 2-4 weeks after the 
last natalizumab infusion and alemtuzumab 6-12 months thereafter. Our data 
support a switch from natalizumab to alemtuzumab in less than 4 months, 
without the use of a bridging DMT, to maximise disease-free survival and limit 
breakthrough disease activity during the switch. 
Overall, there is a lack of evidence on the best approach to switching from 
natalizumab to alemtuzumab and the literature available is based on small 
cohorts, short follow-up or both. ANSWERS MS provides much needed evidence of 
the safety and efficacy of switching natalizumab to alemtuzumab using real-
world data with long-term follow-up unique to our cohort. 
 
Conclusions 
This real-world multicentre retrospective observational study suggests that 
alemtuzumab is effective when natalizumab fails in patients with active RRMS, 
and that sequencing these treatments does not increase risk beyond what is 
expected with alemtuzumab use first-line. Follow-up of almost 3 years for safety 
outcomes in 79 patients and 4.8 years for efficacy outcomes in 51 patients 
provides the largest dataset with longitudinal outcomes available worldwide for 
this increasingly used treatment strategy. Despite sequential high-efficacy DMTs 
and robust suppression of inflammatory disease activity particularly during the 
first 2 years of alemtuzumab treatment, our cohort had gradually worsening 
disability with time, although this plateaued after alemtuzumab treatment. Our 
data support switching from natalizumab to alemtuzumab directly within at most 
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4 months to maximise disease-free survival, but would caution to balance this 
with safety by excluding (subclinical) PML as far as possible before making the 
switch to an irreversible immunosuppressant. There remains ongoing worldwide 
interest in this approach to treatment with a prospective study now underway in 
the United States which may overcome some of the limitations of our study. 
Until this is reported, however, our data can help guide clinicians to counsel 
patients on the safety and efficacy of switching from natalizumab to 
alemtuzumab in active RRMS. 
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Final conclusions and recommendations 
Based on a sound understanding of the natural history of MS and a detailed 
review of the literature pertaining to DMTs, this thesis has explored current 
treatment strategies at local, national and international levels and their 
potential impact on patients now and in the future. Cohort studies detailing the 
natural history of MS in the pre-treatment era will not be replicated, but provide 
the foundation of understanding against which the utility of treatments is 
measured. However, changes in society, healthcare and MS diagnostic 
definitions, amongst other factors, mean that true comparisons of treatment 
strategies are possible only between contemporary cohorts.  
The lifelong nature of MS and the practicalities of longitudinal interventions and 
data collection limit the use of gold-standard randomised controlled trials in 
establishing the utility of treatments in the long-term, against either placebo or 
each other. The clear short- to medium-term benefits of DMTs in RRMS largely 
preclude further placebo-controlled trials on both ethical and methodological 
grounds, with both clinicians and patients opting for active treatment with 
increasing disease activity. This thesis is therefore part of the growing body of 
work recognising the necessity and utility of (particularly long-term) real-world 
observational studies in determining the true value of MS therapeutics. We have 
provided safety and efficacy data on commonly used DMTs in our centre as well 
as less common sequencing strategies with highly efficacious treatments using 
multicentre data. Additionally, we have demonstrated the variability of DMT use 
within Scotland and the potential impact this can have even within a relatively 
small cohort.  
The pivotal randomised trials of current and emerging therapies in MS have been 
appraised here and the need for ongoing post-licensing evaluation recognised. 
The use of DMTs early in the disease course of MS is supported by current 
literature and our local data, but important safety issues may only emerge once 
treatments are used on a wider scale outwith research trials. Evaluating the 
relatively recent introduction of oral therapies for RRMS in our centre, we have 
found that efficacy outcomes are comparable to that expected from randomised 
trials, but rates of both physical and biochemical side effects were often higher 
than expected and should inform decision-making regarding their use. 
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Using Scottish real-world data, we have established the variability in use of DMTs 
in RRMS, both in terms of their initiation and escalation. We identified variation 
in the use of DMTs in Scotland not accounted for by disease characteristics 
alone, suggesting similar patients are being treated differently for other reasons 
– this is the first time that this variation has been confirmed scientifically, 
though it has long been suspected. As outlined, there is clear support in the 
literature for early DMT initiation in RRMS, raising questions as to why such 
variation exists in Scotland. We also identified evidence of benefit on relapse 
activity in early treated patients, in keeping with the expectation from 
published literature. 
Other decisions in MS therapeutics have much less of an evidence-base, 
specifically sequencing and switching DMTs. With this in mind, we evaluated all 
patients we could identify in the UK & Ireland with longitudinal follow-up after 
switching between two highly effective DMTs, natalizumab and alemtuzumab, to 
clarify the safety and efficacy of this increasingly used approach. Reassuringly, 
we found no new concerning safety signals, and there were clear benefits in 
using alemtuzumab where natalizumab failed in terms of inflammatory disease 
activity. Additionally, we have been able to provide guidance on the switching 
process, suggesting a shorter switch time has efficacy benefits if balanced 
against potential risks.  
Both ANSWERS and MODERATE are examples of the power of collaboration 
between centres, in order to pool data and provide more robust generally 
applicable results than a single centre alone. The limitations common to 
observational studies were not averted entirely in our studies but we have taken 
steps to minimise at least some of these where possible, such as statistical 
matching, to reduce bias. Inherent limitations, particularly unequal follow-up in 
MODERATE, limited conclusions on the impact of treatment variability. 
Meaningful long-term outcomes are what really matters in MS and the prospect 
of future study of both the MODERATE and ANSWERS MS cohorts may provide 
further data to achieve this goal more fully. 
The challenge going forward is to expand the scope and quality of real-world 
observational data so that robust conclusions can be drawn. International, 
multicentre, collaborative studies have already provided the beginnings of this in 
harnessing large datasets to report on safety and efficacy of treatments in a way 
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that short-term randomised trials simply cannot. We hope to use the methods 
and results presented here as a springboard for further pragmatic study of DMTs 
in MS, to enhance our understanding of the role of current and emerging 
therapies in improving the lives of people with MS.  
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Appendices 
Appendix 1: ANSWERS MS database software - Patient table 
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Appendix 2: ANSWERS MS database software - Adding a controller 
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Appendix 3: ANSWERS MS Clinical database outline 
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Appendix 4: ANSWERS MS MRI database outline 
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Appendix 5: ANSWERS MS Data Flow map 
 
 
  
   
 
370 
References 
 
1. World Health Organisation. Atlas: Multiple Sclerosis Resources in the 
World. Vasa (2008). doi:ISBN 978 92 4 156375 8 
2. Trisolini M, Honeycutt A, Wiener J, L. S. Global Economic Impact of 
Multiple Sclerosis. Mult. Scler. Int. Fed. (2010). 
3. Koch-Henriksen, N. & Sørensen, P. S. The changing demographic pattern of 
multiple sclerosis epidemiology. Lancet Neurol. 9, 520–532 (2010). 
4. Pugliatti, M. et al. The epidemiology of multiple sclerosis in Europe. Eur. 
J. Neurol. 13, 700–722 (2006). 
5. Lucchinetti, C. et al. Heterogeneity of multiple sclerosis lesions: 
Implications for the pathogenesis of demyelination. Ann. Neurol. 47, 707–
717 (2000). 
6. König, F. B. et al. Persistence of immunopathological and radiological 
traits in multiple sclerosis. Arch. Neurol. 65, 1527–32 (2008). 
7. Metz, I. et al. Pathologic heterogeneity persists in early active multiple 
sclerosis lesions. Ann. Neurol. 75, 728–738 (2014). 
8. Keegan, M. et al. Relation between humoral pathological changes in 
multiple sclerosis and response to therapeutic plasma exchange. Lancet 
(London, England) 366, 579–82 (2005). 
9. Pittock, S. J. et al. Clinical course, pathological correlations, and outcome 
of biopsy proved inflammatory demyelinating disease. J. Neurol. 
Neurosurg. Psychiatry 76, 1693–7 (2005). 
10. Goodin, D. S. Magnetic resonance imaging as a surrogate outcome measure 
of disability in multiple sclerosis: Have we been overly harsh in our 
assessment? Ann. Neurol. 59, 597–605 (2006). 
11. Palace, J. et al. Effectiveness and cost-effectiveness of interferon beta 
and glatiramer acetate in the UK Multiple Sclerosis Risk Sharing Scheme at 
6 years: a clinical cohort study with natural history comparator. Lancet 
Neurol. 14, 497–505 (2015). 
   
 
371 
12. Weinshenker, B. G. et al. The natural history of multiple sclerosis: a 
geographically based study. 2. Predictive value of the early clinical course. 
Brain 112 ( Pt 6, 1419–1428 (1989). 
13. Confavreux, C., Vukusic, S. & Adeleine, P. Early clinical predictors and 
progression of irreversible disability in multiple sclerosis: An amnesic 
process. Brain 126, 770–782 (2003). 
14. Pittock, S. J. et al. Disability profile of MS did not change over 10 years in 
a population-based prevalence cohort. Neurology 62, 601–606 (2004). 
15. Tremlett, H., Paty, D. & Devonshire, V. Disability progression in multiple 
sclerosis is slower than previously reported. Neurology 66, 172–177 (2006). 
16. Brown, M. G. et al. Estimating typical multiple sclerosis disability 
progression speed from clinical observations. PLoS One 9, (2014). 
17. Leray, E. et al. Evidence for a two-stage disability progression in multiple 
sclerosis. Brain 133, 1900–1913 (2010). 
18. Debouverie, M., Pittion-Vouyovitch, S., Louis, S. & Guillemin, F. Natural 
history of multiple sclerosis in a population-based cohort. Eur. J. Neurol. 
15, 916–921 (2008). 
19. Debouverie, M., Louis, S., Pittion-Vouyovitch, S., Roederer, T. & 
Vespignani, H. Multiple sclerosis with a progressive course from onset in 
Lorraine-Eastern France. J. Neurol. 254, 1370–1375 (2007). 
20. Tremlett, H., Zhao, Y., Rieckmann, P. & Hutchinson, M. New perspectives 
in the natural history of multiple sclerosis. Neurology 74, 2004–2015 
(2010). 
21. Weinshenker, B. G. et al. The natural history of multiple sclerosis: a 
geographically based study. I. Clinical course and disability. Brain 112 ( Pt 
1, 133–46 (1989). 
22. Poser, C. M. et al. New diagnostic criteria for multiple sclerosis: guidelines 
for research protocols. Ann. Neurol. 13, 227–231 (1983). 
23. McDonald, W. I. et al. Recommended diagnostic criteria for multiple 
   
 
372 
sclerosis: Guidelines from the International Panel on the Diagnosis of 
Multiple Sclerosis. Ann. Neurol. 50, 121–127 (2001). 
24. Weinshenker, B. G. et al. The natural history of multiple sclerosis: a 
geographically based study. 3. Multivariate analysis of predictive factors 
and models of outcome. Brain 114 ( Pt 2, 1045–1056 (1991). 
25. Kurtzke, J. F. A new scale for evaluating disability in multiple sclerosis. 
Neurology 5, 580–583 (1955). 
26. Kurtzke, J. F. Rating neurologic impairment in multiple sclerosis: An 
expnaded disability status scale (EDSS). Neurology 15, 654–661 (1983). 
27. Bonduellle, M. & Albaranes, R. Etude statistique de 145 cas de la sclerose 
en plaque. Sem Hop Paris 38, 3762–3773 (1962). 
28. Minderhoud, J. M., van der Hoeven, J. H. & Prange,  a J. Course and 
prognosis of chronic progressive multiple sclerosis. Results of an 
epidemiological study. Acta Neurol. Scand. 78, 10–15 (1988). 
29. Cottrell, D. A. et al. The natural history of multiple sclerosis: a 
geographically based study. 5. The clinical features and natural history of 
primary progressive multiple sclerosis. Brain 122 ( Pt 4, 625–639 (1999). 
30. Kremenchutzky, M. et al. The natural history of multiple sclerosis: a 
geographically based study. 7. Progressive-relapsing and relapsing-
progressive multiple sclerosis: a re-evaluation. Brain 122 ( Pt 1, 1941–1950 
(1999). 
31. Kremenchutzky, M., Rice, G. P. A., Baskerville, J., Wingerchuk, D. M. & 
Ebers, G. C. The natural history of multiple sclerosis: A geographically 
based study 9: Observations on the progressive phase of the disease. Brain 
129, 584–594 (2006). 
32. Scalfari, A. et al. The natural history of multiple sclerosis, a geographically 
based study 10: Relapses and long-term disability. Brain 133, 1914–1929 
(2010). 
33. Tremlett, H., Yousefi, M., Devonshire, V., Rieckmann, P. & Zhao, Y. 
Impact of multiple sclerosis relapses on progression diminishes with time. 
   
 
373 
Neurology 73, 1616–1623 (2009). 
34. Lublin, F. D., Baier, M. & Cutter, G. Effect of relapses on development of 
residual deficit in multiple sclerosis. Neurology 61, 1528–1532 (2003). 
35. Kalincik, T. et al. Defining reliable disability outcomes in multiple 
sclerosis. Brain 138, 3287–3298 (2015). 
36. Liu, C. & Blumhardt, L. D. Disability outcome measures in therapeutic 
trials of relapsing-remitting multiple sclerosis: effects of heterogeneity of 
disease course in placebo cohorts. J. Neurol. Neurosurg. Psychiatry 68, 
450–457 (2000). 
37. Tremlett, H., Zhao, Y., Joseph, J. & Devonshire, V. Relapses in multiple 
sclerosis are age- and time-dependent. J. Neurol. Neurosurg. Psychiatry 
79, 1368–1374 (2008). 
38. Murray, T. J. The history of multiple sclerosis: the changing frame of the 
disease over the centuries. J. Neurol. Sci. 277, (2009). 
39. Brain, R. Critical review: disseminating sclerosis. Q. J. Med. 23, 343 
(1930). 
40. Miller, H., Newewll, D. & Ridley, A. Multiple Sclerosis: Trials of 
maintenance treatment with prednisolone and soluble aspirin. Lancet 1, 
127–9 (1961). 
41. Brown, J. R. et al. The design of clinical studies to assess therapeutic 
efficacy in multiple sclerosis. Neurology 29, 3–23 (1979). 
42. Schumacher, G., Beebe, G., Kibler, R. & Kurland, L. Problems of 
experimental trials of therapy in multiple sclerosis. Ann. N. Y. Acad. Sci. 
122, 552–68 (1965). 
43. Goodin, D. S. Disease-modifying therapy in MS: a critical review of the 
literature. Part I: Analysis of clinical trial errors. J. Neurol. 251 Suppl, v3–
v11 (2004). 
44. Montalban, X. Review of methodological issues of clinical trials in multiple 
sclerosis. J. Neurol. Sci. 311, (2011). 
   
 
374 
45. Goodin, D. S. Disease-modifying therapy in MS: A critical review of the 
literature. Part II: Assessing efficacy and dose-response. in Journal of 
Neurology, Supplement 251, (2004). 
46. Goodman, S. N. p Values, Hypothesis Tests, and Likelihood: Implications 
for Epidemiology of a Neglected Historical Debate. Am. J. Epidemiol. 137, 
485–501 (1993). 
47. Panitch, H. et al. Randomized, comparative study of interferon beta-1a 
treatment regimens in MS: The EVIDENCE Trial. Neurology 59, 1496–1506 
(2002). 
48. Van Walraven, C., Davis, D., Forster, A. J. & Wells, G. A. Time-dependent 
bias was common in survival analyses published in leading clinical journals. 
J. Clin. Epidemiol. 57, 672–682 (2004). 
49. Cohen, J. a et al. Alemtuzumab versus interferon beta 1a as first-line 
treatment for patients with relapsing-remitting multiple sclerosis: a 
randomised controlled phase 3 trial. Lancet 380, 1819–28 (2012). 
50. Dahdaleh, D. & Sharrack, B. We can compare the relative efficacy of 
multiple sclerosis medications by examining the results of indpendent 
clinical trials: Yes. Mult. Scler. J. 21, 35–36 (2015). 
51. Ciccarelli, O. & Chataway, J. We can compare the relative efficacy of 
multiple sclerosis medications by examining the results of indpendent 
clinical trials: No. Mult. Scler. J. 21, 37–38 (2015). 
52. Tramacere, I., Del Giovane, C., Salanti, G., D’Amico, R. & Filippini, G. 
Immunomodulators and immunosuppressants for multiple sclerosis: a 
network meta-analysis. Cochrane database Syst. Rev. CD011381 (2015). 
doi:10.1002/14651858.CD008933.pub2 
53. Del Santo, F., Maratea, D., Fadda, V., Trippoli, S. & Messori, A. 
Treatments for relapsing-remitting multiple sclerosis: Summarising current 
information by network meta-analysis. Eur. J. Clin. Pharmacol. 68, 441–
448 (2012). 
54. Benson, K. & Hartz, A. J. A comparison of observational studies and 
   
 
375 
randomized, controlled trials. N. Engl. J. Med. 342, 1878–86 (2000). 
55. Montalban, X. Review of methodological issues of clinical trials in multiple 
sclerosis. J. Neurol. Sci. 311, S35–S42 (2011). 
56. Fogarty, E., Schmitz, S., Tubridy, N., Walsh, C. & Barry, M. Comparaitve 
efficacy of disease-modifying therapies for patients with relapsing 
remitting multiple sclerosis: systematic review and network meta-analysis. 
Mult. Scler. Relat. Disord. 9, 23–30 (2016). 
57. Jacobs, L. D. et al. Intramuscular interferon beta-1a for disease 
progression in relapsing multiple sclerosis. The Multiple Sclerosis 
Collaborative Research Group (MSCRG). Ann. Neurol. 39, 285–294 (1996). 
58. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in 
relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, 
randomized, double-blind, placebo-controlled trial. Neurology 43, 655–661 
(1993). 
59. Ebers, G. C. Randomised double-blind placebo-controlled study of 
interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS 
(Prevention of Relapses and Disability by Interferon beta-1a 
Subcutaneously in Multiple Sclerosis) Study Group. Lancet 352, 1498–504 
(1998). 
60. Calabresi, P. A. et al. Pegylated interferon beta-1a for relapsing-remitting 
multiple sclerosis (ADVANCE): A randomised, phase 3, double-blind study. 
Lancet Neurol. 13, 657–665 (2014). 
61. Johnson, K. P. et al. Copolymer 1 reduces relapse rate and improves 
disability in relapsing-remitting multiple sclerosis: results of a phase III 
multicenter, double-blind placebo-controlled trial. The Copolymer 1 
Multiple Sclerosis Study Group. Neurology 45, 1268–1276 (1995). 
62. O’Connor, P. et al. Randomized trial of oral teriflunomide for relapsing 
multiple sclerosis. N. Engl. J. Med. 365, 1293–303 (2011). 
63. Confavreux, C. et al. Oral teriflunomide for patients with relapsing 
multiple sclerosis (TOWER): A randomised, double-blind, placebo-
   
 
376 
controlled, phase 3 trial. Lancet Neurol. 13, 247–256 (2014). 
64. Gold, R. et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing 
multiple sclerosis. N. Engl. J. Med. 367, 1098–107 (2012). 
65. Fox, R. J. et al. Placebo-controlled phase 3 study of oral BG-12 or 
glatiramer in multiple sclerosis. N. Engl. J. Med. 367, 1087–97 (2012). 
66. Kappos, L. et al. A placebo-controlled trial of oral fingolimod in relapsing 
multiple sclerosis. N. Engl. J. Med. 362, 387–401 (2010). 
67. Calabresi, P. a et al. Safety and efficacy of fingolimod in patients with 
relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, 
randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 13, 545–56 
(2014). 
68. Polman, C. H. et al. A randomized, placebo-controlled trial of natalizumab 
for relapsing multiple sclerosis. N. Engl. J. Med. 354, 899–910 (2006). 
69. Cohen, J. A. et al. Alemtuzumab versus interferon beta 1a as first-line 
treatment for patients with relapsing-remitting multiple sclerosis: a 
randomised controlled phase 3 trial. Lancet 380, 1819–1828 (2012). 
70. Coles, A. J. et al. Alemtuzumab for patients with relapsing multiple 
sclerosis after disease-modifying therapy: A randomised controlled phase 3 
trial. Lancet 380, 1829–1839 (2012). 
71. Hauser, S. L., Bar-Or, A., Comi, G. & Giovannoni, G. Ocrelizumab versus 
Interferon Beta-1a in Relapsing Multiple Sclerosis. N. Engl. J. Med. 376, 
221–34 (2017). 
72. Giovannoni, G. et al. A placebo-controlled trial of oral cladribine for 
relapsing multiple sclerosis. N. Engl. J. Med. 362, 416–426 (2010). 
73. Comi, G. et al. Placebo-controlled trial of oral laquinimod for multiple 
sclerosis. Supplementary Appendix. N. Engl. J. Med. 366, 1000–9 (2012). 
74. Gold, R. et al. Daclizumab high-yield process in relapsing-remitting 
multiple sclerosis (SELECT): A randomised, double-blind, placebo-
controlled trial. Lancet 381, 2167–75 (2013). 
   
 
377 
75. European Medicines Agency. EMA review of Zinbryta confirms medicine’s 
risks outweigh its benefits. (2018). 
76. Meuth, S. et al. Therapeutic approaches to multiple sclerosis: an update 
on failed, interrupted or inconclusive trials of neuroprotective and 
alternative treatment strategies. Biodrugs 24, 317–330 (2010). 
77. Cadavid, D. et al. Efficacy and analysis of opicinumab in relapsing 
remitting multiple sclerosis: The phase 2b SYNERGY trial. Mult. Scler. 22, 
66 (2016). 
78. Raftopoulos, R. et al. Phenytoin for neuroprotection in patients with acute 
optic neuritis: a randomised, placebo-controlled, phase 2 trial. Lancet 
Neurol. 15, 259–69 (2016). 
79. Metz, L. M. et al. Trial of minocycline in a clinically isolated syndrome of 
multiple sclerosis. N. Engl. J. Med. 376, 2122–33 (2017). 
80. Green, A. J. et al. Clemastine fumarate as a remyelinating therapy for 
multiple sclerosis (ReBUILD): a randomised, controlled, double-blind, 
crossover trial. Lancet 390, 2481–89 (2017). 
81. Montalban, X., Hauser, S. L., Kappos, L., Arnold, D. L. & Bar-Or, A. 
Ocrelizumab versus placebo in primary progressive multiple sclerosis. N. 
Engl. J. Med. 376, 209–20 (2017). 
82. Kappos, L. et al. Siponimod versus placebo in secondary progressive 
multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. 
Lancet 391, 1263–73 (2018). 
83. Tourbah, A. et al. MD1003 (high-dose biotin) for the treatment of 
progressive multiple sclerosis: A randomised, double-blind, placebo-
controlled study. Mult. Scler. 22, 1719–1731 (2016). 
84. Giovannoni, G. et al. Is multiple sclerosis a length-dependent central 
axonopathy? The case for therapeutic lag and the asynchronous progressive 
MS hypotheses. Mult. Scler. Relat. Disord. 12, 70–78 (2017). 
85. Marrie, R. A., Cohen, J. & Stuve, O. A systematic review of the incidence 
and prevalance of comorbidity in multiple sclerosis. Mult. Scler. 1–19 
   
 
378 
(2015). doi:10.1177/ 1352458514564491 
86. Thompson, P. A., Banwell, M. P. B., Barkhof, P. F. & Et.al. Diagnosis of 
multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 
17, 162–173 (2018). 
87. Okuda, D. T. et al. Incidental MRI anomalies suggestive of multiple 
sclerosis: The radiologically isolated syndrome. Neurology 72, 800–805 
(2009). 
88. Granberg, T., Martola, J., Kristoffersen-Wiberg, M., Aspelin, P. & 
Fredrikson, S. Radiologically isolated syndrome - incidental magnetic 
resonance imaging findings suggestive of multiple sclerosis, a systematic 
review. Mult. Scler. J. 19, 271–80 (2013). 
89. Sorensen, P. S. Early-stage multiple sclerosis: What are the treatment 
options? Drugs 64, 2021–2029 (2004). 
90. Tuohy, V. K. et al. The epitope spreading cascade during progression of 
experimental autoimmune encephalomyelitis and multiple sclerosis. 
Immunol. Rev. 164, 93–100 (1998). 
91. Trapp, B. D. et al. Axonal transection in the lesions of multiple sclerosis. 
N. Engl. J. Med. 338, 278–285 (1998). 
92. Kuhlmann, T., Lingfeld, G., Bitsch, A., Schuchardt, J. & Brück, W. Acute 
axonal damage in multiple sclerosis is most extensive in early disease 
stages and decreases over time. Brain 125, 2202–2212 (2002). 
93. Brex, P. A. et al. Detection of ventricular enlargement in patients at the 
earliest clinical stage of MS. Neurology 54, 1689–1691 (2000). 
94. Audoin, B. et al. Onset and underpinnings of white matter atrophy at the 
very early stage of multiple sclerosis - a two-year longitudinal MRI/MRSI 
study of corpus callosum. Mult. Scler. 13, 41–51 (2007). 
95. Liu, C., Edwards, S., Gong, Q., Roberts, N. & Blumhardt, L. D. Three 
dimensional MRI estimates of brain and spinal cord atrophy in multiple 
sclerosis. J Neurol Neurosurg Psychiatry 66, 323–330 (1999). 
   
 
379 
96. Schlaeger, R. et al. Spinal cord gray matter atrophy correlates with 
multiple sclerosis disability. Annals of Neurology (2014). 
doi:10.1002/ana.24241 
97. Fisher, E. et al. Eight-year follow-up study of brain atrophy in patients 
with MS. Neurology 59, 1412–1420 (2002). 
98. Sormani, M. P., Arnold, D. L. & De Stefano, N. Treatment effect on brain 
atrophy correlates with treatment effect on disability in multiple sclerosis. 
Ann. Neurol. 75, 43–49 (2014). 
99. Coles, A. J. et al. The window of therapeutic opportunity in multiple 
sclerosis: Evidence from monoclonal antibody therapy. J. Neurol. 253, 98–
108 (2006). 
100. Lorscheider, J. et al. Defining secondary progressive multiple sclerosis. 
Brain 139, 2395–2405 (2016). 
101. Lublin, F. D. et al. Defining the clinical course of multiple sclerosis: The 
2013 revisions. Neurology 83, 278–286 (2014). 
102. Nicoletti, F. et al. Elevated serum levels of interleukin-12 in chronic 
progressive multiple sclerosis. J. Neuroimmunol. 70, 87–90 (1996). 
103. Jacobs, L. D. et al. Intramuscular interferon beta-1a therapy initiated 
during a first demyelinating event in multiple sclerosis. CHAMPS Study 
Group. N. Engl. J. Med. 343, 898–904 (2000). 
104. Comi, G. et al. Effect of early interferon treatment on conversion to 
definite multiple sclerosis: A randomised study. Lancet 357, 1576–1582 
(2001). 
105. Kappos, L. et al. Treatment with interferon beta-1b delays conversion to 
clinically definite and McDonald MS in patients with clinically isolated 
syndromes. Neurology 67, 1242–1249 (2006). 
106. Comi, G. et al. Effect of glatiramer acetate on conversion to clinically 
definite multiple sclerosis in patients with clinically isolated syndrome 
(PreCISe study): a randomised, double-blind, placebo-controlled trial. 
Lancet 374, 1503–1511 (2009). 
   
 
380 
107. Kappos, L. et al. Long-term subcutaneous interferon beta-1a therapy in 
patients with relapsing-remitting MS. Neurology 67, 944–953 (2006). 
108. Goodin, D. S. et al. Relationship between early clinical characteristics and 
long term disability outcomes: 16 year cohort study (follow-up) of the 
pivotal interferon β-1b trial in multiple sclerosis. J. Neurol. Neurosurg. 
Psychiatry 83, 282–7 (2012). 
109. Goodin, D. S. et al. Survival in MS A randomized cohort study 21 years 
after the start of the pivotal IFN-1b trial. Neurology 78, 1315–1322 (2012). 
110. Chalmer, T. A. et al. Early versus later treatment start in multiple 
sclerosis: a register-based cohort study. Eur. J. Neurol. 25, 1262–1270 
(2018). 
111. Trojano, M. et al. New natural history of interferon-beta-treated relapsing 
multiple sclerosis. Ann. Neurol. 61, 300–306 (2007). 
112. Freedman, M. S. Induction vs. escalation of therapy for relapsing Multiple 
Sclerosis: The evidence. Neurol. Sci. 29, (2008). 
113. Rieckmann, P. Concepts of induction and escalation therapy in multiple 
sclerosis. J. Neurol. Sci. 277, (2009). 
114. Coles, A. J. et al. Pulsed monoclonal antibody treatment and autoimmune 
thyroid disease in multiple sclerosis. Lancet 354, 1691–1695 (1999). 
115. Jayne, D. Challenges in the management of microscopic polyangiitis: past, 
present and future. Curr. Opin. Rheumatol. 20, 3–9 (2008). 
116. Pui, C.-H. & Evans, W. E. Treatment of acute lymphoblastic leukemia. N. 
Engl. J. Med. 354, 166–178 (2006). 
117. Hauser, S. et al. B-Cell Depletion with Rituximab in Relapsing–Remitting 
Multiple Sclerosis. N. Engl. J. Med. 358, 676–88 (2008). 
118. Salzer, J. et al. Rituximab in multiple sclerosis. Neurology 87, 2074–2081 
(2016). 
119. Montalbán, X., Hauser, S. L., Kappos, L. & Arnold, D. L. Ocrelizumab 
versus Placebo in Primary Progressive Multiple Sclerosis. N. Engl. J. Med. 
   
 
381 
376, 209–20 (2017). 
120. Coles, A. J. et al. Alemtuzumab for patients with relapsing multiple 
sclerosis after disease-modifying therapy: a randomised controlled phase 3 
trial. Lancet 380, 1829–39 (2012). 
121. Rudick, R. A. et al. Natalizumab plus Interferon Beta-1a for Relapsing 
Multiple Sclerosis. N. Engl. J. Med. 354, 911–923 (2006). 
122. Goodman, A. D. et al. Glance: Results of a phase 2, randomized, double-
blind, placebo-controlled study. Neurology 72, 806–812 (2009). 
123. Cohen, J. A. et al. Oral fingolimod or intramuscular interferon for 
relapsing multiple sclerosis. N. Engl. J. Med. 362, 402–415 (2010). 
124. Vermersch, P. et al. Teriflunomide versus subcutaneous interferon beta-1a 
in patients with relapsing multiple sclerosis: a randomised, controlled 
phase 3 trial. Mult. Scler. 20, 705–716 (2014). 
125. Durelli, L. et al. Every-other-day interferon beta-1b versus once-weekly 
interferon beta-1a for multiple sclerosis: Results of a 2-year prospective 
randomised multicentre study (INCOMIN). Lancet 359, 1453–1460 (2002). 
126. Mikol, D., Barkhof, F., Chang, P. & Coyle, P. Comparison of subcutaneous 
interferon beta-1a with glatiramer acetate in patients with relapsng 
multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease 
[REGARD] study): a multicentre, randomsed, parallel,open-label trial. 
Lancet Neurol. 7, 903–14 (2008). 
127. O’Connor, P. et al. 250 Microg or 500 Microg Interferon Beta-1B Versus 20 
Mg Glatiramer Acetate in Relapsing-Remitting Multiple Sclerosis: a 
Prospective, Randomised, Multicentre Study. Lancet Neurol. 8, 889–97 
(2009). 
128. MHRA. Fingolimod (Gilenya▼): risks of progressive multifocal 
leukoencephalopathy, basal-cell carcinoma, and opportunistic infections. 
Available at: https://www.gov.uk/drug-safety-update/fingolimod-gilenya-
risks-of-progressive-multifocal-leukoencephalopathy-basal-cell-carcinoma-
and-opportunistic-infections.  
   
 
382 
129. MHRA. Dimethyl fumarate (Tecfidera): updated advice on risk of 
progressive multifocal leukoencephalopathy. Available at: 
https://www.gov.uk/drug-safety-update/dimethyl-fumarate-tecfidera-
updated-advice-on-risk-of-progressive-multifocal-leukoencephalopathy.  
130. Rio, J. Any evident MRI T2 lesion activity should guide change of therapy in 
multiple sclerosis: No. Mult. Scler. J. 21, 132–133 (2015). 
131. Giovannoni, G. Any evident MRI T2 lesion activity should guide change of 
therapy in multiple sclerosis: Yes. Mutiple Scler. J. 21, 124–126 (2015). 
132. Bermel, R. A. et al. Predictors of long-term outcome in multiple sclerosis 
patients treated with interferon beta. Ann. Neurol. 73, 95–103 (2013). 
133. Sormani, M. P. & De Stefano, N. Defining and scoring response to IFN-β in 
multiple sclerosis. Nat. Rev. Neurol. 9, 504–12 (2013). 
134. Horakova, D. et al. Early predictors of non-response to interferon in 
multiple sclerosis. Acta Neurol. Scand. 126, 390–397 (2012). 
135. Prosperini, L. et al. Interferon beta failure predicted by EMA criteria or 
isolated MRI activity in multiple sclerosis. Mult. Scler. 20, 566–76 (2014). 
136. Sormani, M. P. et al. Assessing response to interferon-Beta in a 
multicenter dataset of patients with MS. Neurology 87, 134–140 (2016). 
137. Freedman, M. S. et al. Treatment optimization in MS: Canadian MS 
Working Group updated recommendations. Can. J. Neurol. Sci. 40, 307–23 
(2013). 
138. Sormani, M. P. et al. Scoring treatment response in patients with relapsing 
multiple sclerosis. Mult. Scler. 19, 605–12 (2013). 
139. Ebers, G. C. Randomised double-blind placebo-controlled study of 
interferon β-1a in relapsing/remitting multiple sclerosis. The Lancet 352, 
1498–1504 (1998). 
140. Jacobs, L. et al. Intramuscular interferon beta‐1a for disease progression 
in relapsing multiple sclerosis. Ann. Neurol. 39, 285–294 (1996). 
141. Kalincik, T. et al. Interferon, azathioprine and corticosteroids in multiple 
   
 
383 
sclerosis: 6-year follow-up of the ASA cohort. Clin. Neurol. Neurosurg. 
114, 940–946 (2012). 
142. Davis, M., Ashtamker, N., Steinerman, J. & Knappertz, V. Time course of 
glatiramer acetate efficacy in patients with RRMS in the GALA study. 
Neurol. Neuroimmunol. Neuroinflammation 4, e327 (2017). 
143. Calabresi, P. a et al. The incidence and significance of anti-natalizumab 
antibodies. Neurology 69, 1391–1403 (2007). 
144. Prosperini, L. et al. Escalation to natalizumab or switching among 
immunomodulators in relapsing multiple sclerosis. Mult. Scler. J. 18, 64–71 
(2012). 
145. Spelman, T. et al. Comparative efficacy of switching to natalizumab in 
active multiple sclerosis. Ann. Clin. Transl. Neurol. 2, 373–387 (2015). 
146. D’Amico, E., Leone, C., Zanghi, A., Fermo, S. Lo & Patti, F. Lateral and 
escalation therapy in relapsing-remitting multiple sclerosis: a comparative 
study. J. Neurol. 263, 1802–1809 (2016). 
147. Spelman, T. et al. Risk of early relapse following the switch from 
injectables to oral agents for multiple sclerosis. Eur. J. Neurol. 23, 729–
736 (2016). 
148. Trojano, M., Tintoré, M., Montalbán, X. & Hillert, J. Treatment decisions 
in multipe sclerosis- insights from real-world observational studies. Nat. 
Rev. Neurol. 13, 105–118 (2017). 
149. Ingwersen, J. et al. Fingolimod in multiple sclerosis: Mechanisms of action 
and clinical efficacy. Clinical Immunology 142, 15–24 (2012). 
150. Subei, A. M. & Cohen, J. A. Sphingosine 1-Phosphate Receptor Modulators 
in Multiple Sclerosis. CNS Drugs 29, 565–575 (2015). 
151. Zarbin, M. A. et al. Ophthalmic evaluations in clinical studies of fingolimod 
(FTY720) in multiple sclerosis. Ophthalmology 120, 1432–1439 (2013). 
152. Novartis Pharmaceuticals UK Ltd. Gilenya 0.5mg hard capsules - Summary 
of Product Charcateristics. Available at: 
   
 
384 
https://www.medicines.org.uk/EMC/medicine/24443/SPC/Gilenya+0.5mg
+hard+capsules.  
153. Scottish Medicines Consortium. Fingolimod (as hydrochloride), 0.5mg hard 
capsules (Gilenya). (2012). Available at: 
https://www.scottishmedicines.org.uk/files/advice/fingolimod_Gilenya_R
ESUBMISSION_FINAL_August_2012_amended_30.08.12.pdf.  
154. Rosenkranz, T., Novas, M. & Terborg, C. PML in a Patient with 
Lymphocytopenia Treated with Dimethyl Fumarate. N. Engl. J. Med. 372, 
1476–1478 (2015). 
155. Gyang, T. V., Hamel, J., Goodman, A. D., Gross, R. A. & Samkoff, L. 
Fingolimod-associated PML in a patient with prior immunosuppression. 
Neurology 86, 1843–45 (2016). 
156. Fox, R. J. et al. Characterizing absolute lymphocyte count profiles in 
dimethyl fumarate’treated patients with MS Patient management 
considerations. Neurol. Clin. Pract. 6, 220–229 (2016). 
157. Hunt, D., Kavanagh, D., Drummond, I. & Weller, B. Thrombotic 
microangiopathy associated with interferon beta. N. Engl. J. Med. 370, 
1270 [Letter] (2014). 
158. Río, J. et al. Measures in the first year of therapy predict the response to 
interferon β in MS. Mult. Scler. 15, 848–853 (2009). 
159. Spelman, T. et al. Comparative efficacy of first-line natalizumab vs IFN-β 
or glatiramer acetate in relapsing MS. Neurol. Clin. Pract. 6, 102–115 
(2016). 
160. Richards, R. Interferon beta in multiple sclerosis. BMJ 313, 1159 (1996). 
161. Taylor, D. Funding medicines for people with multiple sclerosis. BMJ 323, 
1379–80 (2001). 
162. Richards, R. The multiple sclerosis risk sharing scheme - Plus ca change, 
plus ca meme chose. BMJ 340, 2882 (2010). 
163. Rafferty, J. Multiple sclerosis risk sharing scheme: a costly failure. BMJ 
   
 
385 
340, 1672 (2010). 
164. Confavreux, C. & Vukusic, S. Natural history of multiple sclerosis: a 
unifying concept. Brain 129, 606–616 (2006). 
165. Casserly, C. & Ebers, G. Relapses do not matter in relation to long-term 
disability: Yes. Mult. Scler. J. 17, 1412–1414 (2011). 
166. Ebers, G. C., Heigenhauser, L., Daumer, M., Lederer, C. & Noseworthy, J. 
H. Disability as an outcome in MS clinical trials. Neurology 71, 624–631 
(2008). 
167. Shirani, A. et al. Association between use of interferon beta and 
progression of disability in patients with relapsing-remitting multiple 
sclerosis. JAMA 308, 247–56 (2012). 
168. Drulovic, J. et al. Interferon-beta and disability progression in relapsing-
remitting multiple sclerosis. Clin. Neurol. Neurosurg. 115, (2013). 
169. Simon, J. H. et al. A longitudinal study of brain atrophy in relapsing 
multiple sclerosis. Neurology 53, 139–139 (1999). 
170. Zipoli, V. et al. Cognitive impairment predicts conversion to multiple 
sclerosis in clinically isolated syndromes. Multiple sclerosis (Houndmills, 
Basingstoke, England) 16, (2010). 
171. Popescu, V. et al. Brain atrophy and lesion load predict long term 
disability in multiple sclerosis. J Neurol Neurosurg Psychiatry 84, 1082–
1091 (2013). 
172. Cohen, J. et al. Fingolimod effect on brain atrophy and clinical/MRI 
correlations in three phase 3 studies - TRANSFORMS, FREEDOMS and 
FREEDOMS II. in AAN (2013). 
173. Coles, A. J. Alemtuzumab slows brain volume loss over 4 years despite 
most relapsing-remitting multiple sclerosis patients not receiving 
treatment for 3 years. Neurology 84, Supplement P7.263 (2015). 
174. Portaccio, E. et al. Natalizumab may reduce cognitive changes and brain 
atrophy rate in relapsing-remitting multiple sclerosis: A prospective, non-
   
 
386 
randomized pilot study. Eur. J. Neurol. 20, 986–990 (2013). 
175. Rudick, R. A., Fisher, E., Lee, J. C., Simon, J. & Jacobs, L. Use of the 
brain parenchymal fraction to measure whole brain atrophy in relapsing-
remitting MS. Multiple Sclerosis Collaborative Research Group. Neurology 
53, (1999). 
176. Fisniku, L. K. et al. Disability and T2 MRI lesions: A 20-year follow-up of 
patients with relapse onset of multiple sclerosis. Brain 131, 808–817 
(2008). 
177. Pittock, S. J. et al. Clinical implications of benign multiple sclerosis: A 20-
year population-based follow-up study. Ann. Neurol. 56, 303–306 (2004). 
178. Amato, M. P. & Portaccio, E. Truly benign multiple sclerosis is rare. Mult. 
Scler. J. 18, 13–14 (2012). 
179. Gajofatto, A., Turatti, M., Bianchi, M. & Forlivesi, S. Benign multiple 
sclerosis: physical and cognitive impairment follow distinct evoilutions. 
Acta Neurol. Scand. doi:10.1111/ane.1242 
180. Degenhardt, A., Ramagopalan, S. V, Scalfari, A. & Ebers, G. C. Clinical 
prognostic factors in multiple sclerosis: a natural history review. Nat. Rev. 
Neurol. 5, 672–682 (2009). 
181. Langer-Gould, A. et al. Clinical and demographic predictors of long-term 
disability in patients with relapsing-remitting multiple sclerosis: a 
systematic review. Arch. Neurol. 63, 1686–1691 (2006). 
182. Bergamaschi R, Montomoli C, M. G. BREMSO: a simple clinical score for the 
early prediction of multiple sclerosis long-term evolution. ECTRIMS (2013). 
183. Polman, C. H. et al. Diagnostic criteria for multiple sclerosis: 2010 
Revisions to the McDonald criteria. Ann. Neurol. 69, 292–302 (2011). 
184. Freedman, M. S. Do not treat from CIS onset: evaluate disease course and 
prognosis first: No (treat). Mult. Scler. J. 18, 394–395 (2012). 
185. Bunyan, R. F. & Pittock, S. J. Do not treat from CIS onset: evaluate disease 
course and prognosis first: Yes. Mult. Scler. J. 18, 391–393 (2012). 
   
 
387 
186. Langer-Gould, A., Atlas, S. W., Green, A. J., Bollen, A. W. & Pelletier, D. 
Progressive multifocal leukoencephalopathy in a patient treated with 
natalizumab. The New England journal of medicine 353, 375–381 (2005). 
187. Kleinschmidt-DeMasters, B. K. & Tyler, K. L. Progressive multifocal 
leukoencephalopathy complicating treatment with natalizumab and 
interferon beta-1a for multiple sclerosis. The New England journal of 
medicine 353, 369–374 (2005). 
188. Bloomgren, G. et al. Risk of Natalizumab-Associated Progressive Multifocal 
Leukoencephalopathy. New England Journal of Medicine 366, 1870–1880 
(2012). 
189. Kalincik, T. et al. Sex as a determinant of relapse incidence and 
progressive course of multiple sclerosis. Brain 136, 3609–17 (2013). 
190. MS Society. A lottery of treatment and cae - MS services across Scotland 
and the UK. (2013). 
191. Giovannoni, G. et al. Effect of daclizumab high-yield process in patients 
with highly active relapsing-remitting multiple sclerosis. J. Neurol. 261, 
316–323 (2014). 
192. Trojano, M. et al. Real-life impact of early interferon beta therapy in 
relapsing multiple sclerosis. Ann. Neurol. 66, 513–520 (2009). 
193. Kalincik, T., Horakova, D., Spelman, T. & Jokubaitis, V. Switch to 
Natalizumab versus Fingolimod in Active Relapsing-Remitting Multiple 
Sclerosis. Ann. Neurol. 77, 425–435 (2015). 
194. Grassi, M., Enea, D., Marchetti, R. & Caricati, A. Combined counseling and 
bupropion therapy for smoking cessation: identification of outcome 
predictors. Drug Dev. Res. 67, 208–216 (2006). 
195. Connors, A. F. et al. The effectiveness of right heart catheterization in the 
initial care of critically ill patients. SUPPORT Investigators. JAMA 276, 
889–897 (1996). 
196. MSIF. Atlas of MS 2013: Mapping Multiple Sclerosis Around the World. 
Multiple Sclerosis International Federation (2013). 
   
 
388 
197. Wilsden, T., Barron, A., Mitchell-Heggs, A. & Ginoza, S. Access to 
medicines for multiple sclerosis: Challenges and Opportunities. (2014). 
198. Marziniak, M. et al. Variations in multiple sclerosis practice within Europe 
- Is it time for a new treatment guideline? Mult. Scler. Relat. Disord. 8, 
35–44 (2016). 
199. Swedish National Board of Health and Welfare. Quality and efficiency in 
Swedish Health Care - Regional Comparisosn 2012. (2012). 
200. Cameron, E. et al. Factors influencing multiple sclerosis disease-modifying 
treatment prescribing decisions in the United Kingdom: A qualitative 
interview study. Mult. Scler. Relat. Disord. 27, 378–382 (2019). 
201. Gigerenzer, G., Gaissmaier, W., Kurz-Milcke, E., Schwartz, L. M. & 
Woloshin, S. Helping doctors and patients make sense of health statistics. 
Psychol. Sci. Public Interes. Suppl. 8, 53 (2007). 
202. Deber, R. B., Kraetschmer, N., Urowitz, S. & Sharpe, N. Do people want to 
be autonomous patients? Preferred roles in treatment decision-making in 
several patient populations. Heal. Expect. 10, 248–258 (2007). 
203. Heesen, C. et al. Benefit-risk perception of natalizumab therapy in 
neurologists and a large cohort of multiple sclerosis patients. J. Neurol. 
Sci. 376, 181–190 (2017). 
204. Reen, G. K., Silber, E. & Langdon, D. W. Multiple sclerosis patients’ 
understanding and preferences for risks and benefits of disease-modifying 
drugs: A systematic review. J. Neurol. Sci. 375, 107–122 (2017). 
205. Col, N. F. et al. Whose Preferences Matter? A Patient-Centered Approach 
for Eliciting Treatment Goals. Med. Decis. Mak. 38, 44–55 (2017). 
206. Kremenchutzky, M. & Walt, L. Perceptions of health status in multiple 
sclerosis patients and their doctors. Can. J. Neurol. Sci. 40, 210 (2013). 
207. Brown, J. W. L., Coles, A. J., Horakova, D., Havrdova, E. & Robertson, N. 
P. Association of initial disease-modifying therapy with later conversion to 
secondary progressive multiple sclerosis. JAMA 321, 175–187 (2019). 
   
 
389 
208. Lunt, M. Selecting an appropriate caliper can be essential for achieving 
good balance with propensity score matching. Am. J. Epidemiol. 179, 226 
(2014). 
209. Austin, P. C. & Stuart, E. A. The performance of inverse probability of 
treatment weighting and full matching on the propensity score in the 
presence of model misspecification when estimating the effect of 
treatment on survival outcomes. Stat. Methods Med. Res. 26, 1654 (2017). 
210. DeMaria, A. Lies, damned lies, and statistics. J. Am. Coll. Cardiol. 52, 
1430 (2008). 
211. Nuttall, G. A. & Houle, T. T. Liars, damn liars, and propensity scores. 
Anesthesiology 108, 3–2 (2008). 
212. D’Agostino, R. B. & D’Agostino, R. B. Estimating treatment effects using 
observational data. J. Am. Med. Assoc. 297, 314 (2007). 
213. Kappos, L. et al. A placebo-controlled trial of oral fingolimod in relapsing 
multiple sclerosis. N. Engl. J. Med. 362, 387–401 (2010). 
214. Gold, R. et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing 
multiple sclerosis. N. Engl. J. Med. 367, 1098–107 (2012). 
215. Coles, A. J. Alemtuzumab Therapy for Multiple Sclerosis. 
Neurotherapeutics 10, 29–33 (2013). 
216. Marsh, E. A. et al. Alemtuzumab in the treatment of IVIG-dependent 
chronic inflammatory demyelinating polyneuropathy. J. Neurol. 257, 913–
919 (2010). 
217. Schnitzer, T. J. et al. Subcutaneous administration of CAMPATH-1H: 
clinical and biological outcomes. J. Rheumatol. 24, 1031–1036 (1997). 
218. Lockwood, C. M. et al. Treatment of refractory Wegener’s granulomatosis 
with humanized monoclonal antibodies. QJM 89, 903–912 (1996). 
219. Cox, A. L. et al. Lymphocyte homeostasis following therapeutic 
lymphocyte depletion in multiple sclerosis. Eur. J. Immunol. 35, 3332–
3342 (2005). 
   
 
390 
220. Hirst, C. L. et al. Campath 1-H treatment in patients with aggressive 
relapsing remitting multiple sclerosis. J. Neurol. 255, 231–238 (2008). 
221. Fox, E. J. et al. A single-arm, open-label study of alemtuzumab in 
treatment-refractory patients with multiple sclerosis. Eur. J. Neurol. 19, 
307–311 (2012). 
222. Coles, A. J. et al. Alemtuzumab vs. interferon beta-1a in early multiple 
sclerosis. N. Engl. J. Med. 359, 1786–1801 (2008). 
223. Coles, A. J. et al. Alemtuzumab more effective than interferon ??-1a at 5-
year follow-up of CAMMS223 Clinical Trial. Neurology 78, 1069–1078 
(2012). 
224. Lycke, J. et al. Adverse event profile of alemtuzumab in active relapsing 
remitting multiple sclerosis patients who participated in the CARE-MS 
studies: Three-year follow-up. Mult. Scler. 19, 487–488 (2013). 
225. Brown, J. W. L. & Coles, A. J. Alemtuzumab: evidence for its potential in 
relapsing-remitting multiple sclerosis. Drug Des. Devel. Ther. 7, 131–8 
(2013). 
226. Genzyme. Healthcare Professional Guide: Using LEMTRADA (alemtuzumab) 
in patients with relapsing-remitting multiple sclerosis (RRMS). (2013). 
227. McCormack, P. L. Natalizumab: A review of its use in the management of 
relapsing-remitting multiple sclerosis. Drugs 73, 1463–1481 (2013). 
228. Rudick, R. A. et al. Natalizumab plus interferon beta-1a for relapsing 
multiple sclerosis. N. Engl. J. Med. 354, 911–923 (2006). 
229. Havrdova, E. et al. Effect of natalizumab on clinical and radiological 
disease activity in multiple sclerosis: a retrospective analysis of the 
Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis 
(AFFIRM) study. Lancet Neurol. 8, 254–260 (2009). 
230. Hutchinson, M. et al. The efficacy of natalizumab in patients with 
relapsing multiple sclerosis: Subgroup analyses of AFFIRM and SENTINEL. J. 
Neurol. 256, 405–415 (2009). 
   
 
391 
231. National Institute for Health and Clinical Excellence (NICE) Technology 
Appraisal 127. Natalizumab for the treatment of adults with highly active 
relapsing-remitting multiple sclerosis. (2007). Available at: 
http://www.nice.org.uk/nicemedia/live/11822/36136/36136.pdf.  
232. Tan, C. S. & Koralnik, I. J. Progressive multifocal leukoencephalopathy and 
other disorders caused by JC virus: clinical features and pathogenesis. 
Lancet Neurol. 9, 425–437 (2010). 
233. Barts and The London School of Medicine and Dentistry. Multiple Sclerosis 
research: Natalizumab PML update. 2017. Available at: http://multiple-
sclerosis-research.blogspot.com/2017/11/latest-natalizumab-pml-risk-
update.html.  
234. Isidoro, L., Pires, P., Rito, L. & Cordeiro, G. Progressive multifocal 
leukoencephalopathy in a patient with chronic lymphocytic leukaemia 
treated with alemtuzumab. BMJ Case Rep. 12, 164–79 (2014). 
235. Wingerchuk, D. M. & Carter, J. L. Multiple sclerosis: current and emerging 
disease-modifying therapies and treatment strategies. Mayo Clinic 
proceedings 89, 225–240 (2014). 
236. Liu, C., Li Wan Po, A. & Blumhardt, L. D. ‘Summary measure’ statistic for 
assessing the outcome of treatment trials in relapsing-remitting multiple 
sclerosis. J. Neurol. Neurosurg. Psychiatry 64, 726–729 (1998). 
237. Tuohy, O., Costelloe, L., Hill-Cawthorne, G. & Bjornson, I. Alemtuzumab 
treatment of multiple sclerosis: long-term safety and efficacy. J. Neurol. 
Neurosurg. Psychiatry Published, (2014). 
238. Harris, J. O., Frank, J. A., Patronas, N., McFarlin, D. E. & McFarland, H. F. 
Serial gadolinium‐enhanced magnetic resonance imaging scans in patients 
with early, relapsing‐remitting multiple sclerosis: Implications for clinical 
trials and natural history. Ann. Neurol. 29, 548–555 (1991). 
239. Kappos, L. et al. Switching from natalizumab to fingolimod : A 
randomized, placebo-controlled study in RRMS. Neurology 85, 29–39 
(2015). 
   
 
392 
240. Kappos, L. et al. Factors influencing long-term outcomes in relapsing-
remitting multiple sclerosis: PRISMS-15. J. Neurol. Neurosurg. Psychiatry 
86, 1202–1207 (2015). 
241. European Medicines Agency. Measures to minimise risk of serious side 
effects of multiple sclerosis medicine Lemtrada. doi:EMA/609015/2019 
242. La Ganke, C. & Adcock, A. Clinical outcomes of 200 multiple sclerosis 
patients switching from natalizumab to alemtuzumab in a single United 
States MS center. in AAN 86 (16 SUPPL 1) (2016). 
243. Berger, T. et al. Alemtuzumab Use in Clinical Practice: Recommendations 
from European Multiple Sclerosis Experts. CNS Drugs 1–18 (2016). 
doi:10.1007/s40263-016-0394-8 
244. Kelly, SB Kinsella, K, Duggan, M, Hutchinson M, Turbidy N, M. C. Initial 
experience of alemtuzumab for patients who fail natalizumab therapy 
[Abstract]. J. Neurol. Neurosurg. Psychiatry 83, e1 (2012). 
245. Fortin, J., Jaques, F., Sikati Fokko, V. & Grand’Maison, F. Switching from 
Natalizumab to Alemtuzumab in patinets with RRMS: Real-world 
experience. in ECTRIMS 22 (pp 783) (2016). 
246. Malucchi, S. et al. High-Risk PML Patients Switching from Natalizumab to 
Alemtuzumab: an Observational Study. Neurol. Ther. 6, 145–152 (2017). 
247. Sorensen, P. S. et al. Recurrence or rebound of clinical relapses after 
discontinuation of natalizumab therapy in highly active MS patients. J. 
Neurol. 261, 1170–1177 (2014). 
248. Giovannoni, G. et al. Switching patients at high risk of PML from 
natalizumab to another disease-modifying therapy. Pract. Neurol. 16, 389–
393 (2016). 
 
